Target Label,Prioritised Features,Entropy Value,Entropy Conf,Gini Index Value,Gini Index Conf,Category,Best Conf,Significant,PlotSig
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),0.03388,0,0.03356,0,Best Maturity,0,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Metabolic Component Category - Signaling Pathway Regulators (6),0.02676,0.00080008,0.03274,0.00020002,Best Maturity,0.00020002,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),0.01956,0.00270027,0.01503,0.00420042,Best Maturity,0.00270027,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),0.01758,0.00110011,0.01239,0.0060006,Best Maturity,0.00110011,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Electrophysiology Analysis Method - Patch Clamp (59),0.01529,0.00790079,0.00955,0.02770277,Best Maturity,0.00790079,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Metabolic Analysis Method - Seahorse (35),0.01498,0.00470047,0.01072,0.01560156,Best Maturity,0.00470047,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Journal - Tissue Eng Part C Methods (6),0.01243,0.01350135,0.01248,0.01490149,Best Maturity,0.01350135,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Electron Imaging - Transmission (62),0.01089,0.03110311,0.00714,0.104610461,Best Maturity,0.03110311,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),0.01059,0.01210121,0.00747,0.055905591,Best Maturity,0.01210121,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),hiPSC-CM Media Supplement - Rare (5),0.01052,0.01280128,0.0157,0.00590059,Best Maturity,0.00590059,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Journal - Biosens Bioelectron (4),0.01042,0.01060106,0.0124,0.010001,Best Maturity,0.010001,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Wnt Inhibitor - IWP (112),0.0102,0.04680468,0.0056,0.330933093,Best Maturity,0.04680468,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),hiPSC-CM Maturation Media - DMEM (35),0.00907,0.04010401,0.00637,0.099209921,Best Maturity,0.04010401,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Insulin Start Day - 6 (20),0.00906,0.03620362,0.00721,0.067306731,Best Maturity,0.03620362,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Cell Line - Cellapy (4),0.009,0.01730173,0.0063,0.070907091,Best Maturity,0.01730173,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),hiPSC Backbone Media - Rare (19),0.00897,0.03230323,0.00474,0.157915792,Best Maturity,0.03230323,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Seeding Confluency 3D (%) - 85 to 89 (12),0.00893,0.03330333,0.00514,0.107210721,Best Maturity,0.03330333,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Wnt Induction - Rare (4),0.00864,0.0180018,0.00475,0.111811181,Best Maturity,0.0180018,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Metabolic Component - Palmitic Acid (11),0.00853,0.03710371,0.00928,0.03050305,Best Maturity,0.03050305,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Coating for Replating - Geltrex (10),0.00839,0.0360036,0.00745,0.04580458,Best Maturity,0.0360036,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Publication Year - 2019 (57),0.00829,0.074507451,0.01058,0.01790179,Best Maturity,0.01790179,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Metabolic Component Category - Kinase Inhibitors (3),0.00819,0.02660266,0.01086,0.01510151,Best Maturity,0.01510151,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Insulin Withdrawal Duration (days) - 6 days (3),0.00795,0.04430443,0.00685,0.079907991,Best Maturity,0.04430443,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Pharmacological Intervention - Caffeine (4),0.00788,0.03030303,0.00613,0.080708071,Best Maturity,0.03030303,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),0.00761,0.03740374,0.00812,0.03540354,Best Maturity,0.03540354,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),0.00753,0.040004,0.00939,0.02570257,Best Maturity,0.02570257,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),hiPSC-CM Purification Duration (days) - 6 days (10),0.00722,0.040004,0.00582,0.070507051,Best Maturity,0.040004,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Publication Year - 2021 (43),0.00713,0.095709571,0.00874,0.03920392,Best Maturity,0.03920392,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Calcium Handling Analysis Method - Visual (104),0.00707,0.169216922,0.00902,0.02720272,Best Maturity,0.02720272,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),hiPSC-CM Media Supplement - GlutaMax (8),0.00682,0.053105311,0.01068,0.02050205,Best Maturity,0.02050205,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),0.00669,0.04360436,0.00795,0.030003,Best Maturity,0.030003,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),0.00647,0.127312731,0.00872,0.04710471,Best Maturity,0.04710471,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Pharmacological Intervention - Blebbistatin (5),0.00639,0.03610361,0.00369,0.130213021,Best Maturity,0.03610361,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Insulin Start Day - 3 (5),0.00546,0.104010401,0.00812,0.04360436,Best Maturity,0.04360436,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),0.00398,0.119711971,0.01174,0.01020102,Best Maturity,0.01020102,TRUE,TRUE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),0.03136,0.00020002,0.02608,0.00040004,Best Maturity,0.00020002,TRUE,TRUE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Number of Cell Lines - 2 (50),0.01937,0.00560056,0.01292,0.01620162,Best Maturity,0.00560056,TRUE,TRUE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),0.0187,0.00170017,0.01207,0.0130013,Best Maturity,0.00170017,TRUE,TRUE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),0.01612,0.00440044,0.01316,0.00670067,Best Maturity,0.00440044,TRUE,TRUE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Coating for Replating - Rare (6),0.01578,0.00450045,0.01653,0.00380038,Best Maturity,0.00380038,TRUE,TRUE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),0.01487,0.00560056,0.01748,0.00440044,Best Maturity,0.00440044,TRUE,TRUE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Journal - Acta Biomater (10),0.01462,0.01120112,0.01184,0.01750175,Best Maturity,0.01120112,TRUE,TRUE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),0.01415,0.01040104,0.01326,0.00910091,Best Maturity,0.00910091,TRUE,TRUE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),0.01343,0.01010101,0.00794,0.082908291,Best Maturity,0.01010101,TRUE,TRUE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Gene Analysis Method - RNA (169),0.01318,0.01030103,0.00479,0.528952895,Best Maturity,0.01030103,TRUE,TRUE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),0.01254,0.00870087,0.01061,0.01750175,Best Maturity,0.00870087,TRUE,TRUE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Disease Modelling - Hypertrophic Cardiomyopathy (6),0.01247,0.01280128,0.01315,0.01310131,Best Maturity,0.01280128,TRUE,TRUE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Deduced Culture Strategy - 2D Only (183),0.01055,0.03690369,0.00641,0.183018302,Best Maturity,0.03690369,TRUE,FALSE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Cell Line - Cellapy (4),0.00979,0.01410141,0.0132,0.00580058,Best Maturity,0.00580058,TRUE,TRUE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Wnt Induction Duration (days) - 3 days (38),0.00954,0.0380038,0.00987,0.0290029,Best Maturity,0.0290029,TRUE,FALSE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Journal - Rare (104),0.00926,0.075107511,0.01602,0.00020002,Best Maturity,0.00020002,TRUE,TRUE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Seeding Confluency 2D (%) - 80 to 84 (5),0.00895,0.03030303,0.00994,0.02440244,Best Maturity,0.02440244,TRUE,TRUE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),2D Surface - Micropatterned (27),0.00876,0.04220422,0.00956,0.02870287,Best Maturity,0.02870287,TRUE,FALSE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),2D Surface - Microparticle/fluid (3),0.00874,0.02330233,0.00834,0.03920392,Best Maturity,0.02330233,TRUE,TRUE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Metabolic Component - Insulin-Transferrin-Selenium (3),0.00814,0.02760276,0.00877,0.03610361,Best Maturity,0.02760276,TRUE,FALSE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),0.00767,0.0440044,0.01003,0.02030203,Best Maturity,0.02030203,TRUE,TRUE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),hiPSC-CM Media Supplement - Rare (5),0.00761,0.056705671,0.01002,0.02810281,Best Maturity,0.02810281,TRUE,FALSE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),2D Surface - Nanotopography (6),0.00725,0.053405341,0.00817,0.04250425,Best Maturity,0.04250425,TRUE,FALSE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),0.00682,0.058605861,0.01053,0.01810181,Best Maturity,0.01810181,TRUE,TRUE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Contractile Analysis Method - Rare (7),0.00602,0.078707871,0.00875,0.03250325,Best Maturity,0.03250325,TRUE,FALSE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),0.0046,0.106110611,0.00918,0.03170317,Best Maturity,0.03170317,TRUE,FALSE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Seeding Confluency (%) - 80 to 84 (12),0.00457,0.143514351,0.00826,0.04530453,Best Maturity,0.04530453,TRUE,FALSE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),hiPSC Matrix Coating - EBs (18),0.00371,0.184918492,0.00875,0.0350035,Best Maturity,0.0350035,TRUE,FALSE
Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),0.00351,0.896489649,0.01084,0.01990199,Best Maturity,0.01990199,TRUE,TRUE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Cell Line - BJ1 (7),0.02304,0.00130013,0.0242,0.0010001,Best Maturity,0.0010001,TRUE,TRUE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Contractile Analysis Method - Force Transducer (27),0.0213,0.00360036,0.01713,0.00320032,Best Maturity,0.00320032,TRUE,TRUE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),3D Tissue Media - Iscove (5),0.0208,0.0020002,0.02286,0.00110011,Best Maturity,0.00110011,TRUE,TRUE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Journal - Circulation (11),0.02042,0.0020002,0.02039,0.00120012,Best Maturity,0.00120012,TRUE,TRUE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Maturation Strategy - Tension (64),0.01998,0.00150015,0.00821,0.077307731,Best Maturity,0.00150015,TRUE,TRUE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),0.01962,0.00320032,0.01349,0.01020102,Best Maturity,0.00320032,TRUE,TRUE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),0.01758,0.00620062,0.01743,0.00580058,Best Maturity,0.00580058,TRUE,TRUE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),0.01529,0.01020102,0.01355,0.01130113,Best Maturity,0.01020102,TRUE,TRUE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),3D Platform - Collagen (38),0.01415,0.01580158,0.01389,0.00730073,Best Maturity,0.00730073,TRUE,TRUE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Number of Cell Lines - 1 (225),0.01407,0.01380138,0.00623,0.216621662,Best Maturity,0.01380138,TRUE,TRUE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),0.01392,0.00770077,0.01162,0.0130013,Best Maturity,0.00770077,TRUE,TRUE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),3D Tissue Media - Growth Factor (12),0.01356,0.00910091,0.0121,0.01240124,Best Maturity,0.00910091,TRUE,TRUE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),hiPSC Backbone Media - DMEM (10),0.01184,0.01780178,0.01073,0.02230223,Best Maturity,0.01780178,TRUE,TRUE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),hiPSC Backbone Media - Conditioned (12),0.01165,0.02360236,0.00916,0.03770377,Best Maturity,0.02360236,TRUE,TRUE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),3D Stromal Cell Source - Human Fibroblast (38),0.01145,0.02650265,0.00599,0.149014901,Best Maturity,0.02650265,TRUE,FALSE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Insulin Start Day - 11 (3),0.01142,0.01940194,0.0088,0.053605361,Best Maturity,0.01940194,TRUE,TRUE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),hiPSC-CM Purification Duration (days) - <3 days (31),0.0114,0.02710271,0.00978,0.03450345,Best Maturity,0.02710271,TRUE,FALSE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Wnt Inhibitor - IWP (112),0.01076,0.04380438,0.0085,0.055105511,Best Maturity,0.04380438,TRUE,FALSE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),0.01036,0.02590259,0.0116,0.01840184,Best Maturity,0.01840184,TRUE,TRUE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Pharmacological Intervention - T3 (3),0.01035,0.0470047,0.01171,0.04410441,Best Maturity,0.04410441,TRUE,FALSE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),0.01034,0.02730273,0.0062,0.086408641,Best Maturity,0.02730273,TRUE,FALSE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),0.00993,0.03670367,0.00847,0.050305031,Best Maturity,0.03670367,TRUE,FALSE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),0.00992,0.02490249,0.00566,0.104810481,Best Maturity,0.02490249,TRUE,TRUE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Cell Coculture - Cardiomyocyte (157),0.00974,0.04030403,0.00604,0.243524352,Best Maturity,0.04030403,TRUE,FALSE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Publication Year - 2014 (3),0.00947,0.02520252,0.0128,0.0130013,Best Maturity,0.0130013,TRUE,TRUE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),3D Stromal Cell Source - hiPSC-SmoothMC (3),0.00904,0.03190319,0.00473,0.084908491,Best Maturity,0.03190319,TRUE,FALSE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Disease Modelling - Genetic Disorders (18),0.00898,0.03770377,0.00716,0.068906891,Best Maturity,0.03770377,TRUE,FALSE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Number of Cell Lines - 3 (29),0.00896,0.04640464,0.00908,0.03760376,Best Maturity,0.03760376,TRUE,FALSE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Disease Modelling - Hypertrophic Cardiomyopathy (6),0.00817,0.04490449,0.00755,0.061906191,Best Maturity,0.04490449,TRUE,FALSE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Electron Imaging - Transmission (62),0.00776,0.106410641,0.01086,0.02920292,Best Maturity,0.02920292,TRUE,FALSE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Day of Insulin Addition - not 9 (3),0.00575,0.066006601,0.00889,0.03850385,Best Maturity,0.03850385,TRUE,FALSE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Journal - Rare (104),0.00384,0.701570157,0.00954,0.02860286,Best Maturity,0.02860286,TRUE,FALSE
Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Day of Insulin Addition - not 18 (10),0.00352,0.168616862,0.00732,0.04930493,Best Maturity,0.04930493,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Contractile Analysis Method - Force Transducer (27),0.03595,0.00010001,0.02703,0.00010001,Best Maturity,0.00010001,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27),0.02346,0.00080008,0.01855,0.0010001,Best Maturity,0.00080008,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Cell Line - BJ1 (7),0.02078,0.0020002,0.02494,0.00050005,Best Maturity,0.00050005,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Purification Protocol - Glucose and Lactate (85),0.01718,0.00460046,0.00637,0.178917892,Best Maturity,0.00460046,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Day of Insulin Addition - not 24 (9),0.01677,0.00280028,0.01274,0.010001,Best Maturity,0.00280028,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Day of Insulin Addition - not 23 (10),0.0163,0.00630063,0.01545,0.00690069,Best Maturity,0.00630063,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),2D Surface - Hydrogel (17),0.01626,0.00740074,0.01304,0.01060106,Best Maturity,0.00740074,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),0.01616,0.00460046,0.01454,0.00610061,Best Maturity,0.00460046,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),0.01433,0.00360036,0.01355,0.00570057,Best Maturity,0.00360036,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Day of Insulin Addition - not 22 (12),0.01405,0.01030103,0.01055,0.02470247,Best Maturity,0.01030103,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Seeding Confluency 3D (%) - 95 to 100 (13),0.01399,0.01320132,0.01066,0.02420242,Best Maturity,0.01320132,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Journal - Circulation (11),0.01353,0.00860086,0.01199,0.0120012,Best Maturity,0.00860086,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Wnt Inhibitor - IWP (112),0.01345,0.02230223,0.00274,0.837483748,Best Maturity,0.02230223,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),0.01307,0.02480248,0.01051,0.03480348,Best Maturity,0.02480248,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Number of Cell Lines - 2 (50),0.01299,0.02170217,0.00949,0.0440044,Best Maturity,0.02170217,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Pharmacological Intervention - Isoproterenol (71),0.01277,0.01740174,0.01146,0.01350135,Best Maturity,0.01350135,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Maturation Strategy - Tension (64),0.01266,0.02230223,0.00792,0.063806381,Best Maturity,0.02230223,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),0.01247,0.01790179,0.0124,0.01180118,Best Maturity,0.01180118,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),0.01216,0.02360236,0.0128,0.01070107,Best Maturity,0.01070107,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),3D Tissue Media - High-glucose DMEM (9),0.01146,0.02150215,0.00703,0.072107211,Best Maturity,0.02150215,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),hiPSC-CM Purification Duration (days) - 7 days (6),0.0109,0.00780078,0.01371,0.00460046,Best Maturity,0.00460046,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Pharmacological Intervention - Adrenaline (83),0.01074,0.04710471,0.00787,0.113311331,Best Maturity,0.04710471,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),hiPSC Backbone Media - Embryonic Stem Cell (127),0.00983,0.0410041,0.01149,0.00190019,Best Maturity,0.00190019,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Electrophysiology Analysis Method - Optical Mapping (39),0.00975,0.04590459,0.00588,0.173017302,Best Maturity,0.04590459,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),hiPSC Backbone Media - StemFlex (5),0.00938,0.02660266,0.00538,0.108710871,Best Maturity,0.02660266,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Cell Line - Cor.4U (16),0.00929,0.03840384,0.00899,0.04120412,Best Maturity,0.03840384,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Publication Year - 2017 (43),0.00913,0.04550455,0.0098,0.03440344,Best Maturity,0.03440344,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Day of Insulin Addition - not 21 (14),0.00888,0.04840484,0.0091,0.03730373,Best Maturity,0.03730373,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Day of Insulin Addition - not 20 (15),0.00883,0.04720472,0.01138,0.01710171,Best Maturity,0.01710171,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),hiPSC-CM Backbone Media - DMEM (18),0.00798,0.062606261,0.00866,0.04690469,Best Maturity,0.04690469,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),0.00641,0.066706671,0.0086,0.04070407,Best Maturity,0.04070407,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),0.00582,0.095109511,0.0106,0.02460246,Best Maturity,0.02460246,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Differentiation Purity Assessment - Visual Inspection (6),0.0054,0.106210621,0.00963,0.02730273,Best Maturity,0.02730273,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),hiPSC-CM Maturation Media - Cor.4U Complete (6),0.00477,0.122212221,0.01105,0.01690169,Best Maturity,0.01690169,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),0.02019,0.00280028,0.01762,0.00410041,Best Maturity,0.00280028,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Contractile Analysis Method - Deflection (39),0.01641,0.00890089,0.00769,0.104710471,Best Maturity,0.00890089,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Metabolic Component - Palmitic Acid (11),0.01484,0.01360136,0.01308,0.01590159,Best Maturity,0.01360136,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),0.01435,0.00860086,0.01005,0.02660266,Best Maturity,0.00860086,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),0.01387,0.00280028,0.00612,0.255725573,Best Maturity,0.00280028,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Cell Line Ancestry - Asian (28),0.01386,0.02110211,0.01128,0.03250325,Best Maturity,0.02110211,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),0.01334,0.01530153,0.00742,0.071907191,Best Maturity,0.01530153,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Metabolic Component - Fatty Acid (13),0.01329,0.02210221,0.00752,0.078607861,Best Maturity,0.02210221,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),3D Stromal Cell Source - Mesenchymal Stem Cell (12),0.01288,0.01550155,0.00877,0.04470447,Best Maturity,0.01550155,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),0.01259,0.02580258,0.01333,0.01690169,Best Maturity,0.01690169,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),0.01254,0.01760176,0.0101,0.030003,Best Maturity,0.01760176,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Journal - Tissue Eng Part C Methods (6),0.01189,0.01540154,0.01377,0.010001,Best Maturity,0.010001,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),0.0115,0.02460246,0.01298,0.01440144,Best Maturity,0.01440144,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),0.01142,0.02470247,0.00917,0.04450445,Best Maturity,0.02470247,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),hiPSC-CM Media Supplement - Rare (5),0.01125,0.02740274,0.00693,0.089108911,Best Maturity,0.02740274,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Cell Line - BJ RiPS (4),0.01122,0.01920192,0.01219,0.02190219,Best Maturity,0.01920192,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),3D Tissue Media - RPMI-1640 (72),0.01113,0.04080408,0.00523,0.337233723,Best Maturity,0.04080408,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Cell Line Sex - Male (64),0.01045,0.04980498,0.01205,0.0230023,Best Maturity,0.0230023,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),0.00966,0.03320332,0.00971,0.03680368,Best Maturity,0.03320332,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Electron Imaging - Transmission (62),0.00946,0.063706371,0.01204,0.02140214,Best Maturity,0.02140214,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),3D Stromal Cell Source - Cardiac Fibroblast (32),0.00926,0.050805081,0.00983,0.03920392,Best Maturity,0.03920392,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Journal - Sci Transl Med (3),0.00924,0.04680468,0.01405,0.02030203,Best Maturity,0.02030203,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Wnt Inhibitor - Wnt-C59 (30),0.00824,0.064906491,0.01093,0.03050305,Best Maturity,0.03050305,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),0.00798,0.078507851,0.01059,0.03970397,Best Maturity,0.03970397,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),hiPSC-CM Purification Duration (days) - >9 days (5),0.0075,0.055905591,0.00846,0.04680468,Best Maturity,0.04680468,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Journal - ACS Biomater Sci Eng (3),0.00632,0.061706171,0.01169,0.02810281,Best Maturity,0.02810281,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Journal - Acta Biomater (10),0.00602,0.106910691,0.00978,0.03970397,Best Maturity,0.03970397,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),0.00471,0.183918392,0.01098,0.03140314,Best Maturity,0.03140314,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Fatty Acid Metabolism Assessed - Yes (20),0.00424,0.213121312,0.0099,0.04610461,Best Maturity,0.04610461,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),0.05408,0,0.05062,0,Best Maturity,0,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Calcium Handling Analysis Method - Visual (104),0.0318,0.00040004,0.01364,0.00250025,Best Maturity,0.00040004,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),0.02226,0.00140014,0.01927,0.00370037,Best Maturity,0.00140014,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Journal - Cell Stem Cell (6),0.02083,0.00320032,0.01924,0.00450045,Best Maturity,0.00320032,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Gene Analysis Method - Rare (5),0.01674,0.0040004,0.01138,0.0160016,Best Maturity,0.0040004,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),0.01594,0.00880088,0.00871,0.063006301,Best Maturity,0.00880088,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Metabolic Component - Palmitic Acid (11),0.01433,0.00890089,0.01491,0.00530053,Best Maturity,0.00530053,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),hiPSC-CM Purification Duration (days) - >9 days (5),0.01406,0.00560056,0.01308,0.00750075,Best Maturity,0.00560056,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Metabolic Component Category - Sugars and Carbohydrates (9),0.01394,0.00840084,0.01509,0.00520052,Best Maturity,0.00520052,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Metabolic Analysis Method - Seahorse (35),0.01362,0.01540154,0.01222,0.01710171,Best Maturity,0.01540154,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Purification Protocol - Glucose and Lactate (85),0.01358,0.01960196,0.00741,0.127312731,Best Maturity,0.01960196,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Metabolic Component Category - Fatty Acids and Lipids (21),0.01319,0.01060106,0.00561,0.116211621,Best Maturity,0.01060106,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Metabolic Component - Fatty Acid (13),0.01198,0.0170017,0.01116,0.02130213,Best Maturity,0.0170017,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),0.01151,0.01140114,0.01537,0.00320032,Best Maturity,0.00320032,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),0.01052,0.02130213,0.01596,0.00630063,Best Maturity,0.00630063,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),0.01046,0.02380238,0.01666,0.00630063,Best Maturity,0.00630063,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Publication Year - Late-2010s (196),0.01016,0.0480048,0.00375,0.704770477,Best Maturity,0.0480048,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Insulin Start Day - 1 (19),0.01007,0.03460346,0.01084,0.0260026,Best Maturity,0.0260026,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Publication Year - 2015 (19),0.00994,0.03620362,0.01141,0.02020202,Best Maturity,0.02020202,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),hiPSC-CM Purification Duration (days) Quantiles - Q1 (>4 and ≤20) (31),0.00936,0.04460446,0.00329,0.336333633,Best Maturity,0.04460446,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Journal - Circ Res (5),0.0093,0.02370237,0.00921,0.02820282,Best Maturity,0.02370237,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),0.00881,0.02790279,0.00915,0.03590359,Best Maturity,0.02790279,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),3D Platform - Matrigel (33),0.00826,0.04980498,0.00542,0.156115612,Best Maturity,0.04980498,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Journal - Stem Cells (11),0.00787,0.04620462,0.00654,0.075807581,Best Maturity,0.04620462,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Publication Year - 2017 (43),0.00763,0.091109111,0.01061,0.02890289,Best Maturity,0.02890289,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Metabolic Component Category - Metabolic Modulation (20),0.00756,0.079807981,0.00883,0.04460446,Best Maturity,0.04460446,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Insulin Start Day - 11 (3),0.00598,0.073007301,0.00968,0.04520452,Best Maturity,0.04520452,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Disease Modelling - Dilated Cardiomyopathy (6),0.00597,0.094909491,0.00851,0.04930493,Best Maturity,0.04930493,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Pharmacological Intervention - Isoproterenol (71),0.02454,0.00010001,0.01472,0.00240024,Best Maturity,0.00010001,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Journal - Cell Stem Cell (6),0.02437,0.0010001,0.0271,0.00060006,Best Maturity,0.00060006,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),hiPSC Matrix Coating - Rare (8),0.02319,0.00130013,0.0185,0.00240024,Best Maturity,0.00130013,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),0.01847,0.00170017,0.01135,0.00950095,Best Maturity,0.00170017,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Purification Protocol - Metabolic (8),0.01506,0.00490049,0.0146,0.00570057,Best Maturity,0.00490049,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Pharmacological Intervention - Adrenaline (83),0.01447,0.00730073,0.01004,0.02360236,Best Maturity,0.00730073,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),0.01403,0.0090009,0.01136,0.01730173,Best Maturity,0.0090009,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Cell Line - 253G1 (10),0.01301,0.01360136,0.0123,0.01460146,Best Maturity,0.01360136,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),hiPSC-CM Purification Duration (days) - 3 days (13),0.01195,0.01630163,0.01323,0.00780078,Best Maturity,0.00780078,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Publication Year - 2024 (7),0.01126,0.01580158,0.00539,0.104510451,Best Maturity,0.01580158,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),3D Platform - Fibronectin (3),0.01124,0.01130113,0.00584,0.083608361,Best Maturity,0.01130113,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Number of Cell Lines - 1 (225),0.01101,0.02990299,0.01405,0.00150015,Best Maturity,0.00150015,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),3D Tissue Media - MEM-α (60),0.01091,0.03060306,0.00361,0.449044904,Best Maturity,0.03060306,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Disease Modelling - Dilated Cardiomyopathy (6),0.01075,0.01480148,0.00711,0.057305731,Best Maturity,0.01480148,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Pharmacological Intervention - Carbamylcholine (6),0.01062,0.01570157,0.01156,0.01420142,Best Maturity,0.01420142,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),3D Platform - Extracellular Scaffold (18),0.01061,0.0260026,0.0129,0.00910091,Best Maturity,0.00910091,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Insulin Start Day - 8 (15),0.01058,0.02530253,0.00901,0.03440344,Best Maturity,0.02530253,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),0.01052,0.01980198,0.01517,0.00620062,Best Maturity,0.00620062,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Pharmacological Intervention - Propranolol (5),0.01042,0.01370137,0.00802,0.04190419,Best Maturity,0.01370137,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Insulin Withdrawal Duration (days) - 3 days (6),0.01038,0.01680168,0.0171,0.00480048,Best Maturity,0.00480048,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Contractile Analysis Method - Deflection (39),0.0103,0.0320032,0.00474,0.223722372,Best Maturity,0.0320032,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Journal - Stem Cell Res Ther (3),0.01018,0.02560256,0.00904,0.04980498,Best Maturity,0.02560256,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Cell Line - Cor.4U (16),0.01005,0.03410341,0.00798,0.04990499,Best Maturity,0.03410341,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Metabolic Analysis Method - Genetic (3),0.00967,0.01050105,0.00916,0.02680268,Best Maturity,0.01050105,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),3D Tissue Media - Rare (13),0.00934,0.030003,0.00538,0.103910391,Best Maturity,0.030003,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Cell Line - SCVI-273 (8),0.00913,0.03320332,0.00455,0.148814881,Best Maturity,0.03320332,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),0.00904,0.03450345,0.00977,0.02430243,Best Maturity,0.02430243,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Pharmacological Intervention - Traditional Chemotherapy Agents (18),0.00864,0.04280428,0.00647,0.080308031,Best Maturity,0.04280428,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),0.00839,0.03020302,0.01073,0.01570157,Best Maturity,0.01570157,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),2D Surface - Microelectrode Array (9),0.00796,0.04280428,0.00925,0.03280328,Best Maturity,0.03280328,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Pharmacological Intervention - Other Antiarrhythmic Agents (13),0.00795,0.059705971,0.00924,0.03490349,Best Maturity,0.03490349,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),hiPSC-CM Media Supplement - VEGF (4),0.00789,0.04910491,0.01052,0.02380238,Best Maturity,0.02380238,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),hiPSC Matrix Coating - Vitronectin (10),0.00734,0.060906091,0.00985,0.03160316,Best Maturity,0.03160316,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),0.00624,0.090809081,0.00908,0.03860386,Best Maturity,0.03860386,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Differentiation Purity Assessment - Visual Inspection (6),0.00598,0.078007801,0.00797,0.04190419,Best Maturity,0.04190419,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Journal - Biomaterials (16),0.00509,0.116211621,0.00824,0.03890389,Best Maturity,0.03890389,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),0.00416,0.145914591,0.00813,0.04440444,Best Maturity,0.04440444,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),0.029,0.00020002,0.02276,0.00060006,Best Maturity,0.00020002,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Seeding Confluency (%) - 80 to 84 (12),0.02806,0.00040004,0.01584,0.00370037,Best Maturity,0.00040004,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Calcium Handling Analysis Method - Visual (104),0.02373,0.00140014,0.01327,0.00310031,Best Maturity,0.00140014,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Seeding Confluency 2D (%) - 80 to 84 (5),0.02096,0.00250025,0.02474,0.0010001,Best Maturity,0.0010001,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Journal - Nano Lett (3),0.01834,0.00240024,0.01877,0.00340034,Best Maturity,0.00240024,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),hiPSC Matrix Coating - Geltrex (33),0.01783,0.00560056,0.013,0.01520152,Best Maturity,0.00560056,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),0.01582,0.00440044,0.01513,0.0040004,Best Maturity,0.0040004,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),0.01566,0.00690069,0.01116,0.02150215,Best Maturity,0.00690069,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Publication Year - 2015 (19),0.0156,0.00850085,0.01607,0.00430043,Best Maturity,0.00430043,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Maturation Strategy - ECM (21),0.01355,0.01510151,0.01199,0.01540154,Best Maturity,0.01510151,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),0.01326,0.01370137,0.01722,0.00420042,Best Maturity,0.00420042,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Journal - Stem Cells (11),0.01264,0.01140114,0.01542,0.00490049,Best Maturity,0.00490049,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Journal - PLoS One (9),0.01258,0.01220122,0.00664,0.065806581,Best Maturity,0.01220122,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Coating for Replating - Fibronectin (32),0.01253,0.02160216,0.01245,0.01330133,Best Maturity,0.01330133,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),hiPSC Backbone Media - mTeSR (106),0.01172,0.0350035,0.01055,0.01570157,Best Maturity,0.01570157,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),0.01157,0.01930193,0.01279,0.00990099,Best Maturity,0.00990099,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),2D Surface - Hydrogel (17),0.01111,0.02410241,0.01028,0.02550255,Best Maturity,0.02410241,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Sacromere or Cellular Alignment Analysis - Yes (72),0.01062,0.0440044,0.01037,0.02790279,Best Maturity,0.02790279,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),0.01046,0.01970197,0.00938,0.02920292,Best Maturity,0.01970197,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Coating for Replating - Matrigel (65),0.0103,0.04860486,0.00876,0.079807981,Best Maturity,0.04860486,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),0.01022,0.0370037,0.01077,0.03750375,Best Maturity,0.0370037,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Seeding Confluency 2D (%) - 70 to 79 (6),0.01015,0.02120212,0.01213,0.01490149,Best Maturity,0.01490149,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),0.01013,0.02250225,0.00667,0.066306631,Best Maturity,0.02250225,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Wnt Inhibitor - IWR (56),0.01007,0.04580458,0.01327,0.00980098,Best Maturity,0.00980098,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Insulin Start Day - 6 (20),0.00958,0.03880388,0.00961,0.0370037,Best Maturity,0.0370037,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),0.00955,0.03480348,0.00968,0.04350435,Best Maturity,0.03480348,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),0.00952,0.03870387,0.00985,0.0340034,Best Maturity,0.0340034,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),0.00946,0.02720272,0.01294,0.010001,Best Maturity,0.010001,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Seeding Confluency (%) - 70 to 79 (11),0.00911,0.03960396,0.01135,0.01990199,Best Maturity,0.01990199,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Seeding Confluency 3D (%) - 80 to 84 (5),0.00886,0.03370337,0.00925,0.0360036,Best Maturity,0.03370337,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),0.00815,0.03550355,0.01034,0.02060206,Best Maturity,0.02060206,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Gene Analysis Method - RNA (169),0.00771,0.119811981,0.00864,0.03240324,Best Maturity,0.03240324,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),0.00744,0.085708571,0.01062,0.02620262,Best Maturity,0.02620262,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),hiPSC-CM Media Supplement - Mercaptoethanol (10),0.00723,0.04880488,0.00738,0.056705671,Best Maturity,0.04880488,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Journal - J Mol Cell Card (6),0.00667,0.071207121,0.01039,0.02080208,Best Maturity,0.02080208,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Cell Line - ATCC (5),0.00656,0.074407441,0.00819,0.04910491,Best Maturity,0.04910491,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),0.03441,0.00060006,0.03565,0,Best Maturity,0,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Publication Year - 2017 (43),0.02539,0.00250025,0.02146,0.00430043,Best Maturity,0.00250025,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Coating for Replating - Gelatin (43),0.02338,0.0050005,0.02513,0.00120012,Best Maturity,0.00120012,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Journal - PNAS (3),0.02277,0.01410141,0.02509,0.01330133,Best Maturity,0.01330133,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Calcium Handling Analysis Method - Visual (104),0.0221,0.00160016,0.01536,0.00150015,Best Maturity,0.00150015,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),0.01808,0.00850085,0.01584,0.01580158,Best Maturity,0.00850085,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Day of Insulin Addition - not 11 (5),0.01722,0.02350235,0.01568,0.02820282,Best Maturity,0.02350235,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Differentiation Purity Assessment - IHC cTnT (7),0.01598,0.02690269,0.01749,0.01370137,Best Maturity,0.01370137,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Insulin Start Day - 0 (7),0.01522,0.02410241,0.007,0.089208921,Best Maturity,0.02410241,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Seeding Confluency 3D (%) - 90 to 94 (13),0.01502,0.02680268,0.0128,0.04230423,Best Maturity,0.02680268,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),hiPSC Backbone Media - DMEM (10),0.01447,0.02770277,0.0153,0.02250225,Best Maturity,0.02250225,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),hiPSC Matrix Coating - MEF feeder cells (8),0.01385,0.03720372,0.00778,0.087108711,Best Maturity,0.03720372,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),hiPSC-CM Media Supplement - Nonessential Amino Acids (8),0.01357,0.02840284,0.01352,0.0250025,Best Maturity,0.0250025,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),0.01326,0.03150315,0.00798,0.082608261,Best Maturity,0.03150315,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Cell Line Ancestry - Caucasian (41),0.01313,0.03460346,0.0107,0.072207221,Best Maturity,0.03460346,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),hiPSC-CM Media Supplement - GlutaMax (8),0.0126,0.030003,0.01025,0.051005101,Best Maturity,0.030003,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Journal - Biomater Sci (7),0.0125,0.03520352,0.0138,0.02740274,Best Maturity,0.02740274,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),3D Tissue Media - Growth Factor (12),0.01238,0.0360036,0.01257,0.040004,Best Maturity,0.0360036,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),hiPSC-CM Media Supplement - FBS (16),0.01151,0.03710371,0.01205,0.055105511,Best Maturity,0.03710371,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),0.01104,0.052805281,0.01762,0.01390139,Best Maturity,0.01390139,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),hiPSC-CM Purification Duration (days) - 3 days (13),0.01079,0.053705371,0.01514,0.01660166,Best Maturity,0.01660166,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),0.00945,0.057005701,0.01365,0.03110311,Best Maturity,0.03110311,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),0.00939,0.082308231,0.011,0.04830483,Best Maturity,0.04830483,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Journal - Biomaterials (16),0.00883,0.083408341,0.01184,0.04290429,Best Maturity,0.04290429,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Cell Line Sex - Both (118),0.00771,0.160516052,0.01057,0.03890389,Best Maturity,0.03890389,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),0.03981,0.00020002,0.02697,0.00150015,Best Maturity,0.00020002,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Disease Modelling - Genetic Disorders (18),0.03151,0.00090009,0.02902,0.00050005,Best Maturity,0.00050005,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Disease Modelling - Arrhythmic (15),0.02815,0.00120012,0.0262,0.00090009,Best Maturity,0.00090009,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Coating for Replating - Fibronectin (32),0.02518,0.00430043,0.02012,0.00720072,Best Maturity,0.00430043,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Journal - Biosens Bioelectron (4),0.0243,0.00290029,0.02164,0.00910091,Best Maturity,0.00290029,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),0.02337,0.00610061,0.02142,0.00760076,Best Maturity,0.00610061,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),0.0218,0.00830083,0.02084,0.00850085,Best Maturity,0.00830083,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Publication Year - 2016 (32),0.02179,0.00660066,0.01561,0.02550255,Best Maturity,0.00660066,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Cell Line - BJ RiPS (4),0.01949,0.02510251,0.02134,0.02250225,Best Maturity,0.02250225,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Journal - Circ Res (5),0.01916,0.01230123,0.0216,0.00870087,Best Maturity,0.00870087,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),0.01897,0.01370137,0.01522,0.02560256,Best Maturity,0.01370137,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),0.01753,0.01090109,0.01364,0.02420242,Best Maturity,0.01090109,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),0.01739,0.0260026,0.012,0.070107011,Best Maturity,0.0260026,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),0.01518,0.02090209,0.00982,0.069106911,Best Maturity,0.02090209,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Wnt Inhibitor Duration (days) - Rare (173),0.01377,0.01060106,0.01942,0,Best Maturity,0,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Insulin Start Day - 3 (5),0.01345,0.02930293,0.00639,0.068306831,Best Maturity,0.02930293,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Journal - Acta Biomater (10),0.01313,0.053605361,0.01412,0.03330333,Best Maturity,0.03330333,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Wnt Inhibitor Duration (days) - 3 days (17),0.01255,0.03140314,0.01285,0.03510351,Best Maturity,0.03140314,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),0.01193,0.04530453,0.00807,0.087508751,Best Maturity,0.04530453,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),0.01181,0.056805681,0.0118,0.03350335,Best Maturity,0.03350335,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),0.01133,0.04240424,0.0065,0.096009601,Best Maturity,0.04240424,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Calcium Handling Analysis Method - Visual (104),0.01124,0.04090409,0.00771,0.165016502,Best Maturity,0.04090409,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Cell Line - iCell (47),0.01022,0.061306131,0.01502,0.01650165,Best Maturity,0.01650165,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),2D Surface - ECM-coated (115),0.01008,0.061706171,0.01021,0.04250425,Best Maturity,0.04250425,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Coating for Replating - Laminin (5),0.00974,0.053605361,0.01394,0.02910291,Best Maturity,0.02910291,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Pharmacological Intervention - Propranolol (5),0.00902,0.060706071,0.01381,0.03050305,Best Maturity,0.03050305,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Electrophysiology Analysis Method - Patch Clamp (59),0.0081,0.147114711,0.01241,0.03430343,Best Maturity,0.03430343,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Pharmacological Intervention - Cisapride (8),0.03099,0.00230023,0.02486,0.0040004,Best Maturity,0.00230023,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Publication Year - 2021 (43),0.02405,0.00440044,0.0166,0.00840084,Best Maturity,0.00440044,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),0.02003,0.00870087,0.01703,0.01060106,Best Maturity,0.00870087,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),0.018,0.00860086,0.01122,0.02820282,Best Maturity,0.00860086,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Maturation Strategy - ECM (21),0.01724,0.00860086,0.01465,0.01010101,Best Maturity,0.00860086,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),0.01583,0.01020102,0.01445,0.01240124,Best Maturity,0.01020102,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),hiPSC-CM Media Supplement - L-glutamine (19),0.01554,0.01240124,0.01138,0.02420242,Best Maturity,0.01240124,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Sacromere or Cellular Alignment Analysis - Yes (72),0.01517,0.01760176,0.00696,0.162016202,Best Maturity,0.01760176,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),0.01423,0.01780178,0.0136,0.01850185,Best Maturity,0.01780178,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Electrophysiology Analysis Method - Optical Mapping (39),0.01361,0.0210021,0.01021,0.0470047,Best Maturity,0.0210021,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),0.01337,0.02460246,0.01364,0.0160016,Best Maturity,0.0160016,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Wnt Induction - Rare (4),0.01299,0.01640164,0.01311,0.02270227,Best Maturity,0.01640164,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Pharmacological Intervention - QT-Prolonging Drugs (36),0.01288,0.02890289,0.00818,0.090909091,Best Maturity,0.02890289,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Metabolic Component - Rare (4),0.01277,0.02480248,0.01093,0.04060406,Best Maturity,0.02480248,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),0.01208,0.02730273,0.01061,0.03320332,Best Maturity,0.02730273,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Contractile Analysis Method - Deflection (39),0.01153,0.03920392,0.01063,0.053905391,Best Maturity,0.03920392,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),hiPSC-CM Media Supplement - VEGF (4),0.01136,0.03210321,0.00871,0.060506051,Best Maturity,0.03210321,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),0.00997,0.03250325,0.01008,0.03790379,Best Maturity,0.03250325,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Number of Cell Lines - 3 (29),0.00937,0.058905891,0.01025,0.0450045,Best Maturity,0.0450045,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),0.00902,0.04880488,0.00911,0.04750475,Best Maturity,0.04750475,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Pharmacological Intervention - Metoprolol (5),0.0088,0.03850385,0.01093,0.02850285,Best Maturity,0.02850285,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Number of Cell Lines - >5 (9),0.0086,0.04370437,0.00683,0.080808081,Best Maturity,0.04370437,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Journal - Front Cell Dev Biol (3),0.00859,0.057005701,0.01259,0.04020402,Best Maturity,0.04020402,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),2D Surface - Hydrogel (17),0.0085,0.068506851,0.01659,0.0090009,Best Maturity,0.0090009,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Journal - Rare (104),0.00653,0.282628263,0.01373,0.00610061,Best Maturity,0.00610061,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),0.00541,0.158515852,0.01063,0.04510451,Best Maturity,0.04510451,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Electrophysiology Analysis Method - Patch Clamp (59),0.0703,0,0.04149,0,Best Maturity,0,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),0.0408,0,0.02614,0.00020002,Best Maturity,0,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),0.03335,0.00010001,0.03051,0.00020002,Best Maturity,0.00010001,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),0.02386,0.00120012,0.02395,0.00050005,Best Maturity,0.00050005,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),0.02105,0.00140014,0.02008,0.00160016,Best Maturity,0.00140014,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),0.01815,0.00310031,0.01564,0.00290029,Best Maturity,0.00290029,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),0.01654,0.00450045,0.01807,0.00350035,Best Maturity,0.00350035,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Electron Imaging - Transmission (62),0.0158,0.00980098,0.009,0.073907391,Best Maturity,0.00980098,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),0.01519,0.00820082,0.01465,0.00720072,Best Maturity,0.00720072,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Coating for Replating - Synthemax (3),0.01375,0.00690069,0.01882,0.00350035,Best Maturity,0.00350035,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Metabolic Analysis Method - Seahorse (35),0.01348,0.01970197,0.00826,0.078607861,Best Maturity,0.01970197,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Number of Cell Lines - 3 (29),0.01309,0.01630163,0.01062,0.02730273,Best Maturity,0.01630163,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),2D Surface - Nanotopography (6),0.01283,0.01370137,0.01625,0.00830083,Best Maturity,0.00830083,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Metabolic Component Category - Signaling Pathway Regulators (6),0.01225,0.01060106,0.01465,0.00640064,Best Maturity,0.00640064,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Seeding Confluency (%) - Rare (43),0.01016,0.04590459,0.01208,0.01310131,Best Maturity,0.01310131,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),hiPSC-CM Maturation Media - Commercial Kit (27),0.00926,0.040004,0.01095,0.02090209,Best Maturity,0.02090209,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Contractile Analysis Method - Traction Force Microscopy (9),0.00883,0.03240324,0.00868,0.03620362,Best Maturity,0.03240324,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),hiPSC-CM Media Supplement - L-glutamine (19),0.00836,0.04550455,0.00802,0.0440044,Best Maturity,0.0440044,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),0.00832,0.03510351,0.01254,0.01430143,Best Maturity,0.01430143,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Metabolic Component Category - Kinase Inhibitors (3),0.00809,0.03790379,0.0115,0.01990199,Best Maturity,0.01990199,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Seeding Confluency 2D (%) - Rare (13),0.00795,0.052605261,0.00796,0.04990499,Best Maturity,0.04990499,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Maturation Strategy - Elastomeric (33),0.00789,0.075507551,0.00918,0.04080408,Best Maturity,0.04080408,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),hiPSC-CM Maturation Media - RPMI-1640 (153),0.00699,0.209720972,0.00989,0.00920092,Best Maturity,0.00920092,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Publication Year - 2022 (20),0.00539,0.118511851,0.00811,0.04940494,Best Maturity,0.04940494,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Electrophysiology Analysis Method - Patch Clamp (59),0.06401,0,0.02956,0,Best Maturity,0,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),0.05969,0,0.05962,0,Best Maturity,0,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),0.01526,0.00320032,0.01809,0.00140014,Best Maturity,0.00140014,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Coating for Replating - Rare (6),0.01498,0.00470047,0.01396,0.00690069,Best Maturity,0.00470047,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),0.01433,0.00620062,0.01196,0.01140114,Best Maturity,0.00620062,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Number of Cell Lines - 3 (29),0.01357,0.00910091,0.00843,0.04480448,Best Maturity,0.00910091,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),0.01219,0.01240124,0.01397,0.00770077,Best Maturity,0.00770077,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Journal - Rare (104),0.01195,0.01910191,0.00897,0.03830383,Best Maturity,0.01910191,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),hiPSC-CM Media Supplement - Polyvinylalchohol (6),0.01095,0.01370137,0.01759,0.0020002,Best Maturity,0.0020002,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),2D Surface - ECM-coated (115),0.01079,0.03660366,0.01121,0.00870087,Best Maturity,0.00870087,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Wnt Induction - Rare (4),0.01064,0.0120012,0.01189,0.0110011,Best Maturity,0.0110011,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),hiPSC-CM Backbone Media - Commercial CM Kit (12),0.01057,0.02560256,0.01185,0.01540154,Best Maturity,0.01540154,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Sacromere or Cellular Alignment Analysis - Yes (72),0.01044,0.0420042,0.0078,0.091509151,Best Maturity,0.0420042,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),0.00968,0.02090209,0.00747,0.04380438,Best Maturity,0.02090209,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Cell Line - C25 (6),0.00907,0.02230223,0.00567,0.086708671,Best Maturity,0.02230223,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),hiPSC Backbone Media - Rare (19),0.00887,0.04350435,0.01077,0.0190019,Best Maturity,0.0190019,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Metabolic Component - Lactate (4),0.00864,0.02730273,0.00843,0.03960396,Best Maturity,0.02730273,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),0.00834,0.02510251,0.01225,0.00980098,Best Maturity,0.00980098,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),0.0083,0.03420342,0.00968,0.02550255,Best Maturity,0.02550255,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Immunofluorescent Imaging - Yes (268),0.00825,0.070107011,0.00942,0.03350335,Best Maturity,0.03350335,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),0.00807,0.088708871,0.00843,0.0440044,Best Maturity,0.0440044,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),0.008,0.04230423,0.00522,0.111511151,Best Maturity,0.04230423,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),hiPSC-CM Media Supplement - Lipids (9),0.00612,0.068106811,0.01007,0.01970197,Best Maturity,0.01970197,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Cell Line - BJ1 (7),0.00608,0.061006101,0.0074,0.03970397,Best Maturity,0.03970397,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),0.00563,0.086908691,0.01019,0.02380238,Best Maturity,0.02380238,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Pharmacological Intervention - Adrenaline (83),0.00555,0.231923192,0.0084,0.04780478,Best Maturity,0.04780478,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),2D Surface - Nanotopography (6),0.00529,0.085608561,0.00728,0.03870387,Best Maturity,0.03870387,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Purification Protocol - Metabolic (8),0.00506,0.090809081,0.00849,0.03310331,Best Maturity,0.03310331,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Wnt Induction - Wnt3a (3),0.03275,0.00040004,0.04232,0.00010001,Best Maturity,0.00010001,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Cell Line - 201B6 (3),0.02973,0.00050005,0.04219,0.00010001,Best Maturity,0.00010001,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),3D Stromal Cell Source - hiPSC-MuralC (3),0.02915,0.0010001,0.03153,0.00110011,Best Maturity,0.0010001,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Maturation Strategy - Other Cells (80),0.0244,0.00190019,0.01216,0.01890189,Best Maturity,0.00190019,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),hiPSC Backbone Media - Conditioned (12),0.02037,0.00580058,0.02575,0.00130013,Best Maturity,0.00130013,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Maturation Strategy - Tension (64),0.01889,0.00620062,0.00767,0.142714271,Best Maturity,0.00620062,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),0.01826,0.00660066,0.01512,0.01250125,Best Maturity,0.00660066,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),0.01762,0.01040104,0.01807,0.01120112,Best Maturity,0.01040104,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),New Media for Maturation - RPMI-1640 (30),0.01667,0.01310131,0.01603,0.00510051,Best Maturity,0.00510051,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),3D Platform - Collagen (38),0.01572,0.01680168,0.00803,0.103310331,Best Maturity,0.01680168,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),0.01405,0.03310331,0.00563,0.256425643,Best Maturity,0.03310331,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Sacromere or Cellular Alignment Analysis - Yes (72),0.01376,0.03080308,0.00977,0.065806581,Best Maturity,0.03080308,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),3D Platform - Matrigel (33),0.01363,0.02830283,0.01209,0.03790379,Best Maturity,0.02830283,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),3D Endothelial Cell Source - hiPSC-EndothelialC (16),0.01335,0.03130313,0.01394,0.01850185,Best Maturity,0.01850185,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Seeding Confluency 3D (%) - 95 to 100 (13),0.01316,0.01970197,0.01594,0.0090009,Best Maturity,0.0090009,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Journal - Cell Stem Cell (6),0.0129,0.0290029,0.01477,0.0190019,Best Maturity,0.0190019,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),0.0128,0.02570257,0.01458,0.01690169,Best Maturity,0.01690169,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Maturation Strategy - Electrical (39),0.01272,0.02810281,0.00532,0.232523252,Best Maturity,0.02810281,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),3D Stromal Cell Source - Rare (4),0.0127,0.02630263,0.0139,0.01980198,Best Maturity,0.01980198,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),0.01266,0.03770377,0.00304,0.459545955,Best Maturity,0.03770377,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Electrophysiology Analysis Method - Patch Clamp (59),0.01164,0.03150315,0.01025,0.052105211,Best Maturity,0.03150315,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),0.01156,0.03220322,0.00809,0.079807981,Best Maturity,0.03220322,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),0.01146,0.02790279,0.01327,0.01810181,Best Maturity,0.01810181,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Insulin Start Day - 5 (14),0.01123,0.03530353,0.01098,0.03650365,Best Maturity,0.03530353,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),3D Stromal Cell Source - Dermal Fibroblast (7),0.0112,0.03230323,0.00913,0.059605961,Best Maturity,0.03230323,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Journal - J Mol Cell Card (6),0.01102,0.02280228,0.0095,0.0420042,Best Maturity,0.02280228,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Metabolic Component - IGF-1 (3),0.01099,0.04040404,0.01219,0.0390039,Best Maturity,0.0390039,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Wnt Inhibitor - VEGF (3),0.01089,0.0340034,0.00973,0.0480048,Best Maturity,0.0340034,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Cell Coculture - Endothelial Cell (35),0.01087,0.050305031,0.01131,0.03510351,Best Maturity,0.03510351,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),0.01076,0.03510351,0.00858,0.061806181,Best Maturity,0.03510351,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Metabolic Component - Dexamethasone (7),0.01029,0.04160416,0.00755,0.084308431,Best Maturity,0.04160416,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Cell Line - BJ1 (7),0.00997,0.04850485,0.01571,0.01030103,Best Maturity,0.01030103,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),0.00952,0.04170417,0.00735,0.078607861,Best Maturity,0.04170417,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),0.00769,0.078207821,0.00984,0.04350435,Best Maturity,0.04350435,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Wnt Inhibitor - Rare (3),0.00286,0.062706271,0.01063,0.03290329,Best Maturity,0.03290329,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),0.08254,0,0.09271,0,Best Maturity,0,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),0.04243,0.00110011,0.05259,0.00090009,Best Maturity,0.00090009,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),0.03962,0.00020002,0.04629,0.00010001,Best Maturity,0.00010001,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Contractile Analysis Method - Rare (7),0.03785,0.00110011,0.02793,0.00710071,Best Maturity,0.00110011,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Journal - Stem Cell Reports (23),0.02746,0.00510051,0.0176,0.0240024,Best Maturity,0.00510051,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),0.02081,0.00880088,0.02091,0.00860086,Best Maturity,0.00860086,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Disease Modelling - Arrhythmic (15),0.02077,0.01320132,0.01651,0.02120212,Best Maturity,0.01320132,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),0.01871,0.01890189,0.01752,0.0260026,Best Maturity,0.01890189,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),0.01776,0.0180018,0.01636,0.02640264,Best Maturity,0.0180018,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Publication Year - 2019 (57),0.01723,0.02590259,0.00707,0.195419542,Best Maturity,0.02590259,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),0.01418,0.04040404,0.01455,0.03490349,Best Maturity,0.03490349,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Disease Modelling - Genetic Disorders (18),0.01392,0.03790379,0.00864,0.106510651,Best Maturity,0.03790379,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),0.01387,0.03280328,0.01758,0.0160016,Best Maturity,0.0160016,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),3D Platform - Extracellular Scaffold (18),0.01308,0.04940494,0.01401,0.03850385,Best Maturity,0.03850385,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),hiPSC-CM Purification Duration (days) - 4 days (29),0.01286,0.03860386,0.01437,0.02570257,Best Maturity,0.02570257,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),2D Surface - Micropatterned (27),0.01169,0.052305231,0.01305,0.04470447,Best Maturity,0.04470447,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Maturation Strategy - Tension (64),0.00915,0.084808481,0.01256,0.04120412,Best Maturity,0.04120412,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Seeding Confluency 2D (%) - 70 to 79 (6),0.00775,0.071307131,0.01426,0.04690469,Best Maturity,0.04690469,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Metabolic Component - B27 (3),0.00142,0.03750375,0.00348,0.03730373,Best Maturity,0.03730373,TRUE,FALSE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),0.05602,0,0.06421,0,Best Maturity,0,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),0.05159,0.00020002,0.05495,0.00040004,Best Maturity,0.00020002,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),0.05138,0.00010001,0.0597,0.00010001,Best Maturity,0.00010001,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Journal - Stem Cell Reports (23),0.03471,0.00120012,0.02342,0.00630063,Best Maturity,0.00120012,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),0.02941,0.00250025,0.03007,0.00290029,Best Maturity,0.00250025,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Number of Cell Lines - 3 (29),0.02046,0.01940194,0.01695,0.02210221,Best Maturity,0.01940194,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),hiPSC-CM Media Supplement - Rare (5),0.01613,0.04270427,0.01516,0.04080408,Best Maturity,0.04080408,TRUE,FALSE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Calcium Handling Analysis Method - Visual (104),0.01612,0.01240124,0.00598,0.234123412,Best Maturity,0.01240124,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Calcium Handling Analysis Method - Rare (4),0.01569,0.01790179,0.0147,0.02250225,Best Maturity,0.01790179,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),0.01545,0.02390239,0.00969,0.081608161,Best Maturity,0.02390239,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),hiPSC-CM Purification Duration (days) - 4 days (29),0.01494,0.03070307,0.01763,0.01120112,Best Maturity,0.01120112,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Number of Cell Lines - 1 (225),0.01424,0.02060206,0.00571,0.325132513,Best Maturity,0.02060206,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),0.01399,0.03860386,0.01478,0.03550355,Best Maturity,0.03550355,TRUE,FALSE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),0.01393,0.04050405,0.01017,0.059705971,Best Maturity,0.04050405,TRUE,FALSE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Maturation Strategy - Elastomeric (33),0.01254,0.064006401,0.01637,0.02770277,Best Maturity,0.02770277,TRUE,FALSE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Pharmacological Intervention - T3 (3),0.01231,0.02870287,0.01153,0.03030303,Best Maturity,0.02870287,TRUE,FALSE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),0.01054,0.0370037,0.00734,0.078107811,Best Maturity,0.0370037,TRUE,FALSE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Maturation Strategy - ECM (21),0.01035,0.079907991,0.01719,0.02050205,Best Maturity,0.02050205,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Publication Year - 2019 (57),0.00936,0.105110511,0.01313,0.04620462,Best Maturity,0.04620462,TRUE,FALSE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Publication Year - 2022 (20),0.00846,0.132713271,0.01864,0.01620162,Best Maturity,0.01620162,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Metabolic Component Category - Kinase Inhibitors (3),0.00179,0.03810381,0.00303,0.03870387,Best Maturity,0.03810381,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),0.06784,0,0.06789,0,Best Maturity,0,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),0.06271,0,0.05478,0,Best Maturity,0,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Journal - Stem Cell Reports (23),0.03143,0.00210021,0.02417,0.00470047,Best Maturity,0.00210021,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),0.02728,0.00340034,0.0264,0.0050005,Best Maturity,0.00340034,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Journal - Tissue Eng Part A (4),0.02367,0.01650165,0.02037,0.02550255,Best Maturity,0.01650165,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),0.02234,0.02010201,0.02481,0.01520152,Best Maturity,0.01520152,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Insulin Withdrawal Duration (days) Quantiles - Q2 (>2 and ≤4) (25),0.0188,0.01970197,0.01002,0.092209221,Best Maturity,0.01970197,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Insulin Withdrawal Duration (days) - 4 days (18),0.01872,0.01390139,0.01485,0.03920392,Best Maturity,0.01390139,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),3D Stromal Cell Source - Cardiac Fibroblast (32),0.01741,0.02050205,0.0069,0.152715272,Best Maturity,0.02050205,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),0.01557,0.03540354,0.00379,0.112011201,Best Maturity,0.03540354,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Journal - Nat Biomed Eng (5),0.01451,0.0440044,0.01049,0.051405141,Best Maturity,0.0440044,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),0.01427,0.02680268,0.01172,0.051905191,Best Maturity,0.02680268,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),0.01403,0.04250425,0.00919,0.094309431,Best Maturity,0.04250425,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),3D Stromal Cell Source - Human Fibroblast (38),0.0131,0.03610361,0.01269,0.03750375,Best Maturity,0.03610361,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),hiPSC-CM Purification Duration (days) - 3 days (13),0.01286,0.03970397,0.01404,0.03460346,Best Maturity,0.03460346,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),3D Stromal Cell Source - Dermal Fibroblast (7),0.01262,0.056305631,0.01701,0.02430243,Best Maturity,0.02430243,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Calcium Handling Analysis Method - Visual (104),0.0122,0.04040404,0.00518,0.329532953,Best Maturity,0.04040404,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),0.01131,0.03670367,0.00371,0.113611361,Best Maturity,0.03670367,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Publication Year - 2019 (57),0.01012,0.086208621,0.01285,0.04930493,Best Maturity,0.04930493,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),0.00929,0.085108511,0.01451,0.02950295,Best Maturity,0.02950295,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),3D Tissue Media - RPMI-1640 (72),0.00908,0.121212121,0.01427,0.03750375,Best Maturity,0.03750375,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Maturation Strategy - Elastomeric (33),0.00864,0.135913591,0.01988,0.01610161,Best Maturity,0.01610161,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),3D Stromal Cell Source - hiPSC-CardiacF (8),0.00584,0.091109111,0.01357,0.03910391,Best Maturity,0.03910391,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Journal - ACS Biomater Sci Eng (3),0.00113,0.03910391,0.00234,0.03890389,Best Maturity,0.03890389,TRUE,FALSE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Electron Imaging - Transmission (62),0.03962,0,0.02826,0,Best Maturity,0,TRUE,TRUE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),0.01812,0.00210021,0.01489,0.0030003,Best Maturity,0.00210021,TRUE,TRUE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),0.01693,0.00230023,0.00773,0.04580458,Best Maturity,0.00230023,TRUE,TRUE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Disease Modelling - Hypertrophic Cardiomyopathy (6),0.0133,0.0030003,0.01324,0.00390039,Best Maturity,0.0030003,TRUE,TRUE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),0.01317,0.00530053,0.01428,0.00360036,Best Maturity,0.00360036,TRUE,TRUE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Pharmacological Intervention - Caffeine (4),0.01255,0.00660066,0.01214,0.01110111,Best Maturity,0.00660066,TRUE,TRUE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Gene Analysis Method - RNA (169),0.0118,0.01950195,0.00601,0.230723072,Best Maturity,0.01950195,TRUE,TRUE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Metabolic Component - Dexamethasone (7),0.0117,0.00950095,0.01013,0.0180018,Best Maturity,0.00950095,TRUE,TRUE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Number of Cell Lines - 1 (225),0.01161,0.02420242,0.00791,0.052405241,Best Maturity,0.02420242,TRUE,TRUE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),0.01006,0.04080408,0.00774,0.059905991,Best Maturity,0.04080408,TRUE,FALSE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),0.00957,0.01090109,0.01299,0.00250025,Best Maturity,0.00250025,TRUE,TRUE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),0.00942,0.01820182,0.00849,0.02270227,Best Maturity,0.01820182,TRUE,TRUE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Number of Cell Lines - 2 (50),0.00873,0.03460346,0.00817,0.03180318,Best Maturity,0.03180318,TRUE,FALSE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Cell Line Sex - Female (40),0.00866,0.04060406,0.00756,0.052305231,Best Maturity,0.04060406,TRUE,FALSE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Seeding Confluency (%) - 95 to 100 (23),0.00795,0.03550355,0.00999,0.01130113,Best Maturity,0.01130113,TRUE,TRUE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),0.00762,0.03030303,0.00823,0.02430243,Best Maturity,0.02430243,TRUE,TRUE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),hiPSC-CM Purification Duration (days) Quantiles - Q1 (>4 and ≤20) (31),0.00761,0.056605661,0.00894,0.02130213,Best Maturity,0.02130213,TRUE,TRUE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Wnt Inhibitor Duration (days) - 4 days (19),0.0076,0.04010401,0.00437,0.146514651,Best Maturity,0.04010401,TRUE,FALSE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),0.00744,0.030003,0.00824,0.02830283,Best Maturity,0.02830283,TRUE,FALSE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),hiPSC Matrix Coating - EBs (18),0.00734,0.0450045,0.00256,0.316031603,Best Maturity,0.0450045,TRUE,FALSE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),3D Stromal Cell Source - hiPSC-CardiacF (8),0.00727,0.0330033,0.00665,0.04350435,Best Maturity,0.0330033,TRUE,FALSE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Pharmacological Intervention - Doxorubicin (17),0.00716,0.04740474,0.00515,0.093409341,Best Maturity,0.04740474,TRUE,FALSE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),0.00695,0.02960296,0.00787,0.02270227,Best Maturity,0.02270227,TRUE,TRUE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Calcium Handling Analysis Method - Visual (104),0.00671,0.230223022,0.0084,0.03250325,Best Maturity,0.03250325,TRUE,FALSE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Cell Line - 201B7 (9),0.00661,0.04020402,0.00769,0.02740274,Best Maturity,0.02740274,TRUE,FALSE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Seeding Confluency 2D (%) - 70 to 79 (6),0.00615,0.04230423,0.00671,0.04190419,Best Maturity,0.04190419,TRUE,FALSE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Publication Year - 2016 (32),0.00598,0.085808581,0.00922,0.01850185,Best Maturity,0.01850185,TRUE,TRUE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Pharmacological Intervention - Verapamil (27),0.00598,0.081808181,0.01103,0.00790079,Best Maturity,0.00790079,TRUE,TRUE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Cell Line - ATCC (5),0.00583,0.04210421,0.00751,0.02790279,Best Maturity,0.02790279,TRUE,FALSE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Wnt Inhibitor Duration (days) - 3 days (17),0.005,0.099709971,0.00844,0.02660266,Best Maturity,0.02660266,TRUE,FALSE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Metabolic Analysis Method - Seahorse (35),0.00438,0.190819082,0.00867,0.02560256,Best Maturity,0.02560256,TRUE,FALSE
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),0.00415,0.107810781,0.00632,0.04740474,Best Maturity,0.04740474,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D Platform - Collagen (38),0.02041,0.00050005,0.02004,0.00010001,Best Maturity,0.00010001,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Contractile Analysis Method - Deflection (39),0.01871,0.00080008,0.01432,0.00130013,Best Maturity,0.00080008,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),0.01844,0.00050005,0.01765,0.00040004,Best Maturity,0.00040004,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Cell Coculture - Cardiomyocyte (157),0.01835,0.00070007,0.00568,0.320632063,Best Maturity,0.00070007,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),0.01834,0.00020002,0.02111,0,Best Maturity,0,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Deduced Culture Strategy - 3D Only (157),0.01817,0.00180018,0.00528,0.476547655,Best Maturity,0.00180018,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D Stromal Cell Source - Human Fibroblast (38),0.01815,0.00070007,0.01612,0.00040004,Best Maturity,0.00040004,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),0.01669,0.00150015,0.00875,0.01570157,Best Maturity,0.00150015,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Cell Coculture - Stromal Cell (78),0.01476,0.0060006,0.01117,0.00410041,Best Maturity,0.00410041,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Deduced Culture Strategy - 2D Only (183),0.01383,0.00380038,0.00679,0.117111711,Best Maturity,0.00380038,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Cell Line - BJ1 (7),0.01331,0.00290029,0.01656,0.00140014,Best Maturity,0.00140014,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D Platform - Fibrin (50),0.01322,0.00350035,0.01185,0.00260026,Best Maturity,0.00260026,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Insulin Start Day - 1 (19),0.01316,0.00330033,0.01272,0.00240024,Best Maturity,0.00240024,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Journal - Biomaterials (16),0.01307,0.0020002,0.01133,0.00220022,Best Maturity,0.0020002,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),2D Surface - ECM-coated (115),0.01295,0.0070007,0.00396,0.734173417,Best Maturity,0.0070007,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Maturation Strategy - Other Cells (80),0.0125,0.00720072,0.00778,0.03590359,Best Maturity,0.00720072,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Seeding Confluency 3D (%) - 90 to 94 (13),0.01247,0.00440044,0.01397,0.00210021,Best Maturity,0.00210021,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D Stromal Cell Source - Cardiac Fibroblast (32),0.01223,0.00790079,0.01418,0.00110011,Best Maturity,0.00110011,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29),0.01077,0.0110011,0.00924,0.01160116,Best Maturity,0.0110011,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Pharmacological Intervention - Carbenoxolone (4),0.00997,0.00670067,0.01059,0.01110111,Best Maturity,0.00670067,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Seeding Confluency 3D (%) - 85 to 89 (12),0.00859,0.01810181,0.00773,0.02450245,Best Maturity,0.01810181,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Pharmacological Intervention - Cisapride (8),0.00768,0.02030203,0.00773,0.02270227,Best Maturity,0.02030203,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D Platform - Polyethylene Glycol (8),0.00736,0.02160216,0.01015,0.00970097,Best Maturity,0.00970097,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D Platform - Extracellular Scaffold (18),0.00708,0.03920392,0.00621,0.053005301,Best Maturity,0.03920392,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Maturation Strategy - ECM (21),0.00705,0.03780378,0.00489,0.108910891,Best Maturity,0.03780378,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Seeding Confluency (%) - 90 to 94 (26),0.00701,0.04380438,0.00511,0.110011001,Best Maturity,0.04380438,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),0.00695,0.030003,0.00854,0.02210221,Best Maturity,0.02210221,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Maturation Strategy - Electrical (39),0.00654,0.064206421,0.00845,0.01740174,Best Maturity,0.01740174,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Maturation Strategy - Mechanical (36),0.00625,0.069906991,0.00743,0.03690369,Best Maturity,0.03690369,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Maturation Strategy - Tension (64),0.00623,0.105610561,0.00909,0.01150115,Best Maturity,0.01150115,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D Tissue Media - High-glucose DMEM (9),0.00602,0.03480348,0.00903,0.01050105,Best Maturity,0.01050105,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),0.00601,0.04560456,0.00581,0.056005601,Best Maturity,0.04560456,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Insulin Start Day - After 11 (7),0.00506,0.066506651,0.00799,0.02320232,Best Maturity,0.02320232,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D Tissue Media - Iscove (5),0.00452,0.061506151,0.00683,0.03990399,Best Maturity,0.03990399,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Disease Modelling - Fibrotic (4),0.00422,0.071307131,0.00893,0.02450245,Best Maturity,0.02450245,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Publication Year - 2020 (51),0.00417,0.334433443,0.00721,0.04720472,Best Maturity,0.04720472,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D Tissue Media - Rare (13),0.00385,0.120412041,0.0074,0.02910291,Best Maturity,0.02910291,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D Platform - Nanotechnology (3),0.00351,0.087308731,0.0055,0.04070407,Best Maturity,0.04070407,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),0.00349,0.113611361,0.00714,0.02330233,Best Maturity,0.02330233,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),0.00318,0.118111811,0.00583,0.04170417,Best Maturity,0.04170417,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Deduced Culture Strategy - 3D Only (157),0.03515,0,0.013,0.00010001,Best Maturity,0,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),0.02878,0,0.02109,0,Best Maturity,0,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Contractile Analysis Method - Force Transducer (27),0.01833,0.00060006,0.01674,0.00050005,Best Maturity,0.00050005,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Cell Coculture - Cardiomyocyte (157),0.01809,0.0010001,0.00731,0.055005501,Best Maturity,0.0010001,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),3D Endothelial Cell Source - hiPSC-EndothelialC (16),0.01679,0.0010001,0.01436,0.00260026,Best Maturity,0.0010001,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),0.01558,0.00090009,0.01081,0.00250025,Best Maturity,0.00090009,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Deduced Culture Strategy - 2D Only (183),0.01531,0.00170017,0.00717,0.068406841,Best Maturity,0.00170017,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),0.01337,0.00660066,0.00651,0.124512451,Best Maturity,0.00660066,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),3D Stromal Cell Source - hiPSC-MuralC (3),0.01324,0.00320032,0.01831,0.00130013,Best Maturity,0.00130013,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),3D Platform - Fibrin (50),0.01274,0.00520052,0.01184,0.00340034,Best Maturity,0.00340034,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Cell Line Ancestry - Caucasian (41),0.0118,0.00780078,0.01387,0.00120012,Best Maturity,0.00120012,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17),0.00905,0.01650165,0.0091,0.01470147,Best Maturity,0.01470147,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),0.00889,0.00820082,0.00787,0.01520152,Best Maturity,0.00820082,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),3D Tissue Media - MEM-α (60),0.00884,0.02870287,0.01005,0.00490049,Best Maturity,0.00490049,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),3D Tissue Media - DMEM (53),0.00879,0.02940294,0.00571,0.117111711,Best Maturity,0.02940294,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),0.00864,0.01520152,0.00788,0.01680168,Best Maturity,0.01520152,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),0.00848,0.01560156,0.01303,0.00380038,Best Maturity,0.00380038,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),0.00833,0.02730273,0.00819,0.02060206,Best Maturity,0.02060206,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),3D Platform - Extracellular Scaffold (18),0.00804,0.02270227,0.00911,0.01270127,Best Maturity,0.01270127,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Cell Line Sex - Female (40),0.00802,0.03490349,0.01273,0.00170017,Best Maturity,0.00170017,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Maturation Strategy - Tension (64),0.00796,0.04020402,0.00517,0.176317632,Best Maturity,0.04020402,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Publication Year - 2021 (43),0.00795,0.03690369,0.00711,0.0410041,Best Maturity,0.03690369,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),0.00787,0.02590259,0.00409,0.179817982,Best Maturity,0.02590259,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Gene Analysis Method - RNA (169),0.00753,0.114311431,0.00762,0.03850385,Best Maturity,0.03850385,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Maturation Strategy - ECM (21),0.00728,0.03270327,0.00721,0.03070307,Best Maturity,0.03070307,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),0.00666,0.03550355,0.00529,0.062506251,Best Maturity,0.03550355,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Seeding Confluency 3D (%) - 70 to 79 (3),0.00649,0.01980198,0.00634,0.03220322,Best Maturity,0.01980198,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),3D Tissue Media - Growth Factor (12),0.00632,0.03660366,0.00494,0.068506851,Best Maturity,0.03660366,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Wnt Induction - Wnt3a (3),0.00631,0.02230223,0.01201,0.01090109,Best Maturity,0.01090109,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),0.00627,0.04290429,0.00543,0.062906291,Best Maturity,0.04290429,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Cell Line - 201B6 (3),0.00617,0.01980198,0.0068,0.02370237,Best Maturity,0.01980198,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Maturation Strategy - Electrical (39),0.00573,0.090709071,0.00698,0.03670367,Best Maturity,0.03670367,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),hiPSC Backbone Media - Conditioned (12),0.00467,0.075307531,0.00888,0.01460146,Best Maturity,0.01460146,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Cell Line - C25 (6),0.00462,0.067006701,0.00791,0.0220022,Best Maturity,0.0220022,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),hiPSC-CM Purification Duration (days) - 6 days (10),0.00435,0.068406841,0.00659,0.02950295,Best Maturity,0.02950295,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),hiPSC Matrix Coating - Geltrex (33),0.00418,0.186618662,0.00709,0.03870387,Best Maturity,0.03870387,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Journal - J Tissue Eng (4),0.00347,0.094909491,0.00554,0.04920492,Best Maturity,0.04920492,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Wnt Induction Duration (days) - 3 days (38),0.00337,0.371037104,0.00721,0.04240424,Best Maturity,0.04240424,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Journal - Circulation (11),0.00295,0.159615962,0.00603,0.04050405,Best Maturity,0.04050405,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Pharmacological Intervention - Phenylephrine (3),0.00285,0.155415542,0.00597,0.04390439,Best Maturity,0.04390439,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),3D Platform - 3D printed (9),0.0026,0.170517052,0.00574,0.04490449,Best Maturity,0.04490449,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Metabolic Analysis Method - Genetic (3),0.0163,0.0010001,0.01567,0.00250025,Least Maturity,0.0010001,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Sacromere or Cellular Alignment Analysis - Yes (72),0.01605,0.00560056,0.01283,0.00270027,Least Maturity,0.00270027,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Electron Imaging - Transmission (62),0.01455,0.00860086,0.00975,0.0250025,Least Maturity,0.00860086,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),2D Surface - ECM-coated (115),0.01423,0.0080008,0.00897,0.02770277,Least Maturity,0.0080008,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),0.01384,0.00620062,0.01137,0.01180118,Least Maturity,0.00620062,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),0.01376,0.00990099,0.00966,0.02130213,Least Maturity,0.00990099,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Calcium Handling Analysis Method - Visual (104),0.01325,0.01180118,0.01208,0.00220022,Least Maturity,0.00220022,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Journal - J Mol Cell Cardiol (4),0.01143,0.01070107,0.00909,0.02920292,Least Maturity,0.01070107,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Coating for Replating - Matrigel (65),0.01136,0.02130213,0.00651,0.143514351,Least Maturity,0.02130213,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Publication Year - 2022 (20),0.01076,0.02550255,0.01065,0.01830183,Least Maturity,0.01830183,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Publication Year - 2018 (45),0.01074,0.02220222,0.01315,0.00440044,Least Maturity,0.00440044,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),2D Surface - Electrospun (13),0.01035,0.01790179,0.00848,0.03280328,Least Maturity,0.01790179,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Seeding Confluency (%) - 70 to 79 (11),0.01008,0.02250225,0.00816,0.03780378,Least Maturity,0.02250225,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),hiPSC-CM Backbone Media - RPMI-1640 (167),0.00992,0.04580458,0.00305,0.902690269,Least Maturity,0.04580458,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),hiPSC-CM Maturation Media - RPMI-1640 (153),0.00986,0.055805581,0.0119,0.00150015,Least Maturity,0.00150015,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Journal - Rare (104),0.00962,0.04870487,0.00669,0.148414841,Least Maturity,0.04870487,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Cell Line - Cor.4U (16),0.00914,0.02890289,0.00897,0.0250025,Least Maturity,0.0250025,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),0.0091,0.02730273,0.00753,0.03950395,Least Maturity,0.02730273,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),0.00882,0.03060306,0.01289,0.00780078,Least Maturity,0.00780078,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Pharmacological Intervention - Verapamil (27),0.0085,0.04640464,0.00994,0.02240224,Least Maturity,0.02240224,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Journal - Stem Cell Res (8),0.00835,0.03750375,0.00764,0.04320432,Least Maturity,0.03750375,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Pharmacological Intervention - Phenylephrine (3),0.00835,0.03660366,0.00674,0.084608461,Least Maturity,0.03660366,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Publication Year - 2024 (7),0.0083,0.03410341,0.00968,0.02350235,Least Maturity,0.02350235,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Calcium Handling Analysis Method - Rare (4),0.00794,0.01830183,0.01137,0.00950095,Least Maturity,0.00950095,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),0.00789,0.04220422,0.0069,0.054005401,Least Maturity,0.04220422,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Cell Line - WTC11 (30),0.00713,0.071407141,0.00971,0.02240224,Least Maturity,0.02240224,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Seeding Confluency 2D (%) - 80 to 84 (5),0.00698,0.04150415,0.00693,0.055205521,Least Maturity,0.04150415,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),New Media for Maturation - F12 (7),0.00683,0.03620362,0.0044,0.113311331,Least Maturity,0.03620362,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),0.0065,0.051105111,0.0107,0.01580158,Least Maturity,0.01580158,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Purification Protocol - Metabolic (8),0.00644,0.04240424,0.00615,0.051705171,Least Maturity,0.04240424,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Number of Cell Lines - 1 (225),0.00641,0.202620262,0.00891,0.03190319,Least Maturity,0.03190319,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Cell Line - Cellapy (4),0.00625,0.04740474,0.00833,0.02660266,Least Maturity,0.02660266,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Metabolic Analysis Method - Flux Rates (13),0.00521,0.085408541,0.01106,0.00920092,Least Maturity,0.00920092,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),hiPSC-CM Maturation Media - Cor.4U Complete (6),0.00509,0.095909591,0.00796,0.03640364,Least Maturity,0.03640364,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Pharmacological Intervention - Carbamylcholine (6),0.00401,0.122412241,0.00681,0.04430443,Least Maturity,0.04430443,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Cell Line Sex - Male (64),0.00346,0.484948495,0.00837,0.04020402,Least Maturity,0.04020402,TRUE,FALSE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Publication Year - 2014 (3),0.01863,0.00120012,0.02154,0.00140014,Least Maturity,0.00120012,TRUE,TRUE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Cell Line - IMR90 (19),0.01444,0.00540054,0.01002,0.01990199,Least Maturity,0.00540054,TRUE,TRUE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Seeding Confluency (%) - 90 to 94 (26),0.01356,0.01320132,0.01617,0.00310031,Least Maturity,0.00310031,TRUE,TRUE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),0.01293,0.00670067,0.00839,0.03040304,Least Maturity,0.00670067,TRUE,TRUE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),0.01204,0.01170117,0.01124,0.01570157,Least Maturity,0.01170117,TRUE,TRUE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Sacromere or Cellular Alignment Analysis - Yes (72),0.01177,0.0260026,0.00834,0.056805681,Least Maturity,0.0260026,TRUE,FALSE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),0.01141,0.01550155,0.01175,0.01340134,Least Maturity,0.01340134,TRUE,TRUE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),0.01111,0.01930193,0.0139,0.00750075,Least Maturity,0.00750075,TRUE,TRUE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),hiPSC Backbone Media - Conditioned (12),0.01085,0.01890189,0.01527,0.00330033,Least Maturity,0.00330033,TRUE,TRUE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),0.01071,0.01430143,0.00923,0.02430243,Least Maturity,0.01430143,TRUE,TRUE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),0.01063,0.01520152,0.01009,0.01790179,Least Maturity,0.01520152,TRUE,TRUE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Contractile Analysis Method - Traction Force Microscopy (9),0.01036,0.01460146,0.01121,0.01120112,Least Maturity,0.01120112,TRUE,TRUE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Electrophysiology Analysis Method - Patch Clamp (59),0.01013,0.04260426,0.0071,0.093009301,Least Maturity,0.04260426,TRUE,FALSE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),0.01001,0.02060206,0.00864,0.0290029,Least Maturity,0.02060206,TRUE,TRUE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Journal - J Biomed Mater Res A (3),0.00925,0.01450145,0.00744,0.054405441,Least Maturity,0.01450145,TRUE,TRUE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Wnt Inhibitor - Wnt-C59 (30),0.00901,0.03390339,0.00919,0.0270027,Least Maturity,0.0270027,TRUE,FALSE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),New Media for Maturation - F12 (7),0.00881,0.02290229,0.00931,0.02280228,Least Maturity,0.02280228,TRUE,TRUE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Metabolic Analysis Method - Genetic (3),0.00847,0.04020402,0.00926,0.0460046,Least Maturity,0.04020402,TRUE,FALSE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Number of Cell Lines - 4 (11),0.00838,0.02860286,0.01321,0.00550055,Least Maturity,0.00550055,TRUE,TRUE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Disease Modelling - Dilated Cardiomyopathy (6),0.00825,0.02820282,0.00715,0.050205021,Least Maturity,0.02820282,TRUE,FALSE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Gene Analysis Method - RNA (169),0.00801,0.120412041,0.00961,0.00770077,Least Maturity,0.00770077,TRUE,TRUE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),0.00797,0.0360036,0.00735,0.04240424,Least Maturity,0.0360036,TRUE,FALSE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Cell Line - Gibco episomal (10),0.00796,0.03840384,0.00759,0.04370437,Least Maturity,0.03840384,TRUE,FALSE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Seeding Confluency 2D (%) - 90 to 94 (12),0.00771,0.04770477,0.00467,0.122012201,Least Maturity,0.04770477,TRUE,FALSE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),0.00755,0.03480348,0.00887,0.02640264,Least Maturity,0.02640264,TRUE,FALSE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Journal - J Mol Cell Card (6),0.0075,0.02980298,0.0092,0.02340234,Least Maturity,0.02340234,TRUE,TRUE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Pharmacological Intervention - Blebbistatin (5),0.00559,0.072407241,0.00733,0.04950495,Least Maturity,0.04950495,TRUE,FALSE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),2D Surface - Micropatterned (27),0.00514,0.138313831,0.00786,0.04990499,Least Maturity,0.04990499,TRUE,FALSE
Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Pharmacological Intervention - T3 (3),0.00512,0.073307331,0.00887,0.02240224,Least Maturity,0.02240224,TRUE,TRUE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Contractile Analysis Method - Traction Force Microscopy (9),0.03702,0,0.02735,0.00010001,Least Maturity,0,TRUE,TRUE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),New Media for Maturation - RPMI-1640 (30),0.01709,0.00590059,0.01511,0.00560056,Least Maturity,0.00560056,TRUE,TRUE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),2D Surface - Micropatterned (27),0.01703,0.00740074,0.01523,0.00530053,Least Maturity,0.00530053,TRUE,TRUE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Journal - Stem Cell Res Ther (3),0.01496,0.00590059,0.01762,0.00430043,Least Maturity,0.00430043,TRUE,TRUE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Metabolic Analysis Method - Mitochondrial (4),0.01421,0.00640064,0.01281,0.01720172,Least Maturity,0.00640064,TRUE,TRUE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Maturation Strategy - Cell Alignment (59),0.01413,0.01230123,0.01314,0.00780078,Least Maturity,0.00780078,TRUE,TRUE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Cell Line Ancestry - Asian (28),0.01364,0.01380138,0.00797,0.059705971,Least Maturity,0.01380138,TRUE,TRUE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),hiPSC Matrix Coating - Matrigel (163),0.01301,0.01890189,0.00491,0.545154515,Least Maturity,0.01890189,TRUE,TRUE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Journal - Stem Cell Reports (23),0.01282,0.01910191,0.00818,0.058305831,Least Maturity,0.01910191,TRUE,TRUE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Contractile Analysis Method - Deflection (39),0.01172,0.02420242,0.00646,0.115411541,Least Maturity,0.02420242,TRUE,TRUE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21),0.01144,0.02040204,0.01155,0.01580158,Least Maturity,0.01580158,TRUE,TRUE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),0.01119,0.02790279,0.00782,0.059005901,Least Maturity,0.02790279,TRUE,FALSE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),0.01107,0.02040204,0.01291,0.01230123,Least Maturity,0.01230123,TRUE,TRUE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),0.01017,0.020002,0.01414,0.00720072,Least Maturity,0.00720072,TRUE,TRUE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Insulin Start Day - 6 (20),0.01012,0.03660366,0.00687,0.089308931,Least Maturity,0.03660366,TRUE,FALSE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Journal - Stem Cell Res (8),0.01007,0.03410341,0.0077,0.068306831,Least Maturity,0.03410341,TRUE,FALSE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Coating for Replating - Vitronectin (3),0.01002,0.03050305,0.0093,0.050105011,Least Maturity,0.03050305,TRUE,FALSE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Gene Analysis Method - Rare (5),0.00987,0.02050205,0.00911,0.03150315,Least Maturity,0.02050205,TRUE,TRUE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Day of Insulin Addition - not 22 (12),0.00965,0.03460346,0.00602,0.096909691,Least Maturity,0.03460346,TRUE,FALSE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),0.00943,0.03970397,0.00688,0.080308031,Least Maturity,0.03970397,TRUE,FALSE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),hiPSC-CM Media Supplement - B27 (180),0.00908,0.062606261,0.01113,0.00270027,Least Maturity,0.00270027,TRUE,TRUE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),0.00908,0.04860486,0.0036,0.310931093,Least Maturity,0.04860486,TRUE,FALSE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Seeding Confluency 2D (%) - 90 to 94 (12),0.0089,0.04490449,0.00614,0.093909391,Least Maturity,0.04490449,TRUE,FALSE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),0.00876,0.03990399,0.00994,0.02880288,Least Maturity,0.02880288,TRUE,FALSE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Disease Modelling - Specialised (3),0.0082,0.03510351,0.01477,0.00460046,Least Maturity,0.00460046,TRUE,TRUE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Pharmacological Intervention - Positive Inotropes (9),0.00809,0.03720372,0.01462,0.00450045,Least Maturity,0.00450045,TRUE,TRUE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),hiPSC-CM Backbone Media - Rare (10),0.00796,0.04720472,0.01257,0.01610161,Least Maturity,0.01610161,TRUE,TRUE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Metabolic Component - Palmitic Acid (11),0.00794,0.04280428,0.00644,0.074307431,Least Maturity,0.04280428,TRUE,FALSE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),hiPSC-CM Purification Duration (days) - 6 days (10),0.0076,0.04540454,0.00755,0.054105411,Least Maturity,0.04540454,TRUE,FALSE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Wnt Inhibitor - Wnt-C59 (30),0.00618,0.119211921,0.00935,0.04320432,Least Maturity,0.04320432,TRUE,FALSE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),0.00563,0.082008201,0.00884,0.04380438,Least Maturity,0.04380438,TRUE,FALSE
Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Journal - PLoS One (9),0.00472,0.124512451,0.00965,0.02540254,Least Maturity,0.02540254,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29),0.02388,0.00210021,0.0172,0.00260026,Least Maturity,0.00210021,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),hiPSC Matrix Coating - Matrigel (163),0.01681,0.00780078,0.00629,0.281728173,Least Maturity,0.00780078,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),hiPSC Matrix Coating - Vitronectin (10),0.01595,0.0030003,0.01841,0.00140014,Least Maturity,0.00140014,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Journal - PLoS One (9),0.01592,0.00440044,0.01598,0.00430043,Least Maturity,0.00430043,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Journal - Biomaterials (16),0.01378,0.01330133,0.01254,0.01480148,Least Maturity,0.01330133,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Purification Protocol - Glucose and Lactate (85),0.01369,0.01350135,0.00407,0.498749875,Least Maturity,0.01350135,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),hiPSC-CM Purification Duration (days) - 4 days (29),0.01366,0.01610161,0.00991,0.03360336,Least Maturity,0.01610161,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),0.01361,0.01160116,0.01603,0.00370037,Least Maturity,0.00370037,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),0.01311,0.01720172,0.00906,0.04110411,Least Maturity,0.01720172,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Contractile Analysis Method - Traction Force Microscopy (9),0.01274,0.01380138,0.00904,0.03480348,Least Maturity,0.01380138,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Journal - Stem Cells Int (3),0.01228,0.00810081,0.01333,0.01010101,Least Maturity,0.00810081,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Seeding Confluency 3D (%) - 85 to 89 (12),0.01202,0.0170017,0.00918,0.03320332,Least Maturity,0.0170017,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),0.01172,0.02120212,0.01039,0.02520252,Least Maturity,0.02120212,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),0.01147,0.01790179,0.00814,0.061006101,Least Maturity,0.01790179,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Maturation Strategy - Tension (64),0.01129,0.03040304,0.00454,0.305930593,Least Maturity,0.03040304,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Insulin Start Day - 1 (19),0.01112,0.02320232,0.00663,0.092809281,Least Maturity,0.02320232,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),hiPSC-CM Media Supplement - Ascorbic Acid (41),0.01111,0.03830383,0.0119,0.0190019,Least Maturity,0.0190019,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),3D Tissue Media - High-glucose DMEM (9),0.01081,0.02380238,0.00985,0.02860286,Least Maturity,0.02380238,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),0.01075,0.0420042,0.00744,0.108410841,Least Maturity,0.0420042,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Journal - Stem Cells Transl Med (3),0.01049,0.04760476,0.0147,0.0210021,Least Maturity,0.0210021,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Cell Line - Gibco episomal (10),0.01034,0.02970297,0.01349,0.01270127,Least Maturity,0.01270127,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Wnt Inhibitor Duration (days) - 5 days (6),0.01003,0.02830283,0.00825,0.055905591,Least Maturity,0.02830283,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Contractile Analysis Method - Force Transducer (27),0.00999,0.03680368,0.00924,0.04620462,Least Maturity,0.03680368,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),hiPSC Backbone Media - Essential 8 (82),0.00978,0.0480048,0.00535,0.262226223,Least Maturity,0.0480048,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Publication Year - 2017 (43),0.00974,0.03840384,0.00999,0.0350035,Least Maturity,0.0350035,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Cell Line - DF19-9-11T.H (16),0.00928,0.02570257,0.00801,0.051905191,Least Maturity,0.02570257,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),New Media for Maturation - RPMI-1640 (30),0.00918,0.04320432,0.00579,0.137513751,Least Maturity,0.04320432,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),0.00885,0.030003,0.00571,0.092609261,Least Maturity,0.030003,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Electrophysiology Analysis Method - Genetic (3),0.00879,0.04860486,0.01447,0.01280128,Least Maturity,0.01280128,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Day of Insulin Addition - not 17 (12),0.00844,0.04520452,0.0116,0.01940194,Least Maturity,0.01940194,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Gene Analysis Method - RNA (169),0.00825,0.141014101,0.01184,0.00050005,Least Maturity,0.00050005,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Maturation Strategy - Elastomeric (33),0.00763,0.069006901,0.00892,0.0470047,Least Maturity,0.0470047,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),3D Platform - Gelatin (6),0.00755,0.054705471,0.01345,0.00970097,Least Maturity,0.00970097,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Cell Line - WTC11 (30),0.00723,0.081408141,0.01101,0.02150215,Least Maturity,0.02150215,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Journal - Stem Cells (11),0.00716,0.050405041,0.00753,0.04720472,Least Maturity,0.04720472,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),hiPSC-CM Media Supplement - B27 (180),0.00619,0.396639664,0.0106,0.00980098,Least Maturity,0.00980098,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Insulin Start Day - 3 (5),0.00616,0.065106511,0.00876,0.03020302,Least Maturity,0.03020302,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),0.00544,0.107710771,0.00913,0.03270327,Least Maturity,0.03270327,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Wnt Inhibitor - Wnt-C59 (30),0.0054,0.146014601,0.00978,0.03050305,Least Maturity,0.03050305,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Differentiation Purity Assessment - IHC a-actinin (8),0.00438,0.172417242,0.00911,0.03830383,Least Maturity,0.03830383,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),0.00271,0.248424842,0.00862,0.04310431,Least Maturity,0.04310431,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Contractile Analysis Method - Motion Tracking (93),0.05363,0,0.01584,0.00030003,Least Maturity,0,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),hiPSC Matrix Coating - Geltrex (33),0.01759,0.00330033,0.01534,0.00380038,Least Maturity,0.00330033,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Journal - ACS Appl Mater Interfaces (4),0.0165,0.0040004,0.01764,0.00450045,Least Maturity,0.0040004,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),hiPSC Backbone Media - Essential 8 (82),0.01574,0.00720072,0.00933,0.03260326,Least Maturity,0.00720072,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Purification Protocol - Glucose and Lactate (85),0.01491,0.00790079,0.00808,0.069606961,Least Maturity,0.00790079,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Maturation Strategy - Mechanical (36),0.0138,0.01280128,0.0125,0.010001,Least Maturity,0.010001,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Insulin Start Day - 7 (85),0.01363,0.01960196,0.0108,0.01690169,Least Maturity,0.01690169,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),hiPSC-CM Purification Duration (days) - 6 days (10),0.01102,0.01930193,0.01032,0.02040204,Least Maturity,0.01930193,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Wnt Inhibitor - IWR (56),0.01071,0.03180318,0.00694,0.124512451,Least Maturity,0.03180318,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Seeding Confluency (%) - 85 to 89 (43),0.01028,0.04170417,0.00912,0.04590459,Least Maturity,0.04170417,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Insulin Start Day - 6 (20),0.01011,0.02970297,0.01304,0.01150115,Least Maturity,0.01150115,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),2D Surface - Microparticle/fluid (3),0.00941,0.03180318,0.01108,0.02630263,Least Maturity,0.02630263,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Fatty Acid Metabolism Assessed - Yes (20),0.00924,0.04230423,0.00751,0.071007101,Least Maturity,0.04230423,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Calcium Handling Analysis Method - Rare (4),0.00909,0.02760276,0.0086,0.050205021,Least Maturity,0.02760276,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Maturation Strategy - Cell Alignment (59),0.00905,0.062506251,0.01267,0.01090109,Least Maturity,0.01090109,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Electron Imaging - Scanning (22),0.00897,0.03770377,0.00396,0.235823582,Least Maturity,0.03770377,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),2D Surface - Electrospun (13),0.00892,0.0440044,0.00669,0.080008001,Least Maturity,0.0440044,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Metabolic Component - Rare (4),0.00861,0.04150415,0.01199,0.01690169,Least Maturity,0.01690169,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),0.0086,0.056105611,0.00993,0.03730373,Least Maturity,0.03730373,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Journal - Lab Chip (4),0.00846,0.03630363,0.00803,0.051705171,Least Maturity,0.03630363,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Pharmacological Intervention - Other Antiarrhythmic Agents (13),0.00825,0.04960496,0.00911,0.03460346,Least Maturity,0.03460346,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),0.00806,0.03410341,0.0076,0.04630463,Least Maturity,0.03410341,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Day of Insulin Addition - not 22 (12),0.00802,0.04310431,0.01021,0.02060206,Least Maturity,0.02060206,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),0.00754,0.053105311,0.0121,0.01420142,Least Maturity,0.01420142,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Differentiation Purity Assessment - IHC cTnT (7),0.00745,0.04590459,0.00774,0.04980498,Least Maturity,0.04590459,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),0.00705,0.053705371,0.00808,0.04360436,Least Maturity,0.04360436,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),hiPSC-CM Purification Duration (days) - 3 days (13),0.00701,0.065806581,0.01318,0.00950095,Least Maturity,0.00950095,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Pharmacological Intervention - Metoprolol (5),0.00695,0.03170317,0.00747,0.03750375,Least Maturity,0.03170317,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Insulin Withdrawal Duration (days) Quantiles - Q1 (>4 and ≤10) (11),0.00674,0.071207121,0.009,0.03590359,Least Maturity,0.03590359,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),hiPSC-CM Purification Duration (days) - 8 days (4),0.00645,0.069806981,0.00811,0.04840484,Least Maturity,0.04840484,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Seeding Confluency 2D (%) - 85 to 89 (26),0.00642,0.091709171,0.00868,0.04030403,Least Maturity,0.04030403,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),0.00632,0.073607361,0.00804,0.04840484,Least Maturity,0.04840484,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Pharmacological Intervention - Carbamylcholine (6),0.00594,0.084308431,0.00769,0.04990499,Least Maturity,0.04990499,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Cell Line Ancestry - Asian (28),0.00583,0.132913291,0.00953,0.04030403,Least Maturity,0.04030403,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Insulin Withdrawal Duration (days) - 6 days (3),0.00567,0.084908491,0.01014,0.04420442,Least Maturity,0.04420442,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),hiPSC-CM Maturation Media - RPMI-1640 (153),0.00545,0.485448545,0.0101,0.00550055,Least Maturity,0.00550055,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Journal - Biomater Sci (7),0.00525,0.093209321,0.00966,0.01990199,Least Maturity,0.01990199,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Seeding Confluency 2D (%) - 80 to 84 (5),0.0048,0.090509051,0.00842,0.02660266,Least Maturity,0.02660266,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Journal - Stem Cells (11),0.0041,0.142514251,0.00746,0.04580458,Least Maturity,0.04580458,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Coating for Replating - Geltrex (10),0.00307,0.219821982,0.00785,0.04690469,Least Maturity,0.04690469,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Journal - Stem Cell Reports (23),0.02584,0.00070007,0.02021,0.00070007,Least Maturity,0.00070007,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),0.01484,0.00640064,0.0089,0.03150315,Least Maturity,0.00640064,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),0.01332,0.01080108,0.0122,0.01320132,Least Maturity,0.01080108,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Wnt Induction - StemCell Diff Kit (4),0.01326,0.00850085,0.01149,0.0210021,Least Maturity,0.00850085,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Calcium Handling Analysis Method - Visual (104),0.01294,0.02510251,0.0049,0.447244724,Least Maturity,0.02510251,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),0.01227,0.00870087,0.01308,0.00930093,Least Maturity,0.00870087,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),0.0117,0.02110211,0.01146,0.01690169,Least Maturity,0.01690169,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),0.01158,0.02170217,0.01406,0.00370037,Least Maturity,0.00370037,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),0.01142,0.020002,0.00767,0.04970497,Least Maturity,0.020002,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Cell Line - ATCC (5),0.01135,0.01020102,0.01102,0.01480148,Least Maturity,0.01020102,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Maturation Strategy - Tension (64),0.0112,0.02360236,0.00593,0.202620262,Least Maturity,0.02360236,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),0.01108,0.03590359,0.01233,0.01350135,Least Maturity,0.01350135,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Metabolic Analysis Method - Seahorse (35),0.01071,0.02820282,0.00457,0.238323832,Least Maturity,0.02820282,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),0.01021,0.02420242,0.00968,0.02820282,Least Maturity,0.02420242,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Contractile Analysis Method - Deflection (39),0.00963,0.04120412,0.00584,0.164016402,Least Maturity,0.04120412,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),0.00951,0.04140414,0.00683,0.142014201,Least Maturity,0.04140414,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Cell Line Ancestry - Asian (28),0.00944,0.03890389,0.00773,0.054605461,Least Maturity,0.03890389,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),0.00935,0.0230023,0.00951,0.02840284,Least Maturity,0.0230023,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Publication Year - 2014 (3),0.00929,0.02090209,0.00917,0.03310331,Least Maturity,0.02090209,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),New Media for Maturation - Commercial Kit (5),0.00916,0.02950295,0.00718,0.070607061,Least Maturity,0.02950295,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Cell Line - WTC11 (30),0.00902,0.04340434,0.00937,0.03040304,Least Maturity,0.03040304,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Cell Line - IMR90 (19),0.0089,0.03980398,0.0095,0.02580258,Least Maturity,0.02580258,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),0.00886,0.03540354,0.00962,0.02750275,Least Maturity,0.02750275,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),0.00876,0.03410341,0.00879,0.03140314,Least Maturity,0.03140314,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Wnt Inhibitor - XAV939 (24),0.00842,0.051905191,0.00912,0.04030403,Least Maturity,0.04030403,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),0.00788,0.0410041,0.01112,0.01670167,Least Maturity,0.01670167,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),hiPSC Backbone Media - Conditioned (12),0.00774,0.04910491,0.00984,0.02660266,Least Maturity,0.02660266,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Number of Cell Lines - 1 (225),0.00723,0.145714571,0.00905,0.03610361,Least Maturity,0.03610361,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),0.00551,0.074607461,0.00762,0.03860386,Least Maturity,0.03860386,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),0.00448,0.143214321,0.00937,0.02980298,Least Maturity,0.02980298,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Maturation Strategy - ECM (21),0.00404,0.189618962,0.00816,0.04760476,Least Maturity,0.04760476,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),0.00381,0.149614961,0.00755,0.03860386,Least Maturity,0.03860386,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),2D Surface - Electrospun (13),0.03213,0.00010001,0.02596,0.00050005,Least Maturity,0.00010001,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Publication Year - 2022 (20),0.0297,0.00040004,0.01742,0.00170017,Least Maturity,0.00040004,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Calcium Handling Analysis Method - Visual (104),0.02271,0.00180018,0.00776,0.095509551,Least Maturity,0.00180018,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Pharmacological Intervention - Phenylephrine (3),0.01715,0.00320032,0.02159,0.00260026,Least Maturity,0.00260026,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Coating for Replating - Fibronectin (32),0.01535,0.00780078,0.01416,0.00380038,Least Maturity,0.00380038,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21),0.01286,0.01230123,0.01182,0.01170117,Least Maturity,0.01170117,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Electron Imaging - Scanning (22),0.0123,0.01670167,0.01622,0.00220022,Least Maturity,0.00220022,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),hiPSC Backbone Media - StemFit (5),0.01168,0.00920092,0.00988,0.01780178,Least Maturity,0.00920092,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Publication Year - Post 2020 (122),0.01152,0.03820382,0.00878,0.03050305,Least Maturity,0.03050305,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),0.01118,0.01780178,0.01041,0.01840184,Least Maturity,0.01780178,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Seeding Confluency 3D (%) - 90 to 94 (13),0.01095,0.01780178,0.00656,0.069506951,Least Maturity,0.01780178,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Publication Year - Late-2010s (196),0.0105,0.0410041,0.00831,0.04250425,Least Maturity,0.0410041,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Contractile Analysis Method - Motion Tracking (93),0.01038,0.03630363,0.00692,0.129612961,Least Maturity,0.03630363,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),hiPSC-CM Maturation Media - iCell Maintenance (83),0.00992,0.02910291,0.00796,0.056105611,Least Maturity,0.02910291,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Number of Cell Lines - 4 (11),0.00988,0.02910291,0.00956,0.0320032,Least Maturity,0.02910291,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Journal - J Biomed Mater Res A (3),0.0097,0.02310231,0.01126,0.02040204,Least Maturity,0.02040204,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),hiPSC Matrix Coating - Geltrex (33),0.00959,0.04430443,0.0088,0.056305631,Least Maturity,0.04430443,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Electrophysiology Analysis Method - Microelectrode (31),0.00937,0.0420042,0.00751,0.073507351,Least Maturity,0.0420042,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Journal - Biomaterials (16),0.00929,0.02580258,0.00839,0.03450345,Least Maturity,0.02580258,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Insulin Start Day - 9 (10),0.00901,0.03330333,0.00782,0.04120412,Least Maturity,0.03330333,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),0.00851,0.02010201,0.00852,0.02070207,Least Maturity,0.02010201,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),0.00822,0.03070307,0.00822,0.04430443,Least Maturity,0.03070307,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),3D Stromal Cell Source - Dermal Fibroblast (7),0.00795,0.03970397,0.00914,0.03040304,Least Maturity,0.03040304,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Cell Coculture - Endothelial Cell (35),0.00779,0.060006001,0.009,0.03490349,Least Maturity,0.03490349,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),0.00778,0.04260426,0.00948,0.02350235,Least Maturity,0.02350235,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Pharmacological Intervention - Thalidomide (3),0.00739,0.04150415,0.00761,0.057105711,Least Maturity,0.04150415,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),0.0073,0.04320432,0.00398,0.159715972,Least Maturity,0.04320432,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Pharmacological Intervention - Cardiotoxic Agents (3),0.00719,0.054405441,0.01114,0.0220022,Least Maturity,0.0220022,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Purification Protocol - Metabolic (8),0.00677,0.04150415,0.00575,0.073807381,Least Maturity,0.04150415,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),0.00602,0.072607261,0.00804,0.04330433,Least Maturity,0.04330433,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Pharmacological Intervention - Blebbistatin (5),0.00435,0.093109311,0.00641,0.04710471,Least Maturity,0.04710471,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),0.00434,0.108010801,0.01233,0.01020102,Least Maturity,0.01020102,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),0.00288,0.188518852,0.00644,0.04850485,Least Maturity,0.04850485,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Publication Year - 2021 (43),0.02427,0.00150015,0.01737,0.00190019,Least Maturity,0.00150015,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),0.01834,0.00250025,0.01409,0.0060006,Least Maturity,0.00250025,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Coating for Replating - Rare (6),0.01612,0.00410041,0.01375,0.00760076,Least Maturity,0.00410041,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),0.01573,0.00860086,0.01706,0.00510051,Least Maturity,0.00510051,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),3D Stromal Cell Source - Stromal Cell (35),0.01453,0.01440144,0.00675,0.113211321,Least Maturity,0.01440144,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Seeding Confluency (%) - 80 to 84 (12),0.01405,0.01180118,0.01504,0.00610061,Least Maturity,0.00610061,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Day of Insulin Addition - not 11 (5),0.0134,0.00750075,0.00896,0.03840384,Least Maturity,0.00750075,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Pharmacological Intervention - T3 (3),0.01325,0.01690169,0.01499,0.01760176,Least Maturity,0.01690169,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Metabolic Component Category - Metabolic Modulation (20),0.01273,0.02150215,0.008,0.064706471,Least Maturity,0.02150215,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Journal - Biomater Sci (7),0.01246,0.01380138,0.01759,0.00450045,Least Maturity,0.00450045,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Metabolic Component - IGF-1 (3),0.01222,0.0130013,0.01241,0.0210021,Least Maturity,0.0130013,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Cell Line Sex - Both (118),0.01202,0.0320032,0.00818,0.064706471,Least Maturity,0.0320032,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),0.01189,0.01190119,0.01289,0.00940094,Least Maturity,0.00940094,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Sacromere or Cellular Alignment Analysis - Yes (72),0.01122,0.04330433,0.01152,0.01310131,Least Maturity,0.01310131,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),3D Stromal Cell Source - hiPSC-SmoothMC (3),0.01084,0.0170017,0.00744,0.057805781,Least Maturity,0.0170017,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),0.01038,0.0330033,0.00623,0.094709471,Least Maturity,0.0330033,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Wnt Inhibitor Duration (days) - 5 days (6),0.01,0.02360236,0.01002,0.02450245,Least Maturity,0.02360236,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Metabolic Component Category - Fatty Acids and Lipids (21),0.00887,0.04240424,0.00879,0.04340434,Least Maturity,0.04240424,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Differentiation Purity Assessment - Visual Inspection (6),0.00793,0.04340434,0.00671,0.074307431,Least Maturity,0.04340434,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Cell Line - DF19-9-11T.H (16),0.00792,0.056905691,0.0127,0.01190119,Least Maturity,0.01190119,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),3D Stromal Cell Source - hiPSC-CardiacF (8),0.00748,0.04860486,0.00795,0.04430443,Least Maturity,0.04430443,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Wnt Inhibitor Duration (days) - Rare (173),0.00728,0.164016402,0.0093,0.01730173,Least Maturity,0.01730173,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),0.00677,0.070807081,0.01497,0.00610061,Least Maturity,0.00610061,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),0.00588,0.297829783,0.00832,0.04030403,Least Maturity,0.04030403,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Insulin Withdrawal Duration (days) - 4 days (18),0.00527,0.122312231,0.0088,0.0410041,Least Maturity,0.0410041,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),0.00429,0.153315332,0.00794,0.04670467,Least Maturity,0.04670467,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Journal - Tissue Eng Part A (4),0.02278,0.00350035,0.02051,0.00980098,Least Maturity,0.00350035,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Pharmacological Intervention - Adrenaline (83),0.01991,0.00460046,0.01265,0.0280028,Least Maturity,0.00460046,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),0.01799,0.01060106,0.01296,0.03580358,Least Maturity,0.01060106,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),0.01547,0.01570157,0.01019,0.052405241,Least Maturity,0.01570157,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),0.01499,0.02180218,0.00988,0.063006301,Least Maturity,0.02180218,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),0.01466,0.01460146,0.01505,0.01330133,Least Maturity,0.01330133,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Pharmacological Intervention - Verapamil (27),0.01403,0.03490349,0.01104,0.04470447,Least Maturity,0.03490349,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Seeding Confluency 3D (%) - 80 to 84 (5),0.01394,0.02770277,0.0144,0.02430243,Least Maturity,0.02430243,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),0.01386,0.01510151,0.01519,0.01240124,Least Maturity,0.01240124,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),0.01386,0.02810281,0.01407,0.03020302,Least Maturity,0.02810281,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Maturation Strategy - ECM (21),0.01368,0.01930193,0.01361,0.020002,Least Maturity,0.01930193,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Pharmacological Intervention - Isoproterenol (71),0.01363,0.04340434,0.00256,0.704170417,Least Maturity,0.04340434,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Cell Line Ancestry - Asian (28),0.01338,0.02340234,0.00678,0.123912391,Least Maturity,0.02340234,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Electron Imaging - Transmission (62),0.01331,0.01990199,0.00705,0.121112111,Least Maturity,0.01990199,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),0.01328,0.04110411,0.01256,0.02870287,Least Maturity,0.02870287,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),0.01271,0.04310431,0.00749,0.112611261,Least Maturity,0.04310431,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),hiPSC Backbone Media - mTeSR (106),0.01182,0.03390339,0.01122,0.03150315,Least Maturity,0.03150315,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),3D Platform - Extracellular Scaffold (18),0.01157,0.03350335,0.01419,0.01860186,Least Maturity,0.01860186,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),0.01103,0.02860286,0.01002,0.04820482,Least Maturity,0.02860286,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),3D Tissue Media - RPMI-1640 (72),0.01086,0.054005401,0.01339,0.0210021,Least Maturity,0.0210021,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Journal - J Mol Cell Cardiol (4),0.01059,0.0350035,0.01095,0.03780378,Least Maturity,0.0350035,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Pharmacological Intervention - Carbenoxolone (4),0.00999,0.053605361,0.01112,0.04680468,Least Maturity,0.04680468,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),2D Surface - Decellularized ECM (3),0.00994,0.04550455,0.01272,0.03770377,Least Maturity,0.03770377,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Cell Line - IMR90 (19),0.00948,0.04410441,0.01115,0.03410341,Least Maturity,0.03410341,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Calcium Handling Analysis Method - Rare (4),0.00909,0.04120412,0.01101,0.03510351,Least Maturity,0.03510351,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),0.00821,0.059505951,0.0126,0.03620362,Least Maturity,0.03620362,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),3D Tissue Media - Iscove (5),0.00787,0.04840484,0.00676,0.065406541,Least Maturity,0.04840484,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Wnt Induction Duration (days) Quantiles - Q1 (>2 and ≤5) (61),0.00779,0.137613761,0.01246,0.0320032,Least Maturity,0.0320032,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),0.00778,0.102210221,0.0173,0.01010101,Least Maturity,0.01010101,TRUE,TRUE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),0.00759,0.080308031,0.01113,0.04380438,Least Maturity,0.04380438,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Journal - Biomater Sci (7),0.00619,0.098109811,0.01121,0.03960396,Least Maturity,0.03960396,TRUE,FALSE
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Calcium Handling Analysis Method - Visual (104),0.00542,0.284328433,0.00983,0.03650365,Least Maturity,0.03650365,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Journal - Am J Physiol Heart Circ Physiol (4),0.02732,0.00350035,0.03072,0.00260026,Least Maturity,0.00260026,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Insulin Start Day - 5 (14),0.02613,0.00720072,0.0217,0.00980098,Least Maturity,0.00720072,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Publication Year - 2018 (45),0.02354,0.01510151,0.01461,0.03420342,Least Maturity,0.01510151,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),hiPSC-CM Purification Duration (days) - 5 days (6),0.0225,0.00840084,0.02471,0.00530053,Least Maturity,0.00530053,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Calcium Handling Analysis Method - Visual (104),0.02239,0.00120012,0.01739,0.00370037,Least Maturity,0.00120012,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),3D Tissue Media - iCell Maintenance (12),0.02158,0.00590059,0.0157,0.03520352,Least Maturity,0.00590059,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Journal - Tissue Eng Part A (4),0.01866,0.0230023,0.01575,0.03160316,Least Maturity,0.0230023,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),2D Surface - Electrospun (13),0.01793,0.01920192,0.0097,0.086208621,Least Maturity,0.01920192,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),0.01654,0.04410441,0.01973,0.02090209,Least Maturity,0.02090209,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Journal - J Biomed Mater Res A (3),0.0165,0.02350235,0.01929,0.02020202,Least Maturity,0.02020202,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),0.01598,0.060206021,0.01765,0.02860286,Least Maturity,0.02860286,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),hiPSC-CM Media Supplement - Rare (5),0.01537,0.04150415,0.00931,0.057405741,Least Maturity,0.04150415,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Cell Line - iCell2 (8),0.01503,0.04520452,0.01679,0.02770277,Least Maturity,0.02770277,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),0.01497,0.03440344,0.01182,0.054605461,Least Maturity,0.03440344,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),0.01487,0.02560256,0.01225,0.04620462,Least Maturity,0.02560256,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Differentiation Purity Assessment - IHC cTnT (7),0.0147,0.04150415,0.0136,0.04590459,Least Maturity,0.04150415,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),0.01459,0.03960396,0.01278,0.068406841,Least Maturity,0.03960396,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),0.01453,0.054605461,0.01488,0.04160416,Least Maturity,0.04160416,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Coating for Replating - Geltrex (10),0.01425,0.03650365,0.01728,0.02080208,Least Maturity,0.02080208,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),0.01346,0.03960396,0.01685,0.02270227,Least Maturity,0.02270227,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Publication Year - 2022 (20),0.01339,0.0320032,0.0139,0.04060406,Least Maturity,0.0320032,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),0.0121,0.03970397,0.01199,0.02480248,Least Maturity,0.02480248,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),0.01187,0.064106411,0.01648,0.02710271,Least Maturity,0.02710271,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),0.01167,0.057705771,0.01544,0.02920292,Least Maturity,0.02920292,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),0.01144,0.063506351,0.01375,0.04810481,Least Maturity,0.04810481,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Wnt Induction - bFGF (45),0.0111,0.092209221,0.01407,0.04260426,Least Maturity,0.04260426,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17),0.01089,0.077207721,0.01335,0.04570457,Least Maturity,0.04570457,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Day of Insulin Addition - Known (177),0.01029,0.056205621,0.01278,0.0280028,Least Maturity,0.0280028,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),3D Tissue Media - Commercial Kit (21),0.00967,0.083508351,0.0168,0.020002,Least Maturity,0.020002,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Disease Modelling - Genetic Disorders (18),0.0086,0.099809981,0.01569,0.02370237,Least Maturity,0.02370237,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Journal - Sci Transl Med (3),0.00544,0.03580358,0.00946,0.03380338,Least Maturity,0.03380338,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Electrophysiology Analysis Method - Optical Mapping (39),0.04037,0,0.03082,0,Least Maturity,0,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Electron Imaging - Scanning (22),0.02312,0.00170017,0.02037,0.00180018,Least Maturity,0.00170017,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Maturation Strategy - Mechanical (36),0.02268,0.00290029,0.02035,0.00220022,Least Maturity,0.00220022,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Electron Imaging - Transmission (62),0.02014,0.00490049,0.00676,0.175417542,Least Maturity,0.00490049,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),3D Tissue Media - High-glucose DMEM (9),0.01803,0.01150115,0.01525,0.01660166,Least Maturity,0.01150115,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Wnt Inhibitor - IWR (56),0.01537,0.0160016,0.01268,0.02370237,Least Maturity,0.0160016,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Journal - Cell Stem Cell (6),0.01462,0.01240124,0.01094,0.03530353,Least Maturity,0.01240124,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Journal - ACS Appl Mater Interfaces (4),0.0141,0.01470147,0.00932,0.050805081,Least Maturity,0.01470147,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),0.01408,0.01720172,0.0105,0.04170417,Least Maturity,0.01720172,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),3D Tissue Media - iCell Maintenance (12),0.01392,0.01410141,0.01105,0.02920292,Least Maturity,0.01410141,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),2D Surface - Micropatterned (27),0.01239,0.02310231,0.0081,0.081708171,Least Maturity,0.02310231,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),0.01201,0.0230023,0.00944,0.04760476,Least Maturity,0.0230023,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Maturation Strategy - Electrical (39),0.01174,0.04060406,0.00773,0.115111511,Least Maturity,0.04060406,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),3D Tissue Media - Commercial Kit (21),0.01143,0.0350035,0.01284,0.02040204,Least Maturity,0.02040204,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),0.01122,0.04520452,0.01129,0.03510351,Least Maturity,0.03510351,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),3D Platform - Scaffold Free (43),0.01095,0.053505351,0.01102,0.04340434,Least Maturity,0.04340434,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Cell Line - Rare (132),0.01092,0.050505051,0.01,0.04370437,Least Maturity,0.04370437,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Metabolic Component Category - Signaling Pathway Regulators (6),0.01052,0.03240324,0.00864,0.060006001,Least Maturity,0.03240324,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Journal - PLoS One (9),0.01006,0.03350335,0.0099,0.03660366,Least Maturity,0.03350335,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),3D Tissue Media - Rare (13),0.00986,0.04790479,0.00759,0.090209021,Least Maturity,0.04790479,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Electrophysiology Analysis Method - Microelectrode (31),0.00975,0.053905391,0.01515,0.01420142,Least Maturity,0.01420142,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),0.00929,0.04510451,0.00655,0.095009501,Least Maturity,0.04510451,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Publication Year - 2016 (32),0.00928,0.058705871,0.01164,0.03130313,Least Maturity,0.03130313,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),0.0091,0.0490049,0.00765,0.067506751,Least Maturity,0.0490049,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Publication Year - 2017 (43),0.00818,0.080608061,0.01236,0.02470247,Least Maturity,0.02470247,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Contractile Analysis Method - Motion Tracking (93),0.00814,0.144214421,0.01171,0.02780278,Least Maturity,0.02780278,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),0.00808,0.04930493,0.0085,0.052205221,Least Maturity,0.04930493,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),0.00747,0.080308031,0.01472,0.01180118,Least Maturity,0.01180118,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Insulin Start Day - 4 (11),0.0071,0.083108311,0.0098,0.04360436,Least Maturity,0.04360436,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),0.006,0.087308731,0.01587,0.01180118,Least Maturity,0.01180118,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Electrophysiology Analysis Method - Patch Clamp (59),0.05091,0,0.02934,0,Least Maturity,0,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Gene Analysis Method - RNA (169),0.02659,0.00010001,0.00724,0.129312931,Least Maturity,0.00010001,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),0.0255,0.00030003,0.02328,0.00050005,Least Maturity,0.00030003,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Publication Year - 2017 (43),0.01835,0.00180018,0.0098,0.0260026,Least Maturity,0.00180018,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Cell Line - ATCC (5),0.0166,0.00590059,0.02053,0.00270027,Least Maturity,0.00270027,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Wnt Induction Duration (days) - 3 days (38),0.01574,0.00940094,0.0125,0.01120112,Least Maturity,0.00940094,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Number of Cell Lines - 2 (50),0.01553,0.00950095,0.01389,0.00420042,Least Maturity,0.00420042,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Wnt Inhibitor - XAV939 (24),0.01461,0.00870087,0.01617,0.00330033,Least Maturity,0.00330033,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),hiPSC Backbone Media - Rare (19),0.01405,0.00960096,0.00656,0.079607961,Least Maturity,0.00960096,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Seeding Confluency (%) - 85 to 89 (43),0.01405,0.01390139,0.01143,0.01610161,Least Maturity,0.01390139,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Coating for Replating - Gelatin (43),0.01277,0.02140214,0.01002,0.02770277,Least Maturity,0.02140214,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Journal - Biomaterials (16),0.01215,0.01640164,0.0122,0.01120112,Least Maturity,0.01120112,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Cell Line - BJ1 (7),0.01126,0.01310131,0.01335,0.00750075,Least Maturity,0.00750075,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Wnt Inhibitor Duration (days) - >6 days (12),0.01064,0.0310031,0.01276,0.01270127,Least Maturity,0.01270127,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),0.01055,0.01590159,0.00429,0.135013501,Least Maturity,0.01590159,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Number of Cell Lines - >5 (9),0.01036,0.01640164,0.01033,0.01540154,Least Maturity,0.01540154,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27),0.00989,0.02760276,0.01341,0.0070007,Least Maturity,0.0070007,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Seeding Confluency 2D (%) - 85 to 89 (26),0.00904,0.04170417,0.00963,0.02530253,Least Maturity,0.02530253,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Metabolic Component - Fatty Acid (13),0.00837,0.04790479,0.00849,0.04460446,Least Maturity,0.04460446,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Cell Line - iCell2 (8),0.00826,0.03190319,0.00507,0.109110911,Least Maturity,0.03190319,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Metabolic Component Category - Sugars and Carbohydrates (9),0.00775,0.03640364,0.00843,0.03020302,Least Maturity,0.03020302,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Journal - Sci Transl Med (3),0.00762,0.04540454,0.00707,0.068206821,Least Maturity,0.04540454,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),0.00671,0.04810481,0.00688,0.053005301,Least Maturity,0.04810481,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Pharmacological Intervention - Other Antiarrhythmic Agents (13),0.00585,0.079707971,0.00842,0.03540354,Least Maturity,0.03540354,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Journal - ACS Appl Mater Interfaces (4),0.00573,0.080408041,0.00833,0.03880388,Least Maturity,0.03880388,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Wnt Inhibitor - IWP (112),0.00569,0.407340734,0.00923,0.03230323,Least Maturity,0.03230323,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Cell Line - Rare (132),0.00515,0.589558956,0.00875,0.04050405,Least Maturity,0.04050405,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),hiPSC Backbone Media - Embryonic Stem Cell (127),0.00477,0.555355536,0.00803,0.03910391,Least Maturity,0.03910391,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Electrophysiology Analysis Method - Patch Clamp (59),0.066,0,0.03868,0,Least Maturity,0,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),0.03273,0,0.02953,0,Least Maturity,0,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Number of Cell Lines - 2 (50),0.02468,0.00080008,0.01404,0.00630063,Least Maturity,0.00080008,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),hiPSC Backbone Media - Conditioned (12),0.02215,0.00290029,0.02125,0.00240024,Least Maturity,0.00240024,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),0.0154,0.01040104,0.01511,0.00740074,Least Maturity,0.00740074,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Journal - ACS Appl Mater Interfaces (4),0.01461,0.00970097,0.01124,0.03190319,Least Maturity,0.00970097,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),0.01368,0.01240124,0.01163,0.02820282,Least Maturity,0.01240124,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),0.01352,0.01630163,0.01049,0.0270027,Least Maturity,0.01630163,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),0.01351,0.02210221,0.00913,0.050505051,Least Maturity,0.02210221,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Wnt Induction - Activin A (80),0.01341,0.0160016,0.00845,0.085208521,Least Maturity,0.0160016,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),hiPSC Backbone Media - DMEM (10),0.01327,0.01520152,0.00899,0.03660366,Least Maturity,0.01520152,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),3D Stromal Cell Source - hiPSC-MuralC (3),0.01276,0.03420342,0.01025,0.064606461,Least Maturity,0.03420342,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Wnt Induction - BMP4 (74),0.01246,0.03040304,0.00479,0.399739974,Least Maturity,0.03040304,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Publication Year - 2017 (43),0.01246,0.02650265,0.01126,0.02610261,Least Maturity,0.02610261,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),0.01102,0.02030203,0.01248,0.01660166,Least Maturity,0.01660166,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Insulin Start Day - 4 (11),0.01031,0.03170317,0.0072,0.060706071,Least Maturity,0.03170317,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Journal - Nano Lett (3),0.01016,0.03320332,0.00952,0.04890489,Least Maturity,0.03320332,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),0.01011,0.03480348,0.0036,0.211321132,Least Maturity,0.03480348,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17),0.00994,0.04930493,0.0063,0.109910991,Least Maturity,0.04930493,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Pharmacological Intervention - Carbenoxolone (4),0.00979,0.03630363,0.00575,0.089408941,Least Maturity,0.03630363,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Wnt Induction - Wnt3a (3),0.0093,0.04750475,0.00908,0.058505851,Least Maturity,0.04750475,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Wnt Inhibitor - KY02111 (7),0.00824,0.03330333,0.01054,0.02050205,Least Maturity,0.02050205,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27),0.00784,0.069406941,0.00993,0.03850385,Least Maturity,0.03850385,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),0.00761,0.040004,0.00953,0.02150215,Least Maturity,0.02150215,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),0.00753,0.074707471,0.0101,0.03210321,Least Maturity,0.03210321,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Maturation Strategy - Other Cells (80),0.00709,0.133213321,0.00936,0.04730473,Least Maturity,0.04730473,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58),0.007,0.133813381,0.00965,0.04040404,Least Maturity,0.04040404,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Differentiation Purity Assessment - IHC a-actinin (8),0.00573,0.109010901,0.00973,0.03140314,Least Maturity,0.03140314,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),0.00543,0.104210421,0.00821,0.04150415,Least Maturity,0.04150415,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),0.00303,0.156915692,0.00786,0.04860486,Least Maturity,0.04860486,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),0.02857,0.00160016,0.03227,0.00080008,Least Maturity,0.00080008,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),3D Platform - Collagen (38),0.01973,0.00630063,0.00688,0.111311131,Least Maturity,0.00630063,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Publication Year - 2018 (45),0.01684,0.00950095,0.01629,0.00530053,Least Maturity,0.00530053,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Cell Line - Cor.4U (16),0.01657,0.00440044,0.01196,0.01580158,Least Maturity,0.00440044,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),hiPSC-CM Maturation Media - StemPro-34 (14),0.01613,0.01080108,0.01034,0.03640364,Least Maturity,0.01080108,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),hiPSC-CM Backbone Media - StemPro-34 (14),0.01525,0.01810181,0.01676,0.00790079,Least Maturity,0.00790079,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),0.01511,0.01190119,0.01335,0.01610161,Least Maturity,0.01190119,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),0.01481,0.01260126,0.00843,0.078807881,Least Maturity,0.01260126,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Electrophysiology Analysis Method - Patch Clamp (59),0.01464,0.01160116,0.01667,0.00310031,Least Maturity,0.00310031,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),hiPSC-CM Media Supplement - L-glutamine (19),0.01415,0.01030103,0.01376,0.00910091,Least Maturity,0.00910091,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Seeding Confluency 3D (%) - 70 to 79 (3),0.01333,0.02030203,0.01717,0.01110111,Least Maturity,0.01110111,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Journal - Biomater Sci (7),0.01326,0.01160116,0.00932,0.04320432,Least Maturity,0.01160116,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),3D Stromal Cell Source - Human Fibroblast (38),0.01324,0.02080208,0.01277,0.01650165,Least Maturity,0.01650165,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Maturation Strategy - Other Cells (80),0.0129,0.02570257,0.00883,0.051005101,Least Maturity,0.02570257,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),hiPSC-CM Media Supplement - Ascorbic Acid (41),0.01085,0.0410041,0.01151,0.03050305,Least Maturity,0.03050305,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Immunofluorescent Imaging - Yes (268),0.01007,0.055005501,0.01021,0.0470047,Least Maturity,0.0470047,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),0.00977,0.04880488,0.00569,0.326832683,Least Maturity,0.04880488,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),hiPSC Backbone Media - Conditioned (12),0.00972,0.0360036,0.00888,0.04810481,Least Maturity,0.0360036,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Wnt Induction Duration (days) - 4 days (15),0.00972,0.04070407,0.0103,0.03620362,Least Maturity,0.03620362,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Journal - Lab Chip (4),0.00911,0.03760376,0.01623,0.00550055,Least Maturity,0.00550055,TRUE,TRUE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),0.0091,0.02760276,0.00836,0.0420042,Least Maturity,0.02760276,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),0.00871,0.04020402,0.01062,0.03150315,Least Maturity,0.03150315,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Disease Modelling - Genetic Disorders (18),0.00811,0.061706171,0.01093,0.02760276,Least Maturity,0.02760276,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Journal - Stem Cells Int (3),0.00806,0.04020402,0.00751,0.052805281,Least Maturity,0.04020402,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),0.00776,0.04810481,0.00634,0.084708471,Least Maturity,0.04810481,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Journal - Tissue Eng Part A (4),0.00502,0.088708871,0.01176,0.03370337,Least Maturity,0.03370337,TRUE,FALSE
Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Journal - Stem Cell Res Ther (3),0.00279,0.072207221,0.01051,0.04580458,Least Maturity,0.04580458,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),0.06121,0,0.07488,0,Least Maturity,0,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),0.04889,0.00020002,0.05027,0.00020002,Least Maturity,0.00020002,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),0.04086,0.00030003,0.04044,0.00040004,Least Maturity,0.00030003,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Journal - Nat Biomed Eng (5),0.02643,0.00950095,0.02012,0.02680268,Least Maturity,0.00950095,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),hiPSC-CM Media Supplement - Rare (5),0.02074,0.02410241,0.01011,0.055305531,Least Maturity,0.02410241,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Journal - Tissue Eng Part A (4),0.01815,0.03520352,0.02314,0.01910191,Least Maturity,0.01910191,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),0.0181,0.02060206,0.01849,0.02370237,Least Maturity,0.02060206,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),0.01706,0.02970297,0.0127,0.04340434,Least Maturity,0.02970297,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Insulin Start Day - 0 (7),0.01551,0.03980398,0.0185,0.02210221,Least Maturity,0.02210221,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Calcium Handling Analysis Method - Rare (4),0.01526,0.01970197,0.01885,0.01870187,Least Maturity,0.01870187,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),0.013,0.04390439,0.01061,0.04670467,Least Maturity,0.04390439,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Number of Cell Lines - 3 (29),0.01279,0.052405241,0.01369,0.04260426,Least Maturity,0.04260426,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Calcium Handling Analysis Method - Visual (104),0.0125,0.02730273,0.00915,0.072907291,Least Maturity,0.02730273,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),0.0119,0.03230323,0.01063,0.04930493,Least Maturity,0.03230323,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),0.01051,0.057305731,0.01528,0.02340234,Least Maturity,0.02340234,TRUE,TRUE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Gene Analysis Method - RNA (169),0.01049,0.02980298,0.00756,0.188818882,Least Maturity,0.02980298,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),0.01031,0.093109311,0.01413,0.04490449,Least Maturity,0.04490449,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Pharmacological Intervention - T3 (3),0.01023,0.03350335,0.00668,0.03590359,Least Maturity,0.03350335,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Seeding Confluency (%) - Rare (43),0.01012,0.120112011,0.01464,0.04560456,Least Maturity,0.04560456,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Calcium Handling Analysis Method - Genetic (23),0.00986,0.096209621,0.01266,0.04650465,Least Maturity,0.04650465,TRUE,FALSE
MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Publication Year - 2014 (3),0.0006,0.04450445,0.00115,0.04390439,Least Maturity,0.04390439,TRUE,FALSE
MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),0.0584,0,0.05208,0,Least Maturity,0,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Contractile Analysis Method - Rare (7),0.04244,0.00080008,0.03437,0.00230023,Least Maturity,0.00080008,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),0.04174,0.00030003,0.04752,0.00020002,Least Maturity,0.00020002,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),0.03211,0.00130013,0.03579,0.00120012,Least Maturity,0.00120012,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),0.0254,0.00570057,0.02924,0.00490049,Least Maturity,0.00490049,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Publication Year - 2019 (57),0.02337,0.00920092,0.0251,0.00240024,Least Maturity,0.00240024,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Disease Modelling - Arrhythmic (15),0.02077,0.01440144,0.01808,0.01570157,Least Maturity,0.01440144,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Disease Modelling - Ischemic Infarction (9),0.01806,0.02110211,0.01487,0.03580358,Least Maturity,0.02110211,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),3D Stromal Cell Source - Stromal Cell (35),0.01759,0.01620162,0.00939,0.107010701,Least Maturity,0.01620162,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),0.0174,0.0210021,0.02411,0.00620062,Least Maturity,0.00620062,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Journal - Tissue Eng Part A (4),0.01651,0.03350335,0.01046,0.04180418,Least Maturity,0.03350335,TRUE,FALSE
MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Metabolic Analysis Method - Seahorse (35),0.01546,0.03170317,0.01296,0.058405841,Least Maturity,0.03170317,TRUE,FALSE
MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),0.01532,0.03640364,0.01452,0.03630363,Least Maturity,0.03630363,TRUE,FALSE
MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),0.01521,0.02660266,0.01606,0.02520252,Least Maturity,0.02520252,TRUE,FALSE
MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),0.01482,0.0390039,0.0151,0.02670267,Least Maturity,0.02670267,TRUE,FALSE
MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Disease Modelling - Genetic Disorders (18),0.01382,0.04470447,0.01388,0.04390439,Least Maturity,0.04390439,TRUE,FALSE
MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Journal - Nat Biomed Eng (5),0.01307,0.04810481,0.01334,0.0460046,Least Maturity,0.0460046,TRUE,FALSE
MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Calcium Handling Analysis Method - Visual (104),0.01257,0.0360036,0.01408,0.00980098,Least Maturity,0.00980098,TRUE,TRUE
MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Pharmacological Intervention - ACE Inhibitors (RAAS Modulators) (3),0.00052,0.04940494,0.00104,0.04680468,Least Maturity,0.04680468,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),0.08087,0,0.09741,0,Least Maturity,0,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),0.05068,0.00030003,0.04667,0.00060006,Least Maturity,0.00030003,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),0.03308,0.00060006,0.03736,0.00080008,Least Maturity,0.00060006,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Contractile Analysis Method - Rare (7),0.03269,0.00220022,0.03254,0.00250025,Least Maturity,0.00220022,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),0.02356,0.00740074,0.01649,0.02920292,Least Maturity,0.00740074,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Insulin Start Day - 0 (7),0.02127,0.02150215,0.01633,0.03470347,Least Maturity,0.02150215,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),0.02097,0.00820082,0.02683,0.00290029,Least Maturity,0.00290029,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Disease Modelling - Arrhythmic (15),0.0201,0.01220122,0.01597,0.01950195,Least Maturity,0.01220122,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Maturation Strategy - Mechanical (36),0.01915,0.02820282,0.0136,0.058705871,Least Maturity,0.02820282,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Metabolic Component - Palmitic Acid (11),0.01811,0.01980198,0.01456,0.04010401,Least Maturity,0.01980198,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Calcium Handling Analysis Method - Rare (4),0.01723,0.01320132,0.02076,0.01160116,Least Maturity,0.01160116,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Metabolic Analysis Method - Seahorse (35),0.01706,0.02420242,0.01608,0.04080408,Least Maturity,0.02420242,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),0.01649,0.02490249,0.01003,0.04550455,Least Maturity,0.02490249,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),0.01596,0.02620262,0.01131,0.058405841,Least Maturity,0.02620262,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),0.01539,0.02460246,0.01344,0.03380338,Least Maturity,0.02460246,TRUE,TRUE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),0.01537,0.0290029,0.00935,0.083308331,Least Maturity,0.0290029,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Maturation Strategy - Cell Alignment (59),0.01497,0.0280028,0.01033,0.098309831,Least Maturity,0.0280028,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),2D Surface - Hydrogel (17),0.01338,0.04370437,0.00954,0.100410041,Least Maturity,0.04370437,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Disease Modelling - Genetic Disorders (18),0.01273,0.056805681,0.01584,0.0360036,Least Maturity,0.0360036,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Electron Imaging - Transmission (62),0.01252,0.04460446,0.00975,0.088008801,Least Maturity,0.04460446,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Pharmacological Intervention - T3 (3),0.01066,0.03560356,0.00994,0.03490349,Least Maturity,0.03490349,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Metabolic Component - IGF-1 (3),0.00077,0.04620462,0,0.086908691,Least Maturity,0.04620462,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Pharmacological Intervention - Phenylephrine (3),0.00066,0.04110411,0.0011,0.04510451,Least Maturity,0.04110411,TRUE,FALSE
TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Journal - Sci Adv (3),0.0006,0.04980498,0.00114,0.04990499,Least Maturity,0.04980498,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Platform - Scaffold Free (43),0.05939,0,0.05757,0,Least Maturity,0,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),0.03304,0,0.02902,0,Least Maturity,0,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Deduced Culture Strategy - 3D Only (157),0.02805,0.00010001,0.00898,0.00830083,Least Maturity,0.00010001,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Tissue Media - Commercial Kit (21),0.02536,0,0.03073,0,Least Maturity,0,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Cell Coculture - Cardiomyocyte (157),0.01857,0.00090009,0.00848,0.01050105,Least Maturity,0.00090009,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),0.01284,0.00630063,0.00677,0.079707971,Least Maturity,0.00630063,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Cell Coculture - Endothelial Cell (35),0.01279,0.00460046,0.01231,0.00250025,Least Maturity,0.00250025,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),0.01278,0.00780078,0.01216,0.00310031,Least Maturity,0.00310031,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Deduced Culture Strategy - 2D Only (183),0.0122,0.00910091,0.00696,0.100310031,Least Maturity,0.00910091,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),0.01152,0.00690069,0.00878,0.01590159,Least Maturity,0.00690069,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),0.01119,0.010001,0.00932,0.01220122,Least Maturity,0.010001,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Tissue Media - Growth Factor (12),0.0108,0.00720072,0.01296,0.00310031,Least Maturity,0.00310031,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),0.00979,0.03340334,0.00708,0.080108011,Least Maturity,0.03340334,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Endothelial Cell Source - hiPSC-EndothelialC (16),0.00978,0.01210121,0.00993,0.00860086,Least Maturity,0.00860086,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Electron Imaging - Transmission (62),0.00912,0.03550355,0.00588,0.118011801,Least Maturity,0.03550355,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Tissue Media - iCell Maintenance (12),0.0089,0.01190119,0.0122,0.00360036,Least Maturity,0.00360036,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),0.00852,0.01910191,0.00776,0.02280228,Least Maturity,0.01910191,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Stromal Cell Source - Cardiac Fibroblast (32),0.00838,0.02670267,0.00843,0.01760176,Least Maturity,0.01760176,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),0.00788,0.03690369,0.00756,0.03360336,Least Maturity,0.03360336,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),0.00777,0.03210321,0.00305,0.314931493,Least Maturity,0.03210321,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Contractile Analysis Method - Motion Tracking (93),0.0077,0.075807581,0.00955,0.00820082,Least Maturity,0.00820082,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),hiPSC Backbone Media - StemFit (5),0.00741,0.01640164,0.00833,0.01760176,Least Maturity,0.01640164,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Publication Year - 2021 (43),0.0073,0.055105511,0.00873,0.02110211,Least Maturity,0.02110211,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Pharmacological Intervention - Traditional Chemotherapy Agents (18),0.0072,0.03140314,0.00851,0.0170017,Least Maturity,0.0170017,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),0.00692,0.02620262,0.00874,0.0260026,Least Maturity,0.0260026,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Day of Insulin Addition - not 17 (12),0.00648,0.03190319,0.0043,0.102110211,Least Maturity,0.03190319,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Tissue Media - MEM-α (60),0.00633,0.106910691,0.00723,0.04930493,Least Maturity,0.04930493,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Platform - 3D printed (9),0.00608,0.03520352,0.00577,0.04940494,Least Maturity,0.03520352,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),hiPSC-CM Backbone Media - Rare (10),0.00596,0.052205221,0.00925,0.01790179,Least Maturity,0.01790179,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Stromal Cell Source - Human Fibroblast (38),0.00596,0.084708471,0.0106,0.00790079,Least Maturity,0.00790079,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Journal - Sci Rep (24),0.00576,0.072107211,0.00921,0.01380138,Least Maturity,0.01380138,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Seeding Confluency 3D (%) - 85 to 89 (12),0.00554,0.056505651,0.00798,0.02490249,Least Maturity,0.02490249,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Metabolic Analysis Method - Flux Rates (13),0.00529,0.059505951,0.00586,0.04690469,Least Maturity,0.04690469,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Stromal Cell Source - hiPSC-CardiacF (8),0.00507,0.059405941,0.00594,0.04610461,Least Maturity,0.04610461,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Cell Line - iCell (47),0.00497,0.186718672,0.00705,0.04990499,Least Maturity,0.04990499,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Pharmacological Intervention - Doxorubicin (17),0.00456,0.101110111,0.00851,0.01820182,Least Maturity,0.01820182,TRUE,TRUE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Calcium Handling Analysis Method - Visual (104),0.00447,0.691569157,0.00738,0.04950495,Least Maturity,0.04950495,TRUE,FALSE
3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Purification Protocol - Antibiotic (4),0.0041,0.070007001,0.00566,0.04570457,Least Maturity,0.04570457,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),3D Platform - Scaffold Free (43),0.06345,0,0.05639,0,Least Maturity,0,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Deduced Culture Strategy - 3D Only (157),0.03323,0,0.01426,0,Least Maturity,0,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),0.03181,0,0.02915,0,Least Maturity,0,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),3D Tissue Media - Commercial Kit (21),0.02225,0,0.02456,0,Least Maturity,0,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Cell Coculture - Cardiomyocyte (157),0.0176,0.00080008,0.01004,0.00110011,Least Maturity,0.00080008,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),0.01718,0.00120012,0.01239,0.00070007,Least Maturity,0.00070007,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),0.01583,0.00260026,0.01078,0.00610061,Least Maturity,0.00260026,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),0.01308,0.00560056,0.00888,0.01790179,Least Maturity,0.00560056,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Deduced Culture Strategy - 2D Only (183),0.01238,0.00640064,0.0107,0.00150015,Least Maturity,0.00150015,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Electron Imaging - Transmission (62),0.01113,0.01270127,0.01133,0.00360036,Least Maturity,0.00360036,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),0.01107,0.010001,0.00706,0.053505351,Least Maturity,0.010001,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Contractile Analysis Method - Motion Tracking (93),0.01103,0.01190119,0.01081,0.00240024,Least Maturity,0.00240024,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Journal - Nat Biomed Eng (5),0.01061,0.00440044,0.01156,0.00550055,Least Maturity,0.00440044,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25),0.00898,0.0150015,0.00878,0.01270127,Least Maturity,0.01270127,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),hiPSC-CM Media Supplement - bFGF (3),0.00893,0.00840084,0.00912,0.01450145,Least Maturity,0.00840084,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),3D Tissue Media - iCell Maintenance (12),0.00846,0.01080108,0.01206,0.00240024,Least Maturity,0.00240024,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),hiPSC-CM Maturation Media - Commercial Kit (27),0.00772,0.02990299,0.00607,0.056805681,Least Maturity,0.02990299,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),0.00766,0.01850185,0.00853,0.01260126,Least Maturity,0.01260126,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Cell Line - WTC11 (30),0.00763,0.02970297,0.0029,0.362836284,Least Maturity,0.02970297,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Maturation Strategy - Other Cells (80),0.0075,0.067306731,0.00861,0.01760176,Least Maturity,0.01760176,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Journal - Rare (104),0.00653,0.186018602,0.0074,0.04510451,Least Maturity,0.04510451,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),0.00581,0.427442744,0.0076,0.03810381,Least Maturity,0.03810381,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),hiPSC-CM Media Supplement - VEGF (4),0.00574,0.03370337,0.00969,0.0170017,Least Maturity,0.0170017,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),0.00566,0.110411041,0.00795,0.02370237,Least Maturity,0.02370237,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),0.00531,0.03860386,0.00503,0.053805381,Least Maturity,0.03860386,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Metabolic Analysis Method - Flux Rates (13),0.00503,0.060706071,0.00813,0.01340134,Least Maturity,0.01340134,TRUE,TRUE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Coating for Replating - Fibronectin (32),0.00499,0.110911091,0.00693,0.03880388,Least Maturity,0.03880388,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),hiPSC-CM Backbone Media - Commercial CM Kit (12),0.00402,0.103810381,0.00629,0.03930393,Least Maturity,0.03930393,TRUE,FALSE
3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),3D Platform - 3D printed (9),0.00349,0.110311031,0.00618,0.03610361,Least Maturity,0.03610361,TRUE,FALSE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),0.15461,0,0.16472,0,Average Maturation,0,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),0.10891,0,0.09809,0,Average Maturation,0,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Cell Coculture - Cardiomyocyte (157),0.07494,0,0.05121,0,Average Maturation,0,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Deduced Culture Strategy - 3D Only (157),0.0408,0,0.03464,0,Average Maturation,0,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Cell Coculture - Stromal Cell (78),0.03083,0,0.03408,0,Average Maturation,0,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Maturation Strategy - Other Cells (80),0.02719,0,0.03425,0,Average Maturation,0,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Deduced Culture Strategy - 2D Only (183),0.02541,0,0.01915,0,Average Maturation,0,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),0.02156,0,0.01938,0,Average Maturation,0,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),3D Tissue Media - RPMI-1640 (72),0.01517,0.00030003,0.01399,0.00060006,Average Maturation,0.00030003,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Cell Coculture - Endothelial Cell (35),0.01183,0.00060006,0.01038,0.00240024,Average Maturation,0.00060006,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),0.01078,0.00240024,0.00855,0.00940094,Average Maturation,0.00240024,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),3D Platform - Scaffold Free (43),0.01048,0.00260026,0.01066,0.00320032,Average Maturation,0.00260026,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),3D Stromal Cell Source - Stromal Cell (35),0.00949,0.00740074,0.00685,0.02890289,Average Maturation,0.00740074,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Maturation Strategy - Tension (64),0.00867,0.01350135,0.00677,0.03510351,Average Maturation,0.01350135,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),3D Platform - Fibrin (50),0.0084,0.01060106,0.01064,0.00270027,Average Maturation,0.00270027,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),0.00669,0.02030203,0.00529,0.04950495,Average Maturation,0.02030203,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Seeding Confluency 3D (%) - Rare (26),0.00656,0.01990199,0.01073,0.00260026,Average Maturation,0.00260026,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),3D Stromal Cell Source - Human Fibroblast (38),0.00653,0.03370337,0.00537,0.064906491,Average Maturation,0.03370337,TRUE,FALSE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),0.00634,0.01730173,0.00761,0.00840084,Average Maturation,0.00840084,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),0.00602,0.02630263,0.00644,0.02430243,Average Maturation,0.02430243,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),0.00545,0.04710471,0.00636,0.02820282,Average Maturation,0.02820282,TRUE,FALSE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Seeding Confluency 3D (%) - 85 to 89 (12),0.00426,0.04050405,0.00609,0.02210221,Average Maturation,0.02210221,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Wnt Inhibitor - DS-I-7 (9),0.00375,0.04470447,0.00412,0.055405541,Average Maturation,0.04470447,TRUE,FALSE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),0.12923,0,0.12933,0,Average Maturation,0,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),0.06872,0,0.07393,0,Average Maturation,0,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),Cell Coculture - Stromal Cell (78),0.05676,0,0.05436,0,Average Maturation,0,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),Maturation Strategy - Other Cells (80),0.03962,0,0.03259,0,Average Maturation,0,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),Cell Coculture - Endothelial Cell (35),0.0386,0,0.04786,0,Average Maturation,0,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D Stromal Cell Source - Stromal Cell (35),0.03069,0,0.03262,0,Average Maturation,0,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),Cell Coculture - Cardiomyocyte (157),0.02764,0,0.01511,0,Average Maturation,0,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D Stromal Cell Source - Human Fibroblast (38),0.02271,0,0.02411,0,Average Maturation,0,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),Deduced Culture Strategy - 2D Only (183),0.0225,0,0.01673,0,Average Maturation,0,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),Deduced Culture Strategy - 3D Only (157),0.01858,0.00020002,0.0077,0.02880288,Average Maturation,0.00020002,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D Platform - Collagen (38),0.01154,0.00390039,0.01288,0.00170017,Average Maturation,0.00170017,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D Endothelial Cell Source - hiPSC-EndothelialC (16),0.01105,0.00230023,0.01188,0.00210021,Average Maturation,0.00210021,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D Stromal Cell Source - Cardiac Fibroblast (32),0.01022,0.00590059,0.01131,0.00270027,Average Maturation,0.00270027,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),Maturation Strategy - Tension (64),0.00976,0.0120012,0.00578,0.092909291,Average Maturation,0.0120012,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),0.00959,0.03270327,0.00547,0.338333833,Average Maturation,0.03270327,TRUE,FALSE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),0.00874,0.00370037,0.00863,0.00640064,Average Maturation,0.00370037,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21),0.00846,0.00870087,0.00968,0.00540054,Average Maturation,0.00540054,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29),0.00834,0.01140114,0.01262,0.00090009,Average Maturation,0.00090009,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),hiPSC Backbone Media - Conditioned (12),0.00719,0.01430143,0.00867,0.01140114,Average Maturation,0.01140114,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),0.00634,0.01690169,0.00891,0.01310131,Average Maturation,0.01310131,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17),0.00604,0.02570257,0.00548,0.04340434,Average Maturation,0.02570257,TRUE,FALSE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),0.00584,0.03170317,0.00442,0.092309231,Average Maturation,0.03170317,TRUE,FALSE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),0.0057,0.02190219,0.00753,0.0150015,Average Maturation,0.0150015,TRUE,TRUE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),0.00553,0.04270427,0.00439,0.094809481,Average Maturation,0.04270427,TRUE,FALSE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D Stromal Cell Source - Mesenchymal Stem Cell (12),0.0054,0.03630363,0.00415,0.091009101,Average Maturation,0.03630363,TRUE,FALSE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D Endothelial Cell Source - Rare (3),0.00445,0.04140414,0.00631,0.03650365,Average Maturation,0.03650365,TRUE,FALSE
3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D Stromal Cell Source - Dermal Fibroblast (7),0.00366,0.067306731,0.00644,0.02540254,Average Maturation,0.02540254,TRUE,FALSE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),0.10148,0,0.08896,0,Average Maturation,0,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Cell Coculture - Cardiomyocyte (157),0.0984,0,0.09822,0,Average Maturation,0,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Deduced Culture Strategy - 3D Only (157),0.09233,0,0.09204,0,Average Maturation,0,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),0.0526,0,0.0585,0,Average Maturation,0,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Deduced Culture Strategy - 2D Only (183),0.03278,0,0.0292,0,Average Maturation,0,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Cell Coculture - Endothelial Cell (35),0.02961,0,0.03484,0,Average Maturation,0,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Maturation Strategy - Tension (64),0.02031,0.00010001,0.02275,0,Average Maturation,0,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),2D Surface - ECM-coated (115),0.02024,0,0.01738,0.00020002,Average Maturation,0,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Platform - Fibrin (50),0.01607,0.00020002,0.01871,0.00020002,Average Maturation,0.00020002,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Contractile Analysis Method - Deflection (39),0.01437,0.00030003,0.01546,0.00040004,Average Maturation,0.00030003,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Cell Coculture - Stromal Cell (78),0.01387,0.00040004,0.01121,0.00280028,Average Maturation,0.00040004,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),0.01175,0.0010001,0.01451,0.00050005,Average Maturation,0.00050005,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),0.01049,0.00090009,0.01065,0.00150015,Average Maturation,0.00090009,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),0.01034,0.0040004,0.01001,0.00620062,Average Maturation,0.0040004,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29),0.01015,0.00290029,0.01245,0.00190019,Average Maturation,0.00190019,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),0.00982,0.00160016,0.00967,0.00270027,Average Maturation,0.00160016,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Tissue Media - RPMI-1640 (72),0.00959,0.00730073,0.01067,0.00620062,Average Maturation,0.00620062,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),0.00895,0.00230023,0.00949,0.00350035,Average Maturation,0.00230023,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Platform - Scaffold Free (43),0.00883,0.00880088,0.01074,0.00450045,Average Maturation,0.00450045,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Maturation Strategy - Other Cells (80),0.00868,0.01330133,0.00801,0.02370237,Average Maturation,0.01330133,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),0.0086,0.00510051,0.006,0.0420042,Average Maturation,0.00510051,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Platform - Collagen (38),0.00816,0.00780078,0.00859,0.00940094,Average Maturation,0.00780078,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Endothelial Cell Source - hiPSC-EndothelialC (16),0.00803,0.00430043,0.00977,0.00330033,Average Maturation,0.00330033,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),0.00715,0.00510051,0.00616,0.01620162,Average Maturation,0.00510051,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),0.0066,0.01580158,0.00685,0.01780178,Average Maturation,0.01580158,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),0.00646,0.01850185,0.00517,0.054505451,Average Maturation,0.01850185,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Platform - Matrigel (33),0.00621,0.0240024,0.00759,0.01210121,Average Maturation,0.01210121,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Stromal Cell Source - Human Fibroblast (38),0.00583,0.0390039,0.00494,0.083308331,Average Maturation,0.0390039,TRUE,FALSE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),0.00566,0.00640064,0.0048,0.01940194,Average Maturation,0.00640064,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Stromal Cell Source - Stromal Cell (35),0.00539,0.04470447,0.00528,0.057205721,Average Maturation,0.04470447,TRUE,FALSE
3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Seeding Confluency 3D (%) - 85 to 89 (12),0.00463,0.02020202,0.00394,0.04640464,Average Maturation,0.02020202,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Cell Coculture - Endothelial Cell (35),0.14424,0,0.15772,0,Average Maturation,0,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),0.09849,0,0.08368,0,Average Maturation,0,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D Endothelial Cell Source - hiPSC-EndothelialC (16),0.04892,0,0.05939,0,Average Maturation,0,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Cell Coculture - Stromal Cell (78),0.0288,0,0.02674,0,Average Maturation,0,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),0.02842,0,0.02287,0,Average Maturation,0,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Maturation Strategy - Other Cells (80),0.02639,0,0.01729,0.00010001,Average Maturation,0,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Deduced Culture Strategy - 3D Only (157),0.02496,0.00040004,0.012,0.00060006,Average Maturation,0.00040004,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),0.02289,0.00010001,0.0294,0,Average Maturation,0,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Deduced Culture Strategy - 2D Only (183),0.02101,0.00030003,0.00776,0.02690269,Average Maturation,0.00030003,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Cell Coculture - Cardiomyocyte (157),0.01906,0.00070007,0.00741,0.04970497,Average Maturation,0.00070007,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),0.01181,0.00180018,0.01622,0.00060006,Average Maturation,0.00060006,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),2D Surface - ECM-coated (115),0.01089,0.02360236,0.00219,0.9959996,Average Maturation,0.02360236,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D Stromal Cell Source - Stromal Cell (35),0.01034,0.00760076,0.00961,0.00690069,Average Maturation,0.00690069,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),0.00904,0.02770277,0.00478,0.278327833,Average Maturation,0.02770277,TRUE,FALSE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Contractile Analysis Method - Deflection (39),0.00884,0.02040204,0.00615,0.063206321,Average Maturation,0.02040204,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D Platform - 3D printed (9),0.00864,0.01170117,0.01109,0.00610061,Average Maturation,0.00610061,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D Tissue Media - MEM-α (60),0.00769,0.051105111,0.00694,0.04930493,Average Maturation,0.04930493,TRUE,FALSE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),0.0072,0.02650265,0.0045,0.104110411,Average Maturation,0.02650265,TRUE,FALSE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Pharmacological Intervention - Doxorubicin (17),0.00691,0.02340234,0.00832,0.01140114,Average Maturation,0.01140114,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D Stromal Cell Source - hiPSC-MuralC (3),0.00631,0.0230023,0.00765,0.02380238,Average Maturation,0.0230023,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),0.00623,0.03870387,0.00553,0.057905791,Average Maturation,0.03870387,TRUE,FALSE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Maturation Strategy - Tension (64),0.00617,0.114411441,0.01006,0.00470047,Average Maturation,0.00470047,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),0.0057,0.062606261,0.00777,0.02170217,Average Maturation,0.02170217,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D Endothelial Cell Source - Rare (3),0.00542,0.02130213,0.00618,0.02460246,Average Maturation,0.02130213,TRUE,TRUE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Insulin Start Day - 9 (10),0.00524,0.04880488,0.00453,0.074007401,Average Maturation,0.04880488,TRUE,FALSE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D Stromal Cell Source - hiPSC-SmoothMC (3),0.00509,0.02680268,0.00408,0.059605961,Average Maturation,0.02680268,TRUE,FALSE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Day of Insulin Addition - Known (177),0.00498,0.703070307,0.00755,0.04090409,Average Maturation,0.04090409,TRUE,FALSE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D Stromal Cell Source - hiPSC-CardiacF (8),0.00423,0.080208021,0.00729,0.02650265,Average Maturation,0.02650265,TRUE,FALSE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Journal - Front Cell Dev Biol (3),0.00222,0.165416542,0.00533,0.0390039,Average Maturation,0.0390039,TRUE,FALSE
3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Cell Line - 201B6 (3),0.00158,0.232723272,0.005,0.04860486,Average Maturation,0.04860486,TRUE,FALSE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),0.17457,0,0.17177,0,Average Maturation,0,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),0.09052,0,0.09102,0,Average Maturation,0,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),Cell Coculture - Cardiomyocyte (157),0.07262,0,0.05468,0,Average Maturation,0,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),Deduced Culture Strategy - 3D Only (157),0.05347,0,0.05157,0,Average Maturation,0,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),Cell Coculture - Stromal Cell (78),0.04604,0,0.0489,0,Average Maturation,0,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),Maturation Strategy - Other Cells (80),0.03228,0,0.03468,0,Average Maturation,0,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),Deduced Culture Strategy - 2D Only (183),0.01754,0.00010001,0.0127,0.00040004,Average Maturation,0.00010001,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D Stromal Cell Source - Human Fibroblast (38),0.01644,0.00030003,0.014,0.00150015,Average Maturation,0.00030003,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),0.01272,0.00210021,0.01639,0.00030003,Average Maturation,0.00030003,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D Stromal Cell Source - Cardiac Fibroblast (32),0.01067,0.00290029,0.00929,0.00540054,Average Maturation,0.00290029,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D Stromal Cell Source - Stromal Cell (35),0.01044,0.00470047,0.00828,0.01310131,Average Maturation,0.00470047,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),0.01008,0.00380038,0.01419,0.00110011,Average Maturation,0.00110011,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D Tissue Media - RPMI-1640 (72),0.00957,0.010001,0.00872,0.01110111,Average Maturation,0.010001,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),Seeding Confluency 3D (%) - Rare (26),0.00809,0.00670067,0.00943,0.00430043,Average Maturation,0.00430043,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D Platform - Fibrin (50),0.00774,0.01730173,0.00982,0.00510051,Average Maturation,0.00510051,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),0.00755,0.01090109,0.00765,0.01130113,Average Maturation,0.01090109,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),0.00742,0.01230123,0.00551,0.04510451,Average Maturation,0.01230123,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D Platform - Scaffold Free (43),0.00707,0.02640264,0.0092,0.00710071,Average Maturation,0.00710071,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),0.00582,0.02730273,0.00796,0.00780078,Average Maturation,0.00780078,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),Wnt Inhibitor - DS-I-7 (9),0.00577,0.01340134,0.00595,0.02310231,Average Maturation,0.01340134,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),Cell Coculture - Endothelial Cell (35),0.00575,0.04370437,0.00442,0.103210321,Average Maturation,0.04370437,TRUE,FALSE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D Platform - Collagen (38),0.00509,0.095509551,0.00592,0.04710471,Average Maturation,0.04710471,TRUE,FALSE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),0.00509,0.04540454,0.00512,0.04720472,Average Maturation,0.04540454,TRUE,FALSE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D Endothelial Cell Source - hiPSC-EndothelialC (16),0.00463,0.03730373,0.00171,0.444544454,Average Maturation,0.03730373,TRUE,FALSE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),Seeding Confluency 3D (%) - 85 to 89 (12),0.00429,0.04060406,0.0051,0.03760376,Average Maturation,0.03760376,TRUE,FALSE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D Platform - 3D printed (9),0.00398,0.04640464,0.00417,0.065006501,Average Maturation,0.04640464,TRUE,FALSE
3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),Wnt Inhibitor Duration (days) - >6 days (12),0.00207,0.230723072,0.00493,0.03910391,Average Maturation,0.03910391,TRUE,FALSE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),0.13458,0,0.13531,0,Average Maturation,0,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Cell Coculture - Stromal Cell (78),0.07008,0,0.06177,0,Average Maturation,0,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D Stromal Cell Source - Stromal Cell (35),0.04393,0,0.05245,0,Average Maturation,0,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Maturation Strategy - Other Cells (80),0.04368,0,0.03685,0,Average Maturation,0,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Cell Coculture - Cardiomyocyte (157),0.03465,0,0.01454,0.00010001,Average Maturation,0,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D Stromal Cell Source - Human Fibroblast (38),0.02615,0,0.02587,0,Average Maturation,0,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Deduced Culture Strategy - 2D Only (183),0.02273,0,0.01358,0.00010001,Average Maturation,0,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),0.02216,0.00020002,0.01527,0.00030003,Average Maturation,0.00020002,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Cell Coculture - Endothelial Cell (35),0.01933,0.00020002,0.02131,0,Average Maturation,0,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Deduced Culture Strategy - 3D Only (157),0.01921,0.00010001,0.01044,0.00090009,Average Maturation,0.00010001,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),0.01669,0.00050005,0.02022,0,Average Maturation,0,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D Stromal Cell Source - Cardiac Fibroblast (32),0.01543,0.00040004,0.01494,0.00030003,Average Maturation,0.00030003,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),0.00985,0.00230023,0.00987,0.00350035,Average Maturation,0.00230023,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D Platform - Scaffold Free (43),0.00969,0.01070107,0.0068,0.03550355,Average Maturation,0.01070107,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),0.0076,0.0080008,0.00976,0.00470047,Average Maturation,0.00470047,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D Platform - Collagen (38),0.00754,0.02650265,0.00889,0.00980098,Average Maturation,0.00980098,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),0.00726,0.01820182,0.00725,0.02060206,Average Maturation,0.01820182,TRUE,TRUE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),0.00676,0.161816182,0.00748,0.03330333,Average Maturation,0.03330333,TRUE,FALSE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D Stromal Cell Source - Mesenchymal Stem Cell (12),0.00553,0.03060306,0.00638,0.02540254,Average Maturation,0.02540254,TRUE,FALSE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21),0.00545,0.040004,0.00539,0.04250425,Average Maturation,0.040004,TRUE,FALSE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Disease Modelling - Fibrotic (4),0.00448,0.03940394,0.00517,0.055805581,Average Maturation,0.03940394,TRUE,FALSE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D Endothelial Cell Source - hiPSC-EndothelialC (16),0.00393,0.084808481,0.00519,0.04980498,Average Maturation,0.04980498,TRUE,FALSE
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D Stromal Cell Source - Dermal Fibroblast (7),0.0023,0.158315832,0.00494,0.04620462,Average Maturation,0.04620462,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Publication Year - Post 2020 (122),0.0202,0.00220022,0.00793,0.054005401,Average Maturation,0.00220022,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Publication Year - 2020 (51),0.0191,0.00290029,0.01735,0.00090009,Average Maturation,0.00090009,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),0.01787,0.00390039,0.00981,0.02510251,Average Maturation,0.00390039,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),0.0171,0.00320032,0.02024,0.00050005,Average Maturation,0.00050005,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Sacromere or Cellular Alignment Analysis - Yes (72),0.01659,0.0050005,0.01095,0.00980098,Average Maturation,0.0050005,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Maturation Strategy - Mechanical (36),0.01596,0.00380038,0.01128,0.01170117,Average Maturation,0.00380038,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Disease Modelling - Hypertrophic Cardiomyopathy (6),0.01528,0.00320032,0.0146,0.00620062,Average Maturation,0.00320032,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Publication Year - Late-2010s (196),0.01428,0.00880088,0.00836,0.03430343,Average Maturation,0.00880088,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),hiPSC-CM Purification Duration (days) - <3 days (31),0.01372,0.010001,0.00911,0.03120312,Average Maturation,0.010001,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Contractile Analysis Method - Traction Force Microscopy (9),0.0135,0.00580058,0.0123,0.0080008,Average Maturation,0.00580058,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Journal - Acta Biomater (10),0.01339,0.00720072,0.01006,0.01740174,Average Maturation,0.00720072,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),0.01028,0.04260426,0.0072,0.087208721,Average Maturation,0.04260426,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Electrophysiology Analysis Method - Patch Clamp (59),0.00988,0.0370037,0.0109,0.01250125,Average Maturation,0.01250125,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),0.00974,0.02080208,0.0099,0.01860186,Average Maturation,0.01860186,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Journal - Biosens Bioelectron (4),0.0094,0.01270127,0.0088,0.02310231,Average Maturation,0.01270127,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),0.00936,0.03910391,0.009,0.0370037,Average Maturation,0.0370037,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),0.0091,0.01690169,0.007,0.03570357,Average Maturation,0.01690169,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Coating for Replating - Fibronectin (32),0.00879,0.04430443,0.00517,0.158015802,Average Maturation,0.04430443,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),0.0083,0.03260326,0.0071,0.04940494,Average Maturation,0.03260326,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Pharmacological Intervention - Carbenoxolone (4),0.00814,0.02150215,0.00519,0.096709671,Average Maturation,0.02150215,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),3D Tissue Media - Growth Factor (12),0.00778,0.03480348,0.0095,0.01830183,Average Maturation,0.01830183,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),hiPSC Backbone Media - Conditioned (12),0.0076,0.0480048,0.00799,0.03780378,Average Maturation,0.03780378,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Coating for Replating - Geltrex (10),0.00747,0.04450445,0.00589,0.072907291,Average Maturation,0.04450445,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Journal - Nano Lett (3),0.0074,0.03920392,0.00467,0.106510651,Average Maturation,0.03920392,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),0.00723,0.03370337,0.00719,0.04020402,Average Maturation,0.03370337,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),New Media for Maturation - RPMI-1640 (30),0.00704,0.073707371,0.01048,0.01570157,Average Maturation,0.01570157,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Cell Line - iCell2 (8),0.00704,0.04660466,0.00518,0.090609061,Average Maturation,0.04660466,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),0.00681,0.04450445,0.0093,0.01520152,Average Maturation,0.01520152,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),2D Surface - Microparticle/fluid (3),0.00679,0.03940394,0.009,0.02390239,Average Maturation,0.02390239,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Coating for Replating - Rare (6),0.00652,0.03670367,0.00844,0.02580258,Average Maturation,0.02580258,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Journal - Circ Res (5),0.00402,0.118411841,0.01013,0.0150015,Average Maturation,0.0150015,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27),0.00391,0.202220222,0.00774,0.04310431,Average Maturation,0.04310431,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Seeding Confluency 2D (%) - 95 to 100 (6),0.00354,0.156315632,0.00858,0.02780278,Average Maturation,0.02780278,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Purification Protocol - Cell Sorting (7),0.00315,0.181818182,0.00735,0.03580358,Average Maturation,0.03580358,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Sacromere or Cellular Alignment Analysis - Yes (72),0.02535,0.00040004,0.01677,0.00030003,Average Maturation,0.00030003,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Insulin Start Day - 7 (85),0.01973,0.00170017,0.0079,0.063706371,Average Maturation,0.00170017,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),0.01793,0.00410041,0.01687,0.00470047,Average Maturation,0.00410041,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Wnt Inhibitor Duration (days) - 5 days (6),0.01486,0.0070007,0.01292,0.01190119,Average Maturation,0.0070007,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),0.01394,0.00680068,0.01009,0.01630163,Average Maturation,0.00680068,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),hiPSC-CM Backbone Media - Commercial CM Kit (12),0.01307,0.00840084,0.00769,0.03880388,Average Maturation,0.00840084,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),2D Surface - Micropatterned (27),0.01202,0.01660166,0.01403,0.00530053,Average Maturation,0.00530053,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Metabolic Component - T3 (14),0.01183,0.01420142,0.00667,0.057605761,Average Maturation,0.01420142,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Cell Line - Gibco episomal (10),0.01146,0.00910091,0.01233,0.00760076,Average Maturation,0.00760076,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Disease Modelling - Dilated Cardiomyopathy (6),0.01094,0.01470147,0.0138,0.00750075,Average Maturation,0.00750075,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),0.01007,0.02740274,0.01113,0.01640164,Average Maturation,0.01640164,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),3D Tissue Media - Iscove (5),0.00986,0.01810181,0.00859,0.03020302,Average Maturation,0.01810181,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),0.0098,0.02410241,0.00546,0.096609661,Average Maturation,0.02410241,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),hiPSC-CM Media Supplement - FBS (16),0.00966,0.0210021,0.00608,0.074307431,Average Maturation,0.0210021,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),0.00958,0.02280228,0.00966,0.02020202,Average Maturation,0.02020202,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Deduced Culture Strategy - 2D Only (183),0.00956,0.03880388,0.00752,0.086608661,Average Maturation,0.03880388,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),hiPSC-CM Maturation Media - Commercial Kit (27),0.00934,0.03540354,0.00577,0.106310631,Average Maturation,0.03540354,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Coating for Replating - Gelatin (43),0.00862,0.04780478,0.00706,0.078507851,Average Maturation,0.04780478,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),0.0084,0.03090309,0.00699,0.04780478,Average Maturation,0.03090309,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),0.00805,0.03710371,0.01011,0.01860186,Average Maturation,0.01860186,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),0.00801,0.02440244,0.00851,0.02870287,Average Maturation,0.02440244,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Day of Insulin Addition - not 21 (14),0.00791,0.04190419,0.00629,0.067306731,Average Maturation,0.04190419,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),0.00771,0.04090409,0.00549,0.083208321,Average Maturation,0.04090409,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Seeding Confluency (%) - 85 to 89 (43),0.00761,0.074407441,0.00924,0.03110311,Average Maturation,0.03110311,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),0.00758,0.04940494,0.0064,0.066906691,Average Maturation,0.04940494,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),0.00688,0.03950395,0.00527,0.095509551,Average Maturation,0.03950395,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),0.00687,0.04420442,0.00592,0.095409541,Average Maturation,0.04420442,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),0.00661,0.053905391,0.00765,0.03810381,Average Maturation,0.03810381,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Cell Line - BJ1 (7),0.00636,0.04870487,0.00403,0.144714471,Average Maturation,0.04870487,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Publication Year - 2014 (3),0.0056,0.060406041,0.00882,0.02180218,Average Maturation,0.02180218,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),0.00551,0.077607761,0.01091,0.01530153,Average Maturation,0.01530153,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),0.00503,0.150515052,0.00794,0.04890489,Average Maturation,0.04890489,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),0.00433,0.095109511,0.00624,0.04890489,Average Maturation,0.04890489,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Wnt Inhibitor Duration (days) Quantiles - Q2 (>1 and ≤2) (156),0.00284,0.96559656,0.00793,0.03560356,Average Maturation,0.03560356,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Wnt Inhibitor - XAV939 (24),0.01896,0.00150015,0.01028,0.01850185,Average Maturation,0.00150015,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Sacromere or Cellular Alignment Analysis - Yes (72),0.01802,0.00460046,0.00834,0.04840484,Average Maturation,0.00460046,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Cell Line - IMR90 (19),0.0173,0.00230023,0.0134,0.00510051,Average Maturation,0.00230023,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Number of Cell Lines - 2 (50),0.01604,0.00670067,0.00999,0.02480248,Average Maturation,0.00670067,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Electron Imaging - Transmission (62),0.01417,0.0090009,0.00847,0.050805081,Average Maturation,0.0090009,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Insulin Start Day - 7 (85),0.01407,0.0120012,0.01121,0.0090009,Average Maturation,0.0090009,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),0.0137,0.0050005,0.01024,0.01220122,Average Maturation,0.0050005,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Calcium Handling Analysis Method - Visual (104),0.01366,0.00970097,0.01191,0.00210021,Average Maturation,0.00210021,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),0.0124,0.01130113,0.02215,0.00030003,Average Maturation,0.00030003,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),3D Tissue Media - RPMI-1640 (72),0.01154,0.02190219,0.00762,0.073107311,Average Maturation,0.02190219,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),0.01137,0.01320132,0.00935,0.01860186,Average Maturation,0.01320132,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),0.01108,0.01360136,0.012,0.00860086,Average Maturation,0.00860086,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),hiPSC-CM Purification Duration (days) - 6 days (10),0.01106,0.01260126,0.00764,0.03970397,Average Maturation,0.01260126,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Maturation Strategy - Electrical (39),0.01079,0.02370237,0.00529,0.168316832,Average Maturation,0.02370237,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),hiPSC Backbone Media - mTeSR (106),0.01028,0.04680468,0.00597,0.231323132,Average Maturation,0.04680468,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Number of Cell Lines - 1 (225),0.01025,0.03890389,0.00802,0.055005501,Average Maturation,0.03890389,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),2D Surface - Micropatterned (27),0.01014,0.02940294,0.00823,0.03940394,Average Maturation,0.02940294,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Journal - Nano Lett (3),0.01013,0.01650165,0.01114,0.01960196,Average Maturation,0.01650165,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),0.00954,0.03110311,0.00543,0.111511151,Average Maturation,0.03110311,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Pharmacological Intervention - Adrenaline (83),0.00814,0.072607261,0.00923,0.03020302,Average Maturation,0.03020302,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),0.00744,0.04140414,0.01094,0.01230123,Average Maturation,0.01230123,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Cell Line - DF19-9-11T.H (16),0.00727,0.063006301,0.01007,0.02080208,Average Maturation,0.02080208,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Publication Year - 2016 (32),0.00725,0.071507151,0.00976,0.02290229,Average Maturation,0.02290229,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Journal - Acta Biomater (10),0.00709,0.04780478,0.01012,0.0170017,Average Maturation,0.0170017,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),0.00697,0.0330033,0.00628,0.050805081,Average Maturation,0.0330033,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Journal - ACS Appl Mater Interfaces (4),0.0066,0.055905591,0.00993,0.01760176,Average Maturation,0.01760176,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),0.00647,0.057405741,0.00949,0.02180218,Average Maturation,0.02180218,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),2D Surface - Nanotopography (6),0.00542,0.070207021,0.01098,0.01260126,Average Maturation,0.01260126,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Differentiation Purity Assessment - Visual Inspection (6),0.00536,0.076907691,0.00852,0.02380238,Average Maturation,0.02380238,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),New Media for Maturation - Rare (4),0.00506,0.091009101,0.00792,0.0410041,Average Maturation,0.0410041,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),3D Platform - Polyethylene Glycol (8),0.00506,0.086008601,0.01028,0.01690169,Average Maturation,0.01690169,TRUE,TRUE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Contractile Analysis Method - Rare (7),0.00488,0.089408941,0.00678,0.04730473,Average Maturation,0.04730473,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Pharmacological Intervention - Propranolol (5),0.00347,0.150615062,0.00746,0.03980398,Average Maturation,0.03980398,TRUE,FALSE
Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),0.00314,0.337433743,0.00932,0.03790379,Average Maturation,0.03790379,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Sacromere or Cellular Alignment Analysis - Yes (72),0.02337,0.00140014,0.00884,0.063906391,Average Maturation,0.00140014,TRUE,TRUE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Journal - Am J Physiol Heart Circ Physiol (4),0.0208,0.00230023,0.01875,0.00310031,Average Maturation,0.00230023,TRUE,TRUE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),0.01777,0.00350035,0.01618,0.00570057,Average Maturation,0.00350035,TRUE,TRUE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Cell Line - IMR90 (19),0.01693,0.00450045,0.00863,0.04010401,Average Maturation,0.00450045,TRUE,TRUE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),hiPSC Backbone Media - mTeSR (106),0.01539,0.00610061,0.00414,0.554755476,Average Maturation,0.00610061,TRUE,TRUE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Insulin Start Day - 7 (85),0.01408,0.01370137,0.01019,0.02370237,Average Maturation,0.01370137,TRUE,TRUE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),0.01222,0.01410141,0.01142,0.01860186,Average Maturation,0.01410141,TRUE,TRUE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Number of Cell Lines - 1 (225),0.01188,0.03270327,0.00753,0.119011901,Average Maturation,0.03270327,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Seeding Confluency (%) - 70 to 79 (11),0.01138,0.02610261,0.01246,0.01660166,Average Maturation,0.01660166,TRUE,TRUE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Publication Year - 2016 (32),0.01112,0.02860286,0.00981,0.03360336,Average Maturation,0.02860286,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Journal - Rare (104),0.01103,0.04640464,0.00303,0.771777178,Average Maturation,0.04640464,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Seeding Confluency 2D (%) - 80 to 84 (5),0.01074,0.01960196,0.01029,0.02420242,Average Maturation,0.01960196,TRUE,TRUE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Maturation Strategy - Metabolic (33),0.01062,0.04150415,0.00895,0.054905491,Average Maturation,0.04150415,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Journal - Circ Res (5),0.01061,0.02260226,0.01144,0.02160216,Average Maturation,0.02160216,TRUE,TRUE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),hiPSC Backbone Media - Embryonic Stem Cell (127),0.01038,0.03880388,0.00634,0.202920292,Average Maturation,0.03880388,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),0.01035,0.02330233,0.00697,0.077907791,Average Maturation,0.02330233,TRUE,TRUE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Pharmacological Intervention - Phenylephrine (3),0.01034,0.02590259,0.01216,0.02040204,Average Maturation,0.02040204,TRUE,TRUE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Cell Coculture - Cardiomyocyte (157),0.01031,0.04820482,0.0071,0.183118312,Average Maturation,0.04820482,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Electrophysiology Analysis Method - Patch Clamp (59),0.01004,0.055005501,0.01598,0.00120012,Average Maturation,0.00120012,TRUE,TRUE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Journal - J Mol Cell Cardiol (4),0.00972,0.02850285,0.00614,0.086908691,Average Maturation,0.02850285,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Coating for Replating - Laminin (5),0.0095,0.02220222,0.00844,0.0440044,Average Maturation,0.02220222,TRUE,TRUE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Journal - Circulation (11),0.00948,0.02760276,0.01143,0.01690169,Average Maturation,0.01690169,TRUE,TRUE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Journal - Stem Cells Int (3),0.00937,0.0270027,0.00926,0.04110411,Average Maturation,0.0270027,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Disease Modelling - Arrhythmic (15),0.00927,0.03950395,0.00779,0.056805681,Average Maturation,0.03950395,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),3D Stromal Cell Source - Rare (4),0.00922,0.03860386,0.00783,0.065906591,Average Maturation,0.03860386,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),0.00915,0.04150415,0.00889,0.04190419,Average Maturation,0.04150415,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Publication Year - 2017 (43),0.00912,0.056805681,0.00983,0.03250325,Average Maturation,0.03250325,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Metabolic Component Category - Amino Acids and Derivatives (9),0.00811,0.04380438,0.00546,0.115211521,Average Maturation,0.04380438,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Journal - Cell Stem Cell (6),0.00791,0.03980398,0.00684,0.064406441,Average Maturation,0.03980398,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Metabolic Component - Rare (4),0.00786,0.0350035,0.01031,0.0190019,Average Maturation,0.0190019,TRUE,TRUE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Cell Line - DF19-9-11T.H (16),0.00785,0.053205321,0.01021,0.02630263,Average Maturation,0.02630263,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),0.00778,0.04620462,0.00584,0.094309431,Average Maturation,0.04620462,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Pharmacological Intervention - Caffeine (4),0.00704,0.071507151,0.00932,0.04670467,Average Maturation,0.04670467,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Seeding Confluency 2D (%) - 90 to 94 (12),0.00682,0.074607461,0.01034,0.02950295,Average Maturation,0.02950295,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Seeding Confluency (%) - 80 to 84 (12),0.00679,0.070707071,0.00806,0.04880488,Average Maturation,0.04880488,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Day of Insulin Addition - not 25 (3),0.00648,0.061206121,0.01038,0.02460246,Average Maturation,0.02460246,TRUE,TRUE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Gene Analysis Method - RNA (169),0.00605,0.417841784,0.00975,0.01710171,Average Maturation,0.01710171,TRUE,TRUE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Metabolic Analysis Method - Mitochondrial (4),0.00429,0.100510051,0.00864,0.03310331,Average Maturation,0.03310331,TRUE,FALSE
Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Wnt Inhibitor - IWP (112),0.00141,0.99679968,0.00941,0.040004,Average Maturation,0.040004,TRUE,FALSE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Contractile Analysis Method - Force Transducer (27),0.04184,0.00020002,0.02901,0,Average Maturation,0,TRUE,TRUE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Journal - J Tissue Eng (4),0.02427,0.00240024,0.03024,0.00130013,Average Maturation,0.00130013,TRUE,TRUE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),hiPSC-CM Media Supplement - FBS (16),0.01912,0.00270027,0.01408,0.00780078,Average Maturation,0.00270027,TRUE,TRUE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Cell Line Sex - Both (118),0.01841,0.00450045,0.00624,0.221122112,Average Maturation,0.00450045,TRUE,TRUE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),hiPSC-CM Backbone Media - DMEM (18),0.01776,0.00550055,0.01466,0.00620062,Average Maturation,0.00550055,TRUE,TRUE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),0.01762,0.00740074,0.00978,0.03640364,Average Maturation,0.00740074,TRUE,TRUE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),hiPSC-CM Maturation Media - DMEM (35),0.01659,0.00850085,0.00884,0.04640464,Average Maturation,0.00850085,TRUE,TRUE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Journal - J Tissue Eng Regen Med (3),0.01633,0.00360036,0.02498,0.0020002,Average Maturation,0.0020002,TRUE,TRUE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Publication Year - 2018 (45),0.01574,0.00940094,0.01705,0.00150015,Average Maturation,0.00150015,TRUE,TRUE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),0.01446,0.01010101,0.01565,0.0080008,Average Maturation,0.0080008,TRUE,TRUE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),3D Platform - Fibrin (50),0.01392,0.01190119,0.01402,0.00680068,Average Maturation,0.00680068,TRUE,TRUE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),3D Stromal Cell Source - Rare (4),0.01371,0.00830083,0.0177,0.0050005,Average Maturation,0.0050005,TRUE,TRUE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Deduced Culture Strategy - 3D Only (157),0.01281,0.01890189,0.00448,0.657665767,Average Maturation,0.01890189,TRUE,TRUE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Immunofluorescent Imaging - Yes (268),0.01246,0.0250025,0.00618,0.165816582,Average Maturation,0.0250025,TRUE,FALSE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),0.01236,0.01230123,0.01054,0.01850185,Average Maturation,0.01230123,TRUE,TRUE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Cell Line Sex - Female (40),0.01202,0.03170317,0.00731,0.087308731,Average Maturation,0.03170317,TRUE,FALSE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Cell Line - 201B7 (9),0.01155,0.02150215,0.01936,0.00190019,Average Maturation,0.00190019,TRUE,TRUE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),hiPSC Matrix Coating - MEF feeder cells (8),0.01116,0.0180018,0.01084,0.01950195,Average Maturation,0.0180018,TRUE,TRUE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),0.01108,0.02620262,0.00929,0.04390439,Average Maturation,0.02620262,TRUE,FALSE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Wnt Induction Duration (days) Quantiles - Q1 (>2 and ≤5) (61),0.00992,0.04340434,0.00499,0.265226523,Average Maturation,0.04340434,TRUE,FALSE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Cell Line - IMR90 (19),0.00988,0.0370037,0.01018,0.02750275,Average Maturation,0.02750275,TRUE,FALSE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),hiPSC-CM Maturation Media - F12 (10),0.00974,0.03250325,0.00906,0.03890389,Average Maturation,0.03250325,TRUE,FALSE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),0.0089,0.04190419,0.00761,0.058205821,Average Maturation,0.04190419,TRUE,FALSE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Journal - Stem Cells (11),0.00834,0.03630363,0.01078,0.01960196,Average Maturation,0.01960196,TRUE,TRUE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Maturation Strategy - Other Cells (80),0.00802,0.085408541,0.01085,0.01570157,Average Maturation,0.01570157,TRUE,TRUE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),3D Platform - Polyethylene Glycol (8),0.00796,0.04820482,0.00518,0.120112011,Average Maturation,0.04820482,TRUE,FALSE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),hiPSC-CM Media Supplement - Mercaptoethanol (10),0.00725,0.04330433,0.00265,0.221022102,Average Maturation,0.04330433,TRUE,FALSE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),0.0068,0.100110011,0.01255,0.00880088,Average Maturation,0.00880088,TRUE,TRUE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27),0.00671,0.086708671,0.00861,0.04520452,Average Maturation,0.04520452,TRUE,FALSE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Maturation Strategy - Mechanical (36),0.00658,0.122512251,0.01091,0.03350335,Average Maturation,0.03350335,TRUE,FALSE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),0.00653,0.072107211,0.00992,0.02590259,Average Maturation,0.02590259,TRUE,FALSE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Wnt Induction Duration (days) - 4 days (15),0.00648,0.098709871,0.01035,0.03620362,Average Maturation,0.03620362,TRUE,FALSE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),hiPSC-CM Media Supplement - Nonessential Amino Acids (8),0.00637,0.056805681,0.00737,0.04560456,Average Maturation,0.04560456,TRUE,FALSE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Calcium Handling Analysis Method - Visual (104),0.00562,0.347034703,0.00876,0.04370437,Average Maturation,0.04370437,TRUE,FALSE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),0.0048,0.099209921,0.00871,0.02930293,Average Maturation,0.02930293,TRUE,FALSE
Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),3D Endothelial Cell Source - Rare (3),0.00376,0.083708371,0.00847,0.04980498,Average Maturation,0.04980498,TRUE,FALSE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Contractile Analysis Method - Deflection (39),0.02399,0.00050005,0.01698,0.00140014,Average Maturation,0.00050005,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Publication Year - 2021 (43),0.01662,0.0110011,0.00983,0.04670467,Average Maturation,0.0110011,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),3D Stromal Cell Source - Mesenchymal Stem Cell (12),0.01555,0.00760076,0.01162,0.01780178,Average Maturation,0.00760076,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),hiPSC-CM Media Supplement - Lipid Mix (5),0.0154,0.00670067,0.01428,0.01020102,Average Maturation,0.00670067,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58),0.01491,0.0130013,0.00843,0.071607161,Average Maturation,0.0130013,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),hiPSC-CM Backbone Media - StemPro-34 (14),0.0146,0.00750075,0.0119,0.01510151,Average Maturation,0.00750075,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),0.0144,0.01070107,0.00574,0.145014501,Average Maturation,0.01070107,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),0.01318,0.01530153,0.00889,0.04750475,Average Maturation,0.01530153,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Disease Modelling - Genetic Disorders (18),0.01257,0.01540154,0.01513,0.00460046,Average Maturation,0.00460046,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),hiPSC-CM Maturation Media - StemPro-34 (14),0.01234,0.0140014,0.01234,0.01020102,Average Maturation,0.01020102,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Seeding Confluency (%) - Rare (43),0.01208,0.02250225,0.00928,0.04570457,Average Maturation,0.02250225,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),3D Stromal Cell Source - Stromal Cell (35),0.01192,0.02930293,0.01118,0.02350235,Average Maturation,0.02350235,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),3D Tissue Media - MEM-α (60),0.01157,0.02730273,0.00876,0.04840484,Average Maturation,0.02730273,TRUE,FALSE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Cell Line - PGP1 (11),0.01144,0.02750275,0.00529,0.136413641,Average Maturation,0.02750275,TRUE,FALSE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),hiPSC-CM Media Supplement - Selenium (7),0.01132,0.02010201,0.01014,0.02780278,Average Maturation,0.02010201,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),3D Platform - Matrigel (33),0.0112,0.02330233,0.01406,0.00630063,Average Maturation,0.00630063,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Cell Line - BJ RiPS (4),0.01111,0.01950195,0.00921,0.051205121,Average Maturation,0.01950195,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Insulin Start Day - 6 (20),0.01111,0.02550255,0.01256,0.01430143,Average Maturation,0.01430143,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Maturation Strategy - Tension (64),0.01061,0.04010401,0.01065,0.03170317,Average Maturation,0.03170317,TRUE,FALSE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),hiPSC-CM Media Supplement - Polyvinylalchohol (6),0.01039,0.02120212,0.00764,0.059405941,Average Maturation,0.02120212,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),0.01007,0.03130313,0.0124,0.01480148,Average Maturation,0.01480148,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29),0.00965,0.04830483,0.01333,0.01330133,Average Maturation,0.01330133,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Maturation Strategy - ECM (21),0.00956,0.04020402,0.00947,0.03470347,Average Maturation,0.03470347,TRUE,FALSE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Publication Year - Post 2020 (122),0.00929,0.086708671,0.0089,0.0360036,Average Maturation,0.0360036,TRUE,FALSE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),3D Tissue Media - DMEM (53),0.00927,0.058205821,0.01051,0.02510251,Average Maturation,0.02510251,TRUE,FALSE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),hiPSC-CM Media Supplement - Ascorbic Acid (41),0.00924,0.04240424,0.00458,0.272527253,Average Maturation,0.04240424,TRUE,FALSE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Maturation Strategy - Other Cells (80),0.00902,0.055605561,0.01564,0.00070007,Average Maturation,0.00070007,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Publication Year - 2016 (32),0.00875,0.054405441,0.01013,0.03420342,Average Maturation,0.03420342,TRUE,FALSE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Journal - Lab Chip (4),0.00863,0.04420442,0.01018,0.03130313,Average Maturation,0.03130313,TRUE,FALSE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),hiPSC-CM Media Supplement - Transferrin (11),0.00849,0.03910391,0.01445,0.00510051,Average Maturation,0.00510051,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),hiPSC-CM Media Supplement - Lipids (9),0.0084,0.03760376,0.008,0.04920492,Average Maturation,0.03760376,TRUE,FALSE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),0.00833,0.02760276,0.00956,0.02170217,Average Maturation,0.02170217,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Wnt Inhibitor Duration (days) - 3 days (17),0.00827,0.03910391,0.00536,0.118911891,Average Maturation,0.03910391,TRUE,FALSE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),0.00775,0.052205221,0.00805,0.04760476,Average Maturation,0.04760476,TRUE,FALSE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Insulin Start Day - 3 (5),0.00751,0.074107411,0.00993,0.04060406,Average Maturation,0.04060406,TRUE,FALSE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Journal - Stem Cell Res Ther (3),0.00729,0.062506251,0.01058,0.04130413,Average Maturation,0.04130413,TRUE,FALSE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Journal - ACS Biomater Sci Eng (3),0.00704,0.060106011,0.00943,0.04850485,Average Maturation,0.04850485,TRUE,FALSE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),hiPSC-CM Maturation Media - Commercial Kit (27),0.00632,0.105510551,0.00926,0.03390339,Average Maturation,0.03390339,TRUE,FALSE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),0.00541,0.117411741,0.00915,0.03410341,Average Maturation,0.03410341,TRUE,FALSE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),0.00499,0.095409541,0.0097,0.02180218,Average Maturation,0.02180218,TRUE,TRUE
Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),0.00456,0.122212221,0.01116,0.01410141,Average Maturation,0.01410141,TRUE,TRUE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),0.03074,0.00030003,0.02618,0.00060006,Average Maturation,0.00030003,TRUE,TRUE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),0.02875,0.00080008,0.03078,0.00010001,Average Maturation,0.00010001,TRUE,TRUE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Maturation Strategy - Tension (64),0.0276,0.00020002,0.00939,0.057005701,Average Maturation,0.00020002,TRUE,TRUE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),3D Tissue Media - MEM-α (60),0.02206,0.00170017,0.00686,0.137413741,Average Maturation,0.00170017,TRUE,TRUE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Contractile Analysis Method - Deflection (39),0.01817,0.00640064,0.0145,0.00760076,Average Maturation,0.00640064,TRUE,TRUE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Insulin Withdrawal Duration (days) Quantiles - Q2 (>2 and ≤4) (25),0.01618,0.01040104,0.0167,0.00380038,Average Maturation,0.00380038,TRUE,TRUE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),hiPSC-CM Media Supplement - HEPES (16),0.01509,0.010001,0.00966,0.04110411,Average Maturation,0.010001,TRUE,TRUE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),0.014,0.00990099,0.00438,0.548354835,Average Maturation,0.00990099,TRUE,TRUE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21),0.01369,0.01570157,0.00775,0.081408141,Average Maturation,0.01570157,TRUE,TRUE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),3D Platform - Fibrin (50),0.01302,0.01770177,0.00724,0.127912791,Average Maturation,0.01770177,TRUE,TRUE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),3D Tissue Media - DMEM (53),0.01249,0.02420242,0.01333,0.01070107,Average Maturation,0.01070107,TRUE,TRUE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),0.01225,0.0220022,0.00894,0.04990499,Average Maturation,0.0220022,TRUE,TRUE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Journal - Stem Cell Reports (23),0.01168,0.02620262,0.0164,0.00430043,Average Maturation,0.00430043,TRUE,TRUE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Deduced Culture Strategy - 3D Only (157),0.01166,0.03170317,0.00368,0.803180318,Average Maturation,0.03170317,TRUE,FALSE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),0.01128,0.0220022,0.00727,0.075807581,Average Maturation,0.0220022,TRUE,TRUE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),0.01051,0.0260026,0.01204,0.01890189,Average Maturation,0.01890189,TRUE,TRUE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Insulin Start Day - 6 (20),0.01031,0.03620362,0.01103,0.02680268,Average Maturation,0.02680268,TRUE,FALSE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Seeding Confluency 3D (%) - Rare (26),0.01009,0.03690369,0.00704,0.094109411,Average Maturation,0.03690369,TRUE,FALSE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Pharmacological Intervention - Rare (3),0.00991,0.02710271,0.01089,0.02910291,Average Maturation,0.02710271,TRUE,FALSE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),3D Platform - Extracellular Scaffold (18),0.00945,0.04540454,0.0081,0.060606061,Average Maturation,0.04540454,TRUE,FALSE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Gene Analysis Method - Rare (5),0.00945,0.02770277,0.00245,0.126912691,Average Maturation,0.02770277,TRUE,FALSE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Day of Insulin Addition - not 12 (11),0.00935,0.03550355,0.011,0.02370237,Average Maturation,0.02370237,TRUE,TRUE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Journal - Circulation (11),0.00929,0.03620362,0.00824,0.04960496,Average Maturation,0.03620362,TRUE,FALSE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),3D Platform - Gelatin (6),0.00884,0.0420042,0.00802,0.055805581,Average Maturation,0.0420042,TRUE,FALSE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Insulin Withdrawal Duration (days) - 3 days (6),0.00851,0.051905191,0.01255,0.0150015,Average Maturation,0.0150015,TRUE,TRUE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Journal - Cell Stem Cell (6),0.00756,0.077807781,0.01149,0.02320232,Average Maturation,0.02320232,TRUE,TRUE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Number of Cell Lines - 4 (11),0.00728,0.066206621,0.0106,0.02650265,Average Maturation,0.02650265,TRUE,FALSE
Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),0.00549,0.093609361,0.01039,0.03540354,Average Maturation,0.03540354,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),0.03522,0.00020002,0.02117,0.00060006,Average Maturation,0.00020002,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),0.02738,0.00140014,0.01399,0.00820082,Average Maturation,0.00140014,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Metabolic Component - Dexamethasone (7),0.02337,0.00160016,0.02225,0.00280028,Average Maturation,0.00160016,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Maturation Strategy - Tension (64),0.02184,0.00210021,0.01129,0.01220122,Average Maturation,0.00210021,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),3D Stromal Cell Source - Dermal Fibroblast (7),0.0188,0.00360036,0.02363,0.00110011,Average Maturation,0.00110011,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),3D Tissue Media - RPMI-1640 (72),0.016,0.00860086,0.01061,0.03020302,Average Maturation,0.00860086,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),3D Stromal Cell Source - Cardiac Fibroblast (32),0.01553,0.00970097,0.00582,0.153715372,Average Maturation,0.00970097,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Metabolic Component - IGF-1 (3),0.01535,0.00360036,0.0223,0.00120012,Average Maturation,0.00120012,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),3D Platform - Fibrin (50),0.01445,0.01590159,0.01524,0.00350035,Average Maturation,0.00350035,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Seeding Confluency 3D (%) - 90 to 94 (13),0.01444,0.01120112,0.01871,0.00220022,Average Maturation,0.00220022,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Cell Coculture - Stromal Cell (78),0.01413,0.01880188,0.00306,0.651065107,Average Maturation,0.01880188,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Deduced Culture Strategy - 3D Only (157),0.01343,0.01930193,0.0016,0.97879788,Average Maturation,0.01930193,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Journal - Nat Biomed Eng (5),0.01342,0.00940094,0.01276,0.01520152,Average Maturation,0.00940094,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),0.01311,0.01870187,0.00778,0.077207721,Average Maturation,0.01870187,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),hiPSC Matrix Coating - MEF feeder cells (8),0.01262,0.01390139,0.00952,0.03150315,Average Maturation,0.01390139,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),3D Stromal Cell Source - Human Fibroblast (38),0.01219,0.02630263,0.00825,0.077107711,Average Maturation,0.02630263,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),3D Platform - Extracellular Scaffold (18),0.01194,0.0240024,0.01207,0.01640164,Average Maturation,0.01640164,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),0.01193,0.02320232,0.00331,0.779777978,Average Maturation,0.02320232,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Contractile Analysis Method - Deflection (39),0.01149,0.03110311,0.01069,0.03290329,Average Maturation,0.03110311,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Publication Year - Post 2020 (122),0.01079,0.03680368,0.00987,0.02330233,Average Maturation,0.02330233,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Maturation Strategy - Other Cells (80),0.01055,0.04230423,0.00374,0.471647165,Average Maturation,0.04230423,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Insulin Start Day - 11 (3),0.01052,0.03750375,0.01716,0.00810081,Average Maturation,0.00810081,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),0.01004,0.02960296,0.01072,0.02440244,Average Maturation,0.02440244,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Number of Cell Lines - 4 (11),0.00972,0.03070307,0.009,0.03810381,Average Maturation,0.03070307,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Journal - PLoS One (9),0.00969,0.02790279,0.01011,0.02770277,Average Maturation,0.02770277,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),0.00942,0.03390339,0.00899,0.03960396,Average Maturation,0.03390339,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),0.00917,0.04350435,0.00981,0.04210421,Average Maturation,0.04210421,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Journal - ACS Biomater Sci Eng (3),0.00776,0.04870487,0.01013,0.03360336,Average Maturation,0.03360336,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Journal - J Mol Cell Card (6),0.00602,0.074007401,0.00824,0.040004,Average Maturation,0.040004,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Maturation Strategy - Metabolic (33),0.00592,0.128412841,0.00918,0.04780478,Average Maturation,0.04780478,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),0.00539,0.116911691,0.00849,0.04460446,Average Maturation,0.04460446,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Journal - J Mol Cell Cardiol (4),0.00444,0.091809181,0.00944,0.03660366,Average Maturation,0.03660366,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17),0.03838,0,0.0365,0,Average Maturation,0,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Cell Line - 201B6 (3),0.03011,0.00040004,0.03738,0.00010001,Average Maturation,0.00010001,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),3D Platform - Collagen (38),0.02749,0.00070007,0.01741,0.00180018,Average Maturation,0.00070007,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),hiPSC-CM Purification Duration (days) - 4 days (29),0.02633,0.00040004,0.01585,0.00560056,Average Maturation,0.00040004,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Contractile Analysis Method - Force Transducer (27),0.02221,0.0020002,0.01744,0.0020002,Average Maturation,0.0020002,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Wnt Induction - Wnt3a (3),0.0213,0.00120012,0.03619,0,Average Maturation,0,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),3D Platform - Matrigel (33),0.01992,0.00410041,0.01127,0.01850185,Average Maturation,0.00410041,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Journal - Biosens Bioelectron (4),0.01844,0.00380038,0.01394,0.01660166,Average Maturation,0.00380038,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),3D Stromal Cell Source - hiPSC-MuralC (3),0.01825,0.0030003,0.02334,0.0020002,Average Maturation,0.0020002,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),3D Stromal Cell Source - Stromal Cell (35),0.01655,0.00550055,0.01082,0.02260226,Average Maturation,0.00550055,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Maturation Strategy - Tension (64),0.01566,0.01190119,0.00764,0.088108811,Average Maturation,0.01190119,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Cell Line - iCell2 (8),0.01551,0.01070107,0.01056,0.02550255,Average Maturation,0.01070107,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),3D Endothelial Cell Source - hiPSC-EndothelialC (16),0.01527,0.01170117,0.01278,0.01760176,Average Maturation,0.01170117,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Coating for Replating - Laminin (5),0.01413,0.00710071,0.01157,0.01760176,Average Maturation,0.00710071,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Wnt Induction - Activin A (80),0.01317,0.01640164,0.0077,0.078607861,Average Maturation,0.01640164,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),0.01237,0.01650165,0.01536,0.00990099,Average Maturation,0.00990099,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Cell Line Sex - Female (40),0.01212,0.03780378,0.01369,0.01460146,Average Maturation,0.01460146,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Contractile Analysis Method - Traction Force Microscopy (9),0.01172,0.01830183,0.01188,0.01670167,Average Maturation,0.01670167,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Wnt Inhibitor - XAV939 (24),0.0115,0.02520252,0.0064,0.120912091,Average Maturation,0.02520252,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Publication Year - 2021 (43),0.01138,0.03130313,0.01259,0.01520152,Average Maturation,0.01520152,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),0.0112,0.02150215,0.01223,0.01840184,Average Maturation,0.01840184,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),3D Stromal Cell Source - Mesenchymal Stem Cell (12),0.01096,0.02090209,0.00835,0.04560456,Average Maturation,0.02090209,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),0.01071,0.04790479,0.01303,0.01540154,Average Maturation,0.01540154,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Cell Coculture - Stromal Cell (78),0.01063,0.04560456,0.00288,0.674267427,Average Maturation,0.04560456,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Day of Insulin Addition - not 10 (4),0.0106,0.01730173,0.01197,0.01630163,Average Maturation,0.01630163,TRUE,TRUE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),0.01016,0.04060406,0.00927,0.04410441,Average Maturation,0.04060406,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),hiPSC Backbone Media - Conditioned (12),0.00988,0.02910291,0.00686,0.069206921,Average Maturation,0.02910291,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Maturation Strategy - Mechanical (36),0.00981,0.04990499,0.0073,0.099909991,Average Maturation,0.04990499,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),0.00761,0.070007001,0.00987,0.03580358,Average Maturation,0.03580358,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),0.00534,0.113711371,0.0082,0.0450045,Average Maturation,0.0450045,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Journal - Sci Transl Med (3),0.005,0.081808181,0.01168,0.03370337,Average Maturation,0.03370337,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),0.00383,0.103010301,0.01183,0.0350035,Average Maturation,0.0350035,TRUE,FALSE
Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Wnt Induction Duration (days) - 5 days (8),0.00363,0.170817082,0.00865,0.0470047,Average Maturation,0.0470047,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Contractile Analysis Method - Motion Tracking (93),0.03446,0,0.01448,0.0020002,Average Maturation,0,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),3D Tissue Media - RPMI-1640 (72),0.01689,0.00620062,0.00781,0.121212121,Average Maturation,0.00620062,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Publication Year - 2021 (43),0.01359,0.0190019,0.00923,0.056805681,Average Maturation,0.0190019,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),0.01305,0.01360136,0.01074,0.02140214,Average Maturation,0.01360136,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),3D Platform - Gelatin (6),0.01284,0.01160116,0.01302,0.01260126,Average Maturation,0.01160116,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Pharmacological Intervention - Cardiotoxic Agents (3),0.01201,0.01610161,0.01878,0.00340034,Average Maturation,0.00340034,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Day of Insulin Addition - not 23 (10),0.01171,0.02030203,0.00958,0.03150315,Average Maturation,0.02030203,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),0.01152,0.01450145,0.00983,0.03240324,Average Maturation,0.01450145,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),3D Platform - Fibronectin (3),0.01144,0.01110111,0.01366,0.0080008,Average Maturation,0.0080008,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),0.01126,0.01560156,0.01111,0.01410141,Average Maturation,0.01410141,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Journal - Biomaterials (16),0.01114,0.03060306,0.0088,0.052105211,Average Maturation,0.03060306,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Day of Insulin Addition - not 21 (14),0.0111,0.02410241,0.01106,0.01780178,Average Maturation,0.01780178,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Journal - J Mol Cell Cardiol (4),0.01063,0.01070107,0.01168,0.01260126,Average Maturation,0.01070107,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),0.01011,0.03960396,0.01118,0.02040204,Average Maturation,0.02040204,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Day of Insulin Addition - not 24 (9),0.00999,0.02020202,0.00859,0.03010301,Average Maturation,0.02020202,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Metabolic Component Category - Kinase Inhibitors (3),0.00903,0.02510251,0.00603,0.069206921,Average Maturation,0.02510251,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Wnt Induction Duration (days) Quantiles - Q2 (>1 and ≤2) (75),0.00896,0.062006201,0.01333,0.0070007,Average Maturation,0.0070007,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Journal - Nat Commun (13),0.00895,0.04060406,0.00879,0.04210421,Average Maturation,0.04060406,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Journal - ACS Biomater Sci Eng (3),0.00842,0.03380338,0.01245,0.01250125,Average Maturation,0.01250125,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),0.00837,0.03980398,0.00744,0.059105911,Average Maturation,0.03980398,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),3D Platform - 3D printed (9),0.0083,0.04090409,0.00946,0.03160316,Average Maturation,0.03160316,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Seeding Confluency 2D (%) - 90 to 94 (12),0.00796,0.04160416,0.00701,0.053005301,Average Maturation,0.04160416,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),0.00748,0.055805581,0.00885,0.040004,Average Maturation,0.040004,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Pharmacological Intervention - Thalidomide (3),0.00711,0.057205721,0.00906,0.04750475,Average Maturation,0.04750475,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Cell Line - Cellapy (4),0.00705,0.064806481,0.01361,0.01190119,Average Maturation,0.01190119,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Seeding Confluency 3D (%) - 70 to 79 (3),0.00673,0.054505451,0.00823,0.04710471,Average Maturation,0.04710471,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),3D Platform - Polyethylene Glycol (8),0.00628,0.065206521,0.00998,0.02270227,Average Maturation,0.02270227,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Insulin Withdrawal Duration (days) Quantiles - Q2 (>2 and ≤4) (25),0.00539,0.153115312,0.00917,0.04440444,Average Maturation,0.04440444,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Differentiation Purity Assessment - IHC cTnT (7),0.00528,0.118011801,0.01267,0.01410141,Average Maturation,0.01410141,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Insulin Start Day - 9 (10),0.0052,0.097509751,0.00781,0.04230423,Average Maturation,0.04230423,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),hiPSC-CM Maturation Media - Commercial Kit (27),0.0049,0.156015602,0.00901,0.0420042,Average Maturation,0.0420042,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),0.00432,0.173117312,0.0082,0.04960496,Average Maturation,0.04960496,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Journal - Biomater Sci (7),0.03284,0.00020002,0.03021,0.00060006,Average Maturation,0.00020002,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Sacromere or Cellular Alignment Analysis - Yes (72),0.02106,0.00460046,0.01652,0.00290029,Average Maturation,0.00290029,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),0.02047,0.00260026,0.01484,0.01070107,Average Maturation,0.00260026,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),2D Surface - Decellularized ECM (3),0.01931,0.00510051,0.02201,0.00330033,Average Maturation,0.00330033,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),0.01861,0.01340134,0.01093,0.04830483,Average Maturation,0.01340134,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),0.01814,0.00650065,0.02275,0.00190019,Average Maturation,0.00190019,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Cell Line - 253G1 (10),0.0179,0.01190119,0.01542,0.01350135,Average Maturation,0.01190119,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Contractile Analysis Method - Motion Tracking (93),0.01654,0.01120112,0.01394,0.00760076,Average Maturation,0.00760076,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),3D Platform - Polyethylene Glycol (8),0.01554,0.00990099,0.01272,0.01910191,Average Maturation,0.00990099,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),0.01401,0.03530353,0.01115,0.059005901,Average Maturation,0.03530353,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),3D Tissue Media - DMEM (53),0.01388,0.01870187,0.00988,0.053305331,Average Maturation,0.01870187,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),0.01357,0.01350135,0.02014,0.00330033,Average Maturation,0.00330033,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Calcium Handling Analysis Method - Visual (104),0.01351,0.02280228,0.00586,0.279627963,Average Maturation,0.02280228,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Contractile Analysis Method - Rare (7),0.01215,0.01910191,0.01351,0.01350135,Average Maturation,0.01350135,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Wnt Inhibitor - Rare (3),0.01201,0.03140314,0.00944,0.054405441,Average Maturation,0.03140314,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Wnt Inhibitor - IWP (112),0.01118,0.052105211,0.01177,0.00980098,Average Maturation,0.00980098,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),3D Stromal Cell Source - hiPSC-SmoothMC (3),0.01075,0.04610461,0.00785,0.059305931,Average Maturation,0.04610461,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),2D Surface - Micropatterned (27),0.01069,0.03230323,0.01084,0.03230323,Average Maturation,0.03230323,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Insulin Start Day - 7 (85),0.01064,0.075907591,0.01284,0.01640164,Average Maturation,0.01640164,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Seeding Confluency 2D (%) - 85 to 89 (26),0.01041,0.04660466,0.0097,0.051105111,Average Maturation,0.04660466,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),0.01011,0.04980498,0.01132,0.03760376,Average Maturation,0.03760376,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),0.0098,0.03950395,0.00273,0.157815782,Average Maturation,0.03950395,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Number of Cell Lines - 4 (11),0.00942,0.04310431,0.01398,0.01640164,Average Maturation,0.01640164,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Journal - Acta Biomater (10),0.00838,0.072007201,0.0118,0.0310031,Average Maturation,0.0310031,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Seeding Confluency 2D (%) - Rare (13),0.00817,0.067406741,0.01385,0.01590159,Average Maturation,0.01590159,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),0.00742,0.091709171,0.01196,0.02290229,Average Maturation,0.02290229,TRUE,TRUE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Publication Year - 2017 (43),0.00688,0.129812981,0.01038,0.04780478,Average Maturation,0.04780478,TRUE,FALSE
Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Seeding Confluency (%) - 85 to 89 (43),0.00455,0.258925893,0.01179,0.03640364,Average Maturation,0.03640364,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Electron Imaging - Transmission (62),0.02432,0.00120012,0.01409,0.00710071,Average Maturation,0.00120012,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),0.0229,0.00040004,0.01708,0.00250025,Average Maturation,0.00040004,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),0.02229,0.00120012,0.02133,0.00120012,Average Maturation,0.00120012,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Electrophysiology Analysis Method - Patch Clamp (59),0.02168,0.00290029,0.01066,0.0270027,Average Maturation,0.00290029,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),0.02113,0.00330033,0.01165,0.01930193,Average Maturation,0.00330033,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),0.01458,0.01080108,0.00987,0.02890289,Average Maturation,0.01080108,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),0.01395,0.01450145,0.01234,0.01690169,Average Maturation,0.01450145,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),0.01375,0.00840084,0.00931,0.03190319,Average Maturation,0.00840084,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Electron Imaging - Scanning (22),0.01346,0.01540154,0.0112,0.02050205,Average Maturation,0.01540154,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),0.01203,0.01330133,0.00633,0.096609661,Average Maturation,0.01330133,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Maturation Strategy - Cell Alignment (59),0.01166,0.02610261,0.00894,0.057805781,Average Maturation,0.02610261,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Metabolic Analysis Method - Genetic (3),0.0111,0.00840084,0.01012,0.02320232,Average Maturation,0.00840084,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Metabolic Analysis Method - Flux Rates (13),0.01037,0.02470247,0.01032,0.02420242,Average Maturation,0.02420242,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Journal - ACS Appl Mater Interfaces (4),0.01024,0.02420242,0.00854,0.04920492,Average Maturation,0.02420242,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Cell Line Ancestry - Asian (28),0.00989,0.04440444,0.00566,0.135413541,Average Maturation,0.04440444,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Journal - Acta Biomater (10),0.0094,0.03350335,0.00948,0.03080308,Average Maturation,0.03080308,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),3D Tissue Media - Commercial Kit (21),0.00912,0.053605361,0.01138,0.02420242,Average Maturation,0.02420242,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Publication Year - 2024 (7),0.00909,0.03910391,0.00983,0.03240324,Average Maturation,0.03240324,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),0.00866,0.03470347,0.00893,0.03430343,Average Maturation,0.03430343,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),0.00858,0.03280328,0.01012,0.02050205,Average Maturation,0.02050205,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),0.00811,0.133613361,0.00955,0.01710171,Average Maturation,0.01710171,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Journal - PLoS One (9),0.0078,0.03940394,0.00666,0.065606561,Average Maturation,0.03940394,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),0.00776,0.03290329,0.00495,0.107910791,Average Maturation,0.03290329,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),0.00772,0.04410441,0.00729,0.050105011,Average Maturation,0.04410441,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),3D Stromal Cell Source - Rare (4),0.00766,0.04980498,0.01154,0.01690169,Average Maturation,0.01690169,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Sacromere or Cellular Alignment Analysis - Yes (72),0.00642,0.163416342,0.01233,0.00660066,Average Maturation,0.00660066,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),0.00605,0.095009501,0.01278,0.02280228,Average Maturation,0.02280228,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),0.00588,0.073507351,0.01009,0.01760176,Average Maturation,0.01760176,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Maturation Strategy - Electrical (39),0.00553,0.161716172,0.00947,0.03520352,Average Maturation,0.03520352,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Seeding Confluency (%) - 85 to 89 (43),0.00506,0.222022202,0.01276,0.01370137,Average Maturation,0.01370137,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Cell Line - iCell (47),0.00415,0.302330233,0.01015,0.03160316,Average Maturation,0.03160316,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),New Media for Maturation - DMEM (21),0.00173,0.397139714,0.00836,0.0480048,Average Maturation,0.0480048,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Seeding Confluency 2D (%) - 80 to 84 (5),0.01886,0.00450045,0.02184,0.00240024,Average Maturation,0.00240024,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),0.01728,0.00520052,0.01626,0.00710071,Average Maturation,0.00520052,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Calcium Handling Analysis Method - Genetic (23),0.01664,0.00810081,0.01753,0.00280028,Average Maturation,0.00280028,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Cell Line - Rare (132),0.01634,0.00540054,0.00734,0.106810681,Average Maturation,0.00540054,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),0.01541,0.01190119,0.0212,0.00130013,Average Maturation,0.00130013,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),0.01527,0.00820082,0.01793,0.00310031,Average Maturation,0.00310031,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),0.01492,0.00920092,0.01578,0.00740074,Average Maturation,0.00740074,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Journal - Nano Lett (3),0.01469,0.00460046,0.01901,0.00220022,Average Maturation,0.00220022,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Calcium Handling Analysis Method - Visual (104),0.01432,0.0160016,0.0155,0.00090009,Average Maturation,0.00090009,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Maturation Strategy - Other Cells (80),0.01425,0.01020102,0.00388,0.487448745,Average Maturation,0.01020102,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Seeding Confluency (%) - 80 to 84 (12),0.01337,0.01320132,0.00985,0.03040304,Average Maturation,0.01320132,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Insulin Start Day - 7 (85),0.01313,0.01790179,0.01059,0.02020202,Average Maturation,0.01790179,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),3D Stromal Cell Source - Stromal Cell (35),0.01236,0.02390239,0.00876,0.04680468,Average Maturation,0.02390239,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Sacromere or Cellular Alignment Analysis - Yes (72),0.01232,0.02660266,0.01168,0.01050105,Average Maturation,0.01050105,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),0.01172,0.01330133,0.01114,0.02330233,Average Maturation,0.01330133,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),3D Platform - Scaffold Free (43),0.01151,0.02810281,0.01368,0.00680068,Average Maturation,0.00680068,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Publication Year - 2015 (19),0.0114,0.02150215,0.00568,0.122712271,Average Maturation,0.02150215,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Journal - J Mol Cell Cardiol (4),0.01116,0.02620262,0.00664,0.095409541,Average Maturation,0.02620262,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Journal - Tissue Eng Part A (4),0.01076,0.01870187,0.01392,0.00980098,Average Maturation,0.00980098,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Cell Line - DF19-9-11T.H (16),0.01067,0.02830283,0.01258,0.01380138,Average Maturation,0.01380138,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Cell Line - 253G1 (10),0.01046,0.0230023,0.00717,0.062006201,Average Maturation,0.0230023,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),0.01006,0.02140214,0.01072,0.01680168,Average Maturation,0.01680168,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Journal - J Mol Cell Card (6),0.00998,0.0250025,0.01006,0.02750275,Average Maturation,0.0250025,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),0.00975,0.03870387,0.00978,0.03110311,Average Maturation,0.03110311,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Coating for Replating - Rare (6),0.00932,0.02350235,0.00788,0.04290429,Average Maturation,0.02350235,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Cell Line - Gibco episomal (10),0.00807,0.04250425,0.00681,0.073407341,Average Maturation,0.04250425,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),3D Tissue Media - iCell Maintenance (12),0.00784,0.04630463,0.00655,0.074507451,Average Maturation,0.04630463,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),2D Surface - Nanotopography (6),0.0068,0.054105411,0.00887,0.0290029,Average Maturation,0.0290029,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Publication Year - 2018 (45),0.00666,0.119211921,0.01042,0.03120312,Average Maturation,0.03120312,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),0.00665,0.069706971,0.00909,0.04640464,Average Maturation,0.04640464,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Disease Modelling - Fibrotic (4),0.00562,0.099709971,0.00968,0.04470447,Average Maturation,0.04470447,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),3D Tissue Media - High-glucose DMEM (9),0.00449,0.135313531,0.00829,0.0440044,Average Maturation,0.0440044,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Metabolic Component - Dexamethasone (7),0.02741,0.00020002,0.02744,0.00010001,Average Maturation,0.00010001,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Calcium Handling Analysis Method - Visual (104),0.02634,0.00040004,0.00481,0.440944094,Average Maturation,0.00040004,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Metabolic Component - T3 (14),0.02237,0.00230023,0.01395,0.00980098,Average Maturation,0.00230023,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Seeding Confluency (%) - 80 to 84 (12),0.02136,0.0030003,0.01953,0.00190019,Average Maturation,0.00190019,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),0.02051,0.00140014,0.01626,0.00370037,Average Maturation,0.00140014,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),0.01935,0.0040004,0.01926,0.00420042,Average Maturation,0.0040004,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Seeding Confluency 3D (%) - 80 to 84 (5),0.01716,0.00490049,0.02244,0.00150015,Average Maturation,0.00150015,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Metabolic Component - IGF-1 (3),0.01667,0.00360036,0.01968,0.00350035,Average Maturation,0.00350035,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),0.0135,0.01710171,0.0136,0.01330133,Average Maturation,0.01330133,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),0.0131,0.01950195,0.00887,0.056705671,Average Maturation,0.01950195,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),0.01225,0.01590159,0.00437,0.163216322,Average Maturation,0.01590159,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Maturation Strategy - ECM (21),0.01182,0.02230223,0.00933,0.03650365,Average Maturation,0.02230223,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),3D Platform - Extracellular Scaffold (18),0.01138,0.02430243,0.00809,0.053705371,Average Maturation,0.02430243,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Journal - J Mol Cell Card (6),0.01078,0.01820182,0.01071,0.01980198,Average Maturation,0.01820182,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Pharmacological Intervention - Adrenaline (83),0.01042,0.03260326,0.00683,0.162116212,Average Maturation,0.03260326,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Journal - Tissue Eng Part A (4),0.01024,0.01850185,0.00834,0.04840484,Average Maturation,0.01850185,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Publication Year - 2018 (45),0.00983,0.04110411,0.01058,0.02450245,Average Maturation,0.02450245,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Seeding Confluency 2D (%) - 90 to 94 (12),0.00963,0.03860386,0.00917,0.04050405,Average Maturation,0.03860386,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Journal - Nat Biomed Eng (5),0.0094,0.0310031,0.00945,0.03460346,Average Maturation,0.0310031,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Cell Line - IMR90 (19),0.00939,0.04030403,0.0087,0.0460046,Average Maturation,0.04030403,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Metabolic Component Category - Hormonal Stimulation (14),0.00884,0.03850385,0.01038,0.02350235,Average Maturation,0.02350235,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Seeding Confluency 2D (%) - 95 to 100 (6),0.00862,0.03380338,0.0113,0.01740174,Average Maturation,0.01740174,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),0.0086,0.04960496,0.0062,0.101310131,Average Maturation,0.04960496,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Wnt Inhibitor - IWR (56),0.00824,0.070207021,0.01101,0.01950195,Average Maturation,0.01950195,TRUE,TRUE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58),0.00535,0.241324132,0.00999,0.03730373,Average Maturation,0.03730373,TRUE,FALSE
Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),0.00454,0.117811781,0.00772,0.0420042,Average Maturation,0.0420042,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Journal - Biomater Sci (7),0.02286,0.00070007,0.02129,0.0010001,Average Maturation,0.00070007,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),0.01742,0.00210021,0.01248,0.00780078,Average Maturation,0.00210021,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),0.01693,0.00160016,0.0122,0.00970097,Average Maturation,0.00160016,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Journal - Circ Res (5),0.01607,0.00270027,0.01053,0.01430143,Average Maturation,0.00270027,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),0.01381,0.00470047,0.01755,0.00170017,Average Maturation,0.00170017,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Sacromere or Cellular Alignment Analysis - Yes (72),0.01305,0.01690169,0.00558,0.224722472,Average Maturation,0.01690169,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),hiPSC-CM Backbone Media - Commercial CM Kit (12),0.01264,0.00990099,0.00859,0.03310331,Average Maturation,0.00990099,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),3D Tissue Media - Iscove (5),0.01202,0.01150115,0.01152,0.01470147,Average Maturation,0.01150115,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Calcium Handling Analysis Method - Visual (104),0.01156,0.03350335,0.00801,0.082108211,Average Maturation,0.03350335,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Pharmacological Intervention - Carbamylcholine (6),0.01071,0.01230123,0.00838,0.02430243,Average Maturation,0.01230123,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Contractile Analysis Method - Motion Tracking (93),0.01028,0.03370337,0.009,0.03340334,Average Maturation,0.03340334,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),0.01012,0.01460146,0.01167,0.01280128,Average Maturation,0.01280128,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),0.01007,0.02360236,0.0059,0.074307431,Average Maturation,0.02360236,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Cell Line - PGP1 (11),0.00995,0.0310031,0.01427,0.00850085,Average Maturation,0.00850085,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),0.00973,0.03830383,0.01015,0.02070207,Average Maturation,0.02070207,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Seeding Confluency (%) - 85 to 89 (43),0.00922,0.04810481,0.00419,0.313431343,Average Maturation,0.04810481,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Wnt Induction - StemCell Diff Kit (4),0.00906,0.02960296,0.0072,0.070807081,Average Maturation,0.02960296,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),hiPSC Backbone Media - Embryonic Stem Cell (127),0.00807,0.130913091,0.00899,0.01750175,Average Maturation,0.01750175,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Disease Modelling - Hypertrophic Cardiomyopathy (6),0.00804,0.02730273,0.00574,0.078507851,Average Maturation,0.02730273,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),3D Tissue Media - High-glucose DMEM (9),0.00784,0.03630363,0.00551,0.084708471,Average Maturation,0.03630363,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Journal - Nat Biomed Eng (5),0.00777,0.03520352,0.00694,0.060806081,Average Maturation,0.03520352,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),0.00768,0.03960396,0.00532,0.091509151,Average Maturation,0.03960396,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Disease Modelling - Rare (4),0.00759,0.02090209,0.00664,0.04490449,Average Maturation,0.02090209,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Pharmacological Intervention - Lidocaine (7),0.00737,0.03230323,0.0126,0.00710071,Average Maturation,0.00710071,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),0.00722,0.03930393,0.00616,0.059205921,Average Maturation,0.03930393,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),New Media for Maturation - Commercial Kit (5),0.00714,0.04250425,0.00743,0.04580458,Average Maturation,0.04250425,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Maturation Strategy - Cell Alignment (59),0.00711,0.107310731,0.00914,0.0470047,Average Maturation,0.0470047,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Differentiation Purity Assessment - IHC cTnT (7),0.00711,0.04460446,0.00593,0.077207721,Average Maturation,0.04460446,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Seeding Confluency 2D (%) - 95 to 100 (6),0.00699,0.0390039,0.00688,0.050905091,Average Maturation,0.0390039,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Pharmacological Intervention - Propranolol (5),0.0067,0.04490449,0.00321,0.162316232,Average Maturation,0.04490449,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),0.00631,0.052905291,0.0072,0.04540454,Average Maturation,0.04540454,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Publication Year - 2018 (45),0.00611,0.129912991,0.00852,0.0450045,Average Maturation,0.0450045,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),0.00571,0.067206721,0.00837,0.02820282,Average Maturation,0.02820282,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),0.00532,0.076807681,0.00683,0.04720472,Average Maturation,0.04720472,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Cell Line - Rare (132),0.00501,0.609860986,0.00934,0.01540154,Average Maturation,0.01540154,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),2D Surface - Micropatterned (27),0.01773,0.00520052,0.01022,0.02480248,Average Maturation,0.00520052,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),hiPSC Backbone Media - StemFlex (5),0.01706,0.00310031,0.01552,0.00470047,Average Maturation,0.00310031,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),0.0169,0.00320032,0.00974,0.02020202,Average Maturation,0.00320032,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Calcium Handling Analysis Method - Visual (104),0.01648,0.00920092,0.00726,0.136113611,Average Maturation,0.00920092,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Journal - Tissue Eng Part A (4),0.01609,0.0050005,0.01733,0.00540054,Average Maturation,0.0050005,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),3D Stromal Cell Source - Stromal Cell (35),0.01556,0.01110111,0.01328,0.00950095,Average Maturation,0.00950095,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Seeding Confluency 2D (%) - 70 to 79 (6),0.01554,0.00750075,0.01505,0.00740074,Average Maturation,0.00740074,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Pharmacological Intervention - Isoproterenol (71),0.01465,0.00970097,0.01347,0.00410041,Average Maturation,0.00410041,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),0.0142,0.00920092,0.01155,0.01040104,Average Maturation,0.00920092,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Electrophysiology Analysis Method - Optical Mapping (39),0.01385,0.01660166,0.00563,0.182018202,Average Maturation,0.01660166,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Calcium Handling Analysis Method - Genetic (23),0.01295,0.01540154,0.00706,0.082808281,Average Maturation,0.01540154,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Maturation Strategy - Elastomeric (33),0.01215,0.02310231,0.00971,0.03250325,Average Maturation,0.02310231,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Publication Year - 2016 (32),0.01201,0.0160016,0.01689,0.00120012,Average Maturation,0.00120012,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Pharmacological Intervention - Adrenaline (83),0.01105,0.02380238,0.01019,0.02070207,Average Maturation,0.02070207,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Metabolic Component Category - Kinase Inhibitors (3),0.01045,0.01270127,0.02261,0.00160016,Average Maturation,0.00160016,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Insulin Start Day - 7 (85),0.01038,0.04720472,0.00908,0.0470047,Average Maturation,0.0470047,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Journal - Am J Physiol Heart Circ Physiol (4),0.01014,0.01870187,0.00969,0.03380338,Average Maturation,0.01870187,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),0.00977,0.03120312,0.01084,0.02070207,Average Maturation,0.02070207,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Number of Cell Lines - 3 (29),0.00939,0.03880388,0.00744,0.073407341,Average Maturation,0.03880388,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),0.00906,0.03660366,0.00935,0.03330333,Average Maturation,0.03330333,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Cell Line - WTC11 (30),0.00881,0.04650465,0.00805,0.051905191,Average Maturation,0.04650465,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),0.0087,0.04810481,0.01057,0.01950195,Average Maturation,0.01950195,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Insulin Withdrawal Duration (days) - 8 days (3),0.00863,0.04810481,0.01054,0.03680368,Average Maturation,0.03680368,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),0.00859,0.03460346,0.00839,0.03750375,Average Maturation,0.03460346,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Cell Line Ancestry - Asian (28),0.00818,0.058005801,0.00932,0.03150315,Average Maturation,0.03150315,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),0.00798,0.066106611,0.00951,0.03480348,Average Maturation,0.03480348,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Metabolic Component Category - Signaling Pathway Regulators (6),0.0077,0.04420442,0.01078,0.01690169,Average Maturation,0.01690169,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),3D Platform - Polyethylene Glycol (8),0.00716,0.054705471,0.00893,0.03680368,Average Maturation,0.03680368,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),0.00679,0.186818682,0.01126,0.0040004,Average Maturation,0.0040004,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Seeding Confluency 3D (%) - 80 to 84 (5),0.0067,0.059705971,0.00804,0.04450445,Average Maturation,0.04450445,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27),0.00592,0.107210721,0.00947,0.03060306,Average Maturation,0.03060306,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),hiPSC-CM Purification Duration (days) - 5 days (6),0.00587,0.092809281,0.01232,0.01340134,Average Maturation,0.01340134,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),0.00457,0.109010901,0.00698,0.04730473,Average Maturation,0.04730473,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),0.03604,0,0.02555,0.00030003,Average Maturation,0,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),0.02587,0.00050005,0.01895,0.00220022,Average Maturation,0.00050005,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),0.02224,0.00370037,0.01622,0.00450045,Average Maturation,0.00370037,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),0.02096,0.00110011,0.01666,0.00320032,Average Maturation,0.00110011,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),hiPSC Matrix Coating - Vitronectin (10),0.01669,0.00590059,0.00791,0.055505551,Average Maturation,0.00590059,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Cell Line Sex - Both (118),0.0153,0.01270127,0.00857,0.050605061,Average Maturation,0.01270127,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Publication Year - 2018 (45),0.0148,0.01060106,0.01238,0.01150115,Average Maturation,0.01060106,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),3D Platform - Scaffold Free (43),0.01444,0.01180118,0.01193,0.01560156,Average Maturation,0.01180118,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),0.01405,0.01130113,0.0119,0.01650165,Average Maturation,0.01130113,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Seeding Confluency (%) - 80 to 84 (12),0.01345,0.01810181,0.0098,0.03160316,Average Maturation,0.01810181,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Wnt Inhibitor - IWR (56),0.01328,0.0170017,0.01512,0.0040004,Average Maturation,0.0040004,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),0.0132,0.01240124,0.01,0.02790279,Average Maturation,0.01240124,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Coating for Replating - Vitronectin (3),0.0117,0.01710171,0.01184,0.02750275,Average Maturation,0.01710171,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),0.01006,0.03190319,0.00922,0.03320332,Average Maturation,0.03190319,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17),0.01004,0.04020402,0.0076,0.067406741,Average Maturation,0.04020402,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),3D Stromal Cell Source - Rare (4),0.00988,0.02690269,0.01258,0.01270127,Average Maturation,0.01270127,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Seeding Confluency 3D (%) - 80 to 84 (5),0.00947,0.02890289,0.01317,0.01240124,Average Maturation,0.01240124,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Journal - Stem Cell Reports (23),0.00872,0.053605361,0.00987,0.03380338,Average Maturation,0.03380338,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Cell Line - IMR90 (19),0.00867,0.04620462,0.00817,0.051405141,Average Maturation,0.04620462,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),0.00798,0.074307431,0.01024,0.04750475,Average Maturation,0.04750475,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),0.00776,0.084308431,0.01146,0.01960196,Average Maturation,0.01960196,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Calcium Handling Analysis Method - Visual (104),0.00758,0.161116112,0.01071,0.01470147,Average Maturation,0.01470147,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Calcium Handling Analysis Method - Rare (4),0.00752,0.051805181,0.00912,0.03940394,Average Maturation,0.03940394,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Number of Cell Lines - 4 (11),0.00746,0.050705071,0.01027,0.02460246,Average Maturation,0.02460246,TRUE,TRUE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),2D Surface - Microelectrode Array (9),0.00647,0.074807481,0.00954,0.03090309,Average Maturation,0.03090309,TRUE,FALSE
Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Cell Line - Gibco episomal (10),0.00605,0.079507951,0.00858,0.03840384,Average Maturation,0.03840384,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),0.02782,0,0.02228,0,Average Maturation,0,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),3D Stromal Cell Source - Mesenchymal Stem Cell (12),0.01725,0.00360036,0.01797,0.00150015,Average Maturation,0.00150015,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Pharmacological Intervention - Cisapride (8),0.01469,0.01090109,0.01579,0.00640064,Average Maturation,0.00640064,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),0.0142,0.00990099,0.00745,0.066506651,Average Maturation,0.00990099,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Contractile Analysis Method - Deflection (39),0.01408,0.01210121,0.00949,0.03510351,Average Maturation,0.01210121,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Calcium Handling Analysis Method - Visual (104),0.01323,0.02150215,0.00926,0.03410341,Average Maturation,0.02150215,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),3D Stromal Cell Source - Stromal Cell (35),0.01289,0.02160216,0.00752,0.080808081,Average Maturation,0.02160216,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Cell Coculture - Stromal Cell (78),0.01219,0.02410241,0.00362,0.519351935,Average Maturation,0.02410241,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Seeding Confluency 2D (%) - 70 to 79 (6),0.01153,0.01460146,0.01266,0.01350135,Average Maturation,0.01350135,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),0.01146,0.02240224,0.00797,0.04690469,Average Maturation,0.02240224,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),0.01143,0.0190019,0.01034,0.02360236,Average Maturation,0.0190019,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Seeding Confluency 3D (%) - 90 to 94 (13),0.01108,0.02110211,0.00577,0.105110511,Average Maturation,0.02110211,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),0.01075,0.0160016,0.02006,0.00330033,Average Maturation,0.00330033,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Pharmacological Intervention - QT-Prolonging Drugs (36),0.01068,0.03470347,0.0059,0.139313931,Average Maturation,0.03470347,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Journal - Biomaterials (16),0.01041,0.02010201,0.00715,0.059405941,Average Maturation,0.02010201,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Journal - Circulation (11),0.00931,0.03180318,0.00745,0.050805081,Average Maturation,0.03180318,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),0.00928,0.03780378,0.00476,0.199519952,Average Maturation,0.03780378,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),3D Platform - Nanotechnology (3),0.00888,0.0240024,0.00997,0.02790279,Average Maturation,0.0240024,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Wnt Induction Duration (days) - 3 days (38),0.00875,0.064606461,0.01103,0.02640264,Average Maturation,0.02640264,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21),0.00862,0.04270427,0.00897,0.03760376,Average Maturation,0.03760376,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Pharmacological Intervention - Carbenoxolone (4),0.00823,0.03770377,0.01092,0.01970197,Average Maturation,0.01970197,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Insulin Start Day - After 11 (7),0.0082,0.03980398,0.00605,0.084008401,Average Maturation,0.03980398,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Metabolic Component Category - Kinase Inhibitors (3),0.00768,0.04770477,0.007,0.071307131,Average Maturation,0.04770477,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),hiPSC Backbone Media - StemFlex (5),0.00718,0.04820482,0.00345,0.140914091,Average Maturation,0.04820482,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),3D Tissue Media - High-glucose DMEM (9),0.00693,0.04680468,0.00489,0.121112111,Average Maturation,0.04680468,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Seeding Confluency (%) - 70 to 79 (11),0.00639,0.069306931,0.00879,0.03590359,Average Maturation,0.03590359,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Insulin Start Day - 2 (4),0.00597,0.081208121,0.01007,0.0270027,Average Maturation,0.0270027,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),0.00516,0.106110611,0.00796,0.0430043,Average Maturation,0.0430043,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Seeding Confluency 2D (%) - 90 to 94 (12),0.02083,0.00360036,0.02299,0.00110011,Average Maturation,0.00110011,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Sacromere or Cellular Alignment Analysis - Yes (72),0.02019,0.0040004,0.00822,0.081308131,Average Maturation,0.0040004,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Calcium Handling Analysis Method - Visual (104),0.01512,0.01390139,0.00915,0.04740474,Average Maturation,0.01390139,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),0.01438,0.0120012,0.01013,0.02770277,Average Maturation,0.0120012,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Journal - Rare (104),0.01438,0.01130113,0.00796,0.090209021,Average Maturation,0.01130113,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Maturation Strategy - Other Cells (80),0.01381,0.01260126,0.0056,0.225422542,Average Maturation,0.01260126,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Cell Line Sex - Both (118),0.01342,0.01930193,0.00764,0.100110011,Average Maturation,0.01930193,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Day of Insulin Addition - not 15 (16),0.0131,0.01230123,0.01377,0.0090009,Average Maturation,0.0090009,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),2D Surface - Decellularized ECM (3),0.013,0.02010201,0.01322,0.03210321,Average Maturation,0.02010201,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),0.01227,0.01730173,0.01212,0.01360136,Average Maturation,0.01360136,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Publication Year - 2024 (7),0.01221,0.0170017,0.01217,0.01770177,Average Maturation,0.0170017,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Insulin Start Day - 8 (15),0.01146,0.02540254,0.01149,0.01920192,Average Maturation,0.01920192,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),hiPSC-CM Purification Duration (days) - 4 days (29),0.01121,0.03610361,0.00858,0.065906591,Average Maturation,0.03610361,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Maturation Strategy - Electrical (39),0.01062,0.03410341,0.00881,0.054605461,Average Maturation,0.03410341,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Calcium Handling Analysis Method - Rare (4),0.01052,0.02310231,0.01142,0.02490249,Average Maturation,0.02310231,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Pharmacological Intervention - Adrenaline (83),0.01043,0.03730373,0.00694,0.146214621,Average Maturation,0.03730373,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Differentiation Purity Assessment - Rare (3),0.00978,0.03870387,0.00764,0.069306931,Average Maturation,0.03870387,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Day of Insulin Addition - not 16 (15),0.00964,0.03850385,0.00975,0.03570357,Average Maturation,0.03570357,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Day of Insulin Addition - not 14 (15),0.00955,0.04010401,0.00995,0.03410341,Average Maturation,0.03410341,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Seeding Confluency 2D (%) - 70 to 79 (6),0.00934,0.03630363,0.00843,0.053405341,Average Maturation,0.03630363,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),0.00872,0.04340434,0.00974,0.03130313,Average Maturation,0.03130313,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),0.00872,0.040004,0.00536,0.120812081,Average Maturation,0.040004,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),0.00797,0.04040404,0.01106,0.01630163,Average Maturation,0.01630163,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),0.0079,0.068806881,0.01098,0.03830383,Average Maturation,0.03830383,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),0.00709,0.051305131,0.00841,0.03340334,Average Maturation,0.03340334,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Seeding Confluency (%) - 90 to 94 (26),0.00704,0.098209821,0.01401,0.01260126,Average Maturation,0.01260126,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),0.00696,0.04710471,0.00429,0.144314431,Average Maturation,0.04710471,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),hiPSC Matrix Coating - Vitronectin (10),0.00681,0.080308031,0.00933,0.04320432,Average Maturation,0.04320432,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Publication Year - 2019 (57),0.00623,0.175217522,0.01158,0.02010201,Average Maturation,0.02010201,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),3D Platform - Matrigel (33),0.00554,0.141514151,0.00978,0.03730373,Average Maturation,0.03730373,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),0.00475,0.090709071,0.01169,0.02010201,Average Maturation,0.02010201,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),0.04887,0,0.03615,0,Average Maturation,0,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Gene Analysis Method - Rare (5),0.02059,0.00280028,0.0184,0.00410041,Average Maturation,0.00280028,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),0.01815,0.00610061,0.01767,0.0030003,Average Maturation,0.0030003,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Disease Modelling - Dilated Cardiomyopathy (6),0.01663,0.00710071,0.01221,0.01980198,Average Maturation,0.00710071,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Insulin Start Day - 0 (7),0.01623,0.00730073,0.01378,0.01180118,Average Maturation,0.00730073,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Calcium Handling Analysis Method - Visual (104),0.01585,0.01290129,0.01058,0.0210021,Average Maturation,0.01290129,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Journal - Cell Stem Cell (6),0.01522,0.00850085,0.01243,0.01820182,Average Maturation,0.00850085,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Journal - Am J Physiol Heart Circ Physiol (4),0.01521,0.00960096,0.01276,0.02530253,Average Maturation,0.00960096,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Insulin Start Day - 1 (19),0.01401,0.01660166,0.00423,0.214921492,Average Maturation,0.01660166,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),0.01376,0.02540254,0.00725,0.132413241,Average Maturation,0.02540254,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),hiPSC-CM Media Supplement - Polyvinylalchohol (6),0.01306,0.01320132,0.00916,0.0480048,Average Maturation,0.01320132,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Pharmacological Intervention - Isoproterenol (71),0.01285,0.02050205,0.00705,0.135313531,Average Maturation,0.02050205,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Insulin Start Day - 10 (6),0.01202,0.02150215,0.01073,0.03360336,Average Maturation,0.02150215,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Differentiation Purity Assessment - IHC a-actinin (8),0.0119,0.01510151,0.009,0.04120412,Average Maturation,0.01510151,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Journal - Stem Cells (11),0.01156,0.01940194,0.01001,0.03090309,Average Maturation,0.01940194,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),New Media for Maturation - Commercial Kit (5),0.01084,0.0380038,0.00955,0.060106011,Average Maturation,0.0380038,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),0.01064,0.02530253,0.00975,0.03430343,Average Maturation,0.02530253,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Pharmacological Intervention - Cisapride (8),0.01029,0.03420342,0.01293,0.01880188,Average Maturation,0.01880188,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Journal - Stem Cell Res (8),0.01003,0.056605661,0.01329,0.02110211,Average Maturation,0.02110211,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),0.00956,0.03050305,0.00523,0.134313431,Average Maturation,0.03050305,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Journal - Nano Lett (3),0.00934,0.04990499,0.01389,0.02550255,Average Maturation,0.02550255,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Publication Year - 2015 (19),0.0093,0.04970497,0.00997,0.04110411,Average Maturation,0.04110411,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Publication Year - 2020 (51),0.00928,0.079407941,0.00997,0.04860486,Average Maturation,0.04860486,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Insulin Start Day - 11 (3),0.00927,0.04970497,0.01369,0.02650265,Average Maturation,0.02650265,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),hiPSC-CM Media Supplement - Lipids (9),0.00924,0.0390039,0.00652,0.097409741,Average Maturation,0.0390039,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Pharmacological Intervention - Carbenoxolone (4),0.00885,0.053005301,0.01318,0.01820182,Average Maturation,0.01820182,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Journal - ACS Biomater Sci Eng (3),0.00823,0.059405941,0.01432,0.02380238,Average Maturation,0.02380238,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Journal - Biomater Sci (7),0.0075,0.064406441,0.01149,0.02040204,Average Maturation,0.02040204,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),0.00718,0.088708871,0.01114,0.02880288,Average Maturation,0.02880288,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Electrophysiology Analysis Method - Genetic (3),0.00693,0.058505851,0.00946,0.04530453,Average Maturation,0.04530453,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),0.00666,0.056205621,0.00933,0.04470447,Average Maturation,0.04470447,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Seeding Confluency 3D (%) - 85 to 89 (12),0.0062,0.093909391,0.00894,0.04030403,Average Maturation,0.04030403,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),0.00534,0.145514551,0.01361,0.01690169,Average Maturation,0.01690169,TRUE,TRUE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Metabolic Analysis Method - Seahorse (35),0.00476,0.194019402,0.00958,0.04720472,Average Maturation,0.04720472,TRUE,FALSE
Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Disease Modelling - Rare (4),0.00281,0.090209021,0.00836,0.04610461,Average Maturation,0.04610461,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Cell Line - Rare (132),0.02307,0,0.00816,0.121912191,Average Maturation,0,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Seeding Confluency 3D (%) - 70 to 79 (3),0.01717,0.01240124,0.02143,0.00730073,Average Maturation,0.00730073,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),0.01717,0.02760276,0.0155,0.03750375,Average Maturation,0.02760276,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),2D Surface - Decellularized ECM (3),0.01697,0.02140214,0.02065,0.01450145,Average Maturation,0.01450145,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),hiPSC-CM Media Supplement - Nonessential Amino Acids (8),0.01664,0.02090209,0.0127,0.04890489,Average Maturation,0.02090209,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),3D Platform - Gelatin (6),0.01624,0.01590159,0.03302,0.00060006,Average Maturation,0.00060006,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Journal - Tissue Eng Part C Methods (6),0.01562,0.01620162,0.01648,0.01690169,Average Maturation,0.01620162,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),0.01533,0.020002,0.01864,0.01260126,Average Maturation,0.01260126,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),0.01512,0.01780178,0.01235,0.04080408,Average Maturation,0.01780178,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),0.0151,0.01720172,0.00837,0.071107111,Average Maturation,0.01720172,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),0.01486,0.01940194,0.0116,0.03870387,Average Maturation,0.01940194,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Journal - ACS Appl Mater Interfaces (4),0.01482,0.01650165,0.01496,0.02230223,Average Maturation,0.01650165,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),3D Stromal Cell Source - Rare (4),0.01418,0.040004,0.01645,0.0250025,Average Maturation,0.0250025,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Insulin Start Day - 8 (15),0.01324,0.03940394,0.01053,0.063506351,Average Maturation,0.03940394,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Cell Line Ancestry - Caucasian (41),0.01303,0.04070407,0.00939,0.080208021,Average Maturation,0.04070407,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),hiPSC-CM Media Supplement - Mercaptoethanol (10),0.01299,0.03690369,0.01157,0.04940494,Average Maturation,0.03690369,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),0.01228,0.04610461,0.00833,0.105310531,Average Maturation,0.04610461,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Seeding Confluency (%) - 85 to 89 (43),0.01211,0.066806681,0.01534,0.02730273,Average Maturation,0.02730273,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Wnt Inhibitor - IWR (56),0.01203,0.04030403,0.00837,0.148614861,Average Maturation,0.04030403,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Calcium Handling Analysis Method - Visual (104),0.01169,0.03150315,0.00554,0.265626563,Average Maturation,0.03150315,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Insulin Withdrawal Duration (days) - 8 days (3),0.01115,0.02870287,0.00525,0.04350435,Average Maturation,0.02870287,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),0.01096,0.04690469,0.00642,0.125812581,Average Maturation,0.04690469,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Journal - Stem Cell Res Ther (3),0.01072,0.03530353,0.0196,0.01170117,Average Maturation,0.01170117,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Gene Analysis Method - Rare (5),0.01071,0.04250425,0.01033,0.04780478,Average Maturation,0.04250425,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Journal - Biomaterials (16),0.01044,0.04840484,0.01164,0.04790479,Average Maturation,0.04790479,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),0.01006,0.04780478,0.00603,0.120912091,Average Maturation,0.04780478,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Electron Imaging - Scanning (22),0.00894,0.081108111,0.01548,0.01890189,Average Maturation,0.01890189,TRUE,TRUE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),3D Endothelial Cell Source - hiPSC-EndothelialC (16),0.00689,0.105910591,0.01218,0.03440344,Average Maturation,0.03440344,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Wnt Inhibitor - IWP (112),0.00494,0.303730373,0.01105,0.02510251,Average Maturation,0.02510251,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Coating for Replating - Vitronectin (3),0.00107,0.04880488,0.00228,0.04860486,Average Maturation,0.04860486,TRUE,FALSE
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),3D Stromal Cell Source - hiPSC-SmoothMC (3),0,0.097909791,0.00122,0.04970497,Average Maturation,0.04970497,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Purification Protocol - Cell Sorting (7),0.03091,0.00030003,0.02784,0.00080008,Average Maturation,0.00030003,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),2D Surface - Microelectrode Array (9),0.02543,0.00060006,0.02123,0.00170017,Average Maturation,0.00060006,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),0.01647,0.01470147,0.00472,0.166016602,Average Maturation,0.01470147,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Publication Year - 2016 (32),0.01587,0.01090109,0.01115,0.0290029,Average Maturation,0.01090109,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),hiPSC-CM Media Supplement - Albumin (28),0.01562,0.0120012,0.00726,0.085708571,Average Maturation,0.0120012,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Metabolic Analysis Method - Genetic (3),0.01499,0.00820082,0.01701,0.00750075,Average Maturation,0.00750075,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),hiPSC-CM Media Supplement - B27 (180),0.01424,0.01130113,0.0057,0.356735674,Average Maturation,0.01130113,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Pharmacological Intervention - Caffeine (4),0.01411,0.00750075,0.0179,0.00340034,Average Maturation,0.00340034,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Publication Year - 2018 (45),0.01386,0.02330233,0.01112,0.03690369,Average Maturation,0.02330233,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Insulin Start Day - After 11 (7),0.01343,0.01660166,0.01407,0.01590159,Average Maturation,0.01590159,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Insulin Start Day - 2 (4),0.01317,0.00960096,0.0143,0.00930093,Average Maturation,0.00930093,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),0.01312,0.02380238,0.0066,0.104910491,Average Maturation,0.02380238,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Pharmacological Intervention - QT-Prolonging Drugs (36),0.01293,0.02370237,0.01198,0.02460246,Average Maturation,0.02370237,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Metabolic Component - Dexamethasone (7),0.01238,0.01720172,0.01813,0.00620062,Average Maturation,0.00620062,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),hiPSC-CM Media Supplement - GlutaMax (8),0.01168,0.02220222,0.01119,0.02550255,Average Maturation,0.02220222,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Disease Modelling - Specialised (3),0.01157,0.02570257,0.0066,0.066206621,Average Maturation,0.02570257,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),3D Stromal Cell Source - hiPSC-SmoothMC (3),0.01099,0.04510451,0.01511,0.02520252,Average Maturation,0.02520252,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Maturation Strategy - Mechanical (36),0.01086,0.0420042,0.01266,0.01670167,Average Maturation,0.01670167,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Electrophysiology Analysis Method - Microelectrode (31),0.01057,0.03710371,0.00908,0.072907291,Average Maturation,0.03710371,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),3D Tissue Media - Rare (13),0.01038,0.0420042,0.00946,0.04540454,Average Maturation,0.0420042,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Journal - Stem Cells Int (3),0.01006,0.03290329,0.01308,0.02150215,Average Maturation,0.02150215,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Metabolic Component - Palmitic Acid (11),0.01006,0.03530353,0.00359,0.183418342,Average Maturation,0.03530353,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),2D Surface - Micropatterned (27),0.00874,0.04930493,0.00894,0.050905091,Average Maturation,0.04930493,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),0.00843,0.0410041,0.00766,0.055305531,Average Maturation,0.0410041,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),0.00827,0.0440044,0.01241,0.01640164,Average Maturation,0.01640164,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),hiPSC-CM Backbone Media - Cor.4U Complete (6),0.00785,0.071807181,0.00959,0.04190419,Average Maturation,0.04190419,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Journal - Biomaterials (16),0.00764,0.077507751,0.01447,0.01240124,Average Maturation,0.01240124,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),0.00712,0.068106811,0.00947,0.04910491,Average Maturation,0.04910491,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Publication Year - 2014 (3),0.00702,0.062506251,0.01017,0.04760476,Average Maturation,0.04760476,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),hiPSC-CM Media Supplement - bFGF (3),0.00643,0.068406841,0.01419,0.01920192,Average Maturation,0.01920192,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Journal - Stem Cells (11),0.00574,0.103410341,0.00977,0.03370337,Average Maturation,0.03370337,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Journal - Circulation (11),0.00314,0.184818482,0.00906,0.0380038,Average Maturation,0.0380038,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Disease Modelling - Arrhythmic (15),0.02854,0.00110011,0.03163,0.00050005,Average Maturation,0.00050005,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Insulin Start Day - 9 (10),0.0254,0.00190019,0.02272,0.00210021,Average Maturation,0.00190019,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Differentiation Purity Assessment - IHC a-actinin (8),0.02523,0.00540054,0.01723,0.01310131,Average Maturation,0.00540054,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Electrophysiology Analysis Method - Optical Mapping (39),0.01956,0.00680068,0.01483,0.01310131,Average Maturation,0.00680068,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),0.01921,0.0140014,0.01693,0.01070107,Average Maturation,0.01070107,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Coating for Replating - Gelatin (43),0.01844,0.01320132,0.01977,0.00340034,Average Maturation,0.00340034,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Publication Year - 2020 (51),0.01738,0.01020102,0.01332,0.02060206,Average Maturation,0.01020102,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Journal - Biosens Bioelectron (4),0.01732,0.01840184,0.01341,0.04380438,Average Maturation,0.01840184,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Day of Insulin Addition - not 9 (3),0.01691,0.01050105,0.01107,0.03610361,Average Maturation,0.01050105,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Wnt Inhibitor - Rare (3),0.01435,0.02540254,0.01373,0.03290329,Average Maturation,0.02540254,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),0.01424,0.02160216,0.00832,0.083208321,Average Maturation,0.02160216,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Pharmacological Intervention - Cisapride (8),0.01415,0.0380038,0.00752,0.109710971,Average Maturation,0.0380038,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),0.01382,0.02120212,0.01543,0.01920192,Average Maturation,0.01920192,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Cell Line - iCell2 (8),0.01314,0.0270027,0.01423,0.02170217,Average Maturation,0.02170217,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Calcium Handling Analysis Method - Visual (104),0.0127,0.02270227,0.01365,0.00930093,Average Maturation,0.00930093,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),0.01267,0.03670367,0.01325,0.02380238,Average Maturation,0.02380238,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Pharmacological Intervention - Carbenoxolone (4),0.01089,0.04940494,0.01014,0.053205321,Average Maturation,0.04940494,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Cell Line - ATCC (5),0.01063,0.057705771,0.01148,0.04460446,Average Maturation,0.04460446,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Coating for Replating - Laminin (5),0.01053,0.04430443,0.01169,0.040004,Average Maturation,0.040004,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Journal - J Mol Cell Cardiol (4),0.01011,0.04560456,0.01048,0.04590459,Average Maturation,0.04560456,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Seeding Confluency 3D (%) - 80 to 84 (5),0.01008,0.04030403,0.01071,0.03970397,Average Maturation,0.03970397,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Maturation Strategy - ECM (21),0.01001,0.04920492,0.00484,0.175917592,Average Maturation,0.04920492,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Day of Insulin Addition - not 10 (4),0.00863,0.04870487,0.00694,0.061406141,Average Maturation,0.04870487,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),3D Stromal Cell Source - hiPSC-SmoothMC (3),0.00846,0.052305231,0.01238,0.04520452,Average Maturation,0.04520452,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Pharmacological Intervention - E4031 (22),0.00796,0.081008101,0.01018,0.04670467,Average Maturation,0.04670467,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Journal - Nano Lett (3),0.0079,0.04780478,0.01594,0.02090209,Average Maturation,0.02090209,TRUE,TRUE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Metabolic Component - IGF-1 (3),0.0076,0.050305031,0.01366,0.02770277,Average Maturation,0.02770277,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),0.00751,0.073907391,0.01056,0.04410441,Average Maturation,0.04410441,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),0.00678,0.106710671,0.01086,0.040004,Average Maturation,0.040004,TRUE,FALSE
Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Sacromere or Cellular Alignment Analysis - Yes (72),0.0066,0.197519752,0.01038,0.04460446,Average Maturation,0.04460446,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Electrophysiology Analysis Method - Patch Clamp (59),0.05998,0,0.03163,0,Average Maturation,0,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),0.05408,0,0.04705,0,Average Maturation,0,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Cell Line - C25 (6),0.01812,0.00520052,0.01875,0.0040004,Average Maturation,0.0040004,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),0.01774,0.00530053,0.01177,0.01680168,Average Maturation,0.00530053,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Pharmacological Intervention - E4031 (22),0.01388,0.01440144,0.01672,0.00260026,Average Maturation,0.00260026,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Journal - Stem Cells (11),0.01365,0.00670067,0.01099,0.01740174,Average Maturation,0.00670067,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),0.01321,0.0120012,0.01461,0.00690069,Average Maturation,0.00690069,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Journal - Cell Stem Cell (6),0.01283,0.01370137,0.01964,0.0040004,Average Maturation,0.0040004,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Pharmacological Intervention - QT-Prolonging Drugs (36),0.01236,0.02420242,0.0109,0.02690269,Average Maturation,0.02420242,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),hiPSC Backbone Media - Rare (19),0.01209,0.02190219,0.01036,0.03590359,Average Maturation,0.02190219,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),0.01208,0.01170117,0.00721,0.054105411,Average Maturation,0.01170117,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Metabolic Analysis Method - Seahorse (35),0.01194,0.03010301,0.00877,0.075007501,Average Maturation,0.03010301,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),3D Stromal Cell Source - Rare (4),0.01152,0.01750175,0.00724,0.078407841,Average Maturation,0.01750175,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Wnt Inhibitor - KY02111 (7),0.00991,0.02810281,0.01447,0.01240124,Average Maturation,0.01240124,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),0.00964,0.0240024,0.01018,0.02290229,Average Maturation,0.02290229,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),hiPSC-CM Media Supplement - Polyvinylalchohol (6),0.00962,0.0230023,0.00712,0.067406741,Average Maturation,0.0230023,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Insulin Start Day - 6 (20),0.00921,0.04160416,0.008,0.066806681,Average Maturation,0.04160416,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),0.00916,0.02310231,0.0091,0.02840284,Average Maturation,0.02310231,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Number of Cell Lines - 3 (29),0.00907,0.04520452,0.01092,0.02120212,Average Maturation,0.02120212,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),0.00804,0.051605161,0.01023,0.0220022,Average Maturation,0.0220022,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),hiPSC-CM Media Supplement - Selenium (7),0.00794,0.03890389,0.00846,0.0380038,Average Maturation,0.0380038,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Calcium Handling Analysis Method - Rare (4),0.00777,0.04550455,0.00865,0.04260426,Average Maturation,0.04260426,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),hiPSC-CM Media Supplement - Lipids (9),0.0061,0.078007801,0.00892,0.03530353,Average Maturation,0.03530353,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Electrophysiology Analysis Method - Patch Clamp (59),0.03725,0.00010001,0.01714,0.00140014,Average Maturation,0.00010001,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Insulin Start Day - 2 (4),0.01964,0.00130013,0.02122,0.00180018,Average Maturation,0.00130013,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),0.01921,0.0020002,0.02681,0,Average Maturation,0,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Journal - Int J Mol Sci (3),0.01628,0.00220022,0.02452,0.00060006,Average Maturation,0.00060006,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Number of Cell Lines - 4 (11),0.01601,0.00590059,0.01627,0.00360036,Average Maturation,0.00360036,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),hiPSC Matrix Coating - Matrigel (163),0.01496,0.01040104,0.005,0.522152215,Average Maturation,0.01040104,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Purification Protocol - Cell Sorting (7),0.01472,0.00790079,0.01445,0.00630063,Average Maturation,0.00630063,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Pharmacological Intervention - Caffeine (4),0.01388,0.00560056,0.01582,0.00420042,Average Maturation,0.00420042,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),2D Surface - Electrospun (13),0.01373,0.01780178,0.01321,0.0170017,Average Maturation,0.0170017,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),New Media for Maturation - Commercial Kit (5),0.01312,0.00810081,0.01164,0.01340134,Average Maturation,0.00810081,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Wnt Induction - Rare (4),0.01168,0.00920092,0.00821,0.04770477,Average Maturation,0.00920092,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),hiPSC-CM Media Supplement - Lipids (9),0.01157,0.0170017,0.01276,0.01040104,Average Maturation,0.01040104,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Number of Cell Lines - 1 (225),0.01086,0.03670367,0.00737,0.121012101,Average Maturation,0.03670367,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Pharmacological Intervention - E4031 (22),0.01075,0.02980298,0.01016,0.02870287,Average Maturation,0.02870287,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Wnt Induction - BMP4 (74),0.01069,0.04480448,0.00891,0.04890489,Average Maturation,0.04480448,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Insulin Start Day - 8 (15),0.01046,0.02170217,0.01129,0.0150015,Average Maturation,0.0150015,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),2D Surface - Microelectrode Array (9),0.0102,0.0260026,0.00697,0.073807381,Average Maturation,0.0260026,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),0.01005,0.03450345,0.00801,0.0480048,Average Maturation,0.03450345,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),0.00988,0.0330033,0.00658,0.090409041,Average Maturation,0.0330033,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Wnt Inhibitor Duration (days) - 4 days (19),0.00976,0.0320032,0.00354,0.241224122,Average Maturation,0.0320032,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),hiPSC-CM Purification Duration (days) - <3 days (31),0.00958,0.04610461,0.01266,0.01170117,Average Maturation,0.01170117,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Seeding Confluency (%) - 70 to 79 (11),0.00955,0.02380238,0.01007,0.020002,Average Maturation,0.020002,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Electrophysiology Analysis Method - Microelectrode (31),0.00926,0.03960396,0.01214,0.01780178,Average Maturation,0.01780178,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),0.0089,0.03450345,0.0083,0.054605461,Average Maturation,0.03450345,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Wnt Inhibitor - bFGF (8),0.00869,0.03510351,0.00438,0.152415242,Average Maturation,0.03510351,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Coating for Replating - Matrigel (65),0.00833,0.083108311,0.01018,0.03010301,Average Maturation,0.03010301,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),0.00812,0.04320432,0.01051,0.02210221,Average Maturation,0.02210221,TRUE,TRUE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Purification Protocol - Metabolic (8),0.00797,0.04520452,0.00906,0.03420342,Average Maturation,0.03420342,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Cell Line - iCell (47),0.00756,0.077707771,0.00997,0.02970297,Average Maturation,0.02970297,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),0.00677,0.053505351,0.00867,0.03150315,Average Maturation,0.03150315,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),hiPSC-CM Maturation Media - RPMI-1640 (153),0.00597,0.381838184,0.00866,0.03370337,Average Maturation,0.03370337,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),hiPSC-CM Media Supplement - Albumin (28),0.00543,0.139213921,0.0085,0.04750475,Average Maturation,0.04750475,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),New Media for Maturation - F12 (7),0.005,0.101610161,0.00765,0.04530453,Average Maturation,0.04530453,TRUE,FALSE
Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Cell Line - BJ1 (7),0.00369,0.162616262,0.00809,0.04610461,Average Maturation,0.04610461,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Electrophysiology Analysis Method - Patch Clamp (59),0.04863,0,0.02527,0,Average Maturation,0,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),0.01994,0.00240024,0.02163,0.00180018,Average Maturation,0.00180018,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),hiPSC-CM Maturation Media - RPMI-1640 (153),0.01803,0.00210021,0.00549,0.467146715,Average Maturation,0.00210021,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),0.01773,0.00520052,0.00941,0.03350335,Average Maturation,0.00520052,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),hiPSC-CM Backbone Media - RPMI-1640 (167),0.01733,0.00330033,0.00365,0.749274927,Average Maturation,0.00330033,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),0.01436,0.01430143,0.01504,0.01150115,Average Maturation,0.01150115,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Pharmacological Intervention - Other Antiarrhythmic Agents (13),0.01384,0.0190019,0.0125,0.01490149,Average Maturation,0.01490149,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Publication Year - 2015 (19),0.01276,0.01620162,0.01028,0.02950295,Average Maturation,0.01620162,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Coating for Replating - Synthemax (3),0.01231,0.00990099,0.01317,0.01220122,Average Maturation,0.00990099,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Journal - Tissue Eng Part C Methods (6),0.01199,0.01950195,0.01135,0.02380238,Average Maturation,0.01950195,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Seeding Confluency (%) - Rare (43),0.01148,0.03150315,0.00722,0.113211321,Average Maturation,0.03150315,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Pharmacological Intervention - E4031 (22),0.01125,0.03020302,0.00795,0.066206621,Average Maturation,0.03020302,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Calcium Handling Analysis Method - Genetic (23),0.01089,0.03260326,0.01616,0.00690069,Average Maturation,0.00690069,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),0.01021,0.01940194,0.01304,0.00860086,Average Maturation,0.00860086,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),3D Stromal Cell Source - Cardiac Fibroblast (32),0.01006,0.03970397,0.01155,0.01430143,Average Maturation,0.01430143,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Cell Line Ancestry - Asian (28),0.0094,0.04820482,0.00647,0.117311731,Average Maturation,0.04820482,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),0.00904,0.03270327,0.01027,0.02450245,Average Maturation,0.02450245,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Pharmacological Intervention - Lidocaine (7),0.00776,0.04720472,0.00821,0.0480048,Average Maturation,0.04720472,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),0.0075,0.066406641,0.01045,0.03220322,Average Maturation,0.03220322,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Journal - Sci Transl Med (3),0.00678,0.064806481,0.0123,0.0280028,Average Maturation,0.0280028,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Cell Line Sex - Both (118),0.00676,0.272627263,0.01006,0.01850185,Average Maturation,0.01850185,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Wnt Induction - bFGF (45),0.00646,0.163116312,0.01093,0.03190319,Average Maturation,0.03190319,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),0.00631,0.089408941,0.00988,0.03170317,Average Maturation,0.03170317,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Cell Line - iCell2 (8),0.00575,0.116411641,0.00933,0.04550455,Average Maturation,0.04550455,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),0.00467,0.091909191,0.00901,0.04040404,Average Maturation,0.04040404,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Electrophysiology Analysis Method - Patch Clamp (59),0.04287,0,0.01673,0.00240024,Average Maturation,0,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),0.03561,0.00010001,0.03815,0,Average Maturation,0,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Journal - Int J Mol Sci (3),0.03262,0.00110011,0.03801,0.00060006,Average Maturation,0.00060006,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Seeding Confluency (%) - 70 to 79 (11),0.02793,0.00080008,0.01675,0.0080008,Average Maturation,0.00080008,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Journal - Am J Physiol Heart Circ Physiol (4),0.02244,0.00240024,0.02474,0.00190019,Average Maturation,0.00190019,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Cell Line - C25 (6),0.02111,0.0040004,0.0144,0.01250125,Average Maturation,0.0040004,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),0.01982,0.00560056,0.02224,0.00240024,Average Maturation,0.00240024,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Coating for Replating - Laminin (5),0.01872,0.0030003,0.0162,0.00630063,Average Maturation,0.0030003,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Journal - PLoS One (9),0.01558,0.00820082,0.01725,0.00470047,Average Maturation,0.00470047,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),0.0144,0.01140114,0.01599,0.0060006,Average Maturation,0.0060006,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),hiPSC Matrix Coating - EBs (18),0.01424,0.02170217,0.00869,0.060906091,Average Maturation,0.02170217,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),hiPSC-CM Purification Duration (days) - 6 days (10),0.01189,0.01910191,0.01211,0.01970197,Average Maturation,0.01910191,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Disease Modelling - Genetic Disorders (18),0.01159,0.0270027,0.00932,0.04360436,Average Maturation,0.0270027,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),0.01128,0.02810281,0.01305,0.01520152,Average Maturation,0.01520152,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Publication Year - Post 2020 (122),0.01128,0.04430443,0.00695,0.183618362,Average Maturation,0.04430443,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),hiPSC Backbone Media - Rare (19),0.01105,0.03770377,0.00506,0.188818882,Average Maturation,0.03770377,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Cell Line - BJ RiPS (4),0.01088,0.03920392,0.0087,0.064606461,Average Maturation,0.03920392,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),0.01084,0.02490249,0.00709,0.079507951,Average Maturation,0.02490249,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Pharmacological Intervention - Carbamylcholine (6),0.01066,0.0230023,0.00784,0.066306631,Average Maturation,0.0230023,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Publication Year - Late-2010s (196),0.0106,0.04030403,0.00871,0.060306031,Average Maturation,0.04030403,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),0.01009,0.02250225,0.0122,0.01410141,Average Maturation,0.01410141,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Seeding Confluency 2D (%) - 70 to 79 (6),0.00957,0.04770477,0.01115,0.02660266,Average Maturation,0.02660266,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),0.00928,0.0370037,0.00623,0.101910191,Average Maturation,0.0370037,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),2D Surface - Electrospun (13),0.00921,0.04520452,0.00585,0.122812281,Average Maturation,0.04520452,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Insulin Start Day - 3 (5),0.00921,0.071507151,0.01138,0.04290429,Average Maturation,0.04290429,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Cell Line Sex - Female (40),0.00892,0.082908291,0.01012,0.04960496,Average Maturation,0.04960496,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),0.00729,0.072707271,0.00966,0.03950395,Average Maturation,0.03950395,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Wnt Inhibitor Duration (days) - 5 days (6),0.00462,0.127812781,0.00973,0.04710471,Average Maturation,0.04710471,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Publication Year - 2017 (43),0.00415,0.291029103,0.01029,0.04580458,Average Maturation,0.04580458,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Electrophysiology Analysis Method - Patch Clamp (59),0.048,0,0.01677,0.00340034,Average Maturation,0,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Journal - Cell Stem Cell (6),0.02577,0.00150015,0.02728,0.0010001,Average Maturation,0.0010001,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Number of Cell Lines - 4 (11),0.02022,0.00430043,0.01561,0.01070107,Average Maturation,0.00430043,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Electron Imaging - Transmission (62),0.01931,0.00570057,0.01385,0.010001,Average Maturation,0.00570057,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Metabolic Component - Palmitic Acid (11),0.01758,0.00690069,0.01036,0.02910291,Average Maturation,0.00690069,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),0.01643,0.01640164,0.01018,0.050405041,Average Maturation,0.01640164,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),3D Stromal Cell Source - Rare (4),0.01526,0.00770077,0.01815,0.00510051,Average Maturation,0.00510051,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Disease Modelling - Genetic Disorders (18),0.0151,0.01270127,0.00687,0.095309531,Average Maturation,0.01270127,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Metabolic Component - Dexamethasone (7),0.01474,0.01030103,0.01466,0.01150115,Average Maturation,0.01030103,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),0.01367,0.02020202,0.01612,0.01290129,Average Maturation,0.01290129,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Journal - Nat Commun (13),0.01328,0.01380138,0.00934,0.04090409,Average Maturation,0.01380138,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Wnt Induction - BMP4 (74),0.01282,0.02570257,0.00802,0.117511751,Average Maturation,0.02570257,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),hiPSC-CM Maturation Media - RPMI-1640 (153),0.01279,0.01430143,0.006,0.327232723,Average Maturation,0.01430143,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),0.01271,0.01560156,0.0121,0.0140014,Average Maturation,0.0140014,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Metabolic Component - Galactose (4),0.01172,0.03470347,0.00687,0.084708471,Average Maturation,0.03470347,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Calcium Handling Analysis Method - Visual (104),0.01166,0.0380038,0.00658,0.203720372,Average Maturation,0.0380038,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Seeding Confluency 3D (%) - 95 to 100 (13),0.01149,0.01710171,0.00563,0.112111211,Average Maturation,0.01710171,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Metabolic Analysis Method - Seahorse (35),0.01111,0.03190319,0.00914,0.055505551,Average Maturation,0.03190319,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),hiPSC-CM Media Supplement - Ascorbic Acid (41),0.01103,0.02470247,0.0028,0.419841984,Average Maturation,0.02470247,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),3D Platform - Scaffold Free (43),0.01089,0.04350435,0.00717,0.130113011,Average Maturation,0.04350435,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),hiPSC-CM Media Supplement - 1-thioglycerol (14),0.01081,0.03810381,0.00948,0.051905191,Average Maturation,0.03810381,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),0.01061,0.04330433,0.00573,0.338933893,Average Maturation,0.04330433,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),0.00971,0.050805081,0.01164,0.03540354,Average Maturation,0.03540354,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),3D Tissue Media - Growth Factor (12),0.00953,0.03510351,0.01365,0.01150115,Average Maturation,0.01150115,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),0.00946,0.0430043,0.00967,0.03810381,Average Maturation,0.03810381,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),0.00904,0.03150315,0.01089,0.02230223,Average Maturation,0.02230223,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Wnt Inhibitor - VEGF (3),0.0089,0.04740474,0.01006,0.04370437,Average Maturation,0.04370437,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),hiPSC-CM Backbone Media - StemPro-34 (14),0.00885,0.04330433,0.01031,0.0330033,Average Maturation,0.0330033,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Insulin Start Day - 2 (4),0.00789,0.055605561,0.00945,0.04380438,Average Maturation,0.04380438,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Wnt Inhibitor - bFGF (8),0.00748,0.065006501,0.01286,0.01530153,Average Maturation,0.01530153,TRUE,TRUE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Pharmacological Intervention - Caffeine (4),0.00714,0.073207321,0.00945,0.04970497,Average Maturation,0.04970497,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Purification Protocol - Cell Sorting (7),0.00667,0.094809481,0.01147,0.02580258,Average Maturation,0.02580258,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),0.00661,0.105210521,0.00944,0.0450045,Average Maturation,0.0450045,TRUE,FALSE
Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Wnt Inhibitor Duration (days) - Rare (173),0.00285,0.931093109,0.00855,0.04980498,Average Maturation,0.04980498,TRUE,FALSE
Cell Line Sex - Both (118),Cell Line Ancestry - Caucasian (41),0.06297,0,0.06483,0,Other Applications,0,TRUE,TRUE
Cell Line Sex - Both (118),Cell Line - Rare (132),0.04021,0,0.04587,0,Other Applications,0,TRUE,TRUE
Cell Line Sex - Both (118),Cell Line - WTC11 (30),0.03244,0,0.0296,0,Other Applications,0,TRUE,TRUE
Cell Line Sex - Both (118),Cell Line - IMR90 (19),0.02747,0,0.02657,0,Other Applications,0,TRUE,TRUE
Cell Line Sex - Both (118),Cell Line Ancestry - Asian (28),0.02659,0,0.03054,0,Other Applications,0,TRUE,TRUE
Cell Line Sex - Both (118),Cell Line - DF19-9-11T.H (16),0.02063,0,0.02305,0,Other Applications,0,TRUE,TRUE
Cell Line Sex - Both (118),hiPSC Matrix Coating - Matrigel (163),0.01536,0.00050005,0.01615,0.00050005,Other Applications,0.00050005,TRUE,TRUE
Cell Line Sex - Both (118),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),0.01306,0.00130013,0.01552,0.00050005,Other Applications,0.00050005,TRUE,TRUE
Cell Line Sex - Both (118),Cell Line - 201B7 (9),0.01263,0.00030003,0.01151,0.0010001,Other Applications,0.00030003,TRUE,TRUE
Cell Line Sex - Both (118),Day of Insulin Addition - Known (177),0.01106,0.00420042,0.01029,0.00690069,Other Applications,0.00420042,TRUE,TRUE
Cell Line Sex - Both (118),hiPSC Backbone Media - Embryonic Stem Cell (127),0.0108,0.0060006,0.01106,0.00620062,Other Applications,0.0060006,TRUE,TRUE
Cell Line Sex - Both (118),Cell Line - PGP1 (11),0.01051,0.00020002,0.00846,0.00230023,Other Applications,0.00020002,TRUE,TRUE
Cell Line Sex - Both (118),Wnt Induction - CHIR99021 (184),0.00976,0.01090109,0.00821,0.03340334,Other Applications,0.01090109,TRUE,TRUE
Cell Line Sex - Both (118),Wnt Inhibitor Duration (days) - Rare (173),0.00961,0.01220122,0.00958,0.01390139,Other Applications,0.01220122,TRUE,TRUE
Cell Line Sex - Both (118),hiPSC-CM Media Supplement - B27 (180),0.00958,0.00960096,0.00883,0.01660166,Other Applications,0.00960096,TRUE,TRUE
Cell Line Sex - Both (118),Wnt Inhibitor - IWP (112),0.00894,0.01250125,0.0108,0.00490049,Other Applications,0.00490049,TRUE,TRUE
Cell Line Sex - Both (118),Wnt Induction - BMP4 (74),0.0073,0.02990299,0.00801,0.02040204,Other Applications,0.02040204,TRUE,TRUE
Cell Line Sex - Both (118),hiPSC Backbone Media - mTeSR (106),0.00679,0.065406541,0.00843,0.01890189,Other Applications,0.01890189,TRUE,TRUE
Cell Line Sex - Both (118),Cell Line - BJ1 (7),0.00548,0.00560056,0.0037,0.03650365,Other Applications,0.00560056,TRUE,TRUE
Cell Line Sex - Both (118),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),0.00522,0.01090109,0.00444,0.03170317,Other Applications,0.01090109,TRUE,TRUE
Cell Line Sex - Both (118),Seeding Confluency 3D (%) - 85 to 89 (12),0.00438,0.03210321,0.00416,0.050205021,Other Applications,0.03210321,TRUE,FALSE
Cell Line Sex - Both (118),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),0.00397,0.02480248,0.00515,0.01670167,Other Applications,0.01670167,TRUE,TRUE
Cell Line Sex - Both (118),hiPSC-CM Media Supplement - Mercaptoethanol (10),0.00396,0.03340334,0.00567,0.01450145,Other Applications,0.01450145,TRUE,TRUE
Cell Line Sex - Both (118),Cell Line - C25 (6),0.00388,0.01660166,0.00384,0.02580258,Other Applications,0.01660166,TRUE,TRUE
Cell Line Sex - Both (118),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),0.00381,0.03460346,0.00372,0.04680468,Other Applications,0.03460346,TRUE,FALSE
Cell Line Sex - Both (118),hiPSC-CM Media Supplement - Selenium (7),0.00339,0.03210321,0.00298,0.068606861,Other Applications,0.03210321,TRUE,FALSE
Cell Line Sex - Both (118),Journal - Stem Cell Res (8),0.00269,0.072607261,0.00348,0.04880488,Other Applications,0.04880488,TRUE,FALSE
Cell Line Sex - Both (118),Pharmacological Intervention - Thalidomide (3),0.00256,0.02130213,0.00318,0.01770177,Other Applications,0.01770177,TRUE,TRUE
Cell Line Sex - Both (118),Pharmacological Intervention - Cardiotoxic Agents (3),0.00209,0.03190319,0.00191,0.053905391,Other Applications,0.03190319,TRUE,FALSE
Cell Line Sex - Both (118),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),0.00176,0.04640464,0.00286,0.02210221,Other Applications,0.02210221,TRUE,TRUE
Cell Line Sex - Male (64),Cell Line Ancestry - Asian (28),0.04942,0,0.05294,0,Other Applications,0,TRUE,TRUE
Cell Line Sex - Male (64),Cell Line - WTC11 (30),0.04531,0,0.05218,0,Other Applications,0,TRUE,TRUE
Cell Line Sex - Male (64),Cell Line - DF19-9-11T.H (16),0.02685,0,0.028,0,Other Applications,0,TRUE,TRUE
Cell Line Sex - Male (64),Wnt Induction - CHIR99021 (184),0.02353,0,0.01413,0.00020002,Other Applications,0,TRUE,TRUE
Cell Line Sex - Male (64),Cell Line - PGP1 (11),0.02298,0,0.0257,0,Other Applications,0,TRUE,TRUE
Cell Line Sex - Male (64),3D Tissue Media - RPMI-1640 (72),0.02015,0,0.02148,0,Other Applications,0,TRUE,TRUE
Cell Line Sex - Male (64),Cell Line - Rare (132),0.0201,0.00020002,0.01816,0.00010001,Other Applications,0.00010001,TRUE,TRUE
Cell Line Sex - Male (64),Day of Insulin Addition - Known (177),0.01979,0,0.01389,0,Other Applications,0,TRUE,TRUE
Cell Line Sex - Male (64),Wnt Inhibitor - IWP (112),0.0196,0.00010001,0.01449,0.00020002,Other Applications,0.00010001,TRUE,TRUE
Cell Line Sex - Male (64),hiPSC Matrix Coating - Matrigel (163),0.01679,0.00040004,0.01349,0.00070007,Other Applications,0.00040004,TRUE,TRUE
Cell Line Sex - Male (64),Purification Protocol - Glucose and Lactate (85),0.01409,0.00110011,0.01019,0.00360036,Other Applications,0.00110011,TRUE,TRUE
Cell Line Sex - Male (64),Wnt Inhibitor Duration (days) Quantiles - Q2 (>1 and ≤2) (156),0.01354,0.00190019,0.01188,0.00120012,Other Applications,0.00120012,TRUE,TRUE
Cell Line Sex - Male (64),hiPSC Backbone Media - Embryonic Stem Cell (127),0.01257,0.00440044,0.00952,0.00670067,Other Applications,0.00440044,TRUE,TRUE
Cell Line Sex - Male (64),hiPSC Backbone Media - mTeSR (106),0.01222,0.00390039,0.01143,0.00130013,Other Applications,0.00130013,TRUE,TRUE
Cell Line Sex - Male (64),Wnt Inhibitor Duration (days) - Rare (173),0.01167,0.00540054,0.00828,0.01780178,Other Applications,0.00540054,TRUE,TRUE
Cell Line Sex - Male (64),hiPSC-CM Media Supplement - B27 (180),0.01135,0.00880088,0.0101,0.00490049,Other Applications,0.00490049,TRUE,TRUE
Cell Line Sex - Male (64),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),0.0105,0.01220122,0.00819,0.01950195,Other Applications,0.01220122,TRUE,TRUE
Cell Line Sex - Male (64),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),0.00828,0.0190019,0.00781,0.01550155,Other Applications,0.01550155,TRUE,TRUE
Cell Line Sex - Male (64),Insulin Start Day - 9 (10),0.00799,0.00660066,0.00799,0.01180118,Other Applications,0.00660066,TRUE,TRUE
Cell Line Sex - Male (64),Cell Line - BJ1 (7),0.00772,0.00510051,0.00684,0.01630163,Other Applications,0.00510051,TRUE,TRUE
Cell Line Sex - Male (64),Cell Line Ancestry - Caucasian (41),0.00741,0.01590159,0.00815,0.00840084,Other Applications,0.00840084,TRUE,TRUE
Cell Line Sex - Male (64),hiPSC-CM Purification Duration (days) - 4 days (29),0.00696,0.0190019,0.00912,0.00560056,Other Applications,0.00560056,TRUE,TRUE
Cell Line Sex - Male (64),Calcium Handling Analysis Method - Genetic (23),0.00665,0.02680268,0.00804,0.01610161,Other Applications,0.01610161,TRUE,TRUE
Cell Line Sex - Male (64),Insulin Withdrawal Duration (days) - 4 days (18),0.00617,0.02060206,0.00847,0.00890089,Other Applications,0.00890089,TRUE,TRUE
Cell Line Sex - Male (64),Publication Year - 2022 (20),0.00565,0.02790279,0.00781,0.01080108,Other Applications,0.01080108,TRUE,TRUE
Cell Line Sex - Male (64),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),0.00559,0.054205421,0.00597,0.04410441,Other Applications,0.04410441,TRUE,FALSE
Cell Line Sex - Male (64),Pharmacological Intervention - Thalidomide (3),0.00507,0.01070107,0.00498,0.02960296,Other Applications,0.01070107,TRUE,TRUE
Cell Line Sex - Male (64),hiPSC-CM Media Supplement - Mercaptoethanol (10),0.00506,0.03030303,0.00704,0.02060206,Other Applications,0.02060206,TRUE,TRUE
Cell Line Sex - Male (64),Insulin Withdrawal Duration (days) Quantiles - Q2 (>2 and ≤4) (25),0.00446,0.071107111,0.00609,0.02670267,Other Applications,0.02670267,TRUE,FALSE
Cell Line Sex - Male (64),Journal - Nat Biomed Eng (5),0.0035,0.057205721,0.00562,0.0360036,Other Applications,0.0360036,TRUE,FALSE
Cell Line Sex - Male (64),Day of Insulin Addition - not 22 (12),0.00262,0.149014901,0.00495,0.04340434,Other Applications,0.04340434,TRUE,FALSE
Cell Line Sex - Female (40),Cell Line - IMR90 (19),0.07622,0,0.07756,0,Other Applications,0,TRUE,TRUE
Cell Line Sex - Female (40),Cell Line Ancestry - Caucasian (41),0.04018,0,0.03658,0,Other Applications,0,TRUE,TRUE
Cell Line Sex - Female (40),Cell Line - 201B7 (9),0.03973,0,0.05045,0,Other Applications,0,TRUE,TRUE
Cell Line Sex - Female (40),Wnt Induction - BMP4 (74),0.01824,0.00060006,0.01503,0.00040004,Other Applications,0.00040004,TRUE,TRUE
Cell Line Sex - Female (40),Cell Line - Rare (132),0.01763,0.00070007,0.01141,0.00110011,Other Applications,0.00070007,TRUE,TRUE
Cell Line Sex - Female (40),Seeding Confluency 2D (%) - Rare (13),0.01253,0.00170017,0.01315,0.00180018,Other Applications,0.00170017,TRUE,TRUE
Cell Line Sex - Female (40),Wnt Induction Duration (days) Quantiles - Q1 (>2 and ≤5) (61),0.01138,0.00630063,0.01216,0.0020002,Other Applications,0.0020002,TRUE,TRUE
Cell Line Sex - Female (40),Wnt Induction - Activin A (80),0.01044,0.01420142,0.00815,0.01830183,Other Applications,0.01420142,TRUE,TRUE
Cell Line Sex - Female (40),Seeding Confluency (%) - Rare (43),0.01011,0.00910091,0.01006,0.0060006,Other Applications,0.0060006,TRUE,TRUE
Cell Line Sex - Female (40),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),0.00877,0.03380338,0.00533,0.414741474,Other Applications,0.03380338,TRUE,FALSE
Cell Line Sex - Female (40),Cell Line - SCVI-273 (8),0.00831,0.00860086,0.00825,0.01320132,Other Applications,0.00860086,TRUE,TRUE
Cell Line Sex - Female (40),Number of Cell Lines - 2 (50),0.00802,0.03660366,0.00579,0.083808381,Other Applications,0.03660366,TRUE,FALSE
Cell Line Sex - Female (40),Journal - Stem Cell Res (8),0.00801,0.00840084,0.00963,0.00650065,Other Applications,0.00650065,TRUE,TRUE
Cell Line Sex - Female (40),Pharmacological Intervention - Carbamylcholine (6),0.00758,0.00680068,0.00574,0.02780278,Other Applications,0.00680068,TRUE,TRUE
Cell Line Sex - Female (40),Cell Line - 201B6 (3),0.00734,0.00860086,0.01008,0.00560056,Other Applications,0.00560056,TRUE,TRUE
Cell Line Sex - Female (40),Insulin Start Day - 5 (14),0.00675,0.02160216,0.0092,0.00960096,Other Applications,0.00960096,TRUE,TRUE
Cell Line Sex - Female (40),Wnt Induction - bFGF (45),0.00667,0.062906291,0.00655,0.04740474,Other Applications,0.04740474,TRUE,FALSE
Cell Line Sex - Female (40),Insulin Start Day - 4 (11),0.00652,0.02780278,0.00624,0.0360036,Other Applications,0.02780278,TRUE,FALSE
Cell Line Sex - Female (40),Wnt Induction - Wnt3a (3),0.00648,0.01220122,0.00706,0.02250225,Other Applications,0.01220122,TRUE,TRUE
Cell Line Sex - Female (40),3D Stromal Cell Source - hiPSC-MuralC (3),0.00622,0.02340234,0.0092,0.01410141,Other Applications,0.01410141,TRUE,TRUE
Cell Line Sex - Female (40),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),0.00614,0.04280428,0.00714,0.02170217,Other Applications,0.02170217,TRUE,TRUE
Cell Line Sex - Female (40),hiPSC Backbone Media - DMEM (10),0.00603,0.02890289,0.00744,0.0220022,Other Applications,0.0220022,TRUE,TRUE
Cell Line Sex - Female (40),hiPSC-CM Media Supplement - Lipids (9),0.00592,0.03030303,0.00589,0.04060406,Other Applications,0.03030303,TRUE,FALSE
Cell Line Sex - Female (40),hiPSC Backbone Media - Conditioned (12),0.00578,0.02990299,0.00593,0.03180318,Other Applications,0.02990299,TRUE,FALSE
Cell Line Sex - Female (40),hiPSC-CM Media Supplement - GlutaMax (8),0.00552,0.03160316,0.00445,0.065806581,Other Applications,0.03160316,TRUE,FALSE
Cell Line Sex - Female (40),Pharmacological Intervention - Thalidomide (3),0.00539,0.02670267,0.00342,0.087908791,Other Applications,0.02670267,TRUE,FALSE
Cell Line Sex - Female (40),hiPSC-CM Media Supplement - L-glutamine (19),0.00516,0.04870487,0.00493,0.061006101,Other Applications,0.04870487,TRUE,FALSE
Cell Line Sex - Female (40),Contractile Analysis Method - Force Transducer (27),0.00514,0.081608161,0.00667,0.03530353,Other Applications,0.03530353,TRUE,FALSE
Cell Line Sex - Female (40),Metabolic Component - Ascorbic Acid (3),0.00499,0.02290229,0.00467,0.03930393,Other Applications,0.02290229,TRUE,TRUE
Cell Line Sex - Female (40),Wnt Induction Duration (days) - 4 days (15),0.00477,0.054805481,0.00706,0.01810181,Other Applications,0.01810181,TRUE,TRUE
Cell Line Sex - Female (40),Metabolic Component - Rare (4),0.00422,0.0430043,0.00316,0.091309131,Other Applications,0.0430043,TRUE,FALSE
Cell Line Sex - Female (40),Metabolic Component - KOSR (3),0.00412,0.03590359,0.00401,0.051305131,Other Applications,0.03590359,TRUE,FALSE
Cell Line Sex - Female (40),Journal - Stem Cells Int (3),0.00317,0.057705771,0.00469,0.04410441,Other Applications,0.04410441,TRUE,FALSE
Cell Line Sex - Female (40),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),0.00315,0.118911891,0.00678,0.02610261,Other Applications,0.02610261,TRUE,FALSE
Cell Line Ancestry - Caucasian (41),Cell Line Sex - Both (118),0.08641,0,0.05073,0,Other Applications,0,TRUE,TRUE
Cell Line Ancestry - Caucasian (41),Cell Line - PGP1 (11),0.04535,0,0.04719,0,Other Applications,0,TRUE,TRUE
Cell Line Ancestry - Caucasian (41),Cell Line Sex - Female (40),0.04155,0,0.03525,0,Other Applications,0,TRUE,TRUE
Cell Line Ancestry - Caucasian (41),Cell Line - 201B7 (9),0.03817,0,0.04488,0,Other Applications,0,TRUE,TRUE
Cell Line Ancestry - Caucasian (41),Seeding Confluency (%) - Rare (43),0.01734,0.00050005,0.01664,0.00040004,Other Applications,0.00040004,TRUE,TRUE
Cell Line Ancestry - Caucasian (41),hiPSC Backbone Media - mTeSR (106),0.01442,0.00250025,0.00653,0.090809081,Other Applications,0.00250025,TRUE,TRUE
Cell Line Ancestry - Caucasian (41),Cell Line - C25 (6),0.01154,0.00170017,0.01688,0.00040004,Other Applications,0.00040004,TRUE,TRUE
Cell Line Ancestry - Caucasian (41),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),0.00995,0.00630063,0.01117,0.00250025,Other Applications,0.00250025,TRUE,TRUE
Cell Line Ancestry - Caucasian (41),Wnt Induction - Activin A (80),0.0093,0.0310031,0.00613,0.104310431,Other Applications,0.0310031,TRUE,FALSE
Cell Line Ancestry - Caucasian (41),hiPSC Backbone Media - Essential 8 (82),0.0092,0.02160216,0.0048,0.280528053,Other Applications,0.02160216,TRUE,TRUE
Cell Line Ancestry - Caucasian (41),Cell Line - Rare (132),0.00892,0.03740374,0.00832,0.0130013,Other Applications,0.0130013,TRUE,TRUE
Cell Line Ancestry - Caucasian (41),Wnt Induction Duration (days) Quantiles - Q1 (>2 and ≤5) (61),0.0087,0.02150215,0.00735,0.02730273,Other Applications,0.02150215,TRUE,TRUE
Cell Line Ancestry - Caucasian (41),Cell Line Sex - Male (64),0.0087,0.02230223,0.00495,0.163816382,Other Applications,0.02230223,TRUE,TRUE
Cell Line Ancestry - Caucasian (41),Publication Year - 2018 (45),0.00757,0.03110311,0.00643,0.04370437,Other Applications,0.03110311,TRUE,FALSE
Cell Line Ancestry - Caucasian (41),Cell Line - IMR90 (19),0.00754,0.01450145,0.00357,0.147714771,Other Applications,0.01450145,TRUE,TRUE
Cell Line Ancestry - Caucasian (41),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),0.00747,0.04630463,0.00488,0.185618562,Other Applications,0.04630463,TRUE,FALSE
Cell Line Ancestry - Caucasian (41),Wnt Induction - bFGF (45),0.0074,0.04030403,0.00874,0.0130013,Other Applications,0.0130013,TRUE,TRUE
Cell Line Ancestry - Caucasian (41),Wnt Induction - BMP4 (74),0.00711,0.070607061,0.00688,0.04610461,Other Applications,0.04610461,TRUE,FALSE
Cell Line Ancestry - Caucasian (41),Cell Line - 201B6 (3),0.00686,0.01330133,0.00726,0.02840284,Other Applications,0.01330133,TRUE,TRUE
Cell Line Ancestry - Caucasian (41),Wnt Induction - Wnt3a (3),0.00684,0.01430143,0.01036,0.00650065,Other Applications,0.00650065,TRUE,TRUE
Cell Line Ancestry - Caucasian (41),Disease Modelling - Hypertrophic Cardiomyopathy (6),0.00609,0.02740274,0.00987,0.00970097,Other Applications,0.00970097,TRUE,TRUE
Cell Line Ancestry - Caucasian (41),hiPSC-CM Media Supplement - Polyvinylalchohol (6),0.00558,0.02270227,0.00726,0.01770177,Other Applications,0.01770177,TRUE,TRUE
Cell Line Ancestry - Caucasian (41),hiPSC-CM Media Supplement - Nonessential Amino Acids (8),0.00468,0.03770377,0.00488,0.04580458,Other Applications,0.03770377,TRUE,FALSE
Cell Line Ancestry - Caucasian (41),Wnt Induction Duration (days) - 4 days (15),0.00459,0.066706671,0.00705,0.02340234,Other Applications,0.02340234,TRUE,TRUE
Cell Line Ancestry - Caucasian (41),Seeding Confluency 3D (%) - Rare (26),0.00436,0.100610061,0.00648,0.02840284,Other Applications,0.02840284,TRUE,FALSE
Cell Line Ancestry - Caucasian (41),3D Stromal Cell Source - hiPSC-MuralC (3),0.00399,0.03950395,0.00649,0.02610261,Other Applications,0.02610261,TRUE,FALSE
Cell Line Ancestry - Caucasian (41),3D Endothelial Cell Source - hiPSC-EndothelialC (16),0.00398,0.103710371,0.00606,0.0370037,Other Applications,0.0370037,TRUE,FALSE
Cell Line Ancestry - Caucasian (41),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),0.00349,0.0480048,0.00471,0.0440044,Other Applications,0.0440044,TRUE,FALSE
Cell Line Ancestry - Caucasian (41),Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),0.00334,0.074207421,0.00529,0.0350035,Other Applications,0.0350035,TRUE,FALSE
Cell Line Ancestry - Asian (28),Cell Line - WTC11 (30),0.1782,0,0.17928,0,Other Applications,0,TRUE,TRUE
Cell Line Ancestry - Asian (28),Cell Line Sex - Male (64),0.05883,0,0.04285,0,Other Applications,0,TRUE,TRUE
Cell Line Ancestry - Asian (28),Cell Line Sex - Both (118),0.05065,0,0.02544,0,Other Applications,0,TRUE,TRUE
Cell Line Ancestry - Asian (28),Calcium Handling Analysis Method - Genetic (23),0.02828,0,0.02933,0,Other Applications,0,TRUE,TRUE
Cell Line Ancestry - Asian (28),3D Tissue Media - RPMI-1640 (72),0.02317,0,0.01815,0,Other Applications,0,TRUE,TRUE
Cell Line Ancestry - Asian (28),Cell Line - Rare (132),0.02298,0.00020002,0.00911,0.00590059,Other Applications,0.00020002,TRUE,TRUE
Cell Line Ancestry - Asian (28),Publication Year - 2022 (20),0.01395,0.0010001,0.01316,0.00120012,Other Applications,0.0010001,TRUE,TRUE
Cell Line Ancestry - Asian (28),hiPSC Backbone Media - Essential 8 (82),0.01168,0.00910091,0.00922,0.01090109,Other Applications,0.00910091,TRUE,TRUE
Cell Line Ancestry - Asian (28),3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25),0.01125,0.00420042,0.01215,0.00120012,Other Applications,0.00120012,TRUE,TRUE
Cell Line Ancestry - Asian (28),hiPSC Matrix Coating - Matrigel (163),0.01102,0.01430143,0.00476,0.595559556,Other Applications,0.01430143,TRUE,TRUE
Cell Line Ancestry - Asian (28),Day of Insulin Addition - not 20 (15),0.01097,0.0060006,0.01593,0.00050005,Other Applications,0.00050005,TRUE,TRUE
Cell Line Ancestry - Asian (28),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),0.00961,0.0120012,0.00913,0.00830083,Other Applications,0.00830083,TRUE,TRUE
Cell Line Ancestry - Asian (28),hiPSC-CM Purification Duration (days) - 4 days (29),0.00916,0.01670167,0.00974,0.01070107,Other Applications,0.01070107,TRUE,TRUE
Cell Line Ancestry - Asian (28),Journal - Tissue Eng Part A (4),0.00864,0.00960096,0.00899,0.01720172,Other Applications,0.00960096,TRUE,TRUE
Cell Line Ancestry - Asian (28),Day of Insulin Addition - not 21 (14),0.00805,0.01880188,0.01025,0.00820082,Other Applications,0.00820082,TRUE,TRUE
Cell Line Ancestry - Asian (28),Day of Insulin Addition - not 22 (12),0.00622,0.03570357,0.00862,0.01250125,Other Applications,0.01250125,TRUE,TRUE
Cell Line Ancestry - Asian (28),Insulin Withdrawal Duration (days) - 4 days (18),0.00598,0.04940494,0.00867,0.01410141,Other Applications,0.01410141,TRUE,TRUE
Cell Line Ancestry - Asian (28),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),0.00575,0.03850385,0.00424,0.095009501,Other Applications,0.03850385,TRUE,FALSE
Cell Line Ancestry - Asian (28),Day of Insulin Addition - not 24 (9),0.00483,0.054805481,0.00903,0.0090009,Other Applications,0.0090009,TRUE,TRUE
Cell Line Ancestry - Asian (28),Pharmacological Intervention - Cardiotoxic Agents (3),0.0041,0.057605761,0.00552,0.04230423,Other Applications,0.04230423,TRUE,FALSE
Cell Line Ancestry - Asian (28),Journal - Nat Biomed Eng (5),0.00408,0.067406741,0.00736,0.03040304,Other Applications,0.03040304,TRUE,FALSE
Cell Line Ancestry - Asian (28),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),0.00266,0.362936294,0.00801,0.02150215,Other Applications,0.02150215,TRUE,TRUE
Cell Line Ancestry - Asian (28),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),0.00249,0.194119412,0.00748,0.02030203,Other Applications,0.02030203,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),Coating for Replating - Laminin (5),0.01999,0.00080008,0.02083,0.00090009,Other Applications,0.00080008,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),0.01663,0.00090009,0.01323,0.00680068,Other Applications,0.00090009,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),Electrophysiology Analysis Method - Genetic (3),0.01593,0.00320032,0.01695,0.00450045,Other Applications,0.00320032,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),Cell Line - Rare (132),0.01288,0.00970097,0.00741,0.064206421,Other Applications,0.00970097,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),2D Surface - ECM-coated (115),0.01283,0.01240124,0.00773,0.053005301,Other Applications,0.01240124,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),Day of Insulin Addition - Known (177),0.01197,0.01690169,0.00666,0.157115712,Other Applications,0.01690169,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),0.01163,0.00580058,0.0065,0.04540454,Other Applications,0.00580058,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),Coating for Replating - Gelatin (43),0.01121,0.01490149,0.00961,0.01740174,Other Applications,0.01490149,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),Purification Protocol - Cell Sorting (7),0.01113,0.00880088,0.01061,0.01320132,Other Applications,0.00880088,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),Electrophysiology Analysis Method - Patch Clamp (59),0.01052,0.02070207,0.00877,0.02480248,Other Applications,0.02070207,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),Cell Line - iCell (47),0.01012,0.02370237,0.01061,0.01090109,Other Applications,0.01090109,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),3D Tissue Media - RPMI-1640 (72),0.01007,0.03070307,0.00654,0.108710871,Other Applications,0.03070307,TRUE,FALSE
Disease Modelling - Genetic Disorders (18),Contractile Analysis Method - Deflection (39),0.00966,0.02420242,0.00599,0.098409841,Other Applications,0.02420242,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),Publication Year - 2017 (43),0.00952,0.02830283,0.00882,0.02160216,Other Applications,0.02160216,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),0.00891,0.02070207,0.00949,0.01640164,Other Applications,0.01640164,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),0.00872,0.02420242,0.00567,0.059505951,Other Applications,0.02420242,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),hiPSC Matrix Coating - Geltrex (33),0.00858,0.04150415,0.01097,0.00980098,Other Applications,0.00980098,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),Journal - Am J Physiol Heart Circ Physiol (4),0.00853,0.01530153,0.00999,0.01390139,Other Applications,0.01390139,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),0.0085,0.01630163,0.00767,0.02570257,Other Applications,0.01630163,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),Journal - Circulation (11),0.0084,0.0180018,0.00451,0.095609561,Other Applications,0.0180018,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),Journal - Biosens Bioelectron (4),0.00829,0.0150015,0.00578,0.055005501,Other Applications,0.0150015,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),3D Platform - Matrigel (33),0.00824,0.04750475,0.00675,0.076007601,Other Applications,0.04750475,TRUE,FALSE
Disease Modelling - Genetic Disorders (18),Number of Cell Lines - 2 (50),0.00808,0.04650465,0.00712,0.065206521,Other Applications,0.04650465,TRUE,FALSE
Disease Modelling - Genetic Disorders (18),hiPSC-CM Purification Duration (days) - 4 days (29),0.00787,0.04780478,0.0069,0.058705871,Other Applications,0.04780478,TRUE,FALSE
Disease Modelling - Genetic Disorders (18),TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),0.00772,0.02010201,0.00815,0.02350235,Other Applications,0.02010201,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),hiPSC-CM Maturation Media - Cor.4U Complete (6),0.00729,0.03490349,0.00637,0.04930493,Other Applications,0.03490349,TRUE,FALSE
Disease Modelling - Genetic Disorders (18),Number of Cell Lines - 4 (11),0.0069,0.04730473,0.00462,0.112811281,Other Applications,0.04730473,TRUE,FALSE
Disease Modelling - Genetic Disorders (18),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),0.00681,0.02490249,0.00945,0.01690169,Other Applications,0.01690169,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),0.00644,0.04960496,0.00691,0.04730473,Other Applications,0.04730473,TRUE,FALSE
Disease Modelling - Genetic Disorders (18),Journal - Stem Cell Res Ther (3),0.00588,0.060506051,0.00724,0.04840484,Other Applications,0.04840484,TRUE,FALSE
Disease Modelling - Genetic Disorders (18),Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),0.00525,0.04690469,0.00835,0.01770177,Other Applications,0.01770177,TRUE,TRUE
Disease Modelling - Genetic Disorders (18),Insulin Start Day - 2 (4),0.00513,0.04880488,0.00626,0.03660366,Other Applications,0.03660366,TRUE,FALSE
Disease Modelling - Genetic Disorders (18),Journal - Sci Transl Med (3),0.00416,0.115311531,0.00869,0.0260026,Other Applications,0.0260026,TRUE,FALSE
Disease Modelling - Genetic Disorders (18),Journal - Sci Adv (3),0.00234,0.148114811,0.0066,0.03790379,Other Applications,0.03790379,TRUE,FALSE
Disease Modelling - Arrhythmic (15),Coating for Replating - Laminin (5),0.02203,0.00020002,0.02455,0,Other Applications,0,TRUE,TRUE
Disease Modelling - Arrhythmic (15),Electrophysiology Analysis Method - Genetic (3),0.01703,0.00390039,0.02116,0.00320032,Other Applications,0.00320032,TRUE,TRUE
Disease Modelling - Arrhythmic (15),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),0.01546,0.00380038,0.01658,0.00330033,Other Applications,0.00330033,TRUE,TRUE
Disease Modelling - Arrhythmic (15),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),0.01478,0.00530053,0.01601,0.00450045,Other Applications,0.00450045,TRUE,TRUE
Disease Modelling - Arrhythmic (15),Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),0.01258,0.00390039,0.01264,0.00450045,Other Applications,0.00390039,TRUE,TRUE
Disease Modelling - Arrhythmic (15),Journal - Am J Physiol Heart Circ Physiol (4),0.01094,0.00860086,0.01106,0.01080108,Other Applications,0.00860086,TRUE,TRUE
Disease Modelling - Arrhythmic (15),Insulin Start Day - 11 (3),0.0108,0.00750075,0.01262,0.00640064,Other Applications,0.00640064,TRUE,TRUE
Disease Modelling - Arrhythmic (15),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),0.01077,0.00980098,0.01081,0.01180118,Other Applications,0.00980098,TRUE,TRUE
Disease Modelling - Arrhythmic (15),Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),0.01072,0.01890189,0.01044,0.02030203,Other Applications,0.01890189,TRUE,TRUE
Disease Modelling - Arrhythmic (15),hiPSC-CM Purification Duration (days) - 4 days (29),0.01062,0.02110211,0.00936,0.02030203,Other Applications,0.02030203,TRUE,TRUE
Disease Modelling - Arrhythmic (15),Journal - Circulation (11),0.01034,0.01140114,0.00759,0.03310331,Other Applications,0.01140114,TRUE,TRUE
Disease Modelling - Arrhythmic (15),MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),0.00976,0.01290129,0.00844,0.02710271,Other Applications,0.01290129,TRUE,TRUE
Disease Modelling - Arrhythmic (15),Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),0.00941,0.01860186,0.00601,0.060906091,Other Applications,0.01860186,TRUE,TRUE
Disease Modelling - Arrhythmic (15),Maturation Strategy - ECM (21),0.00883,0.03320332,0.00584,0.098309831,Other Applications,0.03320332,TRUE,FALSE
Disease Modelling - Arrhythmic (15),Electrophysiology Analysis Method - Patch Clamp (59),0.00877,0.04970497,0.0062,0.140814081,Other Applications,0.04970497,TRUE,FALSE
Disease Modelling - Arrhythmic (15),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),0.00873,0.02660266,0.00548,0.080208021,Other Applications,0.02660266,TRUE,FALSE
Disease Modelling - Arrhythmic (15),TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),0.00841,0.020002,0.00592,0.086508651,Other Applications,0.020002,TRUE,TRUE
Disease Modelling - Arrhythmic (15),Journal - Sci Transl Med (3),0.00828,0.02650265,0.00608,0.099709971,Other Applications,0.02650265,TRUE,FALSE
Disease Modelling - Arrhythmic (15),Pharmacological Intervention - Lidocaine (7),0.00795,0.03210321,0.01023,0.01980198,Other Applications,0.01980198,TRUE,TRUE
Disease Modelling - Arrhythmic (15),hiPSC-CM Backbone Media - Rare (10),0.00773,0.04020402,0.00457,0.110811081,Other Applications,0.04020402,TRUE,FALSE
Disease Modelling - Arrhythmic (15),Insulin Start Day - 9 (10),0.00755,0.0350035,0.00751,0.03630363,Other Applications,0.0350035,TRUE,FALSE
Disease Modelling - Arrhythmic (15),Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),0.0074,0.04630463,0.00711,0.051905191,Other Applications,0.04630463,TRUE,FALSE
Disease Modelling - Arrhythmic (15),hiPSC-CM Backbone Media - Cor.4U Complete (6),0.0073,0.02690269,0.00429,0.110011001,Other Applications,0.02690269,TRUE,FALSE
Disease Modelling - Arrhythmic (15),hiPSC-CM Purification Duration (days) - 3 days (13),0.00681,0.04940494,0.00294,0.222322232,Other Applications,0.04940494,TRUE,FALSE
Disease Modelling - Arrhythmic (15),hiPSC-CM Maturation Media - Cor.4U Complete (6),0.00648,0.0420042,0.00413,0.137813781,Other Applications,0.0420042,TRUE,FALSE
Disease Modelling - Arrhythmic (15),Maturation Strategy - Mechanical (36),0.00641,0.093909391,0.01058,0.01280128,Other Applications,0.01280128,TRUE,TRUE
Disease Modelling - Arrhythmic (15),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),0.00596,0.101410141,0.00862,0.0340034,Other Applications,0.0340034,TRUE,FALSE
Disease Modelling - Arrhythmic (15),Wnt Induction - Rare (4),0.00517,0.088608861,0.00953,0.01820182,Other Applications,0.01820182,TRUE,TRUE
Disease Modelling - Arrhythmic (15),Cell Line - Rare (132),0.00489,0.628662866,0.00795,0.04770477,Other Applications,0.04770477,TRUE,FALSE
Disease Modelling - Arrhythmic (15),Journal - Biosens Bioelectron (4),0.00487,0.076807681,0.00744,0.03280328,Other Applications,0.03280328,TRUE,FALSE
Disease Modelling - Ischemic Infarction (9),Metabolic Component Category - Sugars and Carbohydrates (9),0.0196,0.00360036,0.01496,0.00840084,Other Applications,0.00360036,TRUE,TRUE
Disease Modelling - Ischemic Infarction (9),Publication Year - 2024 (7),0.01926,0.00540054,0.01846,0.00550055,Other Applications,0.00540054,TRUE,TRUE
Disease Modelling - Ischemic Infarction (9),Metabolic Analysis Method - Genetic (3),0.01875,0.00290029,0.01429,0.0140014,Other Applications,0.00290029,TRUE,TRUE
Disease Modelling - Ischemic Infarction (9),Seeding Confluency 3D (%) - 90 to 94 (13),0.01648,0.01110111,0.00945,0.04850485,Other Applications,0.01110111,TRUE,TRUE
Disease Modelling - Ischemic Infarction (9),Metabolic Component - B27 (3),0.01644,0.00780078,0.01589,0.01240124,Other Applications,0.00780078,TRUE,TRUE
Disease Modelling - Ischemic Infarction (9),Publication Year - Late-2010s (196),0.0158,0.00450045,0.00744,0.124012401,Other Applications,0.00450045,TRUE,TRUE
Disease Modelling - Ischemic Infarction (9),Maturation Strategy - Metabolic (33),0.01574,0.00850085,0.00914,0.04190419,Other Applications,0.00850085,TRUE,TRUE
Disease Modelling - Ischemic Infarction (9),Pharmacological Intervention - Epinephrine (11),0.01468,0.01360136,0.00481,0.148514851,Other Applications,0.01360136,TRUE,TRUE
Disease Modelling - Ischemic Infarction (9),Differentiation Purity Assessment - Rare (3),0.0146,0.00790079,0.0166,0.00710071,Other Applications,0.00710071,TRUE,TRUE
Disease Modelling - Ischemic Infarction (9),Metabolic Component - Albumax (3),0.0135,0.01630163,0.01401,0.01720172,Other Applications,0.01630163,TRUE,TRUE
Disease Modelling - Ischemic Infarction (9),Wnt Inhibitor Duration (days) - 6 days (4),0.01238,0.02710271,0.01482,0.01290129,Other Applications,0.01290129,TRUE,TRUE
Disease Modelling - Ischemic Infarction (9),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),0.01162,0.02930293,0.0071,0.096909691,Other Applications,0.02930293,TRUE,FALSE
Disease Modelling - Ischemic Infarction (9),New Media for Maturation - DMEM (21),0.01122,0.03940394,0.01191,0.02180218,Other Applications,0.02180218,TRUE,TRUE
Disease Modelling - Ischemic Infarction (9),Publication Year - 2022 (20),0.01092,0.03280328,0.0097,0.04140414,Other Applications,0.03280328,TRUE,FALSE
Disease Modelling - Ischemic Infarction (9),hiPSC Backbone Media - mTeSR (106),0.01024,0.03990399,0.01282,0.00580058,Other Applications,0.00580058,TRUE,TRUE
Disease Modelling - Ischemic Infarction (9),Metabolic Component - Ascorbic Acid (3),0.00984,0.03980398,0.0093,0.056905691,Other Applications,0.03980398,TRUE,FALSE
Disease Modelling - Ischemic Infarction (9),Metabolic Component - Fatty Acid (13),0.00972,0.04140414,0.00929,0.04370437,Other Applications,0.04140414,TRUE,FALSE
Disease Modelling - Ischemic Infarction (9),Journal - Rare (104),0.00953,0.04520452,0.01175,0.00940094,Other Applications,0.00940094,TRUE,TRUE
Disease Modelling - Ischemic Infarction (9),Insulin Start Day - After 11 (7),0.00919,0.03730373,0.0081,0.059205921,Other Applications,0.03730373,TRUE,FALSE
Disease Modelling - Ischemic Infarction (9),Contractile Analysis Method - Motion Tracking (93),0.00914,0.054905491,0.0108,0.02140214,Other Applications,0.02140214,TRUE,TRUE
Disease Modelling - Ischemic Infarction (9),Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),0.00886,0.04280428,0.00781,0.062406241,Other Applications,0.04280428,TRUE,FALSE
Disease Modelling - Ischemic Infarction (9),Metabolic Component - KOSR (3),0.00874,0.03960396,0.01069,0.02940294,Other Applications,0.02940294,TRUE,FALSE
Disease Modelling - Ischemic Infarction (9),Insulin Start Day - 9 (10),0.00867,0.04310431,0.00714,0.073907391,Other Applications,0.04310431,TRUE,FALSE
Disease Modelling - Ischemic Infarction (9),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),0.00864,0.054005401,0.00913,0.0440044,Other Applications,0.0440044,TRUE,FALSE
Disease Modelling - Ischemic Infarction (9),hiPSC-CM Media Supplement - Mercaptoethanol (10),0.00835,0.04510451,0.00788,0.056105611,Other Applications,0.04510451,TRUE,FALSE
Disease Modelling - Ischemic Infarction (9),Metabolic Component - Biotin (3),0.0083,0.054605461,0.01374,0.01730173,Other Applications,0.01730173,TRUE,TRUE
Disease Modelling - Ischemic Infarction (9),Coating for Replating - Vitronectin (3),0.00796,0.04580458,0.01086,0.02810281,Other Applications,0.02810281,TRUE,FALSE
Disease Modelling - Ischemic Infarction (9),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),0.00795,0.04610461,0.0056,0.106710671,Other Applications,0.04610461,TRUE,FALSE
Disease Modelling - Ischemic Infarction (9),MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),0.00778,0.060606061,0.00974,0.04490449,Other Applications,0.04490449,TRUE,FALSE
Disease Modelling - Ischemic Infarction (9),Journal - Tissue Eng Part A (4),0.00708,0.083308331,0.01228,0.02720272,Other Applications,0.02720272,TRUE,FALSE
Disease Modelling - Ischemic Infarction (9),Cell Line Sex - Male (64),0.0068,0.160316032,0.00998,0.0410041,Other Applications,0.0410041,TRUE,FALSE
Disease Modelling - Dilated Cardiomyopathy (6),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),0.02756,0.00160016,0.01827,0.00510051,Other Applications,0.00160016,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),2D Surface - Micropatterned (27),0.02617,0.00210021,0.02605,0.00050005,Other Applications,0.00050005,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),hiPSC Matrix Coating - MEF feeder cells (8),0.02199,0.0060006,0.02001,0.00820082,Other Applications,0.0060006,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),Wnt Inhibitor - BMP4 (7),0.02194,0.00390039,0.01503,0.01570157,Other Applications,0.00390039,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),Number of Cell Lines - 3 (29),0.01956,0.00940094,0.01054,0.04610461,Other Applications,0.00940094,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),Insulin Start Day - 7 (85),0.01941,0.01070107,0.00582,0.253525353,Other Applications,0.01070107,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),hiPSC-CM Purification Duration (days) - <3 days (31),0.01773,0.01120112,0.01242,0.02650265,Other Applications,0.01120112,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),3D Stromal Cell Source - Mesenchymal Stem Cell (12),0.01715,0.01390139,0.01512,0.01990199,Other Applications,0.01390139,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),3D Tissue Media - Iscove (5),0.01647,0.01530153,0.01459,0.02210221,Other Applications,0.01530153,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),0.01403,0.03180318,0.00598,0.230223022,Other Applications,0.03180318,TRUE,FALSE
Disease Modelling - Dilated Cardiomyopathy (6),Maturation Strategy - Mechanical (36),0.01388,0.02740274,0.01811,0.00580058,Other Applications,0.00580058,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),0.01372,0.02520252,0.0151,0.01820182,Other Applications,0.01820182,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),Pharmacological Intervention - Positive Inotropes (9),0.01302,0.01330133,0.0143,0.0110011,Other Applications,0.0110011,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),Publication Year - 2015 (19),0.01289,0.03070307,0.01584,0.01490149,Other Applications,0.01490149,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),Publication Year - 2024 (7),0.01275,0.03360336,0.01295,0.03010301,Other Applications,0.03010301,TRUE,FALSE
Disease Modelling - Dilated Cardiomyopathy (6),3D Platform - Collagen (38),0.01254,0.04420442,0.01581,0.01150115,Other Applications,0.01150115,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),hiPSC Backbone Media - DMEM (10),0.01252,0.03360336,0.01226,0.03410341,Other Applications,0.03360336,TRUE,FALSE
Disease Modelling - Dilated Cardiomyopathy (6),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),0.01241,0.02530253,0.00415,0.580958096,Other Applications,0.02530253,TRUE,FALSE
Disease Modelling - Dilated Cardiomyopathy (6),Deduced Culture Strategy - 2D Only (183),0.01207,0.03060306,0.0042,0.569056906,Other Applications,0.03060306,TRUE,FALSE
Disease Modelling - Dilated Cardiomyopathy (6),hiPSC-CM Maturation Media - RPMI-1640 (153),0.01198,0.02120212,0.00552,0.421842184,Other Applications,0.02120212,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25),0.01167,0.058205821,0.01597,0.01580158,Other Applications,0.01580158,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),Coating for Replating - Fibronectin (32),0.01149,0.03840384,0.01047,0.052605261,Other Applications,0.03840384,TRUE,FALSE
Disease Modelling - Dilated Cardiomyopathy (6),Journal - Cell Stem Cell (6),0.01145,0.0370037,0.01102,0.04150415,Other Applications,0.0370037,TRUE,FALSE
Disease Modelling - Dilated Cardiomyopathy (6),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),0.01142,0.04570457,0.01769,0.00480048,Other Applications,0.00480048,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),0.01086,0.04010401,0.01472,0.01270127,Other Applications,0.01270127,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),0.01072,0.04910491,0.01108,0.04330433,Other Applications,0.04330433,TRUE,FALSE
Disease Modelling - Dilated Cardiomyopathy (6),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),0.01009,0.068506851,0.01073,0.0290029,Other Applications,0.0290029,TRUE,FALSE
Disease Modelling - Dilated Cardiomyopathy (6),Sacromere or Cellular Alignment Analysis - Yes (72),0.00954,0.102310231,0.01438,0.01490149,Other Applications,0.01490149,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),3D Tissue Media - Commercial Kit (21),0.00878,0.04870487,0.00508,0.186418642,Other Applications,0.04870487,TRUE,FALSE
Disease Modelling - Dilated Cardiomyopathy (6),Number of Cell Lines - 1 (225),0.00872,0.089708971,0.01534,0.00420042,Other Applications,0.00420042,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),0.00866,0.105210521,0.01136,0.01590159,Other Applications,0.01590159,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),Publication Year - Post 2020 (122),0.00838,0.132813281,0.01137,0.01810181,Other Applications,0.01810181,TRUE,TRUE
Disease Modelling - Dilated Cardiomyopathy (6),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),0.00764,0.094709471,0.01111,0.04140414,Other Applications,0.04140414,TRUE,FALSE
Disease Modelling - Hypertrophic Cardiomyopathy (6),hiPSC-CM Purification Duration (days) - <3 days (31),0.03531,0.00040004,0.02709,0.00070007,Other Applications,0.00040004,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Insulin Start Day - 7 (85),0.02464,0.00470047,0.01196,0.02140214,Other Applications,0.00470047,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Cell Line - PGP1 (11),0.02087,0.00590059,0.02193,0.00240024,Other Applications,0.00240024,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Contractile Analysis Method - Traction Force Microscopy (9),0.02033,0.00590059,0.0184,0.00640064,Other Applications,0.00590059,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Journal - Circ Res (5),0.01915,0.00510051,0.0307,0.00110011,Other Applications,0.00110011,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Coating for Replating - Matrigel (65),0.01867,0.00690069,0.02081,0.00130013,Other Applications,0.00130013,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Journal - ACS Appl Mater Interfaces (4),0.01821,0.01130113,0.01627,0.01950195,Other Applications,0.01130113,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),0.01803,0.00920092,0.02201,0.00150015,Other Applications,0.00150015,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),0.01761,0.00960096,0.00987,0.059505951,Other Applications,0.00960096,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),hiPSC-CM Backbone Media - RPMI-1640 (167),0.0162,0,0.02367,0,Other Applications,0,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Journal - Nat Biomed Eng (5),0.01595,0.01180118,0.01709,0.01440144,Other Applications,0.01180118,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),hiPSC-CM Backbone Media - iCell Maintenance (86),0.01487,0.01340134,0.01755,0.00220022,Other Applications,0.00220022,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Maturation Strategy - Cell Alignment (59),0.01476,0.03290329,0.01138,0.04330433,Other Applications,0.03290329,TRUE,FALSE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Cell Line Ancestry - Caucasian (41),0.01328,0.04310431,0.00912,0.106310631,Other Applications,0.04310431,TRUE,FALSE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Purification Protocol - Glucose and Lactate (85),0.01277,0.03140314,0.01056,0.060206021,Other Applications,0.03140314,TRUE,FALSE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),0.01273,0.02570257,0.00925,0.057205721,Other Applications,0.02570257,TRUE,FALSE
Disease Modelling - Hypertrophic Cardiomyopathy (6),hiPSC-CM Maturation Media - RPMI-1640 (153),0.01258,0.01440144,0.01506,0.00150015,Other Applications,0.00150015,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),0.01216,0.02790279,0.01315,0.0230023,Other Applications,0.0230023,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),hiPSC-CM Maturation Media - iCell Maintenance (83),0.01208,0.03660366,0.01398,0.01020102,Other Applications,0.01020102,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),0.01178,0.04590459,0.00768,0.116911691,Other Applications,0.04590459,TRUE,FALSE
Disease Modelling - Hypertrophic Cardiomyopathy (6),3D Platform - 3D printed (9),0.01162,0.02740274,0.00767,0.082608261,Other Applications,0.02740274,TRUE,FALSE
Disease Modelling - Hypertrophic Cardiomyopathy (6),2D Surface - Micropatterned (27),0.01159,0.03990399,0.0059,0.163916392,Other Applications,0.03990399,TRUE,FALSE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),0.01158,0.04010401,0.01218,0.03650365,Other Applications,0.03650365,TRUE,FALSE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),0.01101,0.052005201,0.01418,0.02030203,Other Applications,0.02030203,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Wnt Inhibitor Duration (days) - Rare (173),0.011,0.04030403,0.0048,0.481548155,Other Applications,0.04030403,TRUE,FALSE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Cell Line - BJ1 (7),0.01052,0.053105311,0.01152,0.04770477,Other Applications,0.04770477,TRUE,FALSE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Journal - Circulation (11),0.01052,0.04770477,0.00701,0.109710971,Other Applications,0.04770477,TRUE,FALSE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),0.01001,0.04710471,0.01312,0.02620262,Other Applications,0.02620262,TRUE,FALSE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Wnt Inhibitor - IWP (112),0.00947,0.064506451,0.01166,0.01430143,Other Applications,0.01430143,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),2D Surface - ECM-coated (115),0.00934,0.100210021,0.01292,0.02020202,Other Applications,0.02020202,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Wnt Inhibitor - Wnt-C59 (30),0.00857,0.075107511,0.01463,0.0160016,Other Applications,0.0160016,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),0.00855,0.058505851,0.01504,0.01360136,Other Applications,0.01360136,TRUE,TRUE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),0.00807,0.101110111,0.01121,0.04250425,Other Applications,0.04250425,TRUE,FALSE
Disease Modelling - Hypertrophic Cardiomyopathy (6),3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25),0.00627,0.150315032,0.01144,0.04810481,Other Applications,0.04810481,TRUE,FALSE
Disease Modelling - Hypertrophic Cardiomyopathy (6),Wnt Inhibitor - XAV939 (24),0.00567,0.172217222,0.01186,0.04190419,Other Applications,0.04190419,TRUE,FALSE
Disease Modelling - Fibrotic (4),Journal - Nat Commun (13),0.02943,0.00330033,0.01897,0.01480148,Other Applications,0.00330033,TRUE,TRUE
Disease Modelling - Fibrotic (4),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),0.02641,0.00870087,0.01743,0.01560156,Other Applications,0.00870087,TRUE,TRUE
Disease Modelling - Fibrotic (4),3D Stromal Cell Source - Human Fibroblast (38),0.02556,0.00610061,0.0072,0.192119212,Other Applications,0.00610061,TRUE,TRUE
Disease Modelling - Fibrotic (4),3D Stromal Cell Source - Cardiac Fibroblast (32),0.02429,0.00950095,0.00548,0.211821182,Other Applications,0.00950095,TRUE,TRUE
Disease Modelling - Fibrotic (4),Number of Cell Lines - 2 (50),0.02408,0.00330033,0.02319,0.00150015,Other Applications,0.00150015,TRUE,TRUE
Disease Modelling - Fibrotic (4),3D Tissue Media - Commercial Kit (21),0.02127,0.00460046,0.02915,0.0010001,Other Applications,0.0010001,TRUE,TRUE
Disease Modelling - Fibrotic (4),Journal - Biomaterials (16),0.01865,0.02010201,0.01743,0.01920192,Other Applications,0.01920192,TRUE,TRUE
Disease Modelling - Fibrotic (4),Number of Cell Lines - 1 (225),0.01727,0.00540054,0.0094,0.081808181,Other Applications,0.00540054,TRUE,TRUE
Disease Modelling - Fibrotic (4),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),0.01626,0.0380038,0.01578,0.02930293,Other Applications,0.02930293,TRUE,FALSE
Disease Modelling - Fibrotic (4),Insulin Start Day - After 11 (7),0.016,0.03460346,0.01242,0.057605761,Other Applications,0.03460346,TRUE,FALSE
Disease Modelling - Fibrotic (4),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),0.01577,0.0240024,0.0083,0.102410241,Other Applications,0.0240024,TRUE,TRUE
Disease Modelling - Fibrotic (4),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),0.01499,0.03190319,0.00735,0.087508751,Other Applications,0.03190319,TRUE,FALSE
Disease Modelling - Fibrotic (4),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),0.01496,0.03410341,0.00999,0.086908691,Other Applications,0.03410341,TRUE,FALSE
Disease Modelling - Fibrotic (4),Differentiation Purity Assessment - Visual Inspection (6),0.0142,0.03980398,0.00828,0.062406241,Other Applications,0.03980398,TRUE,FALSE
Disease Modelling - Fibrotic (4),Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),0.01365,0.04460446,0.01366,0.03860386,Other Applications,0.03860386,TRUE,FALSE
Disease Modelling - Fibrotic (4),3D Platform - Matrigel (33),0.01348,0.04690469,0.00957,0.129412941,Other Applications,0.04690469,TRUE,FALSE
Disease Modelling - Fibrotic (4),3D Tissue Media - Iscove (5),0.01312,0.0460046,0.01658,0.03590359,Other Applications,0.03590359,TRUE,FALSE
Disease Modelling - Fibrotic (4),3D Platform - 3D printed (9),0.013,0.03840384,0.01195,0.056105611,Other Applications,0.03840384,TRUE,FALSE
Disease Modelling - Fibrotic (4),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),0.01265,0.04760476,0.00695,0.203420342,Other Applications,0.04760476,TRUE,FALSE
Disease Modelling - Fibrotic (4),New Media for Maturation - Rare (4),0.01236,0.04550455,0.01359,0.04140414,Other Applications,0.04140414,TRUE,FALSE
Disease Modelling - Fibrotic (4),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),0.01171,0.0320032,0.00877,0.059205921,Other Applications,0.0320032,TRUE,FALSE
Disease Modelling - Fibrotic (4),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),0.01164,0.062006201,0.01624,0.02490249,Other Applications,0.02490249,TRUE,TRUE
Disease Modelling - Fibrotic (4),hiPSC Backbone Media - Conditioned (12),0.01147,0.086608661,0.01511,0.04410441,Other Applications,0.04410441,TRUE,FALSE
Disease Modelling - Fibrotic (4),Deduced Culture Strategy - 2D Only (183),0.01128,0.03470347,0.00738,0.137513751,Other Applications,0.03470347,TRUE,FALSE
Disease Modelling - Fibrotic (4),Contractile Analysis Method - Deflection (39),0.01114,0.054305431,0.01237,0.04970497,Other Applications,0.04970497,TRUE,FALSE
Disease Modelling - Fibrotic (4),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),0.01088,0.054205421,0.01632,0.02450245,Other Applications,0.02450245,TRUE,TRUE
Disease Modelling - Fibrotic (4),Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),0.00915,0.096809681,0.01382,0.04230423,Other Applications,0.04230423,TRUE,FALSE
Disease Modelling - Fibrotic (4),Gene Analysis Method - RNA (169),0.00753,0.143114311,0.01364,0.00760076,Other Applications,0.00760076,TRUE,TRUE
Disease Modelling - Fibrotic (4),Publication Year - 2017 (43),0.00642,0.204520452,0.01444,0.03980398,Other Applications,0.03980398,TRUE,FALSE
Pharmacological Intervention - Adrenaline (83),Calcium Handling Analysis Method - Visual (104),0.02577,0,0.01994,0,Other Applications,0,TRUE,TRUE
Pharmacological Intervention - Adrenaline (83),Electrophysiology Analysis Method - Microelectrode (31),0.01537,0.00020002,0.01579,0.00020002,Other Applications,0.00020002,TRUE,TRUE
Pharmacological Intervention - Adrenaline (83),3D Tissue Media - DMEM (53),0.00976,0.00950095,0.01156,0.00370037,Other Applications,0.00370037,TRUE,TRUE
Pharmacological Intervention - Adrenaline (83),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),0.00957,0.00150015,0.00952,0.00360036,Other Applications,0.00150015,TRUE,TRUE
Pharmacological Intervention - Adrenaline (83),Contractile Analysis Method - Motion Tracking (93),0.00924,0.02010201,0.00831,0.02770277,Other Applications,0.02010201,TRUE,TRUE
Pharmacological Intervention - Adrenaline (83),Cell Coculture - Cardiomyocyte (157),0.00868,0.03630363,0.00645,0.180018002,Other Applications,0.03630363,TRUE,FALSE
Pharmacological Intervention - Adrenaline (83),Electrophysiology Analysis Method - Optical Mapping (39),0.00842,0.01110111,0.00889,0.00930093,Other Applications,0.00930093,TRUE,TRUE
Pharmacological Intervention - Adrenaline (83),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),0.00828,0.04930493,0.00988,0.0120012,Other Applications,0.0120012,TRUE,TRUE
Pharmacological Intervention - Adrenaline (83),Deduced Culture Strategy - 3D Only (157),0.00811,0.065306531,0.00861,0.03260326,Other Applications,0.03260326,TRUE,FALSE
Pharmacological Intervention - Adrenaline (83),hiPSC Backbone Media - Essential 8 (82),0.00809,0.03490349,0.00425,0.625662566,Other Applications,0.03490349,TRUE,FALSE
Pharmacological Intervention - Adrenaline (83),Publication Year - 2016 (32),0.00752,0.01790179,0.0107,0.00480048,Other Applications,0.00480048,TRUE,TRUE
Pharmacological Intervention - Adrenaline (83),3D Tissue Media - MEM-α (60),0.00711,0.0430043,0.00829,0.01670167,Other Applications,0.01670167,TRUE,TRUE
Pharmacological Intervention - Adrenaline (83),Maturation Strategy - Cell Alignment (59),0.00694,0.03830383,0.00471,0.212921292,Other Applications,0.03830383,TRUE,FALSE
Pharmacological Intervention - Adrenaline (83),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),0.00692,0.02380238,0.00502,0.084008401,Other Applications,0.02380238,TRUE,TRUE
Pharmacological Intervention - Adrenaline (83),hiPSC-CM Purification Duration (days) - 5 days (6),0.00674,0.00580058,0.00721,0.01020102,Other Applications,0.00580058,TRUE,TRUE
Pharmacological Intervention - Adrenaline (83),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.00656,0.04040404,0.0047,0.132813281,Other Applications,0.04040404,TRUE,FALSE
Pharmacological Intervention - Adrenaline (83),Contractile Analysis Method - Deflection (39),0.0065,0.03430343,0.00865,0.01040104,Other Applications,0.01040104,TRUE,TRUE
Pharmacological Intervention - Adrenaline (83),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),0.00649,0.01280128,0.00778,0.0130013,Other Applications,0.01280128,TRUE,TRUE
Pharmacological Intervention - Adrenaline (83),3D Stromal Cell Source - Cardiac Fibroblast (32),0.00604,0.03550355,0.00625,0.03530353,Other Applications,0.03530353,TRUE,FALSE
Pharmacological Intervention - Adrenaline (83),Coating for Replating - Fibronectin (32),0.00596,0.04010401,0.00514,0.070307031,Other Applications,0.04010401,TRUE,FALSE
Pharmacological Intervention - Adrenaline (83),Journal - Rare (104),0.00589,0.274227423,0.00757,0.04060406,Other Applications,0.04060406,TRUE,FALSE
Pharmacological Intervention - Adrenaline (83),Seeding Confluency 2D (%) - 85 to 89 (26),0.00557,0.04340434,0.00296,0.308130813,Other Applications,0.04340434,TRUE,FALSE
Pharmacological Intervention - Adrenaline (83),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),0.00555,0.01290129,0.00773,0.00770077,Other Applications,0.00770077,TRUE,TRUE
Pharmacological Intervention - Adrenaline (83),Cell Line - iCell2 (8),0.00502,0.02770277,0.00489,0.050805081,Other Applications,0.02770277,TRUE,FALSE
Pharmacological Intervention - Adrenaline (83),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),0.00491,0.02350235,0.00745,0.01070107,Other Applications,0.01070107,TRUE,TRUE
Pharmacological Intervention - Adrenaline (83),Journal - Lab Chip (4),0.00478,0.0110011,0.00479,0.02890289,Other Applications,0.0110011,TRUE,TRUE
Pharmacological Intervention - Adrenaline (83),hiPSC Matrix Coating - Geltrex (33),0.00475,0.101910191,0.00573,0.04660466,Other Applications,0.04660466,TRUE,FALSE
Pharmacological Intervention - Adrenaline (83),Maturation Strategy - ECM (21),0.00443,0.064806481,0.00559,0.03440344,Other Applications,0.03440344,TRUE,FALSE
Pharmacological Intervention - Adrenaline (83),Journal - Toxicological Sciences (4),0.00419,0.01950195,0.00332,0.060606061,Other Applications,0.01950195,TRUE,TRUE
Pharmacological Intervention - Adrenaline (83),3D Tissue Media - Growth Factor (12),0.00397,0.052105211,0.00529,0.03490349,Other Applications,0.03490349,TRUE,FALSE
Pharmacological Intervention - Adrenaline (83),Purification Protocol - Cell Sorting (7),0.00383,0.04050405,0.0031,0.106010601,Other Applications,0.04050405,TRUE,FALSE
Pharmacological Intervention - Adrenaline (83),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),0.00373,0.058205821,0.00545,0.03250325,Other Applications,0.03250325,TRUE,FALSE
Pharmacological Intervention - Adrenaline (83),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),0.00289,0.113111311,0.00534,0.03610361,Other Applications,0.03610361,TRUE,FALSE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Calcium Handling Analysis Method - Visual (104),0.02425,0,0.02441,0,Other Applications,0,TRUE,TRUE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Electrophysiology Analysis Method - Microelectrode (31),0.0132,0.00040004,0.01341,0.00060006,Other Applications,0.00040004,TRUE,TRUE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),3D Tissue Media - DMEM (53),0.01208,0.00250025,0.009,0.01020102,Other Applications,0.00250025,TRUE,TRUE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Contractile Analysis Method - Motion Tracking (93),0.01125,0.00790079,0.00926,0.01440144,Other Applications,0.00790079,TRUE,TRUE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),0.0112,0.00090009,0.01312,0.00060006,Other Applications,0.00060006,TRUE,TRUE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Electrophysiology Analysis Method - Optical Mapping (39),0.01088,0.00360036,0.00802,0.01630163,Other Applications,0.00360036,TRUE,TRUE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),0.00945,0.02490249,0.00732,0.064606461,Other Applications,0.02490249,TRUE,TRUE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Contractile Analysis Method - Deflection (39),0.00931,0.00740074,0.01275,0.00120012,Other Applications,0.00120012,TRUE,TRUE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),hiPSC Backbone Media - Essential 8 (82),0.00855,0.02920292,0.00966,0.00880088,Other Applications,0.00880088,TRUE,TRUE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Cell Coculture - Cardiomyocyte (157),0.00851,0.04780478,0.00719,0.086508651,Other Applications,0.04780478,TRUE,FALSE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),3D Tissue Media - MEM-α (60),0.00816,0.0230023,0.00696,0.03950395,Other Applications,0.0230023,TRUE,TRUE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),0.00806,0.00430043,0.01,0.00310031,Other Applications,0.00310031,TRUE,TRUE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),0.00762,0.01780178,0.00861,0.01140114,Other Applications,0.01140114,TRUE,TRUE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Publication Year - 2016 (32),0.00659,0.03680368,0.00903,0.01190119,Other Applications,0.01190119,TRUE,TRUE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),3D Stromal Cell Source - Human Fibroblast (38),0.00606,0.063606361,0.00687,0.03390339,Other Applications,0.03390339,TRUE,FALSE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),0.00576,0.01590159,0.00425,0.057105711,Other Applications,0.01590159,TRUE,TRUE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),0.0056,0.02220222,0.00661,0.02230223,Other Applications,0.02220222,TRUE,TRUE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),3D Tissue Media - Growth Factor (12),0.00518,0.02850285,0.00544,0.04090409,Other Applications,0.02850285,TRUE,FALSE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Journal - Sci Rep (24),0.00508,0.062606261,0.00651,0.02990299,Other Applications,0.02990299,TRUE,FALSE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Maturation Strategy - ECM (21),0.00493,0.04760476,0.00525,0.04860486,Other Applications,0.04760476,TRUE,FALSE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Journal - Toxicological Sciences (4),0.00483,0.01550155,0.00626,0.01490149,Other Applications,0.01490149,TRUE,TRUE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),3D Platform - Gelatin (6),0.00468,0.02220222,0.00445,0.04460446,Other Applications,0.02220222,TRUE,TRUE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),0.00455,0.04660466,0.00466,0.070307031,Other Applications,0.04660466,TRUE,FALSE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),0.00455,0.04770477,0.00456,0.073007301,Other Applications,0.04770477,TRUE,FALSE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Purification Protocol - Cell Sorting (7),0.00453,0.03130313,0.00511,0.03890389,Other Applications,0.03130313,TRUE,FALSE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),0.00434,0.04510451,0.00404,0.082308231,Other Applications,0.04510451,TRUE,FALSE
Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),New Media for Maturation - Rare (4),0.00385,0.03710371,0.00426,0.04650465,Other Applications,0.03710371,TRUE,FALSE
Pharmacological Intervention - Isoproterenol (71),Calcium Handling Analysis Method - Visual (104),0.0201,0.00010001,0.01999,0.00010001,Other Applications,0.00010001,TRUE,TRUE
Pharmacological Intervention - Isoproterenol (71),Contractile Analysis Method - Motion Tracking (93),0.01304,0.0030003,0.00952,0.01130113,Other Applications,0.0030003,TRUE,TRUE
Pharmacological Intervention - Isoproterenol (71),Electrophysiology Analysis Method - Microelectrode (31),0.01271,0.00040004,0.01186,0.00110011,Other Applications,0.00040004,TRUE,TRUE
Pharmacological Intervention - Isoproterenol (71),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),0.0123,0.00040004,0.01235,0.00160016,Other Applications,0.00040004,TRUE,TRUE
Pharmacological Intervention - Isoproterenol (71),3D Tissue Media - DMEM (53),0.01087,0.00430043,0.00876,0.01090109,Other Applications,0.00430043,TRUE,TRUE
Pharmacological Intervention - Isoproterenol (71),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),0.01005,0.00160016,0.01137,0.00160016,Other Applications,0.00160016,TRUE,TRUE
Pharmacological Intervention - Isoproterenol (71),Electrophysiology Analysis Method - Optical Mapping (39),0.00938,0.00830083,0.00761,0.02070207,Other Applications,0.00830083,TRUE,TRUE
Pharmacological Intervention - Isoproterenol (71),Contractile Analysis Method - Deflection (39),0.0089,0.00790079,0.01008,0.00410041,Other Applications,0.00410041,TRUE,TRUE
Pharmacological Intervention - Isoproterenol (71),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),0.00871,0.00920092,0.00925,0.00820082,Other Applications,0.00820082,TRUE,TRUE
Pharmacological Intervention - Isoproterenol (71),Cell Coculture - Cardiomyocyte (157),0.00851,0.051805181,0.00797,0.04030403,Other Applications,0.04030403,TRUE,FALSE
Pharmacological Intervention - Isoproterenol (71),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),0.00826,0.053705371,0.00893,0.0180018,Other Applications,0.0180018,TRUE,TRUE
Pharmacological Intervention - Isoproterenol (71),3D Tissue Media - MEM-α (60),0.00772,0.03210321,0.00614,0.070307031,Other Applications,0.03210321,TRUE,FALSE
Pharmacological Intervention - Isoproterenol (71),Deduced Culture Strategy - 3D Only (157),0.00755,0.117111711,0.00835,0.03270327,Other Applications,0.03270327,TRUE,FALSE
Pharmacological Intervention - Isoproterenol (71),Publication Year - 2016 (32),0.00731,0.02380238,0.00871,0.01230123,Other Applications,0.01230123,TRUE,TRUE
Pharmacological Intervention - Isoproterenol (71),hiPSC Backbone Media - Essential 8 (82),0.00668,0.104210421,0.00844,0.01950195,Other Applications,0.01950195,TRUE,TRUE
Pharmacological Intervention - Isoproterenol (71),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),0.00634,0.01090109,0.00589,0.02980298,Other Applications,0.01090109,TRUE,TRUE
Pharmacological Intervention - Isoproterenol (71),Electron Imaging - Scanning (22),0.00607,0.03110311,0.00521,0.059405941,Other Applications,0.03110311,TRUE,FALSE
Pharmacological Intervention - Isoproterenol (71),Journal - Sci Rep (24),0.00595,0.03460346,0.00604,0.03910391,Other Applications,0.03460346,TRUE,FALSE
Pharmacological Intervention - Isoproterenol (71),hiPSC Matrix Coating - Geltrex (33),0.0059,0.0480048,0.00685,0.0260026,Other Applications,0.0260026,TRUE,FALSE
Pharmacological Intervention - Isoproterenol (71),Calcium Handling Analysis Method - Genetic (23),0.00578,0.04410441,0.00429,0.118511851,Other Applications,0.04410441,TRUE,FALSE
Pharmacological Intervention - Isoproterenol (71),3D Stromal Cell Source - Cardiac Fibroblast (32),0.00576,0.050505051,0.00617,0.03960396,Other Applications,0.03960396,TRUE,FALSE
Pharmacological Intervention - Isoproterenol (71),3D Stromal Cell Source - Human Fibroblast (38),0.00572,0.078407841,0.00663,0.04140414,Other Applications,0.04140414,TRUE,FALSE
Pharmacological Intervention - Isoproterenol (71),3D Tissue Media - Growth Factor (12),0.00569,0.02050205,0.00556,0.03660366,Other Applications,0.02050205,TRUE,TRUE
Pharmacological Intervention - Isoproterenol (71),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),0.0056,0.02330233,0.00588,0.03450345,Other Applications,0.02330233,TRUE,TRUE
Pharmacological Intervention - Isoproterenol (71),Maturation Strategy - ECM (21),0.00517,0.03950395,0.00494,0.057005701,Other Applications,0.03950395,TRUE,FALSE
Pharmacological Intervention - Isoproterenol (71),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),0.00513,0.02050205,0.00613,0.02330233,Other Applications,0.02050205,TRUE,TRUE
Pharmacological Intervention - Isoproterenol (71),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),0.00509,0.03090309,0.00447,0.068706871,Other Applications,0.03090309,TRUE,FALSE
Pharmacological Intervention - Isoproterenol (71),Gene Analysis Method - Rare (5),0.00498,0.01960196,0.00447,0.054405441,Other Applications,0.01960196,TRUE,TRUE
Pharmacological Intervention - Isoproterenol (71),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),0.00489,0.02760276,0.00411,0.071507151,Other Applications,0.02760276,TRUE,FALSE
Pharmacological Intervention - Isoproterenol (71),3D Platform - Gelatin (6),0.00476,0.02030203,0.00633,0.01570157,Other Applications,0.01570157,TRUE,TRUE
Pharmacological Intervention - Isoproterenol (71),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),0.00432,0.04980498,0.00464,0.066306631,Other Applications,0.04980498,TRUE,FALSE
Pharmacological Intervention - Isoproterenol (71),Purification Protocol - Cell Sorting (7),0.00421,0.03940394,0.0051,0.0410041,Other Applications,0.03940394,TRUE,FALSE
Pharmacological Intervention - Isoproterenol (71),New Media for Maturation - Rare (4),0.00375,0.03770377,0.00492,0.03490349,Other Applications,0.03490349,TRUE,FALSE
Pharmacological Intervention - Isoproterenol (71),Journal - Toxicological Sciences (4),0.0036,0.0360036,0.00324,0.077607761,Other Applications,0.0360036,TRUE,FALSE
Pharmacological Intervention - Isoproterenol (71),Cell Line - Cellapy (4),0.00339,0.0450045,0.00203,0.192019202,Other Applications,0.0450045,TRUE,FALSE
Pharmacological Intervention - QT-Prolonging Drugs (36),Electrophysiology Analysis Method - Microelectrode (31),0.02976,0,0.02795,0,Other Applications,0,TRUE,TRUE
Pharmacological Intervention - QT-Prolonging Drugs (36),2D Surface - Microelectrode Array (9),0.02572,0,0.03174,0,Other Applications,0,TRUE,TRUE
Pharmacological Intervention - QT-Prolonging Drugs (36),Cell Line - iCell (47),0.01788,0.00090009,0.01695,0.00060006,Other Applications,0.00060006,TRUE,TRUE
Pharmacological Intervention - QT-Prolonging Drugs (36),Cell Line - Cor.4U (16),0.01274,0.00310031,0.01392,0.00150015,Other Applications,0.00150015,TRUE,TRUE
Pharmacological Intervention - QT-Prolonging Drugs (36),Electrophysiology Analysis Method - Patch Clamp (59),0.01153,0.00820082,0.01011,0.00740074,Other Applications,0.00740074,TRUE,TRUE
Pharmacological Intervention - QT-Prolonging Drugs (36),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.01129,0.00810081,0.00834,0.01830183,Other Applications,0.00810081,TRUE,TRUE
Pharmacological Intervention - QT-Prolonging Drugs (36),Coating for Replating - Gelatin (43),0.01051,0.00830083,0.00848,0.01720172,Other Applications,0.00830083,TRUE,TRUE
Pharmacological Intervention - QT-Prolonging Drugs (36),3D Platform - Extracellular Scaffold (18),0.01014,0.00870087,0.00883,0.01320132,Other Applications,0.00870087,TRUE,TRUE
Pharmacological Intervention - QT-Prolonging Drugs (36),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),0.00935,0.00610061,0.00897,0.01080108,Other Applications,0.00610061,TRUE,TRUE
Pharmacological Intervention - QT-Prolonging Drugs (36),Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58),0.00925,0.02940294,0.00607,0.102110211,Other Applications,0.02940294,TRUE,FALSE
Pharmacological Intervention - QT-Prolonging Drugs (36),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),0.00854,0.01370137,0.01008,0.01110111,Other Applications,0.01110111,TRUE,TRUE
Pharmacological Intervention - QT-Prolonging Drugs (36),Journal - Rare (104),0.00814,0.071507151,0.00815,0.02760276,Other Applications,0.02760276,TRUE,FALSE
Pharmacological Intervention - QT-Prolonging Drugs (36),Disease Modelling - Arrhythmic (15),0.00811,0.01480148,0.00721,0.02460246,Other Applications,0.01480148,TRUE,TRUE
Pharmacological Intervention - QT-Prolonging Drugs (36),Number of Cell Lines - 1 (225),0.00746,0.109010901,0.00837,0.0250025,Other Applications,0.0250025,TRUE,FALSE
Pharmacological Intervention - QT-Prolonging Drugs (36),Number of Cell Lines - >5 (9),0.00743,0.01740174,0.00683,0.03240324,Other Applications,0.01740174,TRUE,TRUE
Pharmacological Intervention - QT-Prolonging Drugs (36),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),0.00706,0.03770377,0.00693,0.03680368,Other Applications,0.03680368,TRUE,FALSE
Pharmacological Intervention - QT-Prolonging Drugs (36),Maturation Strategy - Electrical (39),0.00706,0.04620462,0.00825,0.02120212,Other Applications,0.02120212,TRUE,TRUE
Pharmacological Intervention - QT-Prolonging Drugs (36),hiPSC-CM Backbone Media - Cor.4U Complete (6),0.00699,0.01870187,0.00566,0.0470047,Other Applications,0.01870187,TRUE,TRUE
Pharmacological Intervention - QT-Prolonging Drugs (36),Maturation Strategy - ECM (21),0.00692,0.0280028,0.00864,0.01210121,Other Applications,0.01210121,TRUE,TRUE
Pharmacological Intervention - QT-Prolonging Drugs (36),3D Platform - Nanotechnology (3),0.0066,0.01920192,0.00935,0.01270127,Other Applications,0.01270127,TRUE,TRUE
Pharmacological Intervention - QT-Prolonging Drugs (36),Journal - Toxicological Sciences (4),0.00646,0.01930193,0.01151,0.00420042,Other Applications,0.00420042,TRUE,TRUE
Pharmacological Intervention - QT-Prolonging Drugs (36),Publication Year - 2017 (43),0.00636,0.078707871,0.00738,0.0370037,Other Applications,0.0370037,TRUE,FALSE
Pharmacological Intervention - QT-Prolonging Drugs (36),Journal - Biomaterials (16),0.00611,0.040004,0.00825,0.01590159,Other Applications,0.01590159,TRUE,TRUE
Pharmacological Intervention - QT-Prolonging Drugs (36),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),0.006,0.04080408,0.00735,0.03070307,Other Applications,0.03070307,TRUE,FALSE
Pharmacological Intervention - QT-Prolonging Drugs (36),Publication Year - 2016 (32),0.00589,0.081508151,0.00692,0.04590459,Other Applications,0.04590459,TRUE,FALSE
Pharmacological Intervention - QT-Prolonging Drugs (36),Number of Cell Lines - 3 (29),0.00571,0.068406841,0.00687,0.03480348,Other Applications,0.03480348,TRUE,FALSE
Pharmacological Intervention - QT-Prolonging Drugs (36),Publication Year - 2018 (45),0.00541,0.129412941,0.00768,0.02610261,Other Applications,0.02610261,TRUE,FALSE
Pharmacological Intervention - QT-Prolonging Drugs (36),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),0.00516,0.057105711,0.00625,0.0430043,Other Applications,0.0430043,TRUE,FALSE
Pharmacological Intervention - QT-Prolonging Drugs (36),Seeding Confluency 3D (%) - 85 to 89 (12),0.00505,0.058505851,0.0059,0.04590459,Other Applications,0.04590459,TRUE,FALSE
Pharmacological Intervention - QT-Prolonging Drugs (36),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),0.00452,0.084208421,0.00645,0.04140414,Other Applications,0.04140414,TRUE,FALSE
Pharmacological Intervention - QT-Prolonging Drugs (36),Insulin Start Day - 11 (3),0.00419,0.03780378,0.00262,0.191319132,Other Applications,0.03780378,TRUE,FALSE
Pharmacological Intervention - QT-Prolonging Drugs (36),hiPSC-CM Media Supplement - Lipid Mix (5),0.00402,0.077107711,0.00706,0.030003,Other Applications,0.030003,TRUE,FALSE
Pharmacological Intervention - QT-Prolonging Drugs (36),Journal - Int J Mol Sci (3),0.0039,0.04290429,0.00636,0.03070307,Other Applications,0.03070307,TRUE,FALSE
Pharmacological Intervention - QT-Prolonging Drugs (36),hiPSC-CM Media Supplement - Selenium (7),0.00348,0.104210421,0.00626,0.03680368,Other Applications,0.03680368,TRUE,FALSE
Pharmacological Intervention - QT-Prolonging Drugs (36),Cell Line - 253G1 (10),0.00254,0.181218122,0.00647,0.03130313,Other Applications,0.03130313,TRUE,FALSE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Electrophysiology Analysis Method - Microelectrode (31),0.02499,0.00010001,0.02134,0.00020002,Other Applications,0.00010001,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Journal - Toxicological Sciences (4),0.01733,0.00020002,0.02055,0.00030003,Other Applications,0.00020002,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Cell Line - iCell (47),0.01426,0.00350035,0.01312,0.00220022,Other Applications,0.00220022,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),0.01333,0.00240024,0.01525,0.00180018,Other Applications,0.00180018,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.01095,0.01110111,0.0086,0.02170217,Other Applications,0.01110111,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Number of Cell Lines - 4 (11),0.01039,0.00730073,0.01158,0.00530053,Other Applications,0.00530053,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Number of Cell Lines - 1 (225),0.01028,0.02540254,0.01426,0.00060006,Other Applications,0.00060006,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),2D Surface - Decellularized ECM (3),0.00999,0.00440044,0.01029,0.01090109,Other Applications,0.00440044,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),3D Platform - Scaffold Free (43),0.00972,0.01890189,0.00578,0.102210221,Other Applications,0.01890189,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),hiPSC-CM Maturation Media - iCell Maintenance (83),0.00942,0.02450245,0.00899,0.01380138,Other Applications,0.01380138,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),hiPSC-CM Maturation Media - Rare (9),0.00935,0.01190119,0.00846,0.02410241,Other Applications,0.01190119,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),hiPSC Backbone Media - mTeSR (106),0.00925,0.04840484,0.00237,0.9919992,Other Applications,0.04840484,TRUE,FALSE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Cell Line - Cellapy (4),0.00911,0.00890089,0.01294,0.00390039,Other Applications,0.00390039,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Contractile Analysis Method - Motion Tracking (93),0.00869,0.067306731,0.00924,0.01820182,Other Applications,0.01820182,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Electron Imaging - Scanning (22),0.00837,0.02270227,0.0111,0.00870087,Other Applications,0.00870087,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Calcium Handling Analysis Method - Visual (104),0.00824,0.086208621,0.00936,0.01190119,Other Applications,0.01190119,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Journal - Nat Commun (13),0.00824,0.02080208,0.00722,0.03390339,Other Applications,0.02080208,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),hiPSC-CM Backbone Media - iCell Maintenance (86),0.00791,0.067406741,0.00825,0.02920292,Other Applications,0.02920292,TRUE,FALSE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),0.00781,0.02890289,0.00603,0.065206521,Other Applications,0.02890289,TRUE,FALSE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Electrophysiology Analysis Method - Optical Mapping (39),0.00756,0.04170417,0.00745,0.03520352,Other Applications,0.03520352,TRUE,FALSE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Coating for Replating - Gelatin (43),0.00743,0.04180418,0.00877,0.01730173,Other Applications,0.01730173,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),0.00742,0.02260226,0.00489,0.078207821,Other Applications,0.02260226,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Number of Cell Lines - 3 (29),0.00739,0.03630363,0.01044,0.00630063,Other Applications,0.00630063,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Cell Line - Cor.4U (16),0.00726,0.02990299,0.00765,0.02540254,Other Applications,0.02540254,TRUE,FALSE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),0.00712,0.0260026,0.00772,0.02420242,Other Applications,0.02420242,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),hiPSC-CM Backbone Media - Rare (10),0.00708,0.0260026,0.01013,0.00970097,Other Applications,0.00970097,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Cell Line - iCell2 (8),0.00701,0.02830283,0.01078,0.01020102,Other Applications,0.01020102,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Publication Year - 2017 (43),0.00699,0.065106511,0.00867,0.01860186,Other Applications,0.01860186,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Number of Cell Lines - >5 (9),0.00675,0.02980298,0.00601,0.0480048,Other Applications,0.02980298,TRUE,FALSE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Journal - Sci Rep (24),0.00633,0.054305431,0.00691,0.0380038,Other Applications,0.0380038,TRUE,FALSE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Differentiation Purity Assessment - Visual Inspection (6),0.00586,0.03490349,0.00446,0.084808481,Other Applications,0.03490349,TRUE,FALSE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Cell Line Ancestry - Asian (28),0.00584,0.071307131,0.0084,0.01990199,Other Applications,0.01990199,TRUE,TRUE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),2D Surface - Microelectrode Array (9),0.00531,0.04620462,0.00455,0.082008201,Other Applications,0.04620462,TRUE,FALSE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),0.00501,0.072807281,0.00701,0.03830383,Other Applications,0.03830383,TRUE,FALSE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Journal - Rare (104),0.00486,0.669066907,0.0076,0.04950495,Other Applications,0.04950495,TRUE,FALSE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Journal - Front Cell Dev Biol (3),0.00424,0.0470047,0.00217,0.235023502,Other Applications,0.0470047,TRUE,FALSE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),3D Stromal Cell Source - hiPSC-CardiacF (8),0.00421,0.093209321,0.00628,0.0460046,Other Applications,0.0460046,TRUE,FALSE
Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Journal - Circ Res (5),0.00355,0.081808181,0.00642,0.04440444,Other Applications,0.04440444,TRUE,FALSE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Electrophysiology Analysis Method - Microelectrode (31),0.02723,0,0.02045,0,Other Applications,0,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Journal - Toxicological Sciences (4),0.01864,0.00030003,0.01778,0.00050005,Other Applications,0.00030003,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),0.01379,0.00290029,0.01524,0.0030003,Other Applications,0.00290029,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Cell Line - Cellapy (4),0.01131,0.00370037,0.01339,0.00340034,Other Applications,0.00340034,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Calcium Handling Analysis Method - Visual (104),0.01086,0.02750275,0.0092,0.01540154,Other Applications,0.01540154,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Number of Cell Lines - 1 (225),0.01069,0.0210021,0.01125,0.00260026,Other Applications,0.00260026,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.01053,0.0130013,0.01004,0.01070107,Other Applications,0.01070107,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),3D Platform - Scaffold Free (43),0.01034,0.01370137,0.00593,0.092709271,Other Applications,0.01370137,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Cell Line - iCell (47),0.01029,0.02030203,0.01231,0.00520052,Other Applications,0.00520052,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),2D Surface - Decellularized ECM (3),0.01006,0.00410041,0.0117,0.00540054,Other Applications,0.00410041,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Journal - Nat Commun (13),0.00997,0.0130013,0.00728,0.03410341,Other Applications,0.0130013,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Number of Cell Lines - 4 (11),0.00954,0.01130113,0.01154,0.0070007,Other Applications,0.0070007,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),hiPSC-CM Maturation Media - Rare (9),0.00936,0.01230123,0.0097,0.01220122,Other Applications,0.01220122,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Electron Imaging - Scanning (22),0.00925,0.01720172,0.01309,0.00290029,Other Applications,0.00290029,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Cell Line Ancestry - Caucasian (41),0.00922,0.02180218,0.00529,0.134413441,Other Applications,0.02180218,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),hiPSC-CM Backbone Media - iCell Maintenance (86),0.00904,0.03540354,0.00857,0.02320232,Other Applications,0.02320232,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Contractile Analysis Method - Motion Tracking (93),0.00895,0.066006601,0.00891,0.02420242,Other Applications,0.02420242,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Publication Year - 2017 (43),0.00873,0.03250325,0.00998,0.0120012,Other Applications,0.0120012,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),0.0086,0.02110211,0.00642,0.051305131,Other Applications,0.02110211,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Number of Cell Lines - 3 (29),0.00856,0.02160216,0.01072,0.00430043,Other Applications,0.00430043,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Journal - Sci Rep (24),0.00799,0.03120312,0.00601,0.065106511,Other Applications,0.03120312,TRUE,FALSE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),hiPSC-CM Maturation Media - iCell Maintenance (83),0.00762,0.068806881,0.0084,0.02250225,Other Applications,0.02250225,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Number of Cell Lines - >5 (9),0.0075,0.02450245,0.0048,0.083708371,Other Applications,0.02450245,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),hiPSC-CM Backbone Media - Rare (10),0.00727,0.02620262,0.009,0.01520152,Other Applications,0.01520152,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),0.00679,0.0340034,0.00875,0.01750175,Other Applications,0.01750175,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Coating for Replating - Gelatin (43),0.00645,0.072107211,0.00711,0.04560456,Other Applications,0.04560456,TRUE,FALSE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),0.00626,0.04020402,0.00462,0.095409541,Other Applications,0.04020402,TRUE,FALSE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Cell Line - Cor.4U (16),0.00613,0.04730473,0.00887,0.01530153,Other Applications,0.01530153,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),0.00608,0.04810481,0.00519,0.080608061,Other Applications,0.04810481,TRUE,FALSE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Cell Line - iCell2 (8),0.00605,0.04450445,0.0097,0.01710171,Other Applications,0.01710171,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Cell Line Ancestry - Asian (28),0.00586,0.075207521,0.00802,0.02030203,Other Applications,0.02030203,TRUE,TRUE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),2D Surface - Microelectrode Array (9),0.00551,0.04890489,0.00435,0.096309631,Other Applications,0.04890489,TRUE,FALSE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Journal - Front Cell Dev Biol (3),0.00498,0.03480348,0.00294,0.198419842,Other Applications,0.03480348,TRUE,FALSE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Journal - Circ Res (5),0.00393,0.072607261,0.00677,0.04170417,Other Applications,0.04170417,TRUE,FALSE
Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Differentiation Purity Assessment - Visual Inspection (6),0.00309,0.123412341,0.00588,0.04870487,Other Applications,0.04870487,TRUE,FALSE
Pharmacological Intervention - Verapamil (27),Electrophysiology Analysis Method - Microelectrode (31),0.02621,0,0.01975,0,Other Applications,0,TRUE,TRUE
Pharmacological Intervention - Verapamil (27),Journal - Toxicological Sciences (4),0.01682,0.00110011,0.02024,0.00070007,Other Applications,0.00070007,TRUE,TRUE
Pharmacological Intervention - Verapamil (27),Cell Line - Cellapy (4),0.01268,0.00290029,0.01149,0.01150115,Other Applications,0.00290029,TRUE,TRUE
Pharmacological Intervention - Verapamil (27),Number of Cell Lines - 4 (11),0.01264,0.00470047,0.01431,0.00340034,Other Applications,0.00340034,TRUE,TRUE
Pharmacological Intervention - Verapamil (27),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.01202,0.00880088,0.01122,0.0060006,Other Applications,0.0060006,TRUE,TRUE
Pharmacological Intervention - Verapamil (27),Cell Line - iCell (47),0.01143,0.01270127,0.01301,0.00280028,Other Applications,0.00280028,TRUE,TRUE
Pharmacological Intervention - Verapamil (27),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),0.01131,0.00670067,0.01406,0.0040004,Other Applications,0.0040004,TRUE,TRUE
Pharmacological Intervention - Verapamil (27),Cell Line - Cor.4U (16),0.01106,0.00720072,0.00736,0.03140314,Other Applications,0.00720072,TRUE,TRUE
Pharmacological Intervention - Verapamil (27),3D Platform - Scaffold Free (43),0.01048,0.01450145,0.00699,0.055805581,Other Applications,0.01450145,TRUE,TRUE
Pharmacological Intervention - Verapamil (27),hiPSC-CM Maturation Media - iCell Maintenance (83),0.01039,0.01780178,0.01084,0.00390039,Other Applications,0.00390039,TRUE,TRUE
Pharmacological Intervention - Verapamil (27),hiPSC Backbone Media - mTeSR (106),0.01029,0.03050305,0.00505,0.433843384,Other Applications,0.03050305,TRUE,FALSE
Pharmacological Intervention - Verapamil (27),2D Surface - Decellularized ECM (3),0.01016,0.0050005,0.01423,0.00130013,Other Applications,0.00130013,TRUE,TRUE
Pharmacological Intervention - Verapamil (27),Number of Cell Lines - 3 (29),0.0097,0.01730173,0.01099,0.00750075,Other Applications,0.00750075,TRUE,TRUE
Pharmacological Intervention - Verapamil (27),Cell Line - WTC11 (30),0.00934,0.02420242,0.00593,0.081308131,Other Applications,0.02420242,TRUE,TRUE
Pharmacological Intervention - Verapamil (27),hiPSC-CM Backbone Media - iCell Maintenance (86),0.00933,0.02950295,0.00742,0.060406041,Other Applications,0.02950295,TRUE,FALSE
Pharmacological Intervention - Verapamil (27),Number of Cell Lines - 1 (225),0.0093,0.04360436,0.01174,0.00380038,Other Applications,0.00380038,TRUE,TRUE
Pharmacological Intervention - Verapamil (27),Calcium Handling Analysis Method - Visual (104),0.00922,0.057405741,0.00884,0.02220222,Other Applications,0.02220222,TRUE,TRUE
Pharmacological Intervention - Verapamil (27),Cell Line Ancestry - Asian (28),0.00901,0.01880188,0.00714,0.04150415,Other Applications,0.01880188,TRUE,TRUE
Pharmacological Intervention - Verapamil (27),Gene Analysis Method - RNA (169),0.00818,0.141414141,0.0083,0.02750275,Other Applications,0.02750275,TRUE,FALSE
Pharmacological Intervention - Verapamil (27),Publication Year - 2017 (43),0.00804,0.04460446,0.00602,0.099409941,Other Applications,0.04460446,TRUE,FALSE
Pharmacological Intervention - Verapamil (27),Electron Imaging - Scanning (22),0.00785,0.03340334,0.00728,0.03550355,Other Applications,0.03340334,TRUE,FALSE
Pharmacological Intervention - Verapamil (27),Cell Line - iCell2 (8),0.00784,0.02140214,0.00684,0.03920392,Other Applications,0.02140214,TRUE,TRUE
Pharmacological Intervention - Verapamil (27),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),0.00747,0.02350235,0.0077,0.02290229,Other Applications,0.02290229,TRUE,TRUE
Pharmacological Intervention - Verapamil (27),Journal - Sci Rep (24),0.00743,0.04170417,0.00764,0.03110311,Other Applications,0.03110311,TRUE,FALSE
Pharmacological Intervention - Verapamil (27),Immunofluorescent Imaging - Yes (268),0.00677,0.086508651,0.00846,0.02650265,Other Applications,0.02650265,TRUE,FALSE
Pharmacological Intervention - Verapamil (27),Coating for Replating - Gelatin (43),0.00667,0.067606761,0.00762,0.03860386,Other Applications,0.03860386,TRUE,FALSE
Pharmacological Intervention - Verapamil (27),hiPSC-CM Maturation Media - Rare (9),0.00659,0.03460346,0.00729,0.03090309,Other Applications,0.03090309,TRUE,FALSE
Pharmacological Intervention - Verapamil (27),hiPSC-CM Backbone Media - Rare (10),0.00632,0.03650365,0.00585,0.052105211,Other Applications,0.03650365,TRUE,FALSE
Pharmacological Intervention - Verapamil (27),Cell Line Ancestry - Caucasian (41),0.00616,0.095909591,0.00798,0.0340034,Other Applications,0.0340034,TRUE,FALSE
Pharmacological Intervention - Verapamil (27),2D Surface - Microelectrode Array (9),0.00567,0.04150415,0.00554,0.056005601,Other Applications,0.04150415,TRUE,FALSE
Pharmacological Intervention - Verapamil (27),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),0.00561,0.142814281,0.00769,0.03970397,Other Applications,0.03970397,TRUE,FALSE
Pharmacological Intervention - Verapamil (27),Journal - Nat Commun (13),0.00561,0.065306531,0.00718,0.03740374,Other Applications,0.03740374,TRUE,FALSE
Pharmacological Intervention - Verapamil (27),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),0.0046,0.101610161,0.00648,0.0480048,Other Applications,0.0480048,TRUE,FALSE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Journal - Toxicological Sciences (4),0.01806,0.00060006,0.01483,0.00170017,Other Applications,0.00060006,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Wnt Inhibitor - KY02111 (7),0.01514,0.0030003,0.01545,0.0030003,Other Applications,0.0030003,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Journal - Int J Mol Sci (3),0.01328,0.00290029,0.0104,0.01250125,Other Applications,0.00290029,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Number of Cell Lines - 1 (225),0.01253,0.01270127,0.00774,0.063706371,Other Applications,0.01270127,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Wnt Inhibitor - IWP (112),0.01103,0.02320232,0.00433,0.651565157,Other Applications,0.02320232,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Wnt Inhibitor - Others (9),0.01092,0.01070107,0.01154,0.00950095,Other Applications,0.00950095,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),hiPSC-CM Maturation Media - iCell Maintenance (83),0.01085,0.01820182,0.00956,0.01520152,Other Applications,0.01520152,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Gene Analysis Method - RNA (169),0.01026,0.053205321,0.00912,0.01330133,Other Applications,0.01330133,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),0.01023,0.01150115,0.00856,0.02580258,Other Applications,0.01150115,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Journal - Rare (104),0.00991,0.03650365,0.00852,0.02890289,Other Applications,0.02890289,TRUE,FALSE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),3D Stromal Cell Source - Cardiac Fibroblast (32),0.00981,0.01860186,0.00702,0.052305231,Other Applications,0.01860186,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Seeding Confluency 2D (%) - 80 to 84 (5),0.0098,0.0130013,0.00676,0.04420442,Other Applications,0.0130013,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Maturation Strategy - ECM (21),0.00936,0.01550155,0.00667,0.04950495,Other Applications,0.01550155,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Number of Cell Lines - 4 (11),0.00925,0.01820182,0.01087,0.01010101,Other Applications,0.01010101,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Seeding Confluency (%) - 80 to 84 (12),0.00921,0.01760176,0.00844,0.02310231,Other Applications,0.01760176,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),3D Platform - Extracellular Scaffold (18),0.00901,0.02210221,0.00915,0.01750175,Other Applications,0.01750175,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),3D Stromal Cell Source - Human Fibroblast (38),0.00886,0.04530453,0.0074,0.061506151,Other Applications,0.04530453,TRUE,FALSE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Journal - Sci Rep (24),0.00883,0.0310031,0.00687,0.058805881,Other Applications,0.0310031,TRUE,FALSE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Seeding Confluency 3D (%) - 90 to 94 (13),0.00864,0.02190219,0.0082,0.0260026,Other Applications,0.02190219,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),New Media for Maturation - Rare (4),0.0086,0.02120212,0.00869,0.02530253,Other Applications,0.02120212,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Electrophysiology Analysis Method - Patch Clamp (59),0.00851,0.04420442,0.00739,0.059405941,Other Applications,0.04420442,TRUE,FALSE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Number of Cell Lines - 3 (29),0.0085,0.02790279,0.01073,0.00770077,Other Applications,0.00770077,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),0.00791,0.02560256,0.0093,0.020002,Other Applications,0.020002,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Electrophysiology Analysis Method - Microelectrode (31),0.00772,0.03720372,0.00697,0.050905091,Other Applications,0.03720372,TRUE,FALSE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Journal - Cell Rep (6),0.00763,0.02740274,0.01012,0.01460146,Other Applications,0.01460146,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),hiPSC-CM Backbone Media - iCell Maintenance (86),0.00745,0.099909991,0.01057,0.00690069,Other Applications,0.00690069,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.00745,0.062206221,0.00926,0.01950195,Other Applications,0.01950195,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),0.00728,0.02720272,0.00559,0.064106411,Other Applications,0.02720272,TRUE,FALSE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Cell Line - Cellapy (4),0.00705,0.02740274,0.00897,0.0240024,Other Applications,0.0240024,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),2D Surface - ECM-coated (115),0.00675,0.174817482,0.00892,0.01660166,Other Applications,0.01660166,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Number of Cell Lines - >5 (9),0.0067,0.04110411,0.00657,0.04730473,Other Applications,0.04110411,TRUE,FALSE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),hiPSC-CM Media Supplement - GlutaMax (8),0.00665,0.04940494,0.00698,0.0490049,Other Applications,0.0490049,TRUE,FALSE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),hiPSC-CM Maturation Media - Cor.4U Complete (6),0.00629,0.03560356,0.00393,0.103310331,Other Applications,0.03560356,TRUE,FALSE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Coating for Replating - Rare (6),0.00609,0.052205221,0.00742,0.0430043,Other Applications,0.0430043,TRUE,FALSE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),hiPSC-CM Media Supplement - Nonessential Amino Acids (8),0.00607,0.04630463,0.00415,0.102010201,Other Applications,0.04630463,TRUE,FALSE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),hiPSC-CM Media Supplement - HEPES (16),0.00582,0.076207621,0.00896,0.020002,Other Applications,0.020002,TRUE,TRUE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),0.00556,0.080708071,0.007,0.04720472,Other Applications,0.04720472,TRUE,FALSE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Coating for Replating - Synthemax (3),0.00505,0.03930393,0.00608,0.03620362,Other Applications,0.03620362,TRUE,FALSE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),2D Surface - Decellularized ECM (3),0.00458,0.062506251,0.00585,0.04720472,Other Applications,0.04720472,TRUE,FALSE
Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Publication Year - 2017 (43),0.0041,0.303030303,0.00766,0.04960496,Other Applications,0.04960496,TRUE,FALSE
Pharmacological Intervention - E4031 (22),Electrophysiology Analysis Method - Microelectrode (31),0.0255,0,0.02552,0,Other Applications,0,TRUE,TRUE
Pharmacological Intervention - E4031 (22),Maturation Strategy - Electrical (39),0.01435,0.00580058,0.01169,0.0060006,Other Applications,0.00580058,TRUE,TRUE
Pharmacological Intervention - E4031 (22),Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58),0.01378,0.00740074,0.01408,0.00220022,Other Applications,0.00220022,TRUE,TRUE
Pharmacological Intervention - E4031 (22),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),0.01268,0.0030003,0.01367,0.00250025,Other Applications,0.00250025,TRUE,TRUE
Pharmacological Intervention - E4031 (22),Publication Year - 2016 (32),0.01188,0.01460146,0.00992,0.01750175,Other Applications,0.01460146,TRUE,TRUE
Pharmacological Intervention - E4031 (22),Cell Line - Cor.4U (16),0.01138,0.00930093,0.00997,0.01130113,Other Applications,0.00930093,TRUE,TRUE
Pharmacological Intervention - E4031 (22),Publication Year - Late-2010s (196),0.01104,0.02490249,0.00561,0.372137214,Other Applications,0.02490249,TRUE,TRUE
Pharmacological Intervention - E4031 (22),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),0.01013,0.03690369,0.00762,0.070507051,Other Applications,0.03690369,TRUE,FALSE
Pharmacological Intervention - E4031 (22),2D Surface - Microelectrode Array (9),0.00992,0.00980098,0.01077,0.00810081,Other Applications,0.00810081,TRUE,TRUE
Pharmacological Intervention - E4031 (22),Journal - Int J Mol Sci (3),0.00967,0.01020102,0.01205,0.010001,Other Applications,0.010001,TRUE,TRUE
Pharmacological Intervention - E4031 (22),3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25),0.00962,0.01430143,0.00948,0.01120112,Other Applications,0.01120112,TRUE,TRUE
Pharmacological Intervention - E4031 (22),Seeding Confluency 3D (%) - 85 to 89 (12),0.00951,0.01860186,0.01199,0.00580058,Other Applications,0.00580058,TRUE,TRUE
Pharmacological Intervention - E4031 (22),Electron Imaging - Scanning (22),0.00887,0.0250025,0.00858,0.02460246,Other Applications,0.02460246,TRUE,TRUE
Pharmacological Intervention - E4031 (22),Electron Imaging - Transmission (62),0.00884,0.04610461,0.00712,0.080508051,Other Applications,0.04610461,TRUE,FALSE
Pharmacological Intervention - E4031 (22),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),0.00875,0.02130213,0.00917,0.02010201,Other Applications,0.02010201,TRUE,TRUE
Pharmacological Intervention - E4031 (22),Wnt Inhibitor Duration (days) - 4 days (19),0.00804,0.03390339,0.00745,0.04110411,Other Applications,0.03390339,TRUE,FALSE
Pharmacological Intervention - E4031 (22),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),0.00763,0.03830383,0.00631,0.058205821,Other Applications,0.03830383,TRUE,FALSE
Pharmacological Intervention - E4031 (22),2D Surface - Electrospun (13),0.00703,0.04490449,0.00638,0.059305931,Other Applications,0.04490449,TRUE,FALSE
Pharmacological Intervention - E4031 (22),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),0.00688,0.063106311,0.00836,0.02890289,Other Applications,0.02890289,TRUE,FALSE
Pharmacological Intervention - E4031 (22),Cell Line - iCell (47),0.00633,0.115411541,0.00845,0.03810381,Other Applications,0.03810381,TRUE,FALSE
Pharmacological Intervention - E4031 (22),hiPSC-CM Media Supplement - L-glutamine (19),0.00624,0.056505651,0.00646,0.04790479,Other Applications,0.04790479,TRUE,FALSE
Pharmacological Intervention - E4031 (22),Cell Line - 253G1 (10),0.00619,0.04110411,0.00576,0.059905991,Other Applications,0.04110411,TRUE,FALSE
Pharmacological Intervention - E4031 (22),3D Platform - Extracellular Scaffold (18),0.00578,0.072207221,0.00756,0.03290329,Other Applications,0.03290329,TRUE,FALSE
Pharmacological Intervention - E4031 (22),Journal - Rare (104),0.00561,0.415441544,0.01008,0.00810081,Other Applications,0.00810081,TRUE,TRUE
Pharmacological Intervention - E4031 (22),Wnt Inhibitor - XAV939 (24),0.00533,0.104010401,0.0081,0.03050305,Other Applications,0.03050305,TRUE,FALSE
Pharmacological Intervention - E4031 (22),Wnt Induction Duration (days) - 5 days (8),0.0053,0.080608061,0.0084,0.02880288,Other Applications,0.02880288,TRUE,FALSE
Pharmacological Intervention - E4031 (22),3D Platform - Nanotechnology (3),0.005,0.056405641,0.00634,0.04790479,Other Applications,0.04790479,TRUE,FALSE
Pharmacological Intervention - E4031 (22),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),0.00466,0.084308431,0.0061,0.04990499,Other Applications,0.04990499,TRUE,FALSE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Electrophysiology Analysis Method - Microelectrode (31),0.03028,0,0.0297,0,Other Applications,0,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Cell Line - iCell (47),0.01963,0.00280028,0.01659,0.00090009,Other Applications,0.00090009,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Number of Cell Lines - 3 (29),0.01829,0.00140014,0.01622,0.0010001,Other Applications,0.0010001,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Calcium Handling Analysis Method - Visual (104),0.01827,0.00350035,0.01032,0.00760076,Other Applications,0.00350035,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),0.01759,0.00770077,0.00775,0.087108711,Other Applications,0.00770077,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Wnt Inhibitor Duration (days) - Rare (173),0.01742,0.00290029,0.00582,0.399839984,Other Applications,0.00290029,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Journal - Biomaterials (16),0.01581,0.00380038,0.01916,0.00090009,Other Applications,0.00090009,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Electrophysiology Analysis Method - Optical Mapping (39),0.01545,0.00580058,0.01146,0.00970097,Other Applications,0.00580058,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),hiPSC-CM Backbone Media - iCell Maintenance (86),0.01437,0.00530053,0.00896,0.03280328,Other Applications,0.00530053,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Journal - Toxicological Sciences (4),0.01421,0.00350035,0.01595,0.00390039,Other Applications,0.00350035,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Number of Cell Lines - 1 (225),0.01394,0.00920092,0.01041,0.01140114,Other Applications,0.00920092,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Number of Cell Lines - 4 (11),0.01178,0.01170117,0.01054,0.01490149,Other Applications,0.01170117,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Journal - Nat Commun (13),0.01069,0.01860186,0.0095,0.0250025,Other Applications,0.01860186,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),hiPSC-CM Maturation Media - iCell Maintenance (83),0.01063,0.02240224,0.00882,0.02880288,Other Applications,0.02240224,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Publication Year - Late-2010s (196),0.01053,0.03510351,0.00983,0.00890089,Other Applications,0.00890089,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),0.00981,0.00870087,0.01385,0.00650065,Other Applications,0.00650065,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),3D Platform - Polyethylene Glycol (8),0.00978,0.01720172,0.00808,0.03510351,Other Applications,0.01720172,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),3D Tissue Media - Commercial Kit (21),0.00974,0.02240224,0.01087,0.01210121,Other Applications,0.01210121,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),0.00934,0.02530253,0.00844,0.03160316,Other Applications,0.02530253,TRUE,FALSE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Gene Analysis Method - RNA (169),0.00916,0.091709171,0.01056,0.00350035,Other Applications,0.00350035,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Disease Modelling - Arrhythmic (15),0.00898,0.0260026,0.00653,0.060206021,Other Applications,0.0260026,TRUE,FALSE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),hiPSC-CM Backbone Media - RPMI-1640 (167),0.00863,0.101110111,0.00933,0.01140114,Other Applications,0.01140114,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),0.00837,0.04980498,0.00826,0.040004,Other Applications,0.040004,TRUE,FALSE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Publication Year - 2021 (43),0.00829,0.056905691,0.01015,0.0170017,Other Applications,0.0170017,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Coating for Replating - Matrigel (65),0.00777,0.074807481,0.0097,0.01930193,Other Applications,0.01930193,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),0.00727,0.03120312,0.00617,0.052005201,Other Applications,0.03120312,TRUE,FALSE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Cell Line - 253G1 (10),0.00717,0.03570357,0.00424,0.108610861,Other Applications,0.03570357,TRUE,FALSE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Day of Insulin Addition - Known (177),0.00692,0.270627063,0.00942,0.00970097,Other Applications,0.00970097,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Disease Modelling - Fibrotic (4),0.00632,0.03130313,0.00494,0.091709171,Other Applications,0.03130313,TRUE,FALSE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Immunofluorescent Imaging - Yes (268),0.00628,0.131813181,0.00862,0.04170417,Other Applications,0.04170417,TRUE,FALSE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),2D Surface - ECM-coated (115),0.00623,0.254325433,0.01005,0.00530053,Other Applications,0.00530053,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),0.00609,0.076207621,0.00742,0.04910491,Other Applications,0.04910491,TRUE,FALSE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),0.00578,0.074307431,0.00946,0.01910191,Other Applications,0.01910191,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),hiPSC-CM Purification Duration (days) - 5 days (6),0.0054,0.060006001,0.00731,0.04340434,Other Applications,0.04340434,TRUE,FALSE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Cell Line - Rare (132),0.00536,0.625262526,0.00835,0.03910391,Other Applications,0.03910391,TRUE,FALSE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),0.00511,0.069606961,0.00716,0.04340434,Other Applications,0.04340434,TRUE,FALSE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Journal - Cell Rep (6),0.00503,0.069106911,0.00945,0.02490249,Other Applications,0.02490249,TRUE,TRUE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Journal - Sci Rep (24),0.00496,0.144114411,0.00879,0.03180318,Other Applications,0.03180318,TRUE,FALSE
Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Number of Cell Lines - 2 (50),0.00384,0.417941794,0.00868,0.04210421,Other Applications,0.04210421,TRUE,FALSE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Journal - Sci Rep (24),0.02651,0.00040004,0.02396,0.00050005,Other Applications,0.00040004,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Cell Line - iCell (47),0.01806,0.00360036,0.01083,0.01480148,Other Applications,0.00360036,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Immunofluorescent Imaging - Yes (268),0.01733,0.00260026,0.01467,0.0020002,Other Applications,0.0020002,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),hiPSC-CM Maturation Media - iCell Maintenance (83),0.01558,0.0030003,0.01056,0.00850085,Other Applications,0.0030003,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.01478,0.00610061,0.01123,0.01060106,Other Applications,0.00610061,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Journal - Toxicological Sciences (4),0.01474,0.00270027,0.01888,0.00090009,Other Applications,0.00090009,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),0.01369,0.00810081,0.00987,0.01990199,Other Applications,0.00810081,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Coating for Replating - Matrigel (65),0.01354,0.00660066,0.01172,0.00510051,Other Applications,0.00510051,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),hiPSC-CM Backbone Media - iCell Maintenance (86),0.01253,0.01050105,0.01124,0.00530053,Other Applications,0.00530053,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Journal - Rare (104),0.01148,0.02030203,0.00674,0.145414541,Other Applications,0.02030203,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),0.01112,0.01010101,0.02331,0.00040004,Other Applications,0.00040004,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Wnt Induction - CHIR99021 (184),0.01084,0.0440044,0.00638,0.256925693,Other Applications,0.0440044,TRUE,FALSE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Gene Analysis Method - RNA (169),0.01073,0.04360436,0.00747,0.101010101,Other Applications,0.04360436,TRUE,FALSE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),3D Platform - Scaffold Free (43),0.01008,0.0280028,0.00639,0.111411141,Other Applications,0.0280028,TRUE,FALSE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),hiPSC Matrix Coating - Matrigel (163),0.00991,0.03860386,0.00501,0.584858486,Other Applications,0.03860386,TRUE,FALSE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),3D Tissue Media - Rare (13),0.00984,0.02120212,0.0137,0.00540054,Other Applications,0.00540054,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Calcium Handling Analysis Method - Visual (104),0.00982,0.055505551,0.01148,0.0040004,Other Applications,0.0040004,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Journal - Nat Commun (13),0.00952,0.02780278,0.01151,0.01250125,Other Applications,0.01250125,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Contractile Analysis Method - Deflection (39),0.00945,0.03260326,0.01019,0.01840184,Other Applications,0.01840184,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),hiPSC Backbone Media - Embryonic Stem Cell (127),0.0094,0.04340434,0.00354,0.859185919,Other Applications,0.04340434,TRUE,FALSE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Insulin Withdrawal Duration (days) - 8 days (3),0.00937,0.01140114,0.00892,0.02190219,Other Applications,0.01140114,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),hiPSC-CM Purification Duration (days) - 8 days (4),0.0093,0.01680168,0.00921,0.02270227,Other Applications,0.01680168,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Publication Year - Late-2010s (196),0.00929,0.065606561,0.01077,0.00290029,Other Applications,0.00290029,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Publication Year - 2020 (51),0.00904,0.04940494,0.01248,0.00650065,Other Applications,0.00650065,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Publication Year - Post 2020 (122),0.00865,0.118311831,0.00836,0.04660466,Other Applications,0.04660466,TRUE,FALSE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),2D Surface - ECM-coated (115),0.00863,0.04910491,0.00786,0.04420442,Other Applications,0.04420442,TRUE,FALSE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Cell Coculture - Endothelial Cell (35),0.00846,0.054805481,0.01095,0.01460146,Other Applications,0.01460146,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),0.00817,0.0450045,0.00823,0.03810381,Other Applications,0.03810381,TRUE,FALSE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Electrophysiology Analysis Method - Optical Mapping (39),0.00809,0.052705271,0.00882,0.03040304,Other Applications,0.03040304,TRUE,FALSE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Electrophysiology Analysis Method - Microelectrode (31),0.00804,0.0430043,0.00583,0.105710571,Other Applications,0.0430043,TRUE,FALSE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),0.00802,0.03350335,0.00696,0.04770477,Other Applications,0.03350335,TRUE,FALSE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Insulin Start Day - 0 (7),0.00784,0.03430343,0.0074,0.04470447,Other Applications,0.03430343,TRUE,FALSE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),3D Tissue Media - Commercial Kit (21),0.00781,0.04480448,0.00656,0.068306831,Other Applications,0.04480448,TRUE,FALSE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Journal - Biomaterials (16),0.00765,0.04310431,0.01043,0.01510151,Other Applications,0.01510151,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Coating for Replating - Gelatin (43),0.0076,0.062006201,0.01161,0.00910091,Other Applications,0.00910091,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Contractile Analysis Method - Motion Tracking (93),0.00726,0.182118212,0.01032,0.01490149,Other Applications,0.01490149,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),hiPSC-CM Purification Duration (days) - >9 days (5),0.00712,0.02850285,0.0077,0.03070307,Other Applications,0.02850285,TRUE,FALSE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),0.00695,0.228322832,0.00965,0.01790179,Other Applications,0.01790179,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Journal - Tissue Eng Part C Methods (6),0.00681,0.0430043,0.01232,0.01070107,Other Applications,0.01070107,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Maturation Strategy - Mechanical (36),0.00679,0.081408141,0.01283,0.0050005,Other Applications,0.0050005,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Cell Line - Cellapy (4),0.00629,0.04390439,0.00591,0.075807581,Other Applications,0.04390439,TRUE,FALSE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Maturation Strategy - Other Cells (80),0.00604,0.236623662,0.00982,0.01810181,Other Applications,0.01810181,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Journal - Sci Transl Med (3),0.00599,0.056405641,0.00924,0.02230223,Other Applications,0.02230223,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),0.00589,0.121412141,0.00819,0.04540454,Other Applications,0.04540454,TRUE,FALSE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),Purification Protocol - Antibiotic (4),0.00565,0.04120412,0.00826,0.01960196,Other Applications,0.01960196,TRUE,TRUE
Pharmacological Intervention - Traditional Chemotherapy Agents (18),3D Endothelial Cell Source - Rare (3),0.00508,0.075007501,0.00724,0.0460046,Other Applications,0.0460046,TRUE,FALSE
Pharmacological Intervention - Doxorubicin (17),Journal - Sci Rep (24),0.02806,0.00010001,0.02926,0,Other Applications,0,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),hiPSC-CM Maturation Media - iCell Maintenance (83),0.01641,0.0020002,0.00901,0.0270027,Other Applications,0.0020002,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),0.01638,0.0030003,0.00948,0.0250025,Other Applications,0.0030003,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),Coating for Replating - Matrigel (65),0.01569,0.00530053,0.01096,0.01180118,Other Applications,0.00530053,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),Immunofluorescent Imaging - Yes (268),0.01479,0.00540054,0.01355,0.00270027,Other Applications,0.00270027,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),Journal - Toxicological Sciences (4),0.01472,0.00320032,0.01851,0.00150015,Other Applications,0.00150015,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),Publication Year - Late-2010s (196),0.01376,0.01050105,0.01343,0.00060006,Other Applications,0.00060006,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),Cell Line - iCell (47),0.01375,0.01250125,0.0125,0.00720072,Other Applications,0.00720072,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),hiPSC-CM Backbone Media - iCell Maintenance (86),0.01164,0.01740174,0.01317,0.0020002,Other Applications,0.0020002,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),hiPSC-CM Purification Duration (days) - 8 days (4),0.01151,0.00970097,0.00883,0.02510251,Other Applications,0.00970097,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),Publication Year - Post 2020 (122),0.01147,0.03970397,0.00808,0.061906191,Other Applications,0.03970397,TRUE,FALSE
Pharmacological Intervention - Doxorubicin (17),2D Surface - ECM-coated (115),0.01147,0.0120012,0.01066,0.00420042,Other Applications,0.00420042,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),Calcium Handling Analysis Method - Visual (104),0.01136,0.02780278,0.01176,0.00310031,Other Applications,0.00310031,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.01133,0.01980198,0.00885,0.0320032,Other Applications,0.01980198,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),0.01132,0.00860086,0.02436,0.00040004,Other Applications,0.00040004,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),Publication Year - 2016 (32),0.01122,0.02460246,0.00854,0.04120412,Other Applications,0.02460246,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),3D Tissue Media - Commercial Kit (21),0.01111,0.01650165,0.00808,0.03870387,Other Applications,0.01650165,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),Wnt Induction - CHIR99021 (184),0.01095,0.04410441,0.00542,0.466646665,Other Applications,0.04410441,TRUE,FALSE
Pharmacological Intervention - Doxorubicin (17),Gene Analysis Method - RNA (169),0.01084,0.04480448,0.00799,0.063506351,Other Applications,0.04480448,TRUE,FALSE
Pharmacological Intervention - Doxorubicin (17),Cell Coculture - Endothelial Cell (35),0.01072,0.03090309,0.0117,0.01220122,Other Applications,0.01220122,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),Journal - Nat Commun (13),0.01032,0.02120212,0.01027,0.01890189,Other Applications,0.01890189,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),Maturation Strategy - Other Cells (80),0.00972,0.04030403,0.00918,0.03470347,Other Applications,0.03470347,TRUE,FALSE
Pharmacological Intervention - Doxorubicin (17),Insulin Withdrawal Duration (days) - 8 days (3),0.00964,0.010001,0.01284,0.00830083,Other Applications,0.00830083,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),Electrophysiology Analysis Method - Optical Mapping (39),0.00906,0.04350435,0.00928,0.02860286,Other Applications,0.02860286,TRUE,FALSE
Pharmacological Intervention - Doxorubicin (17),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),0.00875,0.03580358,0.00929,0.02360236,Other Applications,0.02360236,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),3D Platform - Scaffold Free (43),0.00819,0.060106011,0.01018,0.01990199,Other Applications,0.01990199,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),Publication Year - 2020 (51),0.00815,0.067706771,0.01083,0.01450145,Other Applications,0.01450145,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),Cell Line - Rare (132),0.00814,0.128312831,0.00999,0.00830083,Other Applications,0.00830083,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),0.00808,0.03560356,0.00931,0.02010201,Other Applications,0.02010201,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),Wnt Inhibitor - VEGF (3),0.00757,0.03510351,0.00639,0.086508651,Other Applications,0.03510351,TRUE,FALSE
Pharmacological Intervention - Doxorubicin (17),Contractile Analysis Method - Motion Tracking (93),0.00756,0.163516352,0.01076,0.01230123,Other Applications,0.01230123,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),Journal - Sci Transl Med (3),0.00727,0.0350035,0.00755,0.051405141,Other Applications,0.0350035,TRUE,FALSE
Pharmacological Intervention - Doxorubicin (17),Insulin Start Day - 0 (7),0.00711,0.04280428,0.00796,0.0370037,Other Applications,0.0370037,TRUE,FALSE
Pharmacological Intervention - Doxorubicin (17),hiPSC-CM Purification Duration (days) - >9 days (5),0.0071,0.02840284,0.00933,0.01870187,Other Applications,0.01870187,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),Journal - Tissue Eng Part C Methods (6),0.00703,0.04080408,0.01204,0.01170117,Other Applications,0.01170117,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),3D Endothelial Cell Source - Rare (3),0.00696,0.03720372,0.00726,0.04810481,Other Applications,0.03720372,TRUE,FALSE
Pharmacological Intervention - Doxorubicin (17),Coating for Replating - Gelatin (43),0.00663,0.095409541,0.01158,0.00840084,Other Applications,0.00840084,TRUE,TRUE
Pharmacological Intervention - Doxorubicin (17),Day of Insulin Addition - not 19 (9),0.00632,0.058205821,0.00816,0.03420342,Other Applications,0.03420342,TRUE,FALSE
Pharmacological Intervention - Doxorubicin (17),Electrophysiology Analysis Method - Microelectrode (31),0.00604,0.095509551,0.00784,0.04410441,Other Applications,0.04410441,TRUE,FALSE
Pharmacological Intervention - Doxorubicin (17),Purification Protocol - Antibiotic (4),0.00567,0.04220422,0.00768,0.02670267,Other Applications,0.02670267,TRUE,FALSE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Electrophysiology Analysis Method - Microelectrode (31),0.03784,0,0.03658,0,Other Applications,0,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Cell Line - iCell (47),0.02311,0.00130013,0.01723,0.00170017,Other Applications,0.00130013,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Journal - Toxicological Sciences (4),0.02109,0.00020002,0.0246,0.00030003,Other Applications,0.00020002,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Journal - Biomaterials (16),0.02066,0.00250025,0.01762,0.00260026,Other Applications,0.00250025,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),0.01802,0.0120012,0.00764,0.119211921,Other Applications,0.0120012,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Calcium Handling Analysis Method - Visual (104),0.0163,0.00880088,0.0148,0.00060006,Other Applications,0.00060006,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Number of Cell Lines - 4 (11),0.01459,0.00720072,0.01749,0.00320032,Other Applications,0.00320032,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Wnt Inhibitor Duration (days) - Rare (173),0.01451,0.01090109,0.00625,0.305630563,Other Applications,0.01090109,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Number of Cell Lines - 3 (29),0.01439,0.01090109,0.02109,0.00050005,Other Applications,0.00050005,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),hiPSC-CM Backbone Media - iCell Maintenance (86),0.01409,0.00870087,0.01504,0.00090009,Other Applications,0.00090009,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Immunofluorescent Imaging - Yes (268),0.01309,0.0130013,0.01041,0.02310231,Other Applications,0.0130013,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Electrophysiology Analysis Method - Optical Mapping (39),0.01253,0.01740174,0.01399,0.00340034,Other Applications,0.00340034,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Number of Cell Lines - 1 (225),0.01157,0.02810281,0.01125,0.01010101,Other Applications,0.01010101,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Publication Year - Late-2010s (196),0.0109,0.0350035,0.00757,0.099509951,Other Applications,0.0350035,TRUE,FALSE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Publication Year - 2021 (43),0.01058,0.03080308,0.01142,0.01320132,Other Applications,0.01320132,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),0.01047,0.02530253,0.00991,0.02630263,Other Applications,0.02530253,TRUE,FALSE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Publication Year - 2016 (32),0.0102,0.04170417,0.01315,0.00790079,Other Applications,0.00790079,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Journal - Nat Commun (13),0.01012,0.02990299,0.01473,0.00730073,Other Applications,0.00730073,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Coating for Replating - Matrigel (65),0.01001,0.03520352,0.01034,0.01930193,Other Applications,0.01930193,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),hiPSC-CM Maturation Media - iCell Maintenance (83),0.00991,0.0340034,0.01583,0.00020002,Other Applications,0.00020002,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Gene Analysis Method - RNA (169),0.00988,0.074907491,0.00881,0.03770377,Other Applications,0.03770377,TRUE,FALSE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),2D Surface - ECM-coated (115),0.0098,0.02710271,0.0096,0.01350135,Other Applications,0.01350135,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),3D Platform - Polyethylene Glycol (8),0.00977,0.02430243,0.00883,0.03040304,Other Applications,0.02430243,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Journal - Rare (104),0.00921,0.061906191,0.00907,0.03040304,Other Applications,0.03040304,TRUE,FALSE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Coating for Replating - Rare (6),0.00902,0.02920292,0.00685,0.065706571,Other Applications,0.02920292,TRUE,FALSE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),0.00877,0.050905091,0.01143,0.01280128,Other Applications,0.01280128,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),0.00829,0.02590259,0.00852,0.03090309,Other Applications,0.02590259,TRUE,FALSE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.00791,0.070507051,0.00852,0.04420442,Other Applications,0.04420442,TRUE,FALSE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),0.00785,0.0310031,0.00441,0.121112111,Other Applications,0.0310031,TRUE,FALSE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Coating for Replating - Gelatin (43),0.00748,0.081708171,0.01106,0.01820182,Other Applications,0.01820182,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Journal - Sci Rep (24),0.00744,0.073707371,0.0108,0.01990199,Other Applications,0.01990199,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),0.00698,0.056005601,0.0078,0.04430443,Other Applications,0.04430443,TRUE,FALSE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),hiPSC-CM Purification Duration (days) - 5 days (6),0.00672,0.04630463,0.00986,0.02630263,Other Applications,0.02630263,TRUE,FALSE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Maturation Strategy - Electrical (39),0.0066,0.113311331,0.00865,0.04710471,Other Applications,0.04710471,TRUE,FALSE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Journal - Cell Rep (6),0.00639,0.055305531,0.00871,0.03050305,Other Applications,0.03050305,TRUE,FALSE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Wnt Inhibitor - BMP4 (7),0.00609,0.060506051,0.00834,0.03480348,Other Applications,0.03480348,TRUE,FALSE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),0.00537,0.091309131,0.01136,0.01940194,Other Applications,0.01940194,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),0.00523,0.078007801,0.00968,0.01860186,Other Applications,0.01860186,TRUE,TRUE
Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),0.00403,0.224122412,0.00877,0.03390339,Other Applications,0.03390339,TRUE,FALSE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Number of Cell Lines - 3 (29),0.02344,0.00110011,0.01655,0.00250025,Other Applications,0.00110011,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Journal - Toxicological Sciences (4),0.01968,0.00140014,0.02182,0.00140014,Other Applications,0.00140014,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Number of Cell Lines - 1 (225),0.01803,0.00410041,0.01743,0.00020002,Other Applications,0.00020002,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.01505,0.01040104,0.01296,0.00740074,Other Applications,0.00740074,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Wnt Inhibitor Duration (days) - >6 days (12),0.01489,0.00760076,0.01581,0.00450045,Other Applications,0.00450045,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Cell Line - Cor.4U (16),0.01449,0.00840084,0.01393,0.0060006,Other Applications,0.0060006,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),0.01399,0.00750075,0.01264,0.01030103,Other Applications,0.00750075,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),hiPSC-CM Purification Duration (days) - 3 days (13),0.01362,0.01090109,0.00942,0.02890289,Other Applications,0.01090109,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Immunofluorescent Imaging - Yes (268),0.01331,0.01490149,0.01472,0.00370037,Other Applications,0.00370037,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Maturation Strategy - ECM (21),0.01296,0.00990099,0.00822,0.04340434,Other Applications,0.00990099,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),0.01164,0.03270327,0.00704,0.177917792,Other Applications,0.03270327,TRUE,FALSE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Cell Line - iCell (47),0.01147,0.03210321,0.00815,0.070507051,Other Applications,0.03210321,TRUE,FALSE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),0.01117,0.02280228,0.01072,0.02270227,Other Applications,0.02270227,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Insulin Start Day - 6 (20),0.01064,0.02390239,0.01035,0.01930193,Other Applications,0.01930193,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Publication Year - 2019 (57),0.0104,0.03330333,0.01417,0.00350035,Other Applications,0.00350035,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),hiPSC Matrix Coating - Matrigel (163),0.01039,0.03710371,0.00732,0.166416642,Other Applications,0.03710371,TRUE,FALSE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),0.01028,0.0340034,0.01081,0.0240024,Other Applications,0.0240024,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Journal - Sci Rep (24),0.00986,0.03920392,0.01126,0.01790179,Other Applications,0.01790179,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Coating for Replating - Gelatin (43),0.00981,0.03950395,0.00837,0.058505851,Other Applications,0.03950395,TRUE,FALSE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Wnt Inhibitor - DS-I-7 (9),0.0095,0.02240224,0.01191,0.00870087,Other Applications,0.00870087,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Cell Line - iCell2 (8),0.00918,0.03530353,0.00943,0.03420342,Other Applications,0.03420342,TRUE,FALSE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Journal - Cell Stem Cell (6),0.00901,0.02640264,0.0047,0.137113711,Other Applications,0.02640264,TRUE,FALSE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Wnt Inhibitor Duration (days) Quantiles - Q2 (>1 and ≤2) (156),0.00878,0.136113611,0.00881,0.0450045,Other Applications,0.0450045,TRUE,FALSE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),hiPSC-CM Media Supplement - Lipid Mix (5),0.0087,0.02510251,0.01041,0.01920192,Other Applications,0.01920192,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Insulin Start Day - 4 (11),0.00838,0.0410041,0.00468,0.126412641,Other Applications,0.0410041,TRUE,FALSE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Cell Line Sex - Both (118),0.00834,0.126412641,0.01052,0.0120012,Other Applications,0.0120012,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),0.008,0.057405741,0.0096,0.02820282,Other Applications,0.02820282,TRUE,FALSE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),2D Surface - ECM-coated (115),0.00779,0.086408641,0.00898,0.02920292,Other Applications,0.02920292,TRUE,FALSE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Wnt Inhibitor - KY02111 (7),0.00779,0.03610361,0.00648,0.066506651,Other Applications,0.03610361,TRUE,FALSE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Journal - Rare (104),0.00738,0.142014201,0.00988,0.01670167,Other Applications,0.01670167,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Journal - J Tissue Eng Regen Med (3),0.00695,0.056405641,0.0104,0.02260226,Other Applications,0.02260226,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Insulin Withdrawal Duration (days) - 3 days (6),0.0069,0.04350435,0.00707,0.04590459,Other Applications,0.04350435,TRUE,FALSE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Insulin Withdrawal Duration (days) Quantiles - Q2 (>2 and ≤4) (25),0.00681,0.087008701,0.01068,0.01990199,Other Applications,0.01990199,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Journal - Cell Rep (6),0.00653,0.056205621,0.0084,0.0340034,Other Applications,0.0340034,TRUE,FALSE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Purification Protocol - Metabolic (8),0.00611,0.056405641,0.00966,0.02280228,Other Applications,0.02280228,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Publication Year - Post 2020 (122),0.00517,0.641464146,0.00878,0.0480048,Other Applications,0.0480048,TRUE,FALSE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Differentiation Purity Assessment - IHC a-actinin (8),0.00514,0.092709271,0.00955,0.0260026,Other Applications,0.0260026,TRUE,FALSE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),2D Surface - Microelectrode Array (9),0.00433,0.126212621,0.00894,0.02880288,Other Applications,0.02880288,TRUE,FALSE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Electrophysiology Analysis Method - Patch Clamp (59),0.00408,0.358335834,0.01086,0.01590159,Other Applications,0.01590159,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),0.0036,0.171617162,0.01004,0.02350235,Other Applications,0.02350235,TRUE,TRUE
Pharmacological Intervention - Other Antiarrhythmic Agents (13),hiPSC-CM Maturation Media - Commercial Kit (27),0.00299,0.344734473,0.00864,0.04940494,Other Applications,0.04940494,TRUE,FALSE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Cell Line - iCell2 (8),0.02208,0.00170017,0.02225,0.00150015,Other Applications,0.00150015,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),hiPSC-CM Maturation Media - iCell Maintenance (83),0.0212,0.00080008,0.01225,0.00380038,Other Applications,0.00080008,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Immunofluorescent Imaging - Yes (268),0.02103,0.00160016,0.016,0.0020002,Other Applications,0.00160016,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Wnt Inhibitor Duration (days) - Rare (173),0.01949,0.00320032,0.01124,0.00380038,Other Applications,0.00320032,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Journal - Toxicological Sciences (4),0.01754,0.00310031,0.02061,0.00260026,Other Applications,0.00260026,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Journal - Nat Commun (13),0.01603,0.00950095,0.01684,0.00550055,Other Applications,0.00550055,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Electrophysiology Analysis Method - Microelectrode (31),0.01532,0.00640064,0.01544,0.00250025,Other Applications,0.00250025,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),0.01491,0.01330133,0.00737,0.136813681,Other Applications,0.01330133,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Journal - Lab Chip (4),0.01437,0.00570057,0.01664,0.00480048,Other Applications,0.00480048,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Calcium Handling Analysis Method - Visual (104),0.01437,0.01450145,0.01033,0.01510151,Other Applications,0.01450145,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),hiPSC-CM Backbone Media - iCell Maintenance (86),0.01343,0.01240124,0.00988,0.03160316,Other Applications,0.01240124,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Wnt Inhibitor Duration (days) Quantiles - Q2 (>1 and ≤2) (156),0.01213,0.03640364,0.00566,0.463346335,Other Applications,0.03640364,TRUE,FALSE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Publication Year - 2017 (43),0.01192,0.02940294,0.00977,0.0350035,Other Applications,0.02940294,TRUE,FALSE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),2D Surface - ECM-coated (115),0.01179,0.01290129,0.00775,0.073907391,Other Applications,0.01290129,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.01132,0.02860286,0.01555,0.00150015,Other Applications,0.00150015,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),hiPSC-CM Purification Duration (days) - 5 days (6),0.01076,0.01690169,0.01302,0.01250125,Other Applications,0.01250125,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Disease Modelling - Ischemic Infarction (9),0.01066,0.02240224,0.01069,0.02140214,Other Applications,0.02140214,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Coating for Replating - Matrigel (65),0.0103,0.03770377,0.01022,0.02440244,Other Applications,0.02440244,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),3D Tissue Media - Rare (13),0.00976,0.03450345,0.01121,0.01840184,Other Applications,0.01840184,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Cell Coculture - Endothelial Cell (35),0.0095,0.056605661,0.0098,0.04480448,Other Applications,0.04480448,TRUE,FALSE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),0.00944,0.04990499,0.00973,0.01510151,Other Applications,0.01510151,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Electrophysiology Analysis Method - Optical Mapping (39),0.00934,0.050805081,0.01563,0.00360036,Other Applications,0.00360036,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),3D Tissue Media - Commercial Kit (21),0.00867,0.04330433,0.00584,0.110111011,Other Applications,0.04330433,TRUE,FALSE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),3D Platform - Extracellular Scaffold (18),0.00866,0.052105211,0.00933,0.03610361,Other Applications,0.03610361,TRUE,FALSE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Journal - Rare (104),0.00833,0.097809781,0.01253,0.00260026,Other Applications,0.00260026,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),0.00821,0.04650465,0.00646,0.082408241,Other Applications,0.04650465,TRUE,FALSE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),0.0082,0.03330333,0.00837,0.03710371,Other Applications,0.03330333,TRUE,FALSE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Publication Year - Post 2020 (122),0.00818,0.168316832,0.01011,0.01740174,Other Applications,0.01740174,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),3D Stromal Cell Source - Cardiac Fibroblast (32),0.00806,0.061906191,0.00858,0.04860486,Other Applications,0.04860486,TRUE,FALSE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),2D Surface - Microelectrode Array (9),0.00771,0.04020402,0.00771,0.04280428,Other Applications,0.04020402,TRUE,FALSE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Publication Year - 2020 (51),0.00708,0.123612361,0.00997,0.03730373,Other Applications,0.03730373,TRUE,FALSE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),0.00705,0.04230423,0.00579,0.079307931,Other Applications,0.04230423,TRUE,FALSE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),0.00657,0.04640464,0.00666,0.058805881,Other Applications,0.04640464,TRUE,FALSE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Wnt Inhibitor - Others (9),0.00519,0.092109211,0.01331,0.00870087,Other Applications,0.00870087,TRUE,TRUE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Deduced Culture Strategy - 2D Only (183),0.00444,0.773877388,0.00858,0.0450045,Other Applications,0.0450045,TRUE,FALSE
Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),2D Surface - Decellularized ECM (3),0.0041,0.092009201,0.00875,0.04120412,Other Applications,0.04120412,TRUE,FALSE
Pharmacological Intervention - Epinephrine (11),Immunofluorescent Imaging - Yes (268),0.02892,0.00030003,0.01878,0.0010001,Other Applications,0.00030003,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),Cell Line - iCell2 (8),0.02378,0.0020002,0.02215,0.00220022,Other Applications,0.0020002,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),Journal - Toxicological Sciences (4),0.02363,0.00090009,0.02956,0.00050005,Other Applications,0.00050005,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),hiPSC-CM Maturation Media - iCell Maintenance (83),0.02078,0.00140014,0.01256,0.0040004,Other Applications,0.00140014,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),0.02031,0.00360036,0.01152,0.010001,Other Applications,0.00360036,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),Electrophysiology Analysis Method - Microelectrode (31),0.01934,0.00360036,0.01613,0.00270027,Other Applications,0.00270027,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),Wnt Inhibitor Duration (days) - Rare (173),0.01677,0.00620062,0.00815,0.077607761,Other Applications,0.00620062,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),Journal - Lab Chip (4),0.01671,0.00480048,0.01689,0.00560056,Other Applications,0.00480048,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),hiPSC-CM Backbone Media - iCell Maintenance (86),0.01418,0.01030103,0.01223,0.00810081,Other Applications,0.00810081,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),Journal - Nat Commun (13),0.01415,0.01510151,0.01742,0.00520052,Other Applications,0.00520052,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),Publication Year - 2017 (43),0.014,0.01820182,0.01041,0.03150315,Other Applications,0.01820182,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),Disease Modelling - Ischemic Infarction (9),0.01241,0.01390139,0.01223,0.01440144,Other Applications,0.01390139,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),Calcium Handling Analysis Method - Visual (104),0.01222,0.02990299,0.012,0.00430043,Other Applications,0.00430043,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),Wnt Inhibitor Duration (days) Quantiles - Q2 (>1 and ≤2) (156),0.01204,0.03530353,0.00467,0.671067107,Other Applications,0.03530353,TRUE,FALSE
Pharmacological Intervention - Epinephrine (11),Cell Line - Rare (132),0.01174,0.0260026,0.00834,0.086208621,Other Applications,0.0260026,TRUE,FALSE
Pharmacological Intervention - Epinephrine (11),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),0.0115,0.01260126,0.01014,0.02280228,Other Applications,0.01260126,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),hiPSC-CM Purification Duration (days) - 5 days (6),0.01145,0.01820182,0.01245,0.0160016,Other Applications,0.0160016,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),0.01139,0.02010201,0.00722,0.131113111,Other Applications,0.02010201,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),Coating for Replating - Matrigel (65),0.0111,0.03090309,0.01027,0.02670267,Other Applications,0.02670267,TRUE,FALSE
Pharmacological Intervention - Epinephrine (11),hiPSC-CM Backbone Media - RPMI-1640 (167),0.01063,0.04110411,0.00796,0.068806881,Other Applications,0.04110411,TRUE,FALSE
Pharmacological Intervention - Epinephrine (11),3D Tissue Media - Rare (13),0.01058,0.03140314,0.00909,0.04140414,Other Applications,0.03140314,TRUE,FALSE
Pharmacological Intervention - Epinephrine (11),2D Surface - ECM-coated (115),0.01012,0.02580258,0.00875,0.03550355,Other Applications,0.02580258,TRUE,FALSE
Pharmacological Intervention - Epinephrine (11),Maturation Strategy - Cell Alignment (59),0.00994,0.04330433,0.00292,0.572457246,Other Applications,0.04330433,TRUE,FALSE
Pharmacological Intervention - Epinephrine (11),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.00966,0.054705471,0.0149,0.00430043,Other Applications,0.00430043,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),Journal - Rare (104),0.00953,0.064506451,0.01152,0.00870087,Other Applications,0.00870087,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),Cell Line - iCell (47),0.00925,0.066106611,0.01055,0.0340034,Other Applications,0.0340034,TRUE,FALSE
Pharmacological Intervention - Epinephrine (11),3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25),0.00896,0.04060406,0.01104,0.01630163,Other Applications,0.01630163,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),Coating for Replating - Fibronectin (32),0.00862,0.064706471,0.01321,0.01020102,Other Applications,0.01020102,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),3D Platform - Extracellular Scaffold (18),0.00822,0.061306131,0.01101,0.02450245,Other Applications,0.02450245,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),3D Stromal Cell Source - Cardiac Fibroblast (32),0.00803,0.066806681,0.00999,0.02920292,Other Applications,0.02920292,TRUE,FALSE
Pharmacological Intervention - Epinephrine (11),Publication Year - Late-2010s (196),0.00791,0.136613661,0.00897,0.04130413,Other Applications,0.04130413,TRUE,FALSE
Pharmacological Intervention - Epinephrine (11),Deduced Culture Strategy - 2D Only (183),0.0076,0.176317632,0.01097,0.00440044,Other Applications,0.00440044,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),2D Surface - Microelectrode Array (9),0.00709,0.051905191,0.013,0.01170117,Other Applications,0.01170117,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),2D Surface - Decellularized ECM (3),0.00706,0.056105611,0.00909,0.04060406,Other Applications,0.04060406,TRUE,FALSE
Pharmacological Intervention - Epinephrine (11),Electrophysiology Analysis Method - Optical Mapping (39),0.00701,0.111211121,0.01351,0.00660066,Other Applications,0.00660066,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),Publication Year - 2019 (57),0.00606,0.173817382,0.01015,0.03430343,Other Applications,0.03430343,TRUE,FALSE
Pharmacological Intervention - Epinephrine (11),Publication Year - 2016 (32),0.00581,0.155015502,0.01235,0.01630163,Other Applications,0.01630163,TRUE,TRUE
Pharmacological Intervention - Epinephrine (11),Wnt Inhibitor - Others (9),0.00481,0.116811681,0.01126,0.01720172,Other Applications,0.01720172,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Number of Cell Lines - 1 (225),0.0293,0.00020002,0.03577,0,Other Applications,0,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Cell Line - iCell (47),0.02674,0.00190019,0.02031,0.00090009,Other Applications,0.00090009,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Number of Cell Lines - 3 (29),0.02424,0.00120012,0.01976,0.00160016,Other Applications,0.00120012,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Disease Modelling - Arrhythmic (15),0.0228,0.00160016,0.01734,0.00440044,Other Applications,0.00160016,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Journal - Cell Rep (6),0.02181,0.00180018,0.02664,0.00070007,Other Applications,0.00070007,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Cell Line - Cor.4U (16),0.0217,0.00250025,0.02675,0.00010001,Other Applications,0.00010001,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),0.02164,0.00160016,0.02846,0.00090009,Other Applications,0.00090009,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Electrophysiology Analysis Method - Microelectrode (31),0.01789,0.00570057,0.01646,0.00330033,Other Applications,0.00330033,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),0.01683,0.00650065,0.00983,0.04010401,Other Applications,0.00650065,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),0.01564,0.0140014,0.0185,0.00390039,Other Applications,0.00390039,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),2D Surface - Microelectrode Array (9),0.01501,0.00750075,0.01586,0.00520052,Other Applications,0.00520052,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),hiPSC-CM Maturation Media - iCell Maintenance (83),0.014,0.01030103,0.00795,0.080708071,Other Applications,0.01030103,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.01298,0.02510251,0.01223,0.01520152,Other Applications,0.01520152,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Immunofluorescent Imaging - Yes (268),0.01297,0.02160216,0.01064,0.03880388,Other Applications,0.02160216,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),hiPSC-CM Media Supplement - Rare (5),0.01218,0.01080108,0.01073,0.02380238,Other Applications,0.01080108,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Wnt Induction - CHIR99021 (184),0.01193,0.04010401,0.0064,0.281428143,Other Applications,0.04010401,TRUE,FALSE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Maturation Strategy - ECM (21),0.01183,0.01720172,0.00821,0.050505051,Other Applications,0.01720172,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Coating for Replating - Gelatin (43),0.01151,0.03180318,0.00845,0.074707471,Other Applications,0.03180318,TRUE,FALSE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Coating for Replating - Geltrex (10),0.01125,0.02360236,0.01301,0.01420142,Other Applications,0.01420142,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),0.01024,0.04020402,0.0126,0.02480248,Other Applications,0.02480248,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Electrophysiology Analysis Method - Patch Clamp (59),0.01015,0.04480448,0.00946,0.04220422,Other Applications,0.04220422,TRUE,FALSE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Journal - Toxicological Sciences (4),0.01002,0.02630263,0.01181,0.01890189,Other Applications,0.01890189,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Disease Modelling - Genetic Disorders (18),0.01001,0.03710371,0.01138,0.02240224,Other Applications,0.02240224,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Number of Cell Lines - 4 (11),0.00992,0.03320332,0.00707,0.085008501,Other Applications,0.03320332,TRUE,FALSE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Electron Imaging - Scanning (22),0.009,0.055005501,0.00927,0.04280428,Other Applications,0.04280428,TRUE,FALSE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),hiPSC-CM Maturation Media - Cor.4U Complete (6),0.00845,0.03090309,0.01095,0.01720172,Other Applications,0.01720172,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),hiPSC-CM Backbone Media - iCell Maintenance (86),0.00842,0.082508251,0.01108,0.0190019,Other Applications,0.0190019,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Coating for Replating - Rare (6),0.00822,0.060506051,0.00961,0.03920392,Other Applications,0.03920392,TRUE,FALSE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Calcium Handling Analysis Method - Visual (104),0.00807,0.136013601,0.01083,0.01830183,Other Applications,0.01830183,TRUE,TRUE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Cell Line - Rare (132),0.00776,0.175017502,0.00974,0.04260426,Other Applications,0.04260426,TRUE,FALSE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Number of Cell Lines - >5 (9),0.00769,0.061606161,0.01024,0.03540354,Other Applications,0.03540354,TRUE,FALSE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Electrophysiology Analysis Method - Genetic (3),0.00684,0.065506551,0.00953,0.04540454,Other Applications,0.04540454,TRUE,FALSE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Purification Protocol - Metabolic (8),0.00683,0.059405941,0.00912,0.02930293,Other Applications,0.02930293,TRUE,FALSE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),2D Surface - ECM-coated (115),0.006,0.269226923,0.00943,0.0430043,Other Applications,0.0430043,TRUE,FALSE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Cell Line Ancestry - Caucasian (41),0.00583,0.175817582,0.0101,0.04440444,Other Applications,0.04440444,TRUE,FALSE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Wnt Induction - Rare (4),0.00565,0.101810181,0.01144,0.03160316,Other Applications,0.03160316,TRUE,FALSE
Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),0.0056,0.115411541,0.01024,0.0290029,Other Applications,0.0290029,TRUE,FALSE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Cell Line - Cor.4U (16),0.03657,0.00040004,0.02988,0.00040004,Other Applications,0.00040004,TRUE,TRUE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Journal - Cell Rep (6),0.03193,0.00010001,0.02722,0.00050005,Other Applications,0.00010001,TRUE,TRUE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Number of Cell Lines - 1 (225),0.03129,0,0.0354,0,Other Applications,0,TRUE,TRUE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Number of Cell Lines - 3 (29),0.02879,0.00040004,0.02381,0.0010001,Other Applications,0.00040004,TRUE,TRUE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Disease Modelling - Arrhythmic (15),0.02126,0.00380038,0.01803,0.00580058,Other Applications,0.00380038,TRUE,TRUE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Journal - Acta Biomater (10),0.0205,0.00360036,0.01325,0.01720172,Other Applications,0.00360036,TRUE,TRUE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),0.02015,0.00330033,0.01058,0.02850285,Other Applications,0.00330033,TRUE,TRUE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Number of Cell Lines - >5 (9),0.01947,0.0070007,0.01833,0.00720072,Other Applications,0.0070007,TRUE,TRUE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Journal - Toxicological Sciences (4),0.01944,0.00290029,0.02162,0.00260026,Other Applications,0.00260026,TRUE,TRUE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Cell Line - iCell (47),0.01898,0.00960096,0.01168,0.03210321,Other Applications,0.00960096,TRUE,TRUE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),0.01614,0.01780178,0.01506,0.01680168,Other Applications,0.01680168,TRUE,TRUE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Journal - Int J Mol Sci (3),0.01537,0.00910091,0.02517,0.00220022,Other Applications,0.00220022,TRUE,TRUE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),0.0136,0.01880188,0.00642,0.100810081,Other Applications,0.01880188,TRUE,TRUE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),0.01328,0.01660166,0.0112,0.02460246,Other Applications,0.01660166,TRUE,TRUE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Coating for Replating - Gelatin (43),0.0131,0.02440244,0.01065,0.03950395,Other Applications,0.02440244,TRUE,TRUE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Publication Year - 2017 (43),0.01219,0.03450345,0.01131,0.02940294,Other Applications,0.02940294,TRUE,FALSE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Number of Cell Lines - 4 (11),0.0114,0.03060306,0.01079,0.03720372,Other Applications,0.03060306,TRUE,FALSE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Contractile Analysis Method - Traction Force Microscopy (9),0.01111,0.02910291,0.00934,0.04550455,Other Applications,0.02910291,TRUE,FALSE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),0.01077,0.0270027,0.01651,0.00680068,Other Applications,0.00680068,TRUE,TRUE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Maturation Strategy - Electrical (39),0.01064,0.0470047,0.00741,0.122212221,Other Applications,0.0470047,TRUE,FALSE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.01056,0.04690469,0.0082,0.080308031,Other Applications,0.04690469,TRUE,FALSE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Journal - Rare (104),0.00987,0.055905591,0.01445,0.00350035,Other Applications,0.00350035,TRUE,TRUE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),3D Tissue Media - Rare (13),0.00985,0.04080408,0.01168,0.02510251,Other Applications,0.02510251,TRUE,FALSE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),hiPSC-CM Maturation Media - Cor.4U Complete (6),0.00975,0.02790279,0.00438,0.131713171,Other Applications,0.02790279,TRUE,FALSE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Immunofluorescent Imaging - Yes (268),0.00949,0.059505951,0.01661,0.00370037,Other Applications,0.00370037,TRUE,TRUE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),hiPSC-CM Backbone Media - Cor.4U Complete (6),0.00825,0.051605161,0.00889,0.0490049,Other Applications,0.0490049,TRUE,FALSE
Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),hiPSC-CM Maturation Media - iCell Maintenance (83),0.00623,0.179017902,0.01068,0.02260226,Other Applications,0.02260226,TRUE,TRUE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Journal - Toxicological Sciences (4),0.04415,0,0.06644,0,Other Applications,0,TRUE,TRUE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Cell Line - iCell (47),0.02114,0.00520052,0.0107,0.04530453,Other Applications,0.00520052,TRUE,TRUE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Number of Cell Lines - 4 (11),0.02034,0.00550055,0.02767,0.00110011,Other Applications,0.00110011,TRUE,TRUE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Number of Cell Lines - 1 (225),0.018,0.0050005,0.01693,0.00020002,Other Applications,0.00020002,TRUE,TRUE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Gene Analysis Method - RNA (169),0.0162,0.00940094,0.01313,0.00220022,Other Applications,0.00220022,TRUE,TRUE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),3D Tissue Media - Commercial Kit (21),0.01505,0.01370137,0.01512,0.00920092,Other Applications,0.00920092,TRUE,TRUE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Cell Line Ancestry - Caucasian (41),0.0142,0.0250025,0.00859,0.082208221,Other Applications,0.0250025,TRUE,FALSE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Publication Year - 2019 (57),0.01382,0.0170017,0.00945,0.060106011,Other Applications,0.0170017,TRUE,TRUE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Immunofluorescent Imaging - Yes (268),0.01362,0.02010201,0.01675,0.00290029,Other Applications,0.00290029,TRUE,TRUE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Journal - Sci Rep (24),0.01356,0.02170217,0.01313,0.01740174,Other Applications,0.01740174,TRUE,TRUE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.0134,0.02710271,0.00872,0.067706771,Other Applications,0.02710271,TRUE,FALSE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),2D Surface - Decellularized ECM (3),0.01312,0.01460146,0.01488,0.01320132,Other Applications,0.01320132,TRUE,TRUE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),0.01297,0.01610161,0.0133,0.01570157,Other Applications,0.01570157,TRUE,TRUE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),hiPSC Matrix Coating - Geltrex (33),0.01284,0.02690269,0.01221,0.02450245,Other Applications,0.02450245,TRUE,TRUE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Insulin Start Day - 6 (20),0.01133,0.02790279,0.00916,0.053905391,Other Applications,0.02790279,TRUE,FALSE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),hiPSC-CM Media Supplement - Nonessential Amino Acids (8),0.01114,0.02170217,0.00808,0.051105111,Other Applications,0.02170217,TRUE,TRUE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Publication Year - 2017 (43),0.01094,0.04660466,0.00999,0.050505051,Other Applications,0.04660466,TRUE,FALSE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Number of Cell Lines - 2 (50),0.01087,0.04530453,0.0064,0.168716872,Other Applications,0.04530453,TRUE,FALSE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Journal - Rare (104),0.01076,0.03790379,0.01144,0.01160116,Other Applications,0.01160116,TRUE,TRUE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),hiPSC Matrix Coating - Matrigel (163),0.01034,0.04180418,0.00603,0.400240024,Other Applications,0.04180418,TRUE,FALSE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),2D Surface - Microelectrode Array (9),0.00956,0.02890289,0.00555,0.114811481,Other Applications,0.02890289,TRUE,FALSE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),hiPSC-CM Purification Duration (days) - <3 days (31),0.00929,0.059005901,0.01379,0.01740174,Other Applications,0.01740174,TRUE,TRUE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Cell Line - Cor.4U (16),0.00916,0.057005701,0.01106,0.03330333,Other Applications,0.03330333,TRUE,FALSE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),0.00889,0.056905691,0.01022,0.03290329,Other Applications,0.03290329,TRUE,FALSE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Coating for Replating - Gelatin (43),0.00851,0.080408041,0.01063,0.03380338,Other Applications,0.03380338,TRUE,FALSE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),0.00813,0.04980498,0.0098,0.03220322,Other Applications,0.03220322,TRUE,FALSE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Cell Line - iCell2 (8),0.0074,0.091709171,0.01143,0.02690269,Other Applications,0.02690269,TRUE,FALSE
Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),0.00552,0.103210321,0.00931,0.04830483,Other Applications,0.04830483,TRUE,FALSE
Pharmacological Intervention - Positive Inotropes (9),Journal - Nat Commun (13),0.03926,0.00050005,0.02932,0.00070007,Other Applications,0.00050005,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),Journal - Toxicological Sciences (4),0.03374,0.00010001,0.0324,0.00040004,Other Applications,0.00010001,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),Immunofluorescent Imaging - Yes (268),0.02407,0.00070007,0.02021,0.00030003,Other Applications,0.00030003,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),Wnt Inhibitor Duration (days) - >6 days (12),0.01803,0.0070007,0.01272,0.02190219,Other Applications,0.0070007,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),0.01718,0.00910091,0.01251,0.02120212,Other Applications,0.00910091,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),Electrophysiology Analysis Method - Optical Mapping (39),0.01709,0.01010101,0.01954,0.00180018,Other Applications,0.00180018,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),Coating for Replating - Matrigel (65),0.01696,0.00570057,0.01997,0.00030003,Other Applications,0.00030003,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),Cell Line - iCell (47),0.016,0.01670167,0.00884,0.080108011,Other Applications,0.01670167,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),3D Platform - Fibrin (50),0.01377,0.01550155,0.01373,0.01020102,Other Applications,0.01020102,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),3D Stromal Cell Source - Human Fibroblast (38),0.01344,0.03850385,0.0134,0.02640264,Other Applications,0.02640264,TRUE,FALSE
Pharmacological Intervention - Positive Inotropes (9),Electrophysiology Analysis Method - Microelectrode (31),0.01324,0.01920192,0.01534,0.00540054,Other Applications,0.00540054,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),Contractile Analysis Method - Deflection (39),0.01319,0.02410241,0.01063,0.03960396,Other Applications,0.02410241,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.01284,0.0260026,0.01523,0.00480048,Other Applications,0.00480048,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),hiPSC-CM Backbone Media - iCell Maintenance (86),0.01245,0.02610261,0.00916,0.072307231,Other Applications,0.02610261,TRUE,FALSE
Pharmacological Intervention - Positive Inotropes (9),Calcium Handling Analysis Method - Visual (104),0.01143,0.0410041,0.01152,0.00780078,Other Applications,0.00780078,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),3D Tissue Media - Commercial Kit (21),0.01136,0.0310031,0.00764,0.074707471,Other Applications,0.0310031,TRUE,FALSE
Pharmacological Intervention - Positive Inotropes (9),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),0.01091,0.053905391,0.00977,0.04260426,Other Applications,0.04260426,TRUE,FALSE
Pharmacological Intervention - Positive Inotropes (9),Deduced Culture Strategy - 2D Only (183),0.01084,0.03660366,0.00422,0.626462646,Other Applications,0.03660366,TRUE,FALSE
Pharmacological Intervention - Positive Inotropes (9),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),0.01084,0.04770477,0.01248,0.02590259,Other Applications,0.02590259,TRUE,FALSE
Pharmacological Intervention - Positive Inotropes (9),3D Platform - Matrigel (33),0.01007,0.04560456,0.00599,0.166016602,Other Applications,0.04560456,TRUE,FALSE
Pharmacological Intervention - Positive Inotropes (9),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),0.00997,0.03760376,0.00928,0.03640364,Other Applications,0.03640364,TRUE,FALSE
Pharmacological Intervention - Positive Inotropes (9),Wnt Inhibitor - DS-I-7 (9),0.00994,0.02870287,0.01265,0.01440144,Other Applications,0.01440144,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29),0.00982,0.060006001,0.01485,0.01080108,Other Applications,0.01080108,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),3D Stromal Cell Source - Cardiac Fibroblast (32),0.00946,0.054105411,0.01127,0.02870287,Other Applications,0.02870287,TRUE,FALSE
Pharmacological Intervention - Positive Inotropes (9),Publication Year - 2019 (57),0.00927,0.065706571,0.01442,0.0080008,Other Applications,0.0080008,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),0.00901,0.03520352,0.0151,0.00720072,Other Applications,0.00720072,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),3D Platform - Collagen (38),0.00846,0.067906791,0.01148,0.02260226,Other Applications,0.02260226,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),Insulin Withdrawal Duration (days) - 3 days (6),0.00762,0.04920492,0.00448,0.124212421,Other Applications,0.04920492,TRUE,FALSE
Pharmacological Intervention - Positive Inotropes (9),hiPSC-CM Purification Duration (days) - 3 days (13),0.0074,0.066306631,0.01131,0.02420242,Other Applications,0.02420242,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),Publication Year - Late-2010s (196),0.00658,0.292229223,0.01266,0.00350035,Other Applications,0.00350035,TRUE,TRUE
Pharmacological Intervention - Positive Inotropes (9),hiPSC-CM Backbone Media - Commercial CM Kit (12),0.00584,0.107710771,0.00933,0.04190419,Other Applications,0.04190419,TRUE,FALSE
Pharmacological Intervention - Positive Inotropes (9),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),0.00514,0.154615462,0.00946,0.03890389,Other Applications,0.03890389,TRUE,FALSE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Cell Line - iCell (47),0.04056,0.00030003,0.02485,0.00050005,Other Applications,0.00030003,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Journal - Toxicological Sciences (4),0.03349,0.00040004,0.04423,0.00010001,Other Applications,0.00010001,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),hiPSC-CM Media Supplement - B27 (180),0.02901,0.00040004,0.00541,0.514451445,Other Applications,0.00040004,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),0.0284,0.00180018,0.02616,0.00140014,Other Applications,0.00140014,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Disease Modelling - Arrhythmic (15),0.02697,0.00110011,0.02513,0.00080008,Other Applications,0.00080008,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.02569,0.00130013,0.01899,0.00160016,Other Applications,0.00130013,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Number of Cell Lines - 1 (225),0.02502,0.00020002,0.02527,0,Other Applications,0,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Number of Cell Lines - 3 (29),0.02288,0.00360036,0.02199,0.00270027,Other Applications,0.00270027,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Maturation Strategy - ECM (21),0.02206,0.00160016,0.0188,0.00110011,Other Applications,0.00110011,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Cell Line - Cor.4U (16),0.01995,0.00710071,0.02814,0.00030003,Other Applications,0.00030003,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Number of Cell Lines - 4 (11),0.01919,0.01050105,0.02639,0.00190019,Other Applications,0.00190019,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Coating for Replating - Gelatin (43),0.01837,0.00890089,0.02116,0.00050005,Other Applications,0.00050005,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),0.01535,0.01780178,0.00741,0.216021602,Other Applications,0.01780178,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Electrophysiology Analysis Method - Microelectrode (31),0.01402,0.01840184,0.01137,0.02850285,Other Applications,0.01840184,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),hiPSC-CM Backbone Media - iCell Maintenance (86),0.01338,0.02130213,0.006,0.321732173,Other Applications,0.02130213,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Day of Insulin Addition - Known (177),0.01242,0.01520152,0.00579,0.379637964,Other Applications,0.01520152,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),3D Tissue Media - Iscove (5),0.01238,0.01860186,0.01379,0.01520152,Other Applications,0.01520152,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),0.01232,0.02160216,0.01895,0.00520052,Other Applications,0.00520052,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Publication Year - 2017 (43),0.01191,0.04310431,0.02086,0.00160016,Other Applications,0.00160016,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Journal - Cell Rep (6),0.01174,0.01970197,0.01631,0.00890089,Other Applications,0.00890089,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Immunofluorescent Imaging - Yes (268),0.01131,0.03940394,0.01368,0.01340134,Other Applications,0.01340134,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Coating for Replating - Rare (6),0.01127,0.04010401,0.01023,0.054605461,Other Applications,0.04010401,TRUE,FALSE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),0.01076,0.03120312,0.00321,0.152315232,Other Applications,0.03120312,TRUE,FALSE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),2D Surface - ECM-coated (115),0.01043,0.02710271,0.01277,0.00460046,Other Applications,0.00460046,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),3D Platform - Extracellular Scaffold (18),0.01034,0.04720472,0.00939,0.055005501,Other Applications,0.04720472,TRUE,FALSE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Electrophysiology Analysis Method - Patch Clamp (59),0.00913,0.080908091,0.01129,0.02370237,Other Applications,0.02370237,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Disease Modelling - Fibrotic (4),0.00884,0.04960496,0.00808,0.065706571,Other Applications,0.04960496,TRUE,FALSE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Gene Analysis Method - RNA (169),0.00878,0.156315632,0.01248,0.00860086,Other Applications,0.00860086,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),0.00816,0.050305031,0.00853,0.04530453,Other Applications,0.04530453,TRUE,FALSE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Purification Protocol - Metabolic (8),0.00734,0.068006801,0.0096,0.03620362,Other Applications,0.03620362,TRUE,FALSE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Wnt Induction - Rare (4),0.00571,0.089808981,0.01154,0.04420442,Other Applications,0.04420442,TRUE,FALSE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),0.00561,0.157315732,0.01407,0.0220022,Other Applications,0.0220022,TRUE,TRUE
Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Number of Cell Lines - 2 (50),0.00557,0.214821482,0.01,0.04930493,Other Applications,0.04930493,TRUE,FALSE
Pharmacological Intervention - Cisapride (8),Cell Line - iCell (47),0.05602,0,0.03856,0,Other Applications,0,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.04011,0.00010001,0.027,0.00010001,Other Applications,0.00010001,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),hiPSC-CM Maturation Media - iCell Maintenance (83),0.02745,0.00040004,0.00877,0.063306331,Other Applications,0.00040004,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Coating for Replating - Gelatin (43),0.02652,0.00170017,0.01864,0.0020002,Other Applications,0.00170017,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Cell Line - Cor.4U (16),0.02435,0.00390039,0.01639,0.01030103,Other Applications,0.00390039,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Publication Year - 2020 (51),0.02269,0.00430043,0.0246,0.00020002,Other Applications,0.00020002,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),0.02191,0.00480048,0.03005,0.00030003,Other Applications,0.00030003,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),hiPSC-CM Backbone Media - iCell Maintenance (86),0.02045,0.00170017,0.01586,0.00360036,Other Applications,0.00170017,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),2D Surface - Microelectrode Array (9),0.01957,0.00310031,0.01756,0.00470047,Other Applications,0.00310031,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Number of Cell Lines - 1 (225),0.01922,0.0040004,0.02354,0,Other Applications,0,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),0.01734,0.01010101,0.01963,0.00470047,Other Applications,0.00470047,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Number of Cell Lines - 3 (29),0.01648,0.01270127,0.01995,0.00320032,Other Applications,0.00320032,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Journal - Toxicological Sciences (4),0.01528,0.00860086,0.02081,0.00370037,Other Applications,0.00370037,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Insulin Start Day - 11 (3),0.01472,0.0110011,0.01834,0.00730073,Other Applications,0.00730073,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Journal - Cell Rep (6),0.0145,0.00880088,0.0151,0.01060106,Other Applications,0.00880088,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),3D Platform - Nanotechnology (3),0.01415,0.01760176,0.01353,0.02830283,Other Applications,0.01760176,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Coating for Replating - Rare (6),0.01402,0.02030203,0.00924,0.066606661,Other Applications,0.02030203,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),0.01354,0.02660266,0.01528,0.01570157,Other Applications,0.01570157,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Number of Cell Lines - >5 (9),0.0125,0.02190219,0.01526,0.01270127,Other Applications,0.01270127,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),0.01175,0.03560356,0.00857,0.063406341,Other Applications,0.03560356,TRUE,FALSE
Pharmacological Intervention - Cisapride (8),Number of Cell Lines - 2 (50),0.01158,0.04440444,0.01474,0.00950095,Other Applications,0.00950095,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Number of Cell Lines - 4 (11),0.01082,0.03290329,0.01501,0.01630163,Other Applications,0.01630163,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),0.01068,0.04530453,0.00897,0.060306031,Other Applications,0.04530453,TRUE,FALSE
Pharmacological Intervention - Cisapride (8),Immunofluorescent Imaging - Yes (268),0.01058,0.04630463,0.01403,0.01180118,Other Applications,0.01180118,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Sacromere or Cellular Alignment Analysis - Yes (72),0.01045,0.059605961,0.01286,0.01810181,Other Applications,0.01810181,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),0.01028,0.03350335,0.01044,0.03540354,Other Applications,0.03350335,TRUE,FALSE
Pharmacological Intervention - Cisapride (8),2D Surface - ECM-coated (115),0.01019,0.0270027,0.01336,0.00380038,Other Applications,0.00380038,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Wnt Induction - CHIR99021 (184),0.00886,0.122912291,0.00951,0.03070307,Other Applications,0.03070307,TRUE,FALSE
Pharmacological Intervention - Cisapride (8),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),0.00859,0.04890489,0.00998,0.03970397,Other Applications,0.03970397,TRUE,FALSE
Pharmacological Intervention - Cisapride (8),3D Stromal Cell Source - hiPSC-CardiacF (8),0.00858,0.081808181,0.0121,0.03460346,Other Applications,0.03460346,TRUE,FALSE
Pharmacological Intervention - Cisapride (8),Electrophysiology Analysis Method - Microelectrode (31),0.00842,0.079107911,0.01472,0.0080008,Other Applications,0.0080008,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Differentiation Purity Assessment - IHC a-actinin (8),0.00831,0.055505551,0.01009,0.03680368,Other Applications,0.03680368,TRUE,FALSE
Pharmacological Intervention - Cisapride (8),Publication Year - Post 2020 (122),0.00767,0.237823782,0.01359,0.00390039,Other Applications,0.00390039,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),3D Tissue Media - iCell Maintenance (12),0.00735,0.080308031,0.01058,0.03640364,Other Applications,0.03640364,TRUE,FALSE
Pharmacological Intervention - Cisapride (8),Electrophysiology Analysis Method - Patch Clamp (59),0.00671,0.146314631,0.01292,0.01070107,Other Applications,0.01070107,TRUE,TRUE
Pharmacological Intervention - Cisapride (8),Maturation Strategy - Cell Alignment (59),0.00585,0.178417842,0.01044,0.0350035,Other Applications,0.0350035,TRUE,FALSE
Pharmacological Intervention - Ranolazine (7),Number of Cell Lines - 3 (29),0.02754,0.00160016,0.02952,0.00060006,Other Applications,0.00060006,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.02578,0.00250025,0.01951,0.00130013,Other Applications,0.00130013,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),Cell Line - Cor.4U (16),0.02481,0.00350035,0.02189,0.00380038,Other Applications,0.00350035,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),Cell Line - iCell (47),0.02416,0.00560056,0.01843,0.00440044,Other Applications,0.00440044,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),Number of Cell Lines - 1 (225),0.02331,0.00130013,0.01839,0.00020002,Other Applications,0.00020002,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),Journal - Toxicological Sciences (4),0.02176,0.00270027,0.02574,0.00210021,Other Applications,0.00210021,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),0.02107,0.00530053,0.02302,0.00360036,Other Applications,0.00360036,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),0.02041,0.00510051,0.01158,0.03080308,Other Applications,0.00510051,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),Journal - Sci Rep (24),0.01888,0.01040104,0.02045,0.00340034,Other Applications,0.00340034,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),Differentiation Purity Assessment - Visual Inspection (6),0.0165,0.00910091,0.0117,0.03740374,Other Applications,0.00910091,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),Calcium Handling Analysis Method - Genetic (23),0.01526,0.02940294,0.01654,0.01140114,Other Applications,0.01140114,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),Immunofluorescent Imaging - Yes (268),0.01487,0.01550155,0.01392,0.0170017,Other Applications,0.01550155,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),Differentiation Purity Assessment - IHC a-actinin (8),0.01484,0.01340134,0.01489,0.01450145,Other Applications,0.01340134,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),Wnt Inhibitor - KY02111 (7),0.01469,0.01220122,0.01243,0.0270027,Other Applications,0.01220122,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),0.01429,0.02450245,0.01251,0.02860286,Other Applications,0.02450245,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),Number of Cell Lines - >5 (9),0.01427,0.01970197,0.01675,0.01050105,Other Applications,0.01050105,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),0.01397,0.02790279,0.01973,0.00960096,Other Applications,0.00960096,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),Journal - Cell Rep (6),0.01348,0.01610161,0.01515,0.01310131,Other Applications,0.01310131,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),Maturation Strategy - ECM (21),0.01326,0.01640164,0.0197,0.0020002,Other Applications,0.0020002,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),Coating for Replating - Gelatin (43),0.01316,0.03230323,0.01413,0.01360136,Other Applications,0.01360136,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),Coating for Replating - Rare (6),0.01173,0.04540454,0.01393,0.02920292,Other Applications,0.02920292,TRUE,FALSE
Pharmacological Intervention - Ranolazine (7),hiPSC-CM Maturation Media - iCell Maintenance (83),0.01147,0.03430343,0.00679,0.178017802,Other Applications,0.03430343,TRUE,FALSE
Pharmacological Intervention - Ranolazine (7),Gene Analysis Method - RNA (169),0.01129,0.055205521,0.01234,0.0130013,Other Applications,0.0130013,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),hiPSC-CM Maturation Media - RPMI-1640 (153),0.01031,0.04660466,0.00766,0.125212521,Other Applications,0.04660466,TRUE,FALSE
Pharmacological Intervention - Ranolazine (7),Disease Modelling - Arrhythmic (15),0.01028,0.04510451,0.01196,0.030003,Other Applications,0.030003,TRUE,FALSE
Pharmacological Intervention - Ranolazine (7),hiPSC-CM Backbone Media - StemPro-34 (14),0.01025,0.04480448,0.00422,0.214521452,Other Applications,0.04480448,TRUE,FALSE
Pharmacological Intervention - Ranolazine (7),2D Surface - ECM-coated (115),0.01023,0.02880288,0.0139,0.00330033,Other Applications,0.00330033,TRUE,TRUE
Pharmacological Intervention - Ranolazine (7),hiPSC Matrix Coating - Matrigel (163),0.01009,0.04390439,0.00811,0.199819982,Other Applications,0.04390439,TRUE,FALSE
Pharmacological Intervention - Ranolazine (7),2D Surface - Microelectrode Array (9),0.01001,0.04150415,0.01028,0.03870387,Other Applications,0.03870387,TRUE,FALSE
Pharmacological Intervention - Ranolazine (7),Sacromere or Cellular Alignment Analysis - Yes (72),0.00977,0.082008201,0.01194,0.03240324,Other Applications,0.03240324,TRUE,FALSE
Pharmacological Intervention - Ranolazine (7),Number of Cell Lines - 2 (50),0.00974,0.072207221,0.01202,0.0250025,Other Applications,0.0250025,TRUE,FALSE
Pharmacological Intervention - Ranolazine (7),Electrophysiology Analysis Method - Microelectrode (31),0.00905,0.074907491,0.01161,0.03370337,Other Applications,0.03370337,TRUE,FALSE
Pharmacological Intervention - Ranolazine (7),Coating for Replating - Matrigel (65),0.00861,0.084808481,0.01127,0.030003,Other Applications,0.030003,TRUE,FALSE
Pharmacological Intervention - Ranolazine (7),Number of Cell Lines - 4 (11),0.00807,0.094509451,0.01276,0.03290329,Other Applications,0.03290329,TRUE,FALSE
Pharmacological Intervention - Ranolazine (7),Insulin Start Day - 4 (11),0.00772,0.078507851,0.01126,0.03160316,Other Applications,0.03160316,TRUE,FALSE
Pharmacological Intervention - Ranolazine (7),Wnt Inhibitor Duration (days) Quantiles - Q2 (>1 and ≤2) (156),0.00753,0.258325833,0.00947,0.04240424,Other Applications,0.04240424,TRUE,FALSE
Pharmacological Intervention - Ranolazine (7),New Media for Maturation - Rare (4),0.00566,0.081808181,0.011,0.04950495,Other Applications,0.04950495,TRUE,FALSE
Pharmacological Intervention - Lidocaine (7),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),0.02527,0.00560056,0.02261,0.00660066,Other Applications,0.00560056,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),Number of Cell Lines - 1 (225),0.02427,0.00190019,0.01762,0.00140014,Other Applications,0.00140014,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),Cell Line - Cor.4U (16),0.02356,0.00470047,0.02,0.00540054,Other Applications,0.00470047,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),0.02356,0.00170017,0.01513,0.01430143,Other Applications,0.00170017,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),Journal - Int J Mol Sci (3),0.02287,0.00250025,0.02944,0.00110011,Other Applications,0.00110011,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),Number of Cell Lines - >5 (9),0.02094,0.00840084,0.02364,0.0040004,Other Applications,0.0040004,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),Publication Year - 2017 (43),0.01851,0.01580158,0.01331,0.02690269,Other Applications,0.01580158,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),hiPSC-CM Maturation Media - Cor.4U Complete (6),0.01653,0.0050005,0.01176,0.02640264,Other Applications,0.0050005,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),3D Tissue Media - Rare (13),0.0162,0.01750175,0.01614,0.01360136,Other Applications,0.01360136,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),Number of Cell Lines - 4 (11),0.01594,0.01740174,0.0149,0.02060206,Other Applications,0.01740174,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),Journal - Acta Biomater (10),0.01541,0.01680168,0.01307,0.02460246,Other Applications,0.01680168,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),Disease Modelling - Arrhythmic (15),0.0153,0.01690169,0.01286,0.02540254,Other Applications,0.01690169,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),Journal - Toxicological Sciences (4),0.01526,0.00960096,0.01999,0.00480048,Other Applications,0.00480048,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),Cell Line - iCell (47),0.01465,0.03570357,0.01266,0.03230323,Other Applications,0.03230323,TRUE,FALSE
Pharmacological Intervention - Lidocaine (7),2D Surface - Nanotopography (6),0.01392,0.01540154,0.01692,0.00960096,Other Applications,0.00960096,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),Calcium Handling Analysis Method - Genetic (23),0.01328,0.04270427,0.01233,0.03550355,Other Applications,0.03550355,TRUE,FALSE
Pharmacological Intervention - Lidocaine (7),Number of Cell Lines - 3 (29),0.01292,0.03730373,0.01687,0.01130113,Other Applications,0.01130113,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),0.01287,0.04090409,0.00878,0.129412941,Other Applications,0.04090409,TRUE,FALSE
Pharmacological Intervention - Lidocaine (7),Number of Cell Lines - 2 (50),0.01285,0.04040404,0.01377,0.01790179,Other Applications,0.01790179,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),Maturation Strategy - Electrical (39),0.01252,0.04080408,0.00949,0.082608261,Other Applications,0.04080408,TRUE,FALSE
Pharmacological Intervention - Lidocaine (7),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),0.01247,0.02640264,0.01392,0.02120212,Other Applications,0.02120212,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),hiPSC-CM Media Supplement - B27 (180),0.01243,0.04370437,0.00787,0.122612261,Other Applications,0.04370437,TRUE,FALSE
Pharmacological Intervention - Lidocaine (7),Day of Insulin Addition - Known (177),0.01223,0.01630163,0.00679,0.245724572,Other Applications,0.01630163,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),hiPSC-CM Media Supplement - Albumin (28),0.01198,0.03870387,0.01178,0.02950295,Other Applications,0.02950295,TRUE,FALSE
Pharmacological Intervention - Lidocaine (7),3D Tissue Media - Iscove (5),0.01141,0.02970297,0.01239,0.03360336,Other Applications,0.02970297,TRUE,FALSE
Pharmacological Intervention - Lidocaine (7),Disease Modelling - Hypertrophic Cardiomyopathy (6),0.01069,0.03440344,0.01285,0.02330233,Other Applications,0.02330233,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),2D Surface - Microelectrode Array (9),0.01003,0.03760376,0.01226,0.02560256,Other Applications,0.02560256,TRUE,FALSE
Pharmacological Intervention - Lidocaine (7),3D Platform - Matrigel (33),0.00942,0.066306631,0.01047,0.04990499,Other Applications,0.04990499,TRUE,FALSE
Pharmacological Intervention - Lidocaine (7),2D Surface - ECM-coated (115),0.00926,0.04360436,0.01066,0.0210021,Other Applications,0.0210021,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),0.00838,0.077707771,0.01274,0.03730373,Other Applications,0.03730373,TRUE,FALSE
Pharmacological Intervention - Lidocaine (7),Contractile Analysis Method - Traction Force Microscopy (9),0.00805,0.086708671,0.01076,0.03980398,Other Applications,0.03980398,TRUE,FALSE
Pharmacological Intervention - Lidocaine (7),Coating for Replating - Gelatin (43),0.00793,0.111811181,0.01116,0.04350435,Other Applications,0.04350435,TRUE,FALSE
Pharmacological Intervention - Lidocaine (7),Journal - Rare (104),0.00752,0.153915392,0.01189,0.02050205,Other Applications,0.02050205,TRUE,TRUE
Pharmacological Intervention - Lidocaine (7),Electron Imaging - Transmission (62),0.00713,0.191419142,0.0127,0.04150415,Other Applications,0.04150415,TRUE,FALSE
Pharmacological Intervention - Lidocaine (7),hiPSC-CM Backbone Media - Cor.4U Complete (6),0.00565,0.102210221,0.00993,0.04860486,Other Applications,0.04860486,TRUE,FALSE
Pharmacological Intervention - Lidocaine (7),Calcium Handling Analysis Method - Visual (104),0.00427,0.610761076,0.00962,0.04110411,Other Applications,0.04110411,TRUE,FALSE
Pharmacological Intervention - Carbamylcholine (6),Wnt Inhibitor Duration (days) - 4 days (19),0.02631,0.00190019,0.01638,0.0140014,Other Applications,0.00190019,TRUE,TRUE
Pharmacological Intervention - Carbamylcholine (6),Insulin Start Day - 5 (14),0.02421,0.00280028,0.0186,0.00650065,Other Applications,0.00280028,TRUE,TRUE
Pharmacological Intervention - Carbamylcholine (6),Seeding Confluency (%) - 85 to 89 (43),0.02192,0.00780078,0.01105,0.060306031,Other Applications,0.00780078,TRUE,TRUE
Pharmacological Intervention - Carbamylcholine (6),Cell Line - SCVI-273 (8),0.02166,0.00790079,0.01793,0.0120012,Other Applications,0.00790079,TRUE,TRUE
Pharmacological Intervention - Carbamylcholine (6),3D Tissue Media - Iscove (5),0.01953,0.00580058,0.01978,0.00940094,Other Applications,0.00580058,TRUE,TRUE
Pharmacological Intervention - Carbamylcholine (6),Seeding Confluency 2D (%) - 85 to 89 (26),0.01851,0.01390139,0.01478,0.020002,Other Applications,0.01390139,TRUE,TRUE
Pharmacological Intervention - Carbamylcholine (6),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),0.01808,0.01250125,0.01398,0.02650265,Other Applications,0.01250125,TRUE,TRUE
Pharmacological Intervention - Carbamylcholine (6),Insulin Start Day - 3 (5),0.01732,0.01080108,0.01356,0.030003,Other Applications,0.01080108,TRUE,TRUE
Pharmacological Intervention - Carbamylcholine (6),hiPSC-CM Purification Duration (days) - 5 days (6),0.01633,0.01770177,0.01361,0.02860286,Other Applications,0.01770177,TRUE,TRUE
Pharmacological Intervention - Carbamylcholine (6),Publication Year - 2018 (45),0.016,0.01940194,0.01068,0.076407641,Other Applications,0.01940194,TRUE,TRUE
Pharmacological Intervention - Carbamylcholine (6),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),0.01593,0.01410141,0.0148,0.01740174,Other Applications,0.01410141,TRUE,TRUE
Pharmacological Intervention - Carbamylcholine (6),Cell Line - C25 (6),0.01566,0.01880188,0.01533,0.02190219,Other Applications,0.01880188,TRUE,TRUE
Pharmacological Intervention - Carbamylcholine (6),Seeding Confluency 2D (%) - 95 to 100 (6),0.01564,0.02140214,0.02353,0.00420042,Other Applications,0.00420042,TRUE,TRUE
Pharmacological Intervention - Carbamylcholine (6),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),0.01536,0.01940194,0.01644,0.01590159,Other Applications,0.01590159,TRUE,TRUE
Pharmacological Intervention - Carbamylcholine (6),Wnt Inhibitor - bFGF (8),0.01457,0.02390239,0.01225,0.04040404,Other Applications,0.02390239,TRUE,TRUE
Pharmacological Intervention - Carbamylcholine (6),Differentiation Purity Assessment - IHC cTnT (7),0.01333,0.03510351,0.01164,0.04880488,Other Applications,0.03510351,TRUE,FALSE
Pharmacological Intervention - Carbamylcholine (6),Wnt Inhibitor - Wnt-C59 (30),0.01314,0.04970497,0.00822,0.126912691,Other Applications,0.04970497,TRUE,FALSE
Pharmacological Intervention - Carbamylcholine (6),Journal - Cell Stem Cell (6),0.01304,0.04150415,0.0094,0.073107311,Other Applications,0.04150415,TRUE,FALSE
Pharmacological Intervention - Carbamylcholine (6),Electrophysiology Analysis Method - Optical Mapping (39),0.01119,0.066406641,0.01615,0.01520152,Other Applications,0.01520152,TRUE,TRUE
Pharmacological Intervention - Carbamylcholine (6),Wnt Inhibitor - Others (9),0.01084,0.04540454,0.00841,0.085708571,Other Applications,0.04540454,TRUE,FALSE
Pharmacological Intervention - Carbamylcholine (6),Differentiation Purity Assessment - IHC a-actinin (8),0.01058,0.04670467,0.01082,0.050905091,Other Applications,0.04670467,TRUE,FALSE
Pharmacological Intervention - Carbamylcholine (6),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),0.00992,0.067806781,0.0154,0.0220022,Other Applications,0.0220022,TRUE,TRUE
Pharmacological Intervention - Carbamylcholine (6),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),0.00964,0.063806381,0.01271,0.03540354,Other Applications,0.03540354,TRUE,FALSE
Pharmacological Intervention - Carbamylcholine (6),Journal - Acta Biomater (10),0.00885,0.099409941,0.01205,0.04460446,Other Applications,0.04460446,TRUE,FALSE
Pharmacological Intervention - Carbamylcholine (6),2D Surface - ECM-coated (115),0.0058,0.215321532,0.01013,0.0370037,Other Applications,0.0370037,TRUE,FALSE
Pharmacological Intervention - Carbamylcholine (6),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),0.0051,0.226422642,0.0155,0.01340134,Other Applications,0.01340134,TRUE,TRUE
Pharmacological Intervention - Carbamylcholine (6),Calcium Handling Analysis Method - Visual (104),0.0051,0.435543554,0.01034,0.04590459,Other Applications,0.04590459,TRUE,FALSE
Pharmacological Intervention - Propranolol (5),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),0.03321,0.00170017,0.02971,0.00050005,Other Applications,0.00050005,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),3D Platform - Polyethylene Glycol (8),0.02767,0.00290029,0.03333,0.0010001,Other Applications,0.0010001,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),0.02736,0.00310031,0.03031,0.00250025,Other Applications,0.00250025,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),0.02528,0.00490049,0.01686,0.00540054,Other Applications,0.00490049,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),Calcium Handling Analysis Method - Visual (104),0.02373,0.00150015,0.01934,0.00060006,Other Applications,0.00060006,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),Cell Line - 253G1 (10),0.02372,0.00450045,0.01663,0.01710171,Other Applications,0.00450045,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),Cell Line - IMR90 (19),0.02342,0.0040004,0.01578,0.01690169,Other Applications,0.0040004,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),Journal - Biomaterials (16),0.02333,0.00980098,0.0202,0.010001,Other Applications,0.00980098,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),Wnt Inhibitor - IWP (112),0.0213,0.00510051,0.01505,0.00370037,Other Applications,0.00370037,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),Publication Year - 2016 (32),0.02122,0.01610161,0.01921,0.0110011,Other Applications,0.0110011,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),hiPSC Matrix Coating - Vitronectin (10),0.02103,0.00360036,0.01614,0.01580158,Other Applications,0.00360036,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),hiPSC-CM Purification Duration (days) - 5 days (6),0.0207,0.01510151,0.01479,0.03610361,Other Applications,0.01510151,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),0.0199,0.01120112,0.02118,0.0110011,Other Applications,0.0110011,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),Wnt Inhibitor - BMP4 (7),0.01733,0.01350135,0.01207,0.04830483,Other Applications,0.01350135,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),Journal - Acta Biomater (10),0.01704,0.02330233,0.01693,0.01980198,Other Applications,0.01980198,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),0.01587,0.0350035,0.01618,0.03050305,Other Applications,0.03050305,TRUE,FALSE
Pharmacological Intervention - Propranolol (5),Number of Cell Lines - 1 (225),0.01376,0.03070307,0.00691,0.257325733,Other Applications,0.03070307,TRUE,FALSE
Pharmacological Intervention - Propranolol (5),Gene Analysis Method - RNA (169),0.01332,0.02210221,0.00251,0.898289829,Other Applications,0.02210221,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),2D Surface - Electrospun (13),0.01308,0.03560356,0.01239,0.03040304,Other Applications,0.03040304,TRUE,FALSE
Pharmacological Intervention - Propranolol (5),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),0.01304,0.03020302,0.01101,0.056605661,Other Applications,0.03020302,TRUE,FALSE
Pharmacological Intervention - Propranolol (5),Publication Year - Late-2010s (196),0.01294,0.01910191,0.00914,0.083908391,Other Applications,0.01910191,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),0.01293,0.03110311,0.02334,0.0030003,Other Applications,0.0030003,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),Cell Line - DF19-9-11T.H (16),0.01265,0.03610361,0.02229,0.00720072,Other Applications,0.00720072,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),0.01231,0.03730373,0.01603,0.02330233,Other Applications,0.02330233,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),Insulin Start Day - 8 (15),0.01202,0.04340434,0.01442,0.03550355,Other Applications,0.03550355,TRUE,FALSE
Pharmacological Intervention - Propranolol (5),Number of Cell Lines - 4 (11),0.01157,0.061506151,0.01475,0.03320332,Other Applications,0.03320332,TRUE,FALSE
Pharmacological Intervention - Propranolol (5),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),0.01112,0.070707071,0.01708,0.00970097,Other Applications,0.00970097,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),2D Surface - ECM-coated (115),0.01032,0.0270027,0.01151,0.03120312,Other Applications,0.0270027,TRUE,FALSE
Pharmacological Intervention - Propranolol (5),Publication Year - 2021 (43),0.00836,0.110111011,0.01286,0.04390439,Other Applications,0.04390439,TRUE,FALSE
Pharmacological Intervention - Propranolol (5),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),0.00751,0.227122712,0.0158,0.00980098,Other Applications,0.00980098,TRUE,TRUE
Pharmacological Intervention - Propranolol (5),Deduced Culture Strategy - 2D Only (183),0.00423,0.649964996,0.00988,0.04610461,Other Applications,0.04610461,TRUE,FALSE
Pharmacological Intervention - Propranolol (5),Journal - Stem Cell Res Ther (3),0.00085,0.04560456,0.00146,0.04760476,Other Applications,0.04560456,TRUE,FALSE
Pharmacological Intervention - Blebbistatin (5),Journal - Tissue Eng Part C Methods (6),0.03247,0.00180018,0.02892,0.00210021,Other Applications,0.00180018,TRUE,TRUE
Pharmacological Intervention - Blebbistatin (5),hiPSC-CM Media Supplement - HEPES (16),0.02445,0.00660066,0.03032,0.00180018,Other Applications,0.00180018,TRUE,TRUE
Pharmacological Intervention - Blebbistatin (5),Day of Insulin Addition - not 25 (3),0.01953,0.01070107,0.01833,0.01980198,Other Applications,0.01070107,TRUE,TRUE
Pharmacological Intervention - Blebbistatin (5),Day of Insulin Addition - not 9 (3),0.01907,0.01170117,0.01516,0.02430243,Other Applications,0.01170117,TRUE,TRUE
Pharmacological Intervention - Blebbistatin (5),3D Tissue Media - Growth Factor (12),0.01703,0.01320132,0.01509,0.02260226,Other Applications,0.01320132,TRUE,TRUE
Pharmacological Intervention - Blebbistatin (5),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),0.01673,0.03670367,0.01452,0.0380038,Other Applications,0.03670367,TRUE,FALSE
Pharmacological Intervention - Blebbistatin (5),Publication Year - 2020 (51),0.0166,0.02150215,0.01668,0.01650165,Other Applications,0.01650165,TRUE,TRUE
Pharmacological Intervention - Blebbistatin (5),Journal - ACS Appl Mater Interfaces (4),0.01578,0.0310031,0.01451,0.03940394,Other Applications,0.0310031,TRUE,FALSE
Pharmacological Intervention - Blebbistatin (5),Journal - Am J Physiol Heart Circ Physiol (4),0.01537,0.03320332,0.01234,0.04690469,Other Applications,0.03320332,TRUE,FALSE
Pharmacological Intervention - Blebbistatin (5),Coating for Replating - Synthemax (3),0.01498,0.02140214,0.01819,0.01670167,Other Applications,0.01670167,TRUE,TRUE
Pharmacological Intervention - Blebbistatin (5),Seeding Confluency (%) - 95 to 100 (23),0.01444,0.02560256,0.01431,0.03190319,Other Applications,0.02560256,TRUE,FALSE
Pharmacological Intervention - Blebbistatin (5),hiPSC-CM Maturation Media - iCell Maintenance (83),0.01441,0.01920192,0.0104,0.057905791,Other Applications,0.01920192,TRUE,TRUE
Pharmacological Intervention - Blebbistatin (5),Seeding Confluency 2D (%) - 95 to 100 (6),0.01418,0.0470047,0.01308,0.04840484,Other Applications,0.0470047,TRUE,FALSE
Pharmacological Intervention - Blebbistatin (5),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),0.01393,0.03870387,0.01455,0.0270027,Other Applications,0.0270027,TRUE,FALSE
Pharmacological Intervention - Blebbistatin (5),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),0.01384,0.03020302,0.00455,0.483648365,Other Applications,0.03020302,TRUE,FALSE
Pharmacological Intervention - Blebbistatin (5),hiPSC-CM Media Supplement - GlutaMax (8),0.01331,0.04780478,0.01212,0.051805181,Other Applications,0.04780478,TRUE,FALSE
Pharmacological Intervention - Blebbistatin (5),hiPSC-CM Backbone Media - iCell Maintenance (86),0.01323,0.02950295,0.01682,0.00670067,Other Applications,0.00670067,TRUE,TRUE
Pharmacological Intervention - Blebbistatin (5),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),0.01319,0.04270427,0.00771,0.172217222,Other Applications,0.04270427,TRUE,FALSE
Pharmacological Intervention - Blebbistatin (5),Insulin Start Day - 9 (10),0.0131,0.040004,0.02304,0.00510051,Other Applications,0.00510051,TRUE,TRUE
Pharmacological Intervention - Blebbistatin (5),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),0.01217,0.070107011,0.01331,0.04950495,Other Applications,0.04950495,TRUE,FALSE
Pharmacological Intervention - Blebbistatin (5),Wnt Inhibitor - Others (9),0.01101,0.056405641,0.01229,0.04470447,Other Applications,0.04470447,TRUE,FALSE
Pharmacological Intervention - Blebbistatin (5),Insulin Withdrawal Duration (days) - 6 days (3),0.01078,0.03710371,0.01689,0.0220022,Other Applications,0.0220022,TRUE,TRUE
Pharmacological Intervention - Blebbistatin (5),Day of Insulin Addition - not 11 (5),0.00999,0.062506251,0.01372,0.04230423,Other Applications,0.04230423,TRUE,FALSE
Pharmacological Intervention - Blebbistatin (5),Immunofluorescent Imaging - Yes (268),0.00877,0.105810581,0.01392,0.0330033,Other Applications,0.0330033,TRUE,FALSE
Pharmacological Intervention - Blebbistatin (5),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),0.0086,0.087008701,0.01302,0.04030403,Other Applications,0.04030403,TRUE,FALSE
Pharmacological Intervention - Blebbistatin (5),Insulin Start Day - 5 (14),0.00747,0.120812081,0.01522,0.01950195,Other Applications,0.01950195,TRUE,TRUE
Pharmacological Intervention - Blebbistatin (5),3D Tissue Media - MEM-α (60),0.0072,0.172817282,0.01345,0.03850385,Other Applications,0.03850385,TRUE,FALSE
Pharmacological Intervention - Blebbistatin (5),Journal - Stem Cell Res Ther (3),0.00016,0.095209521,0.0026,0.04670467,Other Applications,0.04670467,TRUE,FALSE
Pharmacological Intervention - Metoprolol (5),Electrophysiology Analysis Method - Microelectrode (31),0.0396,0.00040004,0.02935,0.00040004,Other Applications,0.00040004,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),Cell Line - iCell (47),0.03481,0.00160016,0.01886,0.00940094,Other Applications,0.00160016,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),Journal - Cell Rep (6),0.03063,0.00190019,0.0353,0.00110011,Other Applications,0.00110011,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),Coating for Replating - Rare (6),0.02304,0.00510051,0.02067,0.01080108,Other Applications,0.00510051,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),Journal - Sci Rep (24),0.02301,0.01060106,0.03282,0.00060006,Other Applications,0.00060006,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),0.02171,0.00760076,0.03045,0.00140014,Other Applications,0.00140014,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),0.02016,0.00950095,0.01308,0.02180218,Other Applications,0.00950095,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),Number of Cell Lines - 3 (29),0.01885,0.01430143,0.01839,0.01130113,Other Applications,0.01130113,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),0.01862,0.01210121,0.01778,0.01530153,Other Applications,0.01210121,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),Wnt Inhibitor Duration (days) - Rare (173),0.01854,0.00050005,0.01106,0.01320132,Other Applications,0.00050005,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),hiPSC-CM Maturation Media - iCell Maintenance (83),0.01815,0.0050005,0.01714,0.00280028,Other Applications,0.00280028,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),2D Surface - Hydrogel (17),0.0179,0.01290129,0.01998,0.00810081,Other Applications,0.00810081,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),0.01782,0.01820182,0.01643,0.0170017,Other Applications,0.0170017,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),Number of Cell Lines - 1 (225),0.01725,0.01120112,0.0181,0.00240024,Other Applications,0.00240024,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),Electrophysiology Analysis Method - Optical Mapping (39),0.01632,0.02650265,0.01147,0.075507551,Other Applications,0.02650265,TRUE,FALSE
Pharmacological Intervention - Metoprolol (5),Cell Line - Cor.4U (16),0.016,0.02250225,0.01988,0.01160116,Other Applications,0.01160116,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.01595,0.03180318,0.0152,0.01960196,Other Applications,0.01960196,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58),0.0156,0.04090409,0.01398,0.03220322,Other Applications,0.03220322,TRUE,FALSE
Pharmacological Intervention - Metoprolol (5),Publication Year - 2021 (43),0.01524,0.02570257,0.03134,0.00010001,Other Applications,0.00010001,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),Wnt Inhibitor Duration (days) Quantiles - Q2 (>1 and ≤2) (156),0.0142,0.01270127,0.00917,0.074607461,Other Applications,0.01270127,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),Maturation Strategy - Electrical (39),0.01388,0.054705471,0.01561,0.03120312,Other Applications,0.03120312,TRUE,FALSE
Pharmacological Intervention - Metoprolol (5),hiPSC-CM Maturation Media - RPMI-1640 (153),0.01387,0.01070107,0.01273,0.0030003,Other Applications,0.0030003,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),Publication Year - Late-2010s (196),0.01294,0.01970197,0.01388,0.00710071,Other Applications,0.00710071,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),Maturation Strategy - Elastomeric (33),0.01266,0.04640464,0.006,0.175317532,Other Applications,0.04640464,TRUE,FALSE
Pharmacological Intervention - Metoprolol (5),Coating for Replating - Gelatin (43),0.01228,0.04940494,0.00685,0.165216522,Other Applications,0.04940494,TRUE,FALSE
Pharmacological Intervention - Metoprolol (5),Maturation Strategy - ECM (21),0.01221,0.04070407,0.01174,0.04360436,Other Applications,0.04070407,TRUE,FALSE
Pharmacological Intervention - Metoprolol (5),Gene Analysis Method - RNA (169),0.01202,0.04880488,0.01233,0.03050305,Other Applications,0.03050305,TRUE,FALSE
Pharmacological Intervention - Metoprolol (5),Calcium Handling Analysis Method - Visual (104),0.01051,0.073307331,0.01106,0.0370037,Other Applications,0.0370037,TRUE,FALSE
Pharmacological Intervention - Metoprolol (5),Publication Year - 2016 (32),0.00989,0.105710571,0.01381,0.03880388,Other Applications,0.03880388,TRUE,FALSE
Pharmacological Intervention - Metoprolol (5),Seeding Confluency 3D (%) - 90 to 94 (13),0.00854,0.098309831,0.01289,0.04130413,Other Applications,0.04130413,TRUE,FALSE
Pharmacological Intervention - Metoprolol (5),hiPSC-CM Backbone Media - RPMI-1640 (167),0.00822,0.120712071,0.01005,0.04910491,Other Applications,0.04910491,TRUE,FALSE
Pharmacological Intervention - Metoprolol (5),hiPSC-CM Backbone Media - iCell Maintenance (86),0.00798,0.124812481,0.01374,0.02310231,Other Applications,0.02310231,TRUE,TRUE
Pharmacological Intervention - Metoprolol (5),2D Surface - ECM-coated (115),0.00796,0.077707771,0.01113,0.02660266,Other Applications,0.02660266,TRUE,FALSE
Pharmacological Intervention - Metoprolol (5),Deduced Culture Strategy - 2D Only (183),0.0075,0.163216322,0.00972,0.03970397,Other Applications,0.03970397,TRUE,FALSE
Pharmacological Intervention - Caffeine (4),Metabolic Component - T3 (14),0.04776,0.00080008,0.03774,0.00170017,Other Applications,0.00080008,TRUE,TRUE
Pharmacological Intervention - Caffeine (4),Metabolic Component - Dexamethasone (7),0.04469,0.0020002,0.03377,0.00350035,Other Applications,0.0020002,TRUE,TRUE
Pharmacological Intervention - Caffeine (4),Insulin Start Day - 2 (4),0.03515,0.00130013,0.03245,0.00290029,Other Applications,0.00130013,TRUE,TRUE
Pharmacological Intervention - Caffeine (4),hiPSC-CM Maturation Media - F12 (10),0.03272,0.00430043,0.03885,0.00110011,Other Applications,0.00110011,TRUE,TRUE
Pharmacological Intervention - Caffeine (4),Wnt Inhibitor - Wnt-C59 (30),0.03039,0.00430043,0.02288,0.00880088,Other Applications,0.00430043,TRUE,TRUE
Pharmacological Intervention - Caffeine (4),Metabolic Component Category - Hormonal Stimulation (14),0.03037,0.00730073,0.02131,0.01520152,Other Applications,0.00730073,TRUE,TRUE
Pharmacological Intervention - Caffeine (4),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),0.02635,0.00370037,0.02641,0.00210021,Other Applications,0.00210021,TRUE,TRUE
Pharmacological Intervention - Caffeine (4),Wnt Inhibitor - bFGF (8),0.02556,0.01260126,0.03066,0.00440044,Other Applications,0.00440044,TRUE,TRUE
Pharmacological Intervention - Caffeine (4),Cell Line - Cellapy (4),0.02375,0.01640164,0.03256,0.00510051,Other Applications,0.00510051,TRUE,TRUE
Pharmacological Intervention - Caffeine (4),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),0.02364,0.00710071,0.02551,0.0050005,Other Applications,0.0050005,TRUE,TRUE
Pharmacological Intervention - Caffeine (4),hiPSC-CM Media Supplement - Albumin (28),0.02342,0.01540154,0.01171,0.074207421,Other Applications,0.01540154,TRUE,TRUE
Pharmacological Intervention - Caffeine (4),Disease Modelling - Genetic Disorders (18),0.02226,0.01050105,0.02682,0.00450045,Other Applications,0.00450045,TRUE,TRUE
Pharmacological Intervention - Caffeine (4),Coating for Replating - Matrigel (65),0.02076,0.00890089,0.0176,0.020002,Other Applications,0.00890089,TRUE,TRUE
Pharmacological Intervention - Caffeine (4),Insulin Start Day - After 11 (7),0.0203,0.0330033,0.01803,0.03430343,Other Applications,0.0330033,TRUE,FALSE
Pharmacological Intervention - Caffeine (4),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),0.01864,0.02230223,0.02619,0.00670067,Other Applications,0.00670067,TRUE,TRUE
Pharmacological Intervention - Caffeine (4),Maturation Strategy - Metabolic (33),0.01829,0.02780278,0.0048,0.258125813,Other Applications,0.02780278,TRUE,FALSE
Pharmacological Intervention - Caffeine (4),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),0.01811,0.02020202,0.01558,0.01120112,Other Applications,0.01120112,TRUE,TRUE
Pharmacological Intervention - Caffeine (4),hiPSC-CM Purification Duration (days) - 5 days (6),0.01798,0.04240424,0.01314,0.050905091,Other Applications,0.04240424,TRUE,FALSE
Pharmacological Intervention - Caffeine (4),hiPSC Backbone Media - Rare (19),0.0178,0.01570157,0.01506,0.03940394,Other Applications,0.01570157,TRUE,TRUE
Pharmacological Intervention - Caffeine (4),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),0.01586,0.02160216,0.01885,0.01620162,Other Applications,0.01620162,TRUE,TRUE
Pharmacological Intervention - Caffeine (4),Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),0.01469,0.0310031,0.00953,0.04160416,Other Applications,0.0310031,TRUE,FALSE
Pharmacological Intervention - Caffeine (4),Seeding Confluency 2D (%) - 85 to 89 (26),0.014,0.04770477,0.0101,0.097609761,Other Applications,0.04770477,TRUE,FALSE
Pharmacological Intervention - Caffeine (4),Purification Protocol - Cell Sorting (7),0.01353,0.056005601,0.01523,0.03660366,Other Applications,0.03660366,TRUE,FALSE
Pharmacological Intervention - Caffeine (4),Journal - Circ Res (5),0.01334,0.04760476,0.0158,0.03820382,Other Applications,0.03820382,TRUE,FALSE
Pharmacological Intervention - Caffeine (4),Seeding Confluency (%) - 70 to 79 (11),0.01325,0.067206721,0.01566,0.04380438,Other Applications,0.04380438,TRUE,FALSE
Pharmacological Intervention - Caffeine (4),Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),0.01319,0.057905791,0.01369,0.0440044,Other Applications,0.0440044,TRUE,FALSE
Pharmacological Intervention - Caffeine (4),Seeding Confluency 2D (%) - 70 to 79 (6),0.012,0.058305831,0.01316,0.04470447,Other Applications,0.04470447,TRUE,FALSE
Pharmacological Intervention - Caffeine (4),Publication Year - 2019 (57),0.0112,0.068606861,0.01445,0.03960396,Other Applications,0.03960396,TRUE,FALSE
Pharmacological Intervention - Caffeine (4),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),0.0109,0.088608861,0.01842,0.03120312,Other Applications,0.03120312,TRUE,FALSE
Pharmacological Intervention - Caffeine (4),New Media for Maturation - F12 (7),0.0101,0.053605361,0.01362,0.03590359,Other Applications,0.03590359,TRUE,FALSE
Pharmacological Intervention - Caffeine (4),hiPSC-CM Media Supplement - bFGF (3),0.00805,0.03570357,0.00701,0.03630363,Other Applications,0.03570357,TRUE,FALSE
Pharmacological Intervention - Caffeine (4),Gene Analysis Method - RNA (169),0.0075,0.327632763,0.01308,0.04510451,Other Applications,0.04510451,TRUE,FALSE
Pharmacological Intervention - Caffeine (4),Metabolic Component - Albumax (3),0.00244,0.03660366,0.00551,0.03660366,Other Applications,0.03660366,TRUE,FALSE
Pharmacological Intervention - Caffeine (4),Metabolic Component - Insulin-Transferrin-Selenium (3),0.00057,0.051505151,0.00118,0.04990499,Other Applications,0.04990499,TRUE,FALSE
Pharmacological Intervention - Carbenoxolone (4),Publication Year - 2015 (19),0.0445,0.00080008,0.03733,0.00070007,Other Applications,0.00070007,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),Electrophysiology Analysis Method - Optical Mapping (39),0.04028,0.00070007,0.05343,0,Other Applications,0,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),Cell Line - iCell (47),0.03645,0.00320032,0.01746,0.0250025,Other Applications,0.00320032,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),0.03206,0.00280028,0.02394,0.00240024,Other Applications,0.00240024,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),0.03161,0.00350035,0.01629,0.02820282,Other Applications,0.00350035,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),Journal - Nano Lett (3),0.03155,0.00480048,0.03821,0.00320032,Other Applications,0.00320032,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),3D Tissue Media - Iscove (5),0.02438,0.00710071,0.03107,0.00320032,Other Applications,0.00320032,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),3D Stromal Cell Source - hiPSC-CardiacF (8),0.02268,0.02320232,0.02334,0.01430143,Other Applications,0.01430143,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),Publication Year - 2020 (51),0.02206,0.01160116,0.02096,0.00780078,Other Applications,0.00780078,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),0.0212,0.01670167,0.02062,0.0190019,Other Applications,0.01670167,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),0.0209,0.03080308,0.01919,0.02760276,Other Applications,0.02760276,TRUE,FALSE
Pharmacological Intervention - Carbenoxolone (4),Coating for Replating - Gelatin (43),0.01953,0.02070207,0.01187,0.064306431,Other Applications,0.02070207,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),0.01757,0.03480348,0.01447,0.04520452,Other Applications,0.03480348,TRUE,FALSE
Pharmacological Intervention - Carbenoxolone (4),hiPSC-CM Maturation Media - iCell Maintenance (83),0.01751,0.01020102,0.00929,0.133413341,Other Applications,0.01020102,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),hiPSC-CM Media Supplement - B27 (180),0.01749,0.00810081,0.00648,0.339633963,Other Applications,0.00810081,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),Differentiation Purity Assessment - IHC a-actinin (8),0.01739,0.02710271,0.02512,0.00550055,Other Applications,0.00550055,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),Maturation Strategy - Cell Alignment (59),0.0169,0.02390239,0.02388,0.00330033,Other Applications,0.00330033,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),0.01682,0.04530453,0.0225,0.02040204,Other Applications,0.02040204,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),Immunofluorescent Imaging - Yes (268),0.01619,0.02040204,0.01984,0.0070007,Other Applications,0.0070007,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),Journal - Rare (104),0.01598,0.01530153,0.01942,0.00230023,Other Applications,0.00230023,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),Seeding Confluency 3D (%) - 85 to 89 (12),0.01579,0.0460046,0.00997,0.092209221,Other Applications,0.0460046,TRUE,FALSE
Pharmacological Intervention - Carbenoxolone (4),Gene Analysis Method - RNA (169),0.01566,0.00550055,0.01104,0.080908091,Other Applications,0.00550055,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),2D Surface - Microelectrode Array (9),0.01555,0.03920392,0.01355,0.04880488,Other Applications,0.03920392,TRUE,FALSE
Pharmacological Intervention - Carbenoxolone (4),hiPSC-CM Backbone Media - iCell Maintenance (86),0.01473,0.02250225,0.00888,0.146914691,Other Applications,0.02250225,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),3D Platform - Nanotechnology (3),0.01428,0.0360036,0.01709,0.03330333,Other Applications,0.03330333,TRUE,FALSE
Pharmacological Intervention - Carbenoxolone (4),3D Tissue Media - iCell Maintenance (12),0.01345,0.04130413,0.01225,0.055405541,Other Applications,0.04130413,TRUE,FALSE
Pharmacological Intervention - Carbenoxolone (4),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),0.01325,0.067706771,0.0188,0.02190219,Other Applications,0.02190219,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),Publication Year - Late-2010s (196),0.01212,0.03070307,0.01222,0.03090309,Other Applications,0.03070307,TRUE,FALSE
Pharmacological Intervention - Carbenoxolone (4),Publication Year - 2019 (57),0.01168,0.068106811,0.01873,0.01310131,Other Applications,0.01310131,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),Publication Year - Post 2020 (122),0.01034,0.100110011,0.01261,0.02320232,Other Applications,0.02320232,TRUE,TRUE
Pharmacological Intervention - Carbenoxolone (4),Sacromere or Cellular Alignment Analysis - Yes (72),0.01027,0.098409841,0.01346,0.03990399,Other Applications,0.03990399,TRUE,FALSE
Pharmacological Intervention - Carbenoxolone (4),3D Tissue Media - Commercial Kit (21),0.01026,0.090509051,0.01442,0.04310431,Other Applications,0.04310431,TRUE,FALSE
Pharmacological Intervention - Carbenoxolone (4),Maturation Strategy - Tension (64),0.00962,0.136313631,0.0149,0.03490349,Other Applications,0.03490349,TRUE,FALSE
Pharmacological Intervention - Carbenoxolone (4),Day of Insulin Addition - Known (177),0.00949,0.04970497,0.00316,0.704470447,Other Applications,0.04970497,TRUE,FALSE
Pharmacological Intervention - Carbenoxolone (4),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),0.009,0.074607461,0.01602,0.03310331,Other Applications,0.03310331,TRUE,FALSE
Pharmacological Intervention - Carbenoxolone (4),3D Platform - Fibronectin (3),0.00086,0.04150415,0,0.075607561,Other Applications,0.04150415,TRUE,FALSE
